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Huntington's  disease  (HD)  is  an  autosomal  dominant,  progressive  neurodegenerative 
disorder,  characterised  by  an  array  of  different  psychiatric  manifestations,  cognitive 
decline  and  choreiform  movement.  The  underlying  molecular  genetic  defect  is  an 
expanded  trinucleotide  (CAG)n  repeat  encoding  a  polyglutamine  stretch  in  the  N-terminus 
of  the  huntingtin  protein.  The  mechanisms  by  which  mutant  huntingtin  causes  neuronal 
dysfunction  and  degeneration  are  not  clear.  The  lack  of  autopsy  brain  material  from 
patients,  especially  presymptomatic  patients,  makes  investigation  of  pathogenesis  difficult. 
Several  transgenic  and  "knock-in"  HD  mouse  models  have  therefore  been  generated  to 
enable  the  exploration  of  pathological,  molecular,  and  cellular  abnormalities  in  HD.  A 
"knock-in"  HD  mouse  model  (Glasgow  HD  mice),  generated  by  introducing  an  extended 
stretch  of  -  80  CAG  repeats  into  the  endogenous  mouse  Hdh  gene  to  mimic  the  molecular 
findings  on  human  HD  chromosomes,  has  shown  neuronal  dysfunction  and 
neuropathological  findings  reminiscent  of  early  stages  of  HD  (Shelbourne  et  al.,  1999;  Li 
et  al.,  2000a;  Usdin  et  al.,  1999).  The  present  study  uses  the  Glasgow  HD  mice  to 
investigate  the  early  phenotypic  and  cellular/molecular  consequences  of  the  expanded 
CAG  repeats  in  HD. 
One  of  current  limitations  of  using  "knock-in"  HD  mice  as  a  tool  to  investigate  HD  is  that 
robust  protocols  for  measuring  modest  behavioural  phenotypes  are  less  well  developed. 
The  combination  of  the  rotarod  apparatus  and  a  more  sensitive  protocol  was  found  to 
provide  a  more  robust  measure  of  the  locomotor  performance  of  the  HD  mice.  Progressive 
motor  deficits  in  both  male  and  female  HD  mice  were  detected  from  4  to  18  months  of  age. 
These  observations  occurred  in  the  absence  of  progressive  weight  loss  or  a  limb-clasping 
phenotype  that  is  common  in  other  mouse  models. 
Although  the  pathogenesis  of  HD  is  not  fully  understood,  several  mechanisms  that  may 
contribute  to  neuronal  dysfunction  and  cell  death  have  been  suggested.  These  include 
defective  energy  metabolism,  mitochondrial  abnormalities,  increased  oxidative  stress,  and 
excitotoxicity  and  the  interplay  between  these  different  mechanisms.  Given  that 
mitochondria  could  play  a  central  role  in  these  processes,  the  integrity  of  mitochondrial 
DNA  (mtDNA)  in  the  tissues  of  HD  mice  was  investigated.  The  result  of  a  competitive 
2 PCR  strategy  showed  that  number  of  total  mtDNA  molecules  was  significantly  decreased 
(-  30  %)  in  the  striatum  (no  reduction  in  the  cortex  and  cerebellum)  of  24-month  old  HD 
mice,  but  not  at  15  months  of  age,  when  compared  to  wild-type  mice,  suggesting  mtDNA 
depletion  is  a  progressive  rather  than  a  developmental  phenomenon. 
In  light  of  the  -  30  %  reduction  of  total  mtDNA  in  the  striatum,  expression  levels  of  the 
mitochondrial  DNA-encoded  respiratory  complex  enzymes,  cytochrome  b  (Cytb), 
cytochrome  c  oxidase  I  (COI)  and  cytochrome  c  oxidase  II  (COIL)  were  investigated  in 
different  brain  regions  of  HD  mice.  At  -25  months  of  age,  there  were  no  significant 
differences  in  mRNA  levels  of  CoII  and  Cytb  in  any  brain  region  (striatum,  cortex  and 
cerebellum)  studied  when  compared  to  normal  littermates.  However,  HD  mice  showed 
significantly  decreased  CO-I  protein  levels  and  marginally  decreased  CoI  mRNA  levels  in 
the  striatum. 
Reduced  levels  of  mtDNA  may  be  caused  by  decreased  replication  of  mtDNA  or  increased 
oxidative  damage  of  mtDNA.  Increased  levels  of  8-OHdG,  a  marker  of  increased  oxidative 
stress,  were  detected  in  the  dorsomedial,  dorsolateral  and  ventromedial  striatum,  but  not  in 
the  cortex  of  24  month-old  HD  mice  providing  direct  evidence  that  increased  oxidative 
stress  specifically  occurs  in  the  striatum  of  HD  mice.  As  no  alterations  in  the 
mitochondrial  transcription  factor  (mtTFA)  in  the  striatum  of  HD  mice  could  be  detected, 
it  is  likely  that  mtDNA  depletion  in  the  HD  mice  is  caused  by  increased  levels  of  oxidative 
stress  rather  than  decreased  replication. 
In  summary,  the  study  shows  early  and  progressive  motor  deficits  and  late-onset 
mitochondrial  abnormalities  in  a  "knock-in"  HD  mouse  model.  The  increased  levels  of 
oxidative  stress  present  in  HD  striatum  may  be  responsible  for  the  mitochondrial 
abnormalities.  The  results  provide  a  basis  for  further  studies  investigating  how  mutant 
huntingtin  causes  increased  levels  of  oxidative  stress  and  for  identifying  novel  therapeutic 
targets. Table  of  contents 
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22 1  Introduction 
1.1  Huntington's  Disease  (HD) 
Huntington's  disease  (HD)  is  an  autosomal  dominant,  progressive  neurodegenerative 
disorder,  characterised  by  an  array  of  different  psychiatric  manifestations,  cognitive 
decline  and  choreiform  movement  (Harper,  1996).  Two  forms  of  HD,  juvenile  HD  and 
adult  HD,  have  been  arbitrarily  divided  by  the  age  of  disease  onset.  The  term  `juvenile 
HD'  is  generally  applied  to  cases  of  HD  with  onset  before  20  years  of  age.  Presentation  of 
juvenile  HD  is  commonly  with  symptoms  of  mental  disturbance  and  rigidity  rather  than 
choreic  movements,  while  HD  presenting  in  mid  life  more  frequently  shows  a  relatively 
pure  movement  disorder.  The  psychiatric  problems  include  a  variety  of  conditions  that 
range  from  antisocial  personality,  psychosomatic  disorder,  delusional  disorder,  and 
affective  disorder  to  schizophrenia.  Although  chorea  is  a  cardinal  sign  of  HD,  other  motor 
abnormalities  such  as  rigidity,  bradykinesia,  dystonia,  cerebellar  ataxia  and  myoclonus  are 
common  either  in  juvenile  HD  or  in  the  late  stage  of  adult  HD.  Family  studies  of  HD  in  the 
pre-molecular  era  had  documented  that  most  juvenile  and  early-onset  cases  of  HD  were 
paternally  transmitted  and  that  there  appeared  to  be  anticipation,  i.  e.  progressively  earlier 
onset  in  successive  generations.  HD  is  a  relentlessly  progressive  disease,  and  survival 
ranges  between  10  and  17  years  from  the  age  at  onset.  In  the  late  stages  of  HD,  cachexia  is 
a  frequent  but  not  invariable  symptom,  although  lack  of  muscle  bulk  is  often  obvious. 
However,  it  has  been  reported  that  weight  loss  occurs  in  patients  with  HD  despite  an 
adequate  diet  and  feeding  (Morales  et  al.,  1989;  Pratley  et  al.,  2000).  Pneumonia  and 
cardiovascular  disease  are  the  commonest  causes  of  death  in  HD  and  usually  result  from 
immobility  and  dysphagia. 
1.1.1  Epidemiology 
The  prevalence  of  HD  in  the  UK  is  4-  8  per  100,000  population,  whilst  in  North  America 
it  is  estimated  to  be  around  4.5  per  100,000.  Variation  in  the  prevalence  of  HD  between 
countries  has  been  recognized  with  a  very  low  prevalence  of  HD  (0.11  to  0.65  per  100,000) 
in  Japan  (Nakashima  et  al.,  1996)  and  Hong  Kong  Chinese  (Chang  et  al.,  1994). 
23 1.1.2  Psychomotor  abnormalities  in  HD 
Behavioural  and  cognitive  changes  and  motor  deficits  are  central  features  of  HD.  Motor 
dysfunction  in  HD  is  thought  to  result  from  the  disruption  of  cortico-basal  ganglia-thalamic 
pathways  regulating  motor  control.  Motor  disturbances  include  choreiform  involuntary 
movements  of  limbs  and  a  progressive  impairment  in  the  co-ordination  of  voluntary 
movements.  In  juvenile-onset  HD,  bradykinesia  and  dystonia  are  the  predominant 
symptoms.  Epileptic  seizures  and  cerebellar  signs  are  often  present  in  juvenile-onset  HD 
(Harper,  1996). 
The  cognitive  impairment  in  HD  is  believed  to  be  a  consequence  of  the  profound 
frontostriatal  pathology  associated  with  the  disease  (Vonsattel  and  DiFiglia,  1998). 
Frontostriatal  dysfunction  has  been  shown  in  HD  patients  who  display  a  decline  in 
visuospatial  skills,  cognitive  flexibility,  and  recall  memory  (Lange  et  al.,  1995;  Lawrence 
et  al.,  1998;  Lawrence  et  al.,  1996;  Lawrence  et  al.,  2000).  Deficits  in  a  visual 
discrimination/set-shifting  task  by  have  been  shown  in  both  symptomatic  HD  patients  and 
presymptomatic  mutation  carriers  (Lawrence  et  al.,  1998;  Lawrence  et  al.,  2000).  They 
exhibit  preservative  responses,  an  inability  to  disengage  their  response  from  a  previously 
positively  reinforced  stimulus,  and  this  appears  to  be  the  result  of  loss  of  inhibition 
function  of  the  frontostriatal  pathway. 
Common  behavioural  problems  in  HD  include  loss  of  energy  and  initiative,  poor 
judgement  and  quality  of  work,  impaired  judgement,  poor  self-care  and  emotional 
blunting.  Affective  symptoms  such  as  depression,  anxiety  and  irritability  are  less  common 
but  not  rare.  Psychotic  symptoms  (hallucinations  and  delusions)  have  been  occasionally 
reported  (Craufurd  et  al.,  2001;  Harper,  1996).  Some  behavioural  changes  (such  as  loss  of 
energy  and  initiative,  poor  judgement,  poor  self-care  and  emotional  blunting)  are  strongly 
correlated  to  the  progression  of  HD,  whilst  others  (such  as  depression,  anxiety,  aggression, 
and  inflexibility)  are  not  (Craufurd  et  al.,  2001).  The  disease  progression-related 
behavioural  changes  might  provide  a  reliable  marker  of  the  onset  and  overall  progression 
of  the  disease,  which  can  be  used  to  evaluate  the  efficacy  of  therapies  in  the  future. 
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Neurodegeneration  in  HD  starts  in  the  striatum,  then  involves  the  cortex  and  in  the  latter 
stages,  also  the  globus  pallidus,  thalamus  and  amygdala.  Astrocytosis  follows  the  path  of 
striatal  cell  loss,  which  develops  in  a  topographically  ordered  manner,  spreading  along  the 
caudal-rostral,  dorsal-ventral  and  medial-lateral  axes  (Vonsattel  and  DiFiglia,  1998).  HD 
neuropathology  has  been  classified  from  grade  0  to  4  with  increasing  severity  and  extent  of 
striatal  involvement  (Vonsattel  et  al.,  1985).  Clinical  manifestations  can  appear  in  the 
absence  of  gross  brain  abnormalities,  neuronal  loss,  and  reactive  gliosis  in  the  striatum 
(grade  0).  In  grade  4,  the  striatum  is  severely  atrophic  with  the  loss  of  more  than  95  %  of 
neurons  and  marked  increases  in  oligodendrocyte  density.  The  majority  of  HD  cases  are 
Grade  3  or  4  at  the  time  of  death  (Vonsattel  and  DiFiglia,  1998).  The  grade  of  striatal 
pathology  appears  to  correlate  closely  with  the  involvement  of  other  cerebral  regions.  Non- 
striatal  regions  are  largely  spared  in  Grade  1  and  2  (Vonsattel  and  DiFiglia,  1998).  In 
contrast,  profound  grade  4  changes  are  more  often  found  in  juvenile  HD  and  neuronal  loss 
extends  into  the  regions  spared  in  adult-onset  patients,  such  as  the  cerebellum,  suggesting  a 
more  aggressive  pathological  process  in  these  individuals  (Myers  et  al.,  1988). 
Different  cell  subtypes  within  the  striatum  also  show  selective  vulnerability  to  the  disease 
process.  Medium  spiny  projection  neurons  are  commonly  lost  while  large  cholinergic 
interneurons  and  medium  aspiny  somatostatin/nitric  oxide  synthase  neurons  are  otherwise 
spared  (Reiner  et  al.,  1988).  The  `indirect  pathway'  neurons  in  striatum,  which  co-express 
proenkephalin/enkephalin  and  are  enriched  in  D2  dopamine  receptors,  appear  to  be 
affected  earlier  than  the  `direct  pathway'  neurons,  co-expressing  substance  P  and  D1 
dopamine  receptors  (Richfield  et  al.,  1995;  Sapp  et  al.,  1995). 
1.2  The  molecular  basis  of  HD 
1.2.1  HD  mutation 
A  novel  gene,  M5  (HD),  containing  a  polymorphic  trinucleotide  (CAG)  repeat  that  is 
expanded  and  unstable  on  HD  chromosomes,  was  identified  by  the  HD  Collaborative 
25 Research  Group  in  1993  (HDCRG,  1993).  The  mutated  gene  carrying  the  expanded  CAG 
repeat  lies  on  chromosome  4  at  4p  16.3.  A  (CAG)n  repeat  longer  than  the  normal  range 
was  observed  on  HD  chromosomes  from  75  disease  families  examined,  comprising  a 
variety  of  ethnic  backgrounds  and  4p16.3  haplotypes.  The  causative  gene  mutation 
responsible  for  HD  thus  involves  an  unstable  (CAG)n  sequence  that  acts  in  the  context  of  a 
novel  gene  to  produce  a  dominant  phenotype.  The  human  HD  gene  has  67  exons,  ranging 
in  length  from  43  to  341  base  pairs  (bp),  that  span  180  kb  of  genomic  DNA  (Ambrose  et 
al.,  1994).  The  (CAG)n  repeat  encoding  a  polyglutamine  tract  is  in  the  first  exon  and  is 
followed  by  a  CCG  repeat  encoding  a  polyproline  region.  The  corresponding  protein 
product  of  the  HD  gene,  huntingtin,  has  an  estimated  molecular  mass  of  348  kDa, 
representing  3144  amino  acids. 
No  clear  homology  with  any  existing  protein  sequence  in  the  databases  has  been 
discovered.  However,  recently  a  Drosophila  homologue  of  HD  gene  has  been  identified 
(Li  et  al.,  1999a).  The  Drosophila  HD  gene  has  29  axons,  compared  with  the  67  exons 
present  in  vertebrate  HD  gene.  The  predicted  Drosophila  huntingtin  protein  has  3853 
amino  acids  and  lacks  the  polyglutamine  and  polyproline  stretches  present  in  its 
mammalian  counterparts.  Drosophila  and  vertebrate  HD  sequences  show  a  high  degree  of 
similarity  in  three  large,  contiguous  regions  at  the  N-terminus,  middle  and  c-terminus  of 
the  protein  and  there  is  an  overall  identity  of  24  %  and  similarity  of  49  %  between  fly  and 
human  sequences. 
The  mouse  orthologue  of  human  HD  gene  is  called  the  Hdh  gene  and  has  been  mapped  to 
chromosome  5  in  a  region  devoid  of  mutations  causing  a  comparable  phenotype.  The 
mouse  Hdh  gene  coding  sequence  is 86  %  identical  to  the  human  HD  gene  at  the  DNA 
level  and  91  %  at  the  protein  level.  The  Hdh  gene  possesses  an  imperfect  CAG  repeat 
encoding  7  consecutive  glutamines  (Barnes  et  al.,  1994). 
1.2.1.1  Clinical  correlates  with  the  (CAG)n  repeat  copy  number  in  HD 
A  progressive  increase  in  the  expressivity  of  an  identical  mutation  over  subsequent 
generations  is  termed  "anticipation".  One  of  the  distinguishing  features  of  trinucleotide 
repeat  mutations  is  that  the  (CAG)n  repeat  allele  can  undergo  `dynamic  mutation'  in  which 
26 the  repeat  number  may  change  when  transmitted  from  parent  to  offspring 
(intergenerational  mutation  instability).  Anticipation  results  from  intergenerational 
mutation  instability  and  its  corresponding  impact  on  phenotype.  Quantitative  molecular 
studies  of  HD  families  have  indicated  that  both  the  anticipation  and  the  parent-of-origin 
differences  are  mediated  principally  through  the  number  of  CAG  repeats  (Ranen  et  al., 
1995;  Trottier  et  al.,  1994).  In  both  studies,  although  a  small  increase  in  repeat  number  (up 
to  7  repeats)  was  seen  in  germline  transmission  by  both  sexes,  larger  increases  were  seen 
almost  exclusively  in  the  offspring  of  affected  males.  The  largest  increases  through 
generational  transmission  were  particularly  likely  to  occur  in  individuals  who  themselves 
had  the  largest  expansions,  confirming  the  size-dependent  instability  of  the  HD  mutation. 
In  terms  of  intergenerational  changes,  it  has  been  noted  that  the  CAG  copy  number  in  the 
HD  mutation  may  decrease  as  well  as  increase,  although  decreases  were  only  found  in  a 
small  proportion  of  transmissions  (Kremer  et  al.,  1994).  In  this  study  a  modest  decrease  of 
between  1  and  4  in  CAG  repeats  was  seen,  but  no  larger  decreases  were  observed  in  the 
next  generation. 
Several  studies  have  shown  that  there  is  a  significant  inverse  correlation  between  age  at 
onset  of  symptoms  and  CAG  repeat  number,  a  trend  that  is  even  stronger  within  the 
juvenile  group  (Brinkman  et  al.,  1997;  Duyao  et  al.,  1993;  Stine  et  al.,  1993;  Trottier  et  al., 
1994).  In  these  studies,  it  was  also  observed  that  the  severity  of  disease  is  proportional  to 
the  number  of  CAG  repeats. 
The  rate  of  progression  has  also  been  correlated  with  the  size  of  CAG  repeat  (Brandt  et  al., 
1996;  Illarioshkin  et  al.,  1994),  although  the  findings  were  not  replicated  in  another  study 
(Kieburtz  et  al.,  1994)  that  followed  the  participants  over  a  shorter  period  of  time. 
Additional  studies  have  revealed  that  the  extent  of  pathological  change  in  HD  is  positively 
related  to  the  CAG  mutation  size  (Furtado  et  al.,  1996;  Penney  et  al.,  1997),  although  in 
one  further  study,  evidence  for  this  correlation  was  not  forthcoming  (Sieradzan  et  al., 
1997). 
The  (CAG)n  repeat  region  shows  a  range  of  11-35  repeats  in  normal  individuals,  while  a 
repeat  number  of  greater  than  35  indicates  a  high  probability  of  developing  HD 
(Rubinsztein  et  al.,  1996).  There  have  been  no  confirmed  reports  of  persons  with  repeats  in 
27 the  range  of  29  to  35  expressing  HD.  There  are,  however,  confirmed  cases  of  paternally 
transmitted  mutation  instability  such  that  descendents  of  fathers  with  an  allele  in  this 
intermediate  range  are  known  to  have  inherited  an  expanded  allele  in  the  clinically  affected 
range  (Myers  et  al.,  1993).  A  repeat  size  of  36  to  39  is  considered  indeterminate  as  to 
whether  the  person  will  develop  HD  at  some  time  in  the  future.  It  appears  that  some 
persons  with  repeats  in  this  range  develop  HD  whilst  others  live  into  their  late  90s  without 
evidence  of  disease  development  (Kremer  et  al.,  1994;  McNeil  et  al.,  1997;  Rubinsztein  et 
al.,  1996). 
1.2.1.2  Germline  and  somatic  mutation  length  variability  in  HD 
As  previously  mentioned  (section  1.2.1.1),  a  larger  CAG  repeat  length  is  associated  with  a 
severe  and  early-onset  clinical  picture.  Understanding  the  molecular  mechanism  that 
underlies  mutation  instability  may  help  explain  the  neuropathological  profiles  of  HD. 
The  expanded  CAG  repeat  stretch  exhibits  striking  length-dependent  intergenerational 
instability  in  HD  patients.  Gametic  CAG  repeat  instability  in  HD  patients  (Leeflang  et  al., 
1995;  MacDonald  et  al.,  1993)  and  in  HD  transgenic  (Mangiarini  et  al.,  1997)  and  "knock 
in"  mice  (Shelbourne  et  al.,  1999;  Wheeler  et  al.,  1999)  has  been  reported.  In  contrast, 
limited  mutation  length  variation  has  been  reported  in  somatic  tissues  of  most  HD  patients 
(Benitez  et  al.,  1995;  De  Rooij  et  al.,  1995;  Giovannone  et  al.,  1997;  MacDonald  et  al., 
1993;  Zuhlke  et  al.,  1993),  suggesting  that  gametogenesis  is  the  primary  source  of  mutation 
length  variability. 
In  contrast,  a  number  of  studies  provide  evidence  that  significant  somatic  instability  is 
present  in  HD.  Firstly,  in  one  HD  post-mortem  study,  all  tissues  examined  were  found  to 
display  some  repeat  mosaicism,  with  the  greatest  levels  detected  in  brain  and  sperm. 
Regions  within  the  brain  showing  most  obvious  neuropathology,  such  as  the  basal  ganglia 
and  the  cerebral  cortex,  displayed  the  greatest  mosaicism,  whereas  the  cerebellar  cortex, 
which  is  seldom  involved,  displayed  the  lowest  degree  of  CAG  instability  (Telenius  et  al., 
1994).  Secondly,  the  greatest  levels  of  somatic  instability  have  been  observed  in  the 
striatum  of  HD  mice  with  highly  expanded  CAG  repeats  (Kennedy  and  Shelbourne,  2000; 
28 Mangiarini  et  al.,  1997).  Thus,  it  is  considered  that  somatic  instability  of  the  CAG  mutation 
may  play  a  role  in  the  cell-specificity  of  the  pathological  HD  phenotype. 
The  molecular  mechanism  underlying  germline  and  somatic  repeat  instability  of 
trinucleotide  repeat  mutations  is  not  well  understood.  Although  unequal  sister  chromatid 
exchange  and  template/DNA  polymerase  slippage  during  DNA  replication  have  been 
proposed,  a  recent  study  using  small  pool  PCR  to  detect  (CAG)n  repeat  length  in  a  "knock- 
in"  HD  mouse  model  has  shown  evidence  that  somatic  trinucleotide  repeat  instability  may 
occur  by  mechanisms  that  are  not  replication-based  (Kennedy  and  Shelbourne,  2000).  The 
non-replication  based  mechanism  is  supported  by  the  study  that  the  transgenic  mice 
carrying  exon  1  of  a  mutant  human  HD  genes  on  a  mismatch  repair  deficient  background 
(Msh2-/-)  showed  a  decreased  variation  in  somatic  CAG  repeat  number,  suggesting  that 
Msh2  is  required  for  the  somatic  instability  of  the  CAG  repeat  (Manley  et  al.,  1999).  As 
Msh2  involved  in  the  mismatch-repair  pathway,  this  finding  implies  that  CAG  expansion 
may  occur  when  DNA  undergoes  repair.  Recently,  a  study  showed  that  expansion  is 
neither  a  mitotic  nor  a  meiotic  event  in  male  mouse  germ  cells.  Rather,  expansion  appears 
to  be  a  post-meiotic  event  that  occurs  late  in  elongating  spermatids,  as  they  become 
spermatozoa  (Kovtun  and  McMurray,  2001).  In  this  study,  the  authors  also  showed  that 
Msh2  is implicated  in  both  germline  and  somatic  mutation  expansion  and  proposed  that 
CAG  expansion  in  the  germ  cells  arises  by  gap  repair  and  depends  on  a  complex 
containing  Msh2.  Alternatively,  as  increased  oxidative  damage  has  been  shown  in  the 
striatum  of  HD  patients  (Browne  et  al.,  1997),  it  is  possible  that  oxidative  damage  of  DNA 
may  initiate  DNA  repair  that  lead  to  mutation  expansion. 
1.2.2  The  HD  gene 
1.2.2.1  Expression  patterns  of  HD  gene 
Two  mRNA  species  (sizes:  10.3  kb  and  13.7  kb),  originating  from  the  HD  gene  and  coding 
the  same  huntingtin  protein,  have  been  reported  (Lin  et  al.,  1993).  The  two  transcripts  are 
thought  to  arise  through  differential  polyadenylation,  which  may  constitute  a  mechanism 
that  regulates  huntingtin  expression  through  the  generating  transcripts  with  different 
stabilities.  The  two  main  mRNA  transcripts  from  the  human  HD  gene  are  present  in  most 
29 tissues  (Lin  et  al.,  1993;  Strong  et  al.,  1993),  although  the  larger  transcript  is  more 
abundant  in  human  brain  (Lin  et  al.,  1993).  Many  studies  have  shown  that  the  levels  of  HD 
gene  mRNA  are  highest  in  cortical  layers  II-IV,  the  hippocampus  and  dentate  gyrus,  and 
lower  in  the  area  of  the  basal  ganglia  that  degenerates  first  and  most  profoundly  in  HD 
(Landwehrmeyer  et  al.,  1995;  Lin  et  al.,  1993;  Strong  et  al.,  1993).  Using  in  situ 
hybridisation,  one  study  concluded  that  there  was  little  difference  in  mRNA  expression 
levels  in  normal  and  HD  brain,  except  for  that  which  could  be  accounted  for  by  tissue  loss 
in  the  striatum  (Landwehrmeyer  et  al.,  1995). 
Similar  to  mRNA  studies,  most  protein  studies  also  indicate  ubiquitous  expression  of 
huntingtin  with  higher  levels  in  brain  and  testis  than  in  other  tissues  (Gutekunst  et  al., 
1995;  Sharp  et  al.,  1995;  Trottier  et  al.,  1995).  Among  the  different  regions  of  brain,  the 
cortex  and  cerebellum  appear  to  show  higher  levels  of  huntingtin  protein  than  the  striatum 
(Gutekunst  et  al.,  1995;  Sharp  et  al.,  1995;  Trottier  et  al.,  1995).  Therefore,  the  wide 
pattern  of  the  HD  gene  mRNA  and  huntingtin  protein  expression  in  the  cytoplasm  of  a 
variety  of  neuronal  and  non-neuronal  cells  and  tissues  does  not  readily  account  for  the 
neuronal  specificity  of  HD  pathology. 
More  recently,  it  appears  that  huntingtin  expression  in  the  brain  may  be  more 
heterogeneous  than  suggested  previously  (Ferrante  et  al.,  1997).  The  authors  conclude  that 
the  spiny  striatal  neurons  and  the  matrix  compartment  observed  in  HD  is  associated  with 
higher  levels  of  huntingtin  expression,  whereas  the  large  and  medium  sized  aspiny  neurons 
and  the  striosome  compartments  is  associated  with  lower  levels  of  huntingtin  expression. 
However  these  conclusions  are  not  supported  by  another  study  showing  that  more  severe 
neuronal  loss  was  found  in  the  striosomal  compartments  than  the  matrix  (Hedreen  et  al., 
1995).  Further  investigation  is  needed  to  resolve  these  conflicting  findings. 
Mutant  huntingtin  can  be  distinguished  from  the  wild-type  huntingtin  protein  on  western 
blot  by  virtue  of  its  anomalous  migration  (Aronin  et  al.,  1995;  Ide  et  al.,  1995;  Jou  and 
Myers,  1995;  Persichetti  et  al.,  1995;  Trottier  et  al.,  1995).  Its  increased  size  in  relation  to 
the  wild  type  protein  is  highly  correlated  with  CAG  repeat  expansion  (Aronin  et  al.,  1995). 
Although,  similar  regional  distribution  of  both  mutant  and  wild-type  huntingtin  is  evident, 
several  studies,  using  a  variety  of  antibodies  to  detect  huntingtin,  have  noted  a  modest 
30 reduction  in  relative  expression  level  of  mutant  protein  in  HD  (Gutekunst  et  al.,  1995;  Ide 
et  al.,  1995;  Persichetti  et  al.,  1996;  Trottier  et  al.,  1995).  It  has  also  been  noted  that  the 
degree  of  reduction  in  mutant  huntingtin  level  appeared  to  be  aggravated  by  increasing 
CAG  repeat  allele  length  (Gutekunst  et  al.,  1995).  However,  it  has  also  been  reported  that  a 
longer  repeat  length  can  generate  a  higher  level  of  mutant  huntingtin  protein  expression 
(Aronin  et  al.,  1995).  It  has  been  suggested  that  the  discrepancy  in  the  studies  of  expression 
levels  of  normal  and  mutant  huntingtin  may  be  due  to  a  sensitivity  bias  favouring  detection 
of  the  disease  isoform  by  the  antiserum  used  (Aronin  et  al.,  1995;  Trottier  et  al.,  1995).  In 
summary,  the  relationship  between  the  level  of  huntingtin  expression  and  selective 
vulnerability  to  HD  is  poorly  understood  at  this  time. 
1.2.2.2  Function  of  normal  huntingtin 
The  function  of  huntingtin  protein  remains  unclear.  Elucidating  the  normal  function  of 
huntingtin  may  help  to  understand  some  aspects  of  the  disease  process,  if  loss  of  normal 
huntingtin  function  contributes  to  HD  pathogenesis. 
Immunocytochemical  studies  show  that  huntingtin  is  exclusively  localized  in  the  neuronal 
cytoplasm,  enriched  in  nerve  endings  and  associated  with  synaptic  vesicles  in  the  human 
brain  (DiFiglia  et  al.,  1995;  Gutekunst  et  al.,  1995;  Sharp  et  al.,  1995;  Trottier  et  al.,  1995). 
Biochemical  evidence  suggests  that  wild-type  and  mutant  huntingtin  are  present  in 
cytosolic  soluble  fractions  and  microsomal  membranes  and  associated  with  the 
cytoskeleton  (DiFiglia  et  al.,  1995;  Gutekunst  et  al.,  1995;  Wood  et  al.,  1996). 
Immunofluorescence  studies  suggest  that  huntingtin  co-localizes  with  the  transferrin 
receptor,  coated  vesicles  in  cytoplasm  and  multivesicular  bodies  that  are  part  of  an 
endosomal-lysosomal  system  and  enriched  in  Golgi  apparatus  (Sapp  et  al.,  1997;  Velier  et 
al.,  1998).  Huntingtin  also  appear  to  be  associated  with  microtubules  and  synaptic  vesicles 
suggesting  that  it  plays  a  role  in  intracellular  organelle  trafficking  or  fast  axonal  transport 
(Sapp  et  al.,  1997;  Tukamoto  et  al.,  1997). 
Studies  using  mouse  models  in  which  targeted  disruption  of  both  mouse  Hdh  alleles  leads 
to  death  of  embryos  in  uterus  between  embryonic  day  7.5  and  10.5,  have  indicated  that 
huntingtin  plays  a  role  in  embryonic  development  during  gastrulation  (Duyao  et  al.,  1995; 
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appear  to  cause  any  overt  abnormalities  in  some  mouse  lines  (Duyao  et  al.,  1995;  Zeitlin  et 
al.,  1995),  neuronal  loss  and  degeneration  in  the  subthalamus  and  globus  pallidus  has  been 
reported  in  another  mutant  line  with  heterozygous  loss  of  huntingtin  (Nasir  et  al.,  1995; 
O'Kusky  et  al.,  1999).  Furthermore,  in  a  mouse  model  where  Hdh  expression  is 
conditionally  inactivated  at  two  developmental  time  points  (after  embryonic  day  15  and 
after  postnatal  day  5),  elimination  of  Hdh  expression  in  the  brain  and  testis  leads  to 
neuronal  degeneration,  motor  phenotypes,  early  mortality  and  sterility,  suggesting  an 
important  role  of  huntingtin  in  postnatal  neuronal  survival  (Dragatsis  et  al.,  2000).  In  cell 
culture,  it  has  been  shown  that  wild-type  huntingtin  up-regulates  transcription  of  brain- 
derived  neurotrophic  factor  (BDNF),  a  pro-survival  factor  produced  by  cortical  neurons 
and  necessary  for  survival  of  striatal  neurons  (Zuccato  et  al.,  2001).  When  huntingtin 
become  mutated,  the  up-regulation  benefit  appears  to  be  lost,  cortical  BDNF  production  is 
decreased  and  striatal  neurons  are  compromised  (Zuccato  et  al.,  2001).  Evidence  of  a  role 
for  wild-type  huntingtin  in  decreasing  the  cellular  toxicity  of  mutant  huntingtin  in  vivo 
(Leavitt  et  al.,  2001)  and  in  vitro  (Ho  et  al.,  2001;  Rigamonti  et  al.,  2000;  Rigamonti  et  al., 
2001)  has  also  been  shown.  Over-expression  of  normal  huntingtin  significantly  attenuates 
neuronal  toxicity  induced  by  both  NMDA  receptor  agonists  and  mutated  huntingtin  (Sun  et 
al.,  2001).  Taken  together,  these  findings  suggest  that  huntingtin  may  be  critical  both  in 
embryogenesis  and  in  neuronal  survival  in  the  adult. 
1.2.3  The  molecular  pathology  of  HD 
1.23.1  Gain  of  function  of  mutant  huntingtin  protein 
Several  human  homozygous  HD  patients  have  provided  evidence  to  support  the  notion  that 
homozygous  HD  individuals  are  no  more  severely  affected  than  their  heterozygous  HD 
sibs  (Myers  et  aL,  1989;  Wexler  et  al.,  1987).  This  observation  is  compatible  with  the 
theory  of  a  gain  of  function  resulting  from  the  mutant  huntingtin  protein. 
Heterozygous  loss  of  huntingtin  in  mice  does  not  appear  to  cause  any  overt  abnormalities, 
indicating  that  loss  of  one  HD  gene  copy  does  not  generate  the  same  phenotype  as  human 
heterozygous  HD  patients  (Duyao  et  al.,  1995;  Zeitlin  et  al.,  1995).  This  finding  also 
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evidence  is  provided  by  a  human  case  of  a  chromosome  4  translocation  that  results  in 
deletion  of  a  copy  of  HD  gene  without  HD  symptoms  (Ambrose  et  al.,  1994).  More  direct 
evidence  comes  from  transgenic  HD  mouse  models.  For  example,  R6/2  mice  that  express 
exon  1  of  the  mutant  human  HD  gene  (in  addition  to  their  two  endogenous  Hdh  genes) 
have  a  progressive  neurological  phenotype  and  neuropathology  reminiscent  of  human  HD 
(Mangiarini  et  al.,  1996). 
1.2.3.2  Loss  of  function  of  normal  huntingtin  in  HD  pathogenesis 
As  previously  mentioned,  huntingtin  may  be  critical  to  neuronal  survival  in  the  adult 
because  of  its  ability  to  up-regulate  BDNF  levels  and  decrease  the  toxicity  of  mutant 
huntingtin  (section  1.2.2.2).  In  addition,  when  cultured  CNS  cells  overexpressing  full- 
length  mutant  huntingtin  were  exposed  to  apoptotic  stimuli,  levels  of  endogenous  full- 
length  wild-type  huntingtin  as  well  as  BDNF  production  were  reduced  (Zuccato  et  al., 
2001).  Further  studies  in  a  symptomatic  transgenic  HD  mouse  model  have  revealed 
decreased  levels  of  full-length  huntingtin  expression  probably  due  to  the  activation  of  an 
apoptotic  cascade  that  increases  endogenous  huntingtin  cleavage  (Ona  et  al.,  1999). 
Therefore,  these  findings  highlight  the  possibility  that  loss  of  wild-type  huntingtin's 
function  may  also  contribute  to  the  disease  phenotype  of  HD. 
1.233  Intracellular  aggregates  in  HD  brain  tissue 
One  feature  of  mutant  huntingtin  is  its  tendency  to  form  intracellular  aggregates,  especially 
following  proteolytic  cleavage.  R6/2  mice  that  express  exon  1  of  the  mutant  human  HD 
gene  were  found  to  develop  pronounced  intranuclear  aggregates  termed  neuronal 
intranuclear  inclusions  (NIIs),  containing  mutant  huntingtin  protein  and  ubiquitin,  prior  to 
developing  a  neurological  phenotype  (Davies  et  al.,  1997).  NIIs  appear  as  roughly  circular 
pale  structures  easily  identified  in  toluidine  blue-stained  semithin  sections,  with  no 
membrane  separating  the  inclusion  from  the  surrounding  nuclear  matrix.  The  NIIs  appear 
to  be  composed  of  fine  granular  material  with  occasional  filamentous  structures.  Such 
aggregates  can  be  formed  in  transfected  yeast  and  cell  cultures  (Cooper  et  al.,  1998; 
Krobitsch  and  Lindquist,  2000;  Li  and  Li,  1998;  Martindale  et  al.,  1998;  Saudou  et  al., 
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different  length  and  CAG  repeat  sizes  (Hodgson  et  al.,  1999;  Li  et  al.,  2000a;  Reddy  et  al., 
1998;  Schilling  et  al.,  1999;  Wheeler  et  al.,  2000;  Yamamoto  et  al.,  2000)  and  in  the  brains 
of  HD  patients  (Becher  et  al.,  1998;  DiFiglia  et  al.,  1997;  Gutekunst  et  al.,  1999;  Sieradzan 
et  al.,  1999). 
Antibodies  against  internal  regions  of  human  huntingtin  (amino  acids  549-670)  do  not 
reveal  huntingtin  aggregates,  suggesting  that  aggregates  are  mostly  composed  of  N- 
terminal  huntingtin  fragments  (Becher  et  al.,  1998;  DiFiglia  et  al.,  1997;  Sieradzan  et  al., 
1999)).  However,  in  addition  to  truncated  huntingtin  fragments,  full-length  mutant  and 
wild-type  huntingtin  can  also  be  recruited  into  nuclear  aggregates  (Wheeler  et  al.,  2000). 
NIIs  are  frequently  present  in  the  striatum,  putamen  and  cortex  of  HD  brains,  but  are  rarely 
seen  in  the  hippocampus,  red  nucleus,  cerebellum  and  other  brain  areas  (Becher  et  al., 
1998;  Sieradzan  et  al.,  1999).  They  appear  to  be  present  in  the  nuclei  of  neurons  but  not 
astrocytes.  Similar  aggregates  are  also  present  in  the  neuropil  (neuropil  aggregates)  or 
dystrophic  neurites  in  both  human  and  mouse  HD  brains  (DiFiglia  et  al.,  1997;  Li  et  al., 
1999b;  Li  et  al.,  2000a;  Maat-Schieman  et  al.,  1999;  Schilling  et  al.,  1999). 
The  presence  of  huntingtin  aggregates  in  brains  of  HD  patients  and  most  HD  mice  raise  the 
possibility  that  such  aggregates  may  play  a  role  in  HD  pathogenesis.  NIIs  in  HD  brains 
may  interfere  with  nuclear  activity  and  lead  to  neuronal  dysfunction.  The  presence  of 
neuropil  aggregates  suggests  that  they  may  be  responsible  for  the  degenerative  dendritic 
and  exonal  changes  that  lead  to  functional  alteration  in  HD  and  the  evidence  is  discussed  in 
later  sections. 
1.2.3.3.1  Mechanism  of  formation  of  aggregates 
The  hypothesis  that  glutamine  repeats  may  form  a  stable  beta-pleated  sheet  via  a  so-called 
"polar  zipper"  held  together  by  hydrogen  bonds  has  been  postulated  for  the  formation  of 
aggregates  (Perutz,  1996).  In  vitro  experiments  (Scherzinger  et  al.,  1997)  have  shown  that 
N-terminal  huntingtin  with  an  expanded  polyglutamine  stretch  can  form  insoluble 
aggregates  with  the  characteristics  of  beta-pleated  sheets.  This  mechanism  operates  above 
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repeat  length  associated  with  the  presentation  of  HD  symptoms. 
Another  hypothesis  postulates  that  aggregate  formation  is  the  result  of  a  tissue 
transglutaminase  (tTG)-catalysed  reaction.  Because  a  polypeptide  bound  glutamine  is  a 
tTG  substrate,  it  has  been  suggested  that  the  addition  of  glutamine  residues  beyond  a 
threshold  length  may  result  in  a  protein  becoming  a  tTG  substrate  causing  formation  of 
isopeptide  bonds  and  insoluble  aggregates  through  crosslinking  (Kahlem  et  al.,  1998).  In 
support  of  this  hypothesis  is  the  fact  that  tTG  activity  and  tTG  levels  are  elevated  in  brain 
regions  affected  in  HD  (Karpuj  et  al.,  1999;  Lesort  et  al.,  1999)  and  that  in  vitro,  mutant 
huntingtin  and  polyglutamine  tract  peptides  are  good  tTG  substrates  (Cooper  et  al.,  1997; 
Kahlem  et  al.,  1996).  However,  the  distribution  of  aggregates  in  HD  brains  (Vonsattel  and 
DiFiglia,  1998)  does  not  correlate  well  with  the  observed  increases  in  tTG  levels  and 
activity  (Karpuj  et  al.,  1999;  Lesort  et  al.,  1999).  Further  studies  in  cell  culture  models 
have  revealed  that  tTG  is  totally  excluded  from  the  huntingtin  aggregates,  and  modification 
of  the  tTG  expression  level  had  no  effect  on  the  frequency  of  the  aggregates  (Chun  et  al., 
2001).  Therefore,  tTG  does  not  appear  to  be  required  for  the  formation  of  aggregates,  and 
likely  does  not  play  a  role  in  the  aggregation  process  of  huntingtin.  Further  studies  need  to 
explore  the  role  of  increased  tTG  in  HD. 
1.2.3.4  Are  intracellular  aggregates  toxic  or  protective  to  neurons? 
A  number  of  studies  have  demonstrated  that  intracellular  aggregates  are  toxic  and  hence 
pathogenic  in  HD.  However,  accumulated  evidence  also  suggests  that  the  intracellular 
aggregates  may  be  protective  rather  than  toxic  to  cells.  The  supported  and  against  evidence 
is  discussed  in  the  following  sections. 
1.2.3.4.1  Evidence  supporting  toxic  intracellular  aggregates 
In  vitro  studies  have  indicated  that  various  N-terminal  fragments  of  mutant  huntingtin, 
rather  than  the  full-length  mutant  huntingtin,  can  form  aggregates  in  cytoplasm  and  nuclei, 
and  that  aggregation  is  prompted  by  lengthening  the  glutamine  repeat  and  by  shortening 
the  huntingtin  amino  acid  sequence  (Cooper  et  al.,  1998;  Li  and  Li,  1998;  Martindale  et  al., 
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to  apoptotic  stress,  which  is  greater  with  increasing  polyglutamine  size,  decreasing  protein 
length  and  formation  of  aggregates.  These  studies  suggest  that  the  formation  of  aggregates 
may  mediate  the  cellular  vulnerability  to  apoptotic  stress. 
Transgenic  mouse  studies  have  shown  that  the  progressive  appearance  of  neuropil 
aggregates  is  highly  correlated  with  the  development  of  neurological  symptoms  (Li  et  al., 
1999b).  Further  studies  also  showed  that  huntingtin  aggregates  selectively  accumulate  in 
striatal  medium  spiny  neurons  and  are  associated  with  synaptic  vesicles  in  axonal 
terminals,  in  `knock  in'  HD  mice  (Li  et  al.,  2000a).  It  was  also  shown  that  glutamate 
uptake  by  synaptic  vesicles  was  inhibited  by  N-terminal  fragments  of  mutant  huntingtin  in 
vitro.  These  findings  suggest  that  intracellular  aggregates  may  contribute  to  the  neuronal 
dysfunction  in  HD. 
In  a  Drosophila  HD  model,  co-expression  of  an  expanded-polyglutamine  tract  with  a 
bivalent  artificial  huntingtin  binding  polypeptide  could  delay  and  limit  the  appearance  of 
aggregates  and  inhibit  both  adult  lethality  and  photoreceptor  neuron  degeneration 
(Kazantsev  et  al.,  2002).  The  results  also  demonstrate  a  strong  correlation  between  the 
accumulation  and  aggregation  of  polyglutamine  protein  and  subsequent  degeneration, 
showing  that  a  delay  in  the  formation  of  aggregates  caused  by  the  suppressor  is  highly 
correlated  with  protection  from  degeneration. 
1.2.3.4.2  Evidence  supporting  non-toxic  intracellular  aggregates 
However,  there  is  also  evidence  that  nuclear  accumulation  of  the  N-terminally  truncated 
mutant  huntingtin  rather  than  aggregates  per  se,  can  lead  to  cell  dysfunction  or  death. 
Indeed,  suppression  of  NII  formation  can  increase  cell  death  in  vitro,  suggesting  that  Nils 
may  be  consequences  of  neuroprotective  packaging  of  the  toxic  soluble  huntingtin 
fragments  into  less  toxic  insoluble  aggregates  (Kim  et  al.,  1999a;  Saudou  et  al.,  1998). 
Also  studies  of  a  transgenic  mouse  model  of  spinocerebellar  ataxia  1  (SCA1)  have  shown 
that  absence  of  ataxin-1  in  the  nucleus  as  a  result  of  a  co-existing  mutated  nuclear 
localization  signal,  results  in  no  pathological  changes  in  their  Purkinje  cells  (Klement  et 
al.,  1998).  In  contrast,  SCA1  transgenic  mice  with  a  deletion  in  the  self-association  region 
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formation  was  completely  blocked  and  only  soluble  ataxin-1  was  present  in  the  nucleus. 
In  HD  post-mortem  brains,  the  distribution  of  huntingtin  aggregates  does  not  correspond 
well  to  the  location  of  neuropathology.  Interestingly,  there  is  a  significant  positive 
correlation  between  nuclear  inclusion  abundance  and  CAG  repeat  length  in  the  cortex  of 
human  HD  brains  but  not  in  the  striatum  (Sieradzan  et  al.,  1999).  Furthermore,  NIIs  appear 
to  be  more  frequent  in  the  cortex  than  in  striatum  in  all  pathological  grades  of  HD 
(DiFiglia  et  al.,  1997;  Gutekunst  et  al.,  1999;  Sieradzan  et  al.,  1999).  In  addition,  it  has 
been  shown  that  most  of  the  nuclear  aggregates  in  post-mortem  striatum  are  observed  in 
populations  of  interneurons  that  are  spared  in  HD  (Kuemmerle  et  al.,  1999).  Collectively, 
these  findings  suggest  that  huntingtin  aggregates  per  se  may  not  be  responsible  for 
initiating  the  pathological  changes  in  HD. 
1.2.3.5  Toxic  fragment  versus  full-length  huntingtin  hypothesis  of  HD 
pathogenesis 
The  "toxic  gain  of  function"  theory  postulates  that  the  expanded  polyglutamine  causes  a 
conformation  change  and  confers  novel  properties  on  the  mutant  huntingtin  proteins,  which 
may  finally  cause  detrimental  effects  on  cells.  It  is  not  clear  whether  the  pathogenic 
properties  act  at  the  level  of  the  full-length  mutant  protein  or  only  after  its  truncation  or 
both. 
1.2.3.5.1  Toxic  fragment  hypothesis  of  HD  pathogenesis 
The  toxic  fragment  hypothesis  postulates  that  huntingtin  is  cleaved  within  cells  by  a 
caspase  or  other  protease  into  a  short  protein  fragment  containing  the  polyglutamine  tract, 
which  is  toxic  to  cells  (Wellington  et  al.,  1998).  An  increasing  body  of  evidence,  showing 
that  pure  polyglutamine  tracts  or  protein  fragments  containing  glutamine  tracts  may  be 
toxic  to  cells,  is  summarized  in  the  following  paragraph. 
Cells  transfected  with  the  truncated  huntingtin  constructs,  when  exposed  to  apoptotic 
stimuli  display  higher  levels  of  death  compared  with  cells  that  expressed  full-length 
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Martindale  et  al.,  1998).  These  studies  also  showed  that  in  both  truncated  and  full-length 
constructs,  increasing  toxicity  is  associated  with  longer  polyglutamine  tracts.  HD  mouse 
models  expressing  truncated  N-terminal  fragments  of  mutant  huntingtin  have  more  rapidly 
progressing  phenotypes  than  those  expressing  full-length  mutant  protein  (see  section  1.4). 
These  findings  support  the  idea  that  truncated  mutant  huntingtin  fragments  play  an 
important  role  in  pathogenesis. 
Moreover,  HD  post-mortem  studies  have  demonstrated  that  N-terminal  fragments  of 
mutant  huntingtin  can  be  detected  in  NIIs,  suggesting  that  huntingtin  proteolysis  may  occur 
in  vivo  (DiFiglia  et  al.,  1997;  Sieradzan  et  al.,  1999).  Occurrence  of  huntingtin  proteolysis 
is  evident  by  the  presence  of  caspase-3  cleaved  N-terminal  fragments  of  wild-type  in 
brains  of  normal  individuals  and  HD  patients  as  well  as  such  fragments  of  mutant 
huntingtin  in  HD  patients  (Kim  et  al.,  2001).  Further  supporting  studies  demonstrated  that 
a  distinct  pattern  of  huntingtin  fragments  generated  by  a  protease  acting  on  protease- 
susceptible  domains  of  huntingtin  exists  in  human  striatum  and  human  HD  striatum 
showed  elevated  levels  of  cleaved  N-  and  C-terminal  fragments  compared  with  those  in 
controls  (Mende-Mueller  et  al.,  2001). 
Huntingtin  does  appear  to  be  a  substrate  for  caspase  cleavage  and  the  rate  of  cleavage  by 
apopain  (a  proapoptotic  cysteine  protease)  increases  with  the  length  of  the  huntingtin 
polyglutamine  tract  (Goldberg  et  al.,  1996).  It  has  also  been  demonstrated  that  huntingtin 
contains  at  least  two  caspase-3  and  one  caspase-1  cleavage  sites  and  when  cleaved  by 
caspase  1  or  caspase  3,  a  polyglutamine-containing  fragment  from  huntingtin  is  released 
(Wellington  et  al.,  1998).  Further  studies  have  shown  that  inhibiting  caspase  cleavage  of 
huntingtin  by  mutagenizing  the  cleavage  sites  reduces  toxicity  in  apoptotically  stressed 
neuronal  and  non-neuronal  cells  (Wellington  et  al.,  2000).  Caspase  inhibitors  significantly 
increased  cell  survival  in  clonal  striatal  cells  expressing  mutant  huntingtin  (Kim  et  al., 
1999a).  Further  studies  have  demonstrated  that  caspase-1  is  activated  in  HD  brains  and 
transgenic  HD  mice  (R6/2)  and  that  inhibiting  its  activity  reduced  endogenous  huntingtin 
cleavage  in  HD  mice  (Ona  et  al.,  1999).  Inactivation  of  caspase-1  also  slowed  the 
progression  of  pathological  features  in  R6/2  mice  (Chen  et  al.,  2000;  Ona  et  al.,  1999). 
However,  R6/2  mice  do  not  have  caspase-1  cleavage  sites  in  their  mutant  huntingtin 
38 protein,  so  it  is  possible  that  inhibition  of  caspase-1  acts  in  general  inhibition  of  pro- 
apoptotic  pathways  rather  than  increasing  the  cleavage  of  huntingtin. 
The  susceptibility  of  huntingtin  to  cleavage  by  caspase  provides  a  mechanism  for 
generating  polyglutamine  fragments,  which  then  may  lead  to  cell  toxicity.  However,  it  is 
not  clear  whether  the  caspase  cleavage  of  huntingtin  is  directly  involved  in  the  disease  or 
the  polyglutamine  acts,  indirectly  by  harbouring  sites  for  caspase  that,  in  turn,  trigger 
apoptosis  when  sequestered  into  aggregates. 
1.2.3.5.2  Does  full-length  mutant  huntingtin  contribute  to  HD  pathogenesis? 
Although  accumulated  evidence  suggests  that  truncated  mutant  huntingtin  is  more  toxic  to 
cells  than  full-length  mutant  huntingtin,  several  studies  suggest  that  the  expanded 
polyglutamine  tract  triggers  HD  pathogenesis  in  the  context  of  full-length  protein.  In  one 
"knock-in"  HD  mouse  model,  the  expanded  polyglutamine  tract  appears  to  alter  mutant 
huntingtin  conformation  and  changes  its  mobility  and  reactivity  with  IFS  (an  antibody 
specific  for  long  soluble  polyglutamine  tract)  (Wheeler  et  al.,  2000).  The  authors  also 
provided  evidence  supporting  a  scenario  in  which  medium  spiny  neurons,  rather  than  large 
interneurons,  can  promote  the  formation  of  a  distinct  version  of  full-length  huntingtin  with 
an  accessible  N-terminus,  rather  than  stable  cleaved  N-  and  C-terminal  products.  In  this 
scenario,  the  N-terminal  accessible  version  of  the  protein  appears  to  be  redistributed  to  the 
nucleus  in  mutant  medium  spiny  neurons.  The  formation  of  nuclear  inclusions  and 
insoluble  aggregates  occurs  at  a  much  later  stage.  The  authors  conclude  that  the  altered 
structure  imposed  on  the  `exposed'  N-terminus  by  an  elongated  polyglutamine  stretch  may 
facilitate  the  interaction  of  huntingtin  with  other  critical  cellular  constituents  and/or  it  may 
lead  to  devastating  consequences  via  gradual  loss  of  an  essential  function  of  huntingtin  in 
mature  striatal  spiny  neurons.  This  finding  may  provide  a  link  between  mutant  huntingtin 
and  selective  vulnerability  in  HD  and  suggests  that  mutant  full-length  huntingtin  and 
partial  loss  of  normal  huntingtin  may  both  play  a  role  in  HD  pathogenesis. 
Further  studies  have  shown  that  full-length  mutant  huntingtin  is  more  resistant  to 
proteolysis  than  normal  huntingtin  and  N-terminal  cleavage  fragments  arising  from  the 
processing  of  normal  huntingtin  in  affected  HD  brain  are  sequestrated  by  full-length 
39 mutant  huntingtin  (Dyer  and  McMurray,  2001).  These  findings  support  a  model  in  which 
the  expanded  polyglutamine  tract  alters  the  protein's  solubility  and  renders  the  mutant 
protein  resistant  to  proteolysis,  This,  in  turn,  allows  the  full-length  mutant  protein  to 
accumulate  and  trigger  subsequent  pathological  changes. 
Although  full-length  mutant  huntingtin  may  be  able  to  initiate  neuropathological  changes 
in  HD,  the  toxic  fragment  theory  can't  be  ruled  out.  Indeed,  a  recent  study  showed  that  the 
HD  disease  process,  initiated  by  full-length  mutant  protein,  is  hastened  by  co-expression  of 
mutant  fragment  (Wheeler  et  al.,  2002).  Therefore,  full-length  and  truncated  mutant 
huntingtin  may  both  contribute  to  HD  pathogenesis. 
1.2.3.6  Chaperones,  the  ubiquitin-proteasome  pathway  and  HD  pathogenesis 
It  has  become  increasingly  well  documented  that  the  expansion  of  a  glutamine  tract  to  a 
length  within  the  pathogenic  range  results  in  the  misfolding  of  the  protein.  This  concept  is 
strongly  supported  by  several  reports  demonstrating  that  nuclear  aggregates  of 
polyglutamine  proteins  are  ubiquitinated  (Davies  et  al.,  1997;  DiFiglia  et  al.,  1997). 
Degradation  of  most  proteins  by  the  proteasome  requires  the  conjugation  of  multiple 
ubiquitin  molecules.  Ubiquitinated  proteins  are  then  recognized  and  hydrolysed  by  the  26S 
proteasome  (Schwartz  and  Ciechanover,  1999).  In  addition  to  ubiqutitin,  nuclear 
aggregates  have  been  shown  to  contain  chaperone  proteins,  including  HSP40  and  HSP70 
heat  shock  proteins  and  components  of  the  proteasome  system  in  vitro  (Chaff  et  al.,  1999; 
Cummings  et  al.,  1998;  Stenoien  et  al.,  1999)  and  in  vivo  (Chai  et  al.,  1999;  Warrick  et  al., 
1999)]. 
In  cell  cultures,  polyglutamine  aggregates  appear  to  sequester  heat  shock  proteins, 
proteasome  components  and  nuclear  proteins  and  are  suppressed  by  over  expression  of  the 
HDJ-2  chaperone  vitro  (Cummings  et  al.,  1998;  Stenoien  et  al.,  1999)  with  a  parallel 
decrease  in  cytotoxicity  (Chai  et  al.,  1999).  HDJ-2  and  HSC70  also  co-localize  with  NIIs 
r  in  brains  of  R6/2  HD  mice  and  over-expression  of  HDJ-1  and  HSC70  can  suppress  the 
formation  of  aggregates  and  cellular  toxicity  in  cell  culture  (Jana  et  al.,  2000).  Hence,  most 
of  the  studies  support  the  postulation  that  aggregates  accumulate  when  the  capacity  of  the 
ubiquitin-proteasome  system  to  degrade  misfolded  huntingtin  is  exhausted  and  over- 
40 expression  of  some  chaperones  may  promote  the  degradation  of  misfolded  huntingtin  and 
reduce  cell  toxicity.  Such  proposals  have  also  been  supported  by  studies  in  SCA1  mice. 
When  SCA1  mice  were  crossbred  with  mice  over-expressing  a  molecular  chaperone 
(inducible  HSP70),  high  levels  of  HSP70  in  the  resulting  progeny  indeed  afforded 
protection  against  neurodegeneration  (Cummings  et  al.,  2001). 
However,  aggregate  formation  is  not  always  inhibited  by  over-expression  of  heat  shock 
protein  in  some  systems.  For  example,  over-expression  of  heat  shock  protein  40  (HDJ-2) 
increases  polyglutamine  inclusion  formation  in  COS-7  cells  expressing  N-terminal 
fragment  of  huntingtin  (Wyttenbach  et  al.,  2000).  Furthermore,  while  directed  expression 
of  HSP70  suppressed  polyglutamine-induced  neurodegeneration  in  a  Drosophila  model  of 
Machado-Joseph  disease,  it  did  not  have  a  visible  effect  on  NII  formation  (Warrick  et  al., 
1999).  Further  studies  demonstrated  that  chaperone-suppressed  cellular  toxicity  of  mutant 
huntingtin  is  independent  of  polyglutamine  aggregates,  but  probably  is  mediated  through 
its  inhibition  of  caspase-3  and  caspase-9  activity  (thou  et  al.,  2001).  These  findings 
suggest  that  evaluating  the  therapeutic  effects  of  drugs  on  HD  pathology  should  not  be 
solely  based  on  their  ability  to  inhibit  huntingtin  aggregation,  since  aggregates  may  not  be 
pernicious  to  cells. 
1.2.3.7  Interaction  of  huntingtin  with  cytoplasmic  proteins 
It  has  been  suggested  that  selective  neuropathological  changes  in  HD  may  relate  to 
aberrant  cell  type-specific  protein  interactions  of  the  mutant  huntingtin  protein.  If  such 
interactions  are  involved  in  HD  pathogenesis,  it  could  be  the  regional  expression  of  these 
proteins  and/or  the  different  lengths  of  polyglutamine  tract  in  different  tissues  that 
determine  the  selective  pattern  of  neurodegeneration. 
A  number  of  huntingtin-interacting  proteins  including  glyceraldehyde-3-phosphate 
dehydrogenase  (Burke  et  al.,  1996),  calmodulin  (Bao  et  al.,  1996),  huntingtin-interacting 
proteinl  (HIP1)  (Kalchman  et  al.,  1997;  Wanker  et  al.,  1997),  huntingtin-interacting 
protein2  (HIP2)  (Kalchman  et  al.,  1996),  huntingtin-associated  protein  1(HAP1)  (Li  et  al., 
1995),  huntingtin-associated  protein  40  (HAP40)  (Peters  and  Ross,  2001),  WW  domain 
41 proteins  (Faber  et  al.,  1998),  cystathionine  ß-synthase  (Boutell  et  al.,  1998)  and  SH3 
containing  Grb-like  protein  (SH3GL3)  (Sittler  et  al.,  1998)  have  been  identified. 
Glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)  has  been  shown  to  interact  directly 
with  the  polyglutamine  tract  of  huntingtin  (Burke  et  al.,  1996).  GAPDH  appears  to  interact 
preferentially  with  smaller  fragments  of  huntingtin  as  opposed  to  the  full-length  huntingtin 
and  preferentially  with  long  lengths  of  polyglutamine  (Burke  et  al.,  1996).  The  strong 
evidence  for  energy  impairment  in  HD  makes  the  association  with  GAPDH  intriguing. 
Such  an  interaction  may  be  the  initial  step  in  the  impairment  of  glycolysis  in  HD.  Although 
post-mortem  HD  studies  have  shown  that  the  activity  of  GAPDH  is  normal  in  brain  tissues 
(Browne  et  al.,  1997;  Kish  et  al.,  1998;  Tabrizi  et  al.,  1999),  further  studies  analysing 
GAPDH  activity  of  subcellular  fractions  demonstrated  that  the  GAPDH  activity  is  reduced 
in  the  nuclear  fraction  of  fibroblasts  from  HD  patients  despite  unchanged  GAPDH  gene 
expression  (Mazzola  and  Sirover,  2001).  Since  GAPDH  is  a  multifunctional  enzyme  with 
roles  in  glycolysis,  DNA  repair  and  replication  and  programmed  cell  death  (Ronai,  1993), 
the  reduction  of  GAPDH  activity  in  the  nucleus  may  cause  impaired  energy  production  and 
the  promotion  of  apoptosis. 
HIP1  is  the  human  orthologue  of  a  yeast  protein  (Sla2p)  with  a  known  role  in  membrane 
and  cytoskeleton  function.  HIP1  is  expressed  throughout  the  brain  with  highest  levels  in 
the  cortex  and  is  present  in  peripheral  tissues  at  low  to  moderate  levels  (Kalchman  et  al., 
1997;  Wanker  et  al.,  1997).  The  interaction  between  HIP1  and  huntingtin  is  modulated  by 
CAG  repeat  length  with  preferential  binding  to  the  smaller  size  of  polyglutamine  stretch 
(blanker  et  al.,  1997).  Recently,  HIP1  has  been  shown  to  be  an  endocytic  protein, 
functioning  in  clathrin-mediated  endocytosis  through  binding  to  clathrin  and  adaptor 
protein  2  (Metzler  et  al.,  2001).  The  structural  integrity  of  HIP1  is  crucial  for  maintaining 
normal  clathrin-coated  vesicle  size  and  function  (Waelter  et  al.,  2001).  HIP1  may 
participate  in  the  transport  of  endocytic  vesicles  to  target  organelles  in  the  cells.  Since 
normal  huntingtin  is  more  strongly  bound  to  HIP1  than  mutant  huntingtin,  it  is  possible 
that  huntingtin  is  important  in  endocytosis  and  mutant  huntingtin  may  compromise  this 
activity.  HIP1  is  also  a  pro-apoptotic  protein  and  over-expression  in  vitro  results  in  rapid 
caspase-3-dependent  cell  death  via  the  intrinsic  pathway  of  apoptosis  (Hackam  et  al., 
2000).  It  has  been  suggested  that  the  association  of  normal  huntingtin  attenuates  the  pro- 
42 apoptotic  actions  of  HIP1.  Further  studies  support  this  proposal  (Gervais  et  al.,  2002).  The 
authors  identified  a  novel  partner  for  HIP1,  called  Hippi  (HIP1  protein  interactor).  The 
presence  of  mutant  huntingtin  favours  the  formation  of  Hippi-HIP1  oligomers  that  can 
recruit  procaspase-8  to  form  a,  complex  of  Hippi,  HIP-1,  and  procaspase-8  and  launch  the 
apoptosis  pathway. 
HAP1  is  predominantly  a  membrane-associated  protein  that  shows  a  subcellular 
distribution  profile  similar  to  synaptophysin,  suggesting  that  HAP1  associated  with  the 
cytoskeleton  or  synaptic  vesicles  (Li  et  al.,  1995).  In  contrast  to  HIP1,  the  interaction 
between  huntingtin  and  HAP1  is  modulated  in  the  opposite  direction.  HAP1  has  increased 
affinity  for  huntingtin  with  increasing  polyglutamine  length  (Li  et  al.,  1995).  Northern  blot 
analysis  shows  that  expression  of  HAP1  mRNA  in  human  is  limited  to  the  brain,  with 
maximal  expression  in  the  caudate,  cortex  and  hippocampus  and  lower  level  in  cerebellum 
(Li  et  al.,  1996).  HAP  1  is  expressed  in  several  brain  regions  in  a  manner  that  is  similar  to 
nitric  oxide  synthase  (nNOS),  an  enzyme  involved  in  the  synthesis  of  nitric  oxide  (NO). 
The  correlation  of  HAPI  and  nNOS  expression  pattern  suggests  that  the  enhanced 
interaction  of  mutant  huntingtin  with  HAP1  might  increase  the  synthesis  of  NO  and  render 
certain  neuronal  populations  more  susceptible  to  excitotoxicity  (Li  et  al.,  1996). 
The  HIP2  gene  encodes  human  ubiquitin-conjugating  enzyme,  hE2-25K  (Chen  and 
Pickart,  1990).  E2  ubiquitinating  enzymes  have  known  roles  in  the  turnover  of  abnormal 
proteins.  The  interaction  between  HIP2  and  huntingtin  is  not  influenced  by  CAG  length 
(Kalchman  et  al.,  1996).  hE2-25K  is  expressed  in  all  assessed  human  tissues  but  enriched 
in  brain.  The  interaction  of  hE2-25K  with  huntingtin  may  provide  important  clues  to  the 
regulated  metabolism  of  huntingtin  protein.  However,  whether  the  interaction  influence  the 
intracellular  processing  of  mutant  huntingtin  is  not  clear. 
Huntingtin  from  HD  brains  appears  to  bind  calmodulin  more  avidly  than  wild-type 
huntingtin  (Bao  et  al.,  1996).  Calmodulin  is  an  intermediate  in  many  calcium-mediated 
signalling  pathways.  Many  cellular  processes  such  as  vesicle  transport  or  fusion  are 
calcium  dependent  and  altered  regulation  of  protein  interactions  in  this  process  may  have 
deleterious  consequences. 
43 Recently,  HAP40  was  identified  as  a  40-kDa  protein  encoded  within  intron  22  of  the  factor 
VIII  gene  (Peters  and  Ross,  2001).  In  the  presence  of  normal  huntingtin,  HAP40  is located 
in  the  cytosol.  However,  in  the  absence  of  huntingtin,  HAP40  is  actively  transferred  to  the 
nucleus  (Peters  and  Ross,  2001).  Although,  the  repercussions  of  the  relationship  between 
HAP40  and  huntingtin  are  not  clear,  these  data  indicate  that  HAP40  may  contribute  to  the 
function  of  normal  huntingtin  and  is  a  candidate  for  involvement  in  the  aberrant  nuclear 
localization  of  mutant  huntingtin  found  in  HD. 
Cystathionine  ß-synthase  has  been  shown  to  specifically  bind  to  huntingtin  but  not  other 
polyglutamine-containing  proteins  (Boutell  et  al.,  1998).  However,  the  interaction  between 
huntingtin  and  cystathionine  ß-synthase  is  independent  of  polyglutamine  repeat  length. 
Cystathionine  ß-synthase  is  a  key  enzyme  in  the  generation  of  cysteine  from  methionine. 
Absence  of  cystathionine  ß-synthase  is  associated  with  homocysteinuria,  an  autosomal 
recessive  disorder,  characterized  by  mental  retardation,  developmental  delay,  seizures  and 
psychiatric  disorders.  Two  of  the  oxidation  products  of  homocysteine,  L-homocysteate  and 
L-homocysteine  sulphinate,  are  known  to  be  potent  agonists  of  NMDA  receptors  (Boutell 
et  al.,  1998)  It  is  conceivable  that  the  interaction  of  mutant  huntingtin  with  cystathionine  ß- 
synthase  may  interfere  with  the  normal  function  of  cystathionine  ß-synthase,  causing 
increased  homocysteine  levels  that  lead  to  excitotoxicity  in  HD.  To  support  this 
postulation,  further  studies  in  examining  the  distribution  of  homocysteate  and  other 
homocysteine  oxidation  products  in  the  brain  tissue  of  HD  patients  and  HD  mice  are 
essential. 
SH3  containing  Grb-like  protein  (SH3GL3)  preferentially  binds  to  the  N-terminal  fragment 
of  huntingtin  with  an  expanded  polyglutamine  tract  (Sittler  et  al.,  1998).  The  formation  of 
huntingtin  aggregates  is  significantly  enhanced  in  the  presence  of  SH3GL3  (Sittler  et  al., 
1998).  SH3GL3  plays  a  major  role  in  the  signal  transduction  from  membrane  receptors  and 
in  the  regulation  of  exo/endocytic  cycle  of  synaptic  vesicles  (Pawson,  1995).  As  SH3GL3 
is  selectively  expressed  in  different  brain  regions  including  striatum  and  cortex  (Sittler  et 
al.,  1998),  the  binding  of  this  protein  to  a  huntingtin  fragment  containing  expanded 
polyglutamine  may  contribute  to  the  selective  vulnerability  of  neurons  in  HD.  However, 
whether  the  normal  function  of  SH3GL3  is  affected  by  the  interaction  with  mutant 
huntingtin  is  not  known  and  requires  further  study. 
44 WW  domain  proteins  are  involved  in  signal  transduction,  proteolysis  and  mRNA  splicing 
(Faber  et  al.,  1998),  but  the  effect  of  polyglutamine  length  on  the  interaction  between 
huntingtin  and  WW  domain  proteins  and  the  role  of  such  interactions  are  not  clear  and 
need  to  be  explored  further. 
Most  of  these  huntingtin-interacting  or  associated  proteins  are  expressed  throughout  the 
brain  and  are  not  especially  enriched  in  regions  most  affected  in  HD.  Therefore  it  remains 
unclear  whether  these  proteins  play  a  role  in  the  selective  vulnerability  of  neuronal  death. 
1.2.3.8  Transcriptional  dysregulation  caused  by  expanded  polyglutamine 
stretches 
The  role  of  the  nuclear  inclusions  in  the  mechanism  of  polyglutamine  diseases  is 
controversial,  as  previously  mentioned,  but  evidence  from  cellular  and  animal  models 
indicates  that  nuclear  localization  of  mutant  protein  is  important  in  toxicity  (Klement  et  al., 
1998;  Saudou  et  al.,  1998).  It  is  possible  that  nuclear  localization  of  mutant  protein 
interferes  with  nuclear  transcription  factors  and  co-factors  leading  to  cellular  toxicity. 
Recently,  CBP  [CAMP-responsive  element  binding  protein  (CREB)-binding  protein],  a 
cofactor  for  CREB-dependent  transcriptional  activation,  has  been  shown  to  co-localize 
with  the  mutant  huntingtin  in  cells  co-transfected  with  expression  plasmids  containing  both 
genes  (Kazantsev  et  al.,  1999;  Nucifora  et  al.,  2001).  Furthermore,  CBP  has  been  found  in 
nuclear  inclusions  formed  in  HD  mice  (Nucifora  et  al.,  2001;  Steffan  et  al.,  2000)  and  in 
human  HD  brains  (Nucifora  et  al.,  2001). 
Several  lines  of  evidence  suggest  the  possibility  that  expanded  polyglutamine  repeats  could 
cause  aberrant  transcriptional  regulation  through  their  interaction  with  nuclear  transcription 
factors.  The  binding  of  TAF1130  (a  cofactor  for  CREB-dependent  transcriptional 
activation)  to  expanded  polyglutamine  stretches  has  been  shown  in  a  cell  culture  model  of 
polyglutamine  disease  to  strongly  suppress  CREB-dependent  transcriptional  activation 
(Shimohata  et  al.,  2000).  It  has  also  been  demonstrated  that  expanded  polyglutamine 
specifically  interferes  with  CBP-activated  gene  transcription,  and  over  expression  of  CBP 
rescues  polyglutamine-induced  neuronal  toxicity  (Nucifora  et  al.,  2001).  A  further  study 
using  cell  lines  expressing  N-terminal  mutant  huntingtin  suggests  that  increased 
45 susceptibility  to  cell  death  and  decreased  neurite  outgrowth  is  partly  due  to  an  impaired 
CRE-transcriptional  response  (Wyttenbach  et  al.,  2001).  A  key  test  of  CBP  involvement  in 
HD  pathogenesis  will  be  to  identify  the  genes  that  are  transcriptionally  regulated  by  this 
factor,  and  that  have  altered  expression  in  cells  containing  the  polyglutamine  expansion 
and  displaying  pathological  changes.  A  reduction  of  CRE-mediated  transcription  is  likely 
in  human  HD,  since  reduced  levels  of  the  CRE-response  genes  such  as  corticotrophin- 
releasing  hormone,  proenkephalin  and  substance  P  are  seen  in  HD  brain  tissue  compared  to 
control  brain  tissue  (Augood  et  al.,  1996;  Desouza,  1995;  Sapp  et  al.,  1995).  This  pathway 
is  also  likely  to  be  impaired  in  HD  mouse  models,  since  cAMP-responsive  genes  are  down 
regulated  in  R6/2  mice  (Luthi-Carter  et  al.,  2000). 
It  has  been  postulated  that  other  transcription  factors  could  also  be  inactivated  by  expanded 
polyglutamine  tract.  At  least  12  such  proteins  have  been  identified  (McCampbell  and 
Fischbeck,  2001a),  but  the  exact  role  these  factors  play  in  disease  pathogenesis  is 
unknown.  Interestingly,  many  of  these  factors  are  involved  in  histone  acetylation.  In  a  cell 
culture  model  of  spinobulbar  muscular  atrophy,  histone  acetylation  was  reduced  in  cells 
expressing  mutant  polyglutamine.  Reversal  of  this  hypoacetylation,  which  can  be  achieved 
by  over  expression  of  CBP  or  its  amino  terminus,  or  by  treatment  with  deacetylase 
inhibitors,  reduced  cell  loss  (McCampbell  et  al.,  2001b).  A  recent  Drosophila  study  also 
demonstrated  that  progressive  neurodegeneration  and  early  adult  lethality,  caused  by 
expression  of  an  expanded  polyglutamine  tract,  were  arrested  by  feeding  flies  with  histone 
deacetylase  inhibitors  (Steffan  et  al.,  2001).  Similar  results  were  shown  in  a  yeast  model 
expressing  nuclear  expanded  polyglutamine  (Hughes  et  al.,  2001).  These  results  provide 
evidence  that  the  use  of  deacetylase  inhibitors  could  be  a  viable  therapeutic  strategy  in  HD. 
However,  as  a  first  step,  it  is  very  important  to  see  what  effect  these  compounds  have  in 
HD  mouse  models. 
In  addition  to  reduced  CRE-mediated  transcription,  other  transcript  expression  appears  to 
be  altered  in  polyglutamine  disease.  Nuclear  proteins  that  interact  with  expanded 
polyglutamine  stretches  include  p53  and  nuclear  receptor  co-repressor  (N-CoR).  In  vitro, 
N-CoR  preferentially  binds  to  huntingtin  protein  containing  longer  polyglutamine  repeats 
(Boutell  et  al.,  1999).  The  N-CoR  protein  is  known  to  repress  transcription  from  ligand- 
activated  receptors  such  as  retinoid  X-thyroid  hormone  receptor  dimers.  In  vivo,  N-CoR  is 
46 redistributed  to  the  cytoplasm  by  mutant  huntingtin,  suggesting  that  altered  transcriptional 
regulation  may  be  involved  in  HD  (Boutell  et  al.,  1999).  Mutant  huntingtin  was  also  found 
to  significantly  repress  transcription  of  a  p53-regulated  promoter  (Steffan  et  al.,  2000)  and 
mimic  the  function  of  p53.  It  was  postulated  that  mutant  protein,  mimicking  the  p53 
function,  triggers  the  apoptotic  pathway  and  this  might  be  partly  responsible  for  the 
neuronal  cell  death  in  HD.  In  vitro  studies  have  recently  demonstrated  that  mutant 
huntingtin  binds  strongly  to  specificity  protein  1(Spl),  a  transcription  factor,  inhibiting  the 
Spl-dependent  transcription  of  genes  such  as  nerve  growth  factor  receptor  (Li  et  al.,  2002). 
Co-expression  of  Spi  and  TAFI1130  in  cultured  striatal  cells  from  wild-type  and  HD 
transgenic  mice  reverse  the  transcriptional  inhibition  of  the  dopamine  D2  receptor  gene 
caused  by  mutant  huntingtin,  as  well  as  protects  neurons  from  huntingtin-induced 
cytotoxicity  (Dunah  et  al.,  2002).  Further  in  vivo  studies  demonstrated  that  soluble  mutant 
huntingtin  inhibit  Spl  binding  to  DNA  in  post-mortem  brain  tissues  of  both 
presymptomatic  and  affected  HD  patients,  suggesting  that  inhibition  of  Spl-mediated 
transcription  may  be  an  early  molecular  event  in  HD  (Dunah  et  al.,  2002). 
Studies  in  HD  mice  revealed  downregulated  genes  encoding  components  of  neuronal 
signalling  systems  including  brain  derived  neurotrophic  factor  (Ferrer  et  al.,  2000), 
glutamate  transporters  (Lievens  et  al.,  2001),  neurotransmitter  receptors,  intracellular 
signal  transducing  enzymes,  retinoic  acid  machinery  and  molecules  that  control  Cat' 
homeostasis  (Luthi-Carter  et  al.,  2000).  Similar  results  were  obtained  in  transgenic  SCA1 
mice,  in  which  down-regulation  of  several  genes  abundantly  expressed  in  Purkinje  cells, 
occurred  before  any  pathological  or  neurobehavioral  abnormalities  (Lin  et  al.,  2000).  In 
this  model,  several  genes  for  proteins  involved  in  Cat'  homeostasis  were  downregulated,  as 
was  the  Purkinje  cell-specific  glutamate  transporter  (Lin  et  al.,  2000).  It  was  thus  suggested 
that  glutamate  neurotoxicity  and  excessive  intracellular  Cat+fluxes  may  be  early 
pathogenic  events  in  SCA1  and  possibly  also  in  other  polyglutamine  disorders. 
1.2.3.9  Channel  hypothesis 
Recently,  the  formation  of  ion  channels  from  long  synthetic  polyglutamine  tracts  in 
artificial  planar  lipid  bilayers  has  been  reported  (Hirakura  et  al.,  2000;  Monoi  et  al.,  2000). 
Both  studies  report  that  a  variety  of  physiological  cations  such  as  KK,  Na+,  Cat+,  and  H+  can 
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channel  formation  could  cause  significant  leakage  in  plasma  and  mitochondrial 
membranes,  leading  to  degraded  membrane  potentials  and  impaired  energy  stores  in  vivo. 
Monoi  and  colleagues,  show  a  threshold  of  polyglutamine  length  required  for  channel 
formation,  i.  e.  a  40-residue  polyglutamine  could  form  channels  whereas  a  29-residue 
polyglutamine  could  not,  consistent  with  the  polyglutamine  length  required  for  disease 
development.  The  authors  propose  that  channel  formation  would  likely  cause  malfunction 
and  death  in  affected  neurons  by  altering  ion  homeostasis,  membrane  potentials,  energy 
stores  and  susceptibility  to  excitotoxicity  and  apoptosis. 
The  channel  mechanism  is  well  established  for  microbial  toxins  and  at  least  six  other 
"amyloid"  channels,  relevant  to  diseases  such  as  Alzheimer's  and  prion  disease,  have  been 
postulated  (Kagan  et  al.,  2001).  The  remarkable  structural  resemblance  between  amyloid 
and  mutant  huntingtin-induced  aggregates,  coupled  with  the  striking  similarity  of  the 
polyglutamine  and  amyloid  channel  properties,  lends  credence  to  the  channel  hypothesis  as 
a  cytotoxic  mechanism  in  both  diseases  (Kagan  et  al.,  2001). 
1.2.4  Neuronal  dysfunction  in  HD 
The  possibility  that  early  stages  of  HD  may  be  primarily  due  to  cell  dysfunction  rather  than 
cell  death  is  suggested  by  the  observation  that  some  symptomatic  HD  patients  have  no 
discernable  neuropathological  abnormalities  (Myers  et  al.,  1988).  This  notion  is  further 
supported  by  studies  in  HD  mouse  models,  which  display  phenotypes  and  cellular 
dysfunction  in  the  absence  of  overt  cell  death  (Davies  et  al.,  1997;  Lin  et  al.,  2001; 
Schilling  et  al.,  1999;  Shelbourne  et  al.,  1999;  Wheeler  et  al.,  2000).  Several  mechanisms 
involved  in  neuronal  dysfunction  have  been  suggested,  although  these  mechanisms  may 
ultimately  contribute  to  cell  death. 
1.2.4.1  Excitotoxicity  in  HD 
Excitotoxicity  has  long  been  implicated  in  the  pathogenesis  of  HD  (Beal  et  al.,  1991; 
Hantraye  et  al.,  1990).  Excitotoxicity  refers  to  neuronal  death  resulting  from  exposure  to 
excitatory  amino  acids  like  glutamate.  The  striatum  receives  abundant  glutamatergic  input 
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(NMDA),  kainate  and  a-amino-3-hydroxy-5-methyl-4-isoxasole  propionate  (AMPA) 
receptors.  They  contribute  to  excitatory  postsynaptic  potentials  recorded  from  striatal 
neurons  after  cortical  stimulation.  In  conditions  of  acute  glutamate  overload,  NMDA 
receptors  are  activated  and  cause  intracellular  influx  of  Cat+,  which  can  lead  to  the 
generation  of  nitric  oxide  and  other  free  radicals,  damage  to  vital  cellular  structures  and 
ultimately  cell  death. 
Several  lines  of  evidence  suggest  that  glutamate  excitotoxicity  is  involved  in  HD 
pathogenesis.  Selective  neuronal  loss,  resembling  the  pattern  seen  in  HD,  may  be  induced 
by  the  NMDA  agonist  (quinolinic  acid)  (Beal  et  al.,  1991;  Ferrante  et  al.,  1993;  Huang  et 
al.,  1995).  In  addition,  post-mortem  analysis  of  human  HD  brains  has  suggested  that  striatal 
neurons  with  high  NMDA  receptor  expression  show  increased  vulnerability  to  degeneration 
(Albin  et  al.,  1990;  Young  et  al.,  1988).  The  membrane  depolarisation  and  inward  current 
produced  by  exogenous  glutamate  receptor  agonists  are  significantly  larger  in  medium 
spiny  neurons  than  in  large  aspiny  cholinergic  interneurons,  suggesting  that  medium  spiny 
neurons  are  more  sensitive  to  glutamate  receptor  agonist  stimulation  (Calabresi  et  al., 
1998).  Indeed,  both  striatal  and  cortical  projection  neurons  in  culture  are  highly  vulnerable 
to  NMDA  agonists,  while  interneurons  are  relatively  spared  (Figueredo-Cardenas  et  al., 
1994).  This  may  account  for  the  cell  type-specific  vulnerability  of  striatal  neurons  in  HD,  if 
glutamate  excitotoxicity  is  involved  in  HD  pathogenesis.  There  are  different  subtypes  of 
glutamate  receptors  in  different  striatal  neurons.  NR1A/NR2B  is  the  predominant  NMDA 
receptor  subtype  in  striatal  medium  spiny  neurons.  Further  studies  showed  that  NMDA- 
induced  apoptotic  death  by  full-length  mutant  huntingtin  is  enhanced  in  NR1A/NR2B- 
expressing  neurons,  but  not  in  NR1A/NR2A-expressing  cells  (Zeron  et  al.,  2001). 
A  recent  study  has  shown  that  normal  huntingtin  binds  to  post-synaptic  density  95  (PSD- 
95),  a  protein  that  binds  to  the  NMDA  receptor  and  regulates  NMDA-dependent  long-term 
potentiation  and  depression,  resulting  in  the  inhibition  of  NMDA  receptor  activity  (Sun  et 
al.,  2001).  The  polyglutamine  expansion  inhibits  huntingtin  binding  to  PSD-95,  resulting  in 
increased  susceptibility  to  glutamate-induced  excitotoxicity.  Over-expression  of  the  normal 
N-terminal  fragment  of  huntingtin  significantly  attenuates  neuronal  toxicity  induced  by 
both  NMDA  receptor  agonists  and  the  mutant  huntingtin  (Sun  et  al.,  2001).  The  association 
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excitotoxicity  and  the  mutant  huntingtin  protein. 
Pathological  changes  in  presynaptic  inputs  involved  in  excitotoxicity  have  also  been  shown 
in  a  number  of  studies.  Changes  in  cortical  projection  neurons  and  the  corticostriatal  input 
have  been  observed  in  HD  (DiFiglia  et  al.,  1997).  Cytoplasmic  accumulation  of  mutant 
huntingtin  occurs  in  pyramidal  neurons  and  is  associated  with  degeneration  of  the 
corticostriatal  pathway  (Sapp  et  al.,  1999).  In  this  study,  the  authors  also  raise  the 
possibility  that  huntingtin  preferentially  damages  the  corticostriatal  pathway  leading  to 
excessive  synaptic  release  of  glutamate  and  excitotoxicity  to  striatal  cells.  Indeed, 
accumulated  evidence  suggests  that  huntingtin  is  associated  with  neuronal  terminal  vesicles 
and  several  exo/endocytic  vesicle  proteins  such  as  HIP-1,  HAP-1  and  SH3GL3  (section 
1.2.3.7).  It  is  therefore  reasonable  to  hypothesize  that  aberrant  interaction  of  mutant 
huntingtin  with  these  proteins  may  interfere  with  the  regulation  of  exo/endocytic  cycle  of 
synaptic  vesicles  and  lead  to  glutamate-induced  excitotoxicity. 
1.2.4.2  Increased  oxidative  stress  in  HD 
A  role  for  oxidative  damage  in  neurodegenerative  diseases  including  HD,  is  gathering 
increasing  experimental  support.  Damage  caused  by  oxidative  stress  includes  lipid 
peroxidation,  protein  oxidation,  and  DNA  mutation.  Immunostaining  for  3-nitrotyrosine 
(3-NT),  a  marker  for  peroxynitrite-mediated  protein  nitration,  and  malondialdehyde 
(MDA),  a  marker  for  oxidative  damage  to  lipid,  has  been  shown  to  increase  in  the  striatum 
of  HD  brains  (Browne  et  al.,  1999).  Increased  immunostaining  for  heure  oxygenase-1, 
formed  in  a  compensatory  response  to  oxidative  stress,  has  also  been  found  in  the  striatum 
of  HD  brains  (Browne  et  al.,  1999).  Furthermore,  levels  of  8-hydroxydeoxyguanosine  (8- 
OHdG),  an  oxidative  damage  product  of  DNA,  in  nuclear  DNA  were  significantly 
increased  in  HD  caudate  (Browne  et  al.,  1997).  Manganese  superoxide  dismutase-2  (SOD- 
2)  up-regulation  has  been  shown  in  cells  expressing  truncated  huntingtin  containing  150 
glutamines  (Li  et  al.,  1999c).  Recently,  oxidative  stress  caused  by  N-terminal  fragments  of 
mutant  huntingtin  has  been  suppressed  by  overexpression  of  heat  shock  protein  27  in  a  HD 
cellular  model  (Wyttenbach  et  al.,  2002).  Collectively,  these  findings  implicate  an 
important  role  of  increased  oxidative  stress  in  HD  pathogenesis. 
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Several  lines  of  evidence  have  indicated  that  abnormalities  of  energy  metabolism  are 
involved  in  HD  pathology. 
Studies  of  cerebral  glucose  metabolism  using  F-18  fluorodeoxyglucose  positron  emission 
tomography  (FDG-PET)  provide  strong  evidence  for  an  impairment  of  energy  metabolism. 
In  HD  patients  and  those  at  risk  of  developing  this  disorder,  decreased  cerebral  metabolic 
rates  for  glucose  were  shown  in  the  caudate  and  putamen  as  well  as  in  frontal  and  parietal 
cortex  (Alavi  et  al.,  1986;  Goto  et  al.,  1993;  Hayden  et  al.,  1986;  Young  et  al.,  1986; 
Andrews  and  Brooks,  1998).  A  further  study  showed  that  basal  ganglia  metabolism  is 
highly  correlated  with  the  functional  capacity  of  individual  patients  and  the  degree  of  their 
motor  dysfunction  (Young  et  al.,  1986).  Using  magnetic  resonance  spectroscopy  (MRS) 
imaging,  increased  lactate  levels  have  been  observed  in  the  striatum  and  occipital  cortex  of 
HD  patients,  suggesting  a  compensatory  glycolytic  response  to  impaired  mitochondrial 
function  (Jenkins  et  al.,  1993).  Recently,  a  proton  magnetic  resonance  spectroscopy  study 
of  cerebrospinal  fluid  from  HD  patients  showed  reduced  levels  of  both  lactate  and  citrate, 
suggesting  an  impairment  of  both  glycolysis  and  tricarboxylic  acid  cycle  function  in  HD 
patients  (Garseth  et  al.,  2000). 
The  basal  ganglia  are  particularly  susceptible  to  mitochondrial  toxins  such  as  3- 
nitropropionic  acid  (3-NP),  which  is  an  inhibitor  of  succinate  dehydrogenase.  Accidental 
ingestion  of  3-nitropropionic  acid  (3-NP)  in  man  produces  selective  basal  ganglia  lesions 
and  dystonia  (Ludolph  et  al.,  1992).  Extensive  behavioural  and  neuropathological 
evaluations  showed  that  a  partial  but  prolonged  energy  impairment  induced  by  3-NP  in 
rodents  and  non-human  primates  is  sufficient  to  replicate  most  of  the  clinical  and 
pathophysiological  hallmarks  of  HD,  including  choreiform  movements,  cognitive  deficits, 
and  progressive  selective  striatal  degeneration  (Borlongan  et  al.,  1997;  Guyot  et  al.,  1997; 
Vis  et  al.,  1999).  Further  supportive  evidence  for  a  metabolic  deficit  in  HD  comes  from 
transgenic  mouse  studies  that  report  progressive  weight  loss  despite  increased  caloric 
intake  (Mangiarini  et  al.,  1996). 
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stress  via  mitochondrial  dysfunction  in  HD 
It  is  widely  accepted  that  defective  energy  metabolism,  oxidative  stress,  and  excitotoxicity 
and  the  interplay  between  these  different  mechanisms  may  contribute  to  HD  pathogenesis. 
Excitotoxicity  and  oxidative  stress  may  both  occur  as  direct  consequences  of  energy  failure 
(Beal,  1998).  An  inability  to  maintain  cellular  ATP  levels  may  lead  to  partial  neuronal 
depolarisation,  relief  of  the  voltage-dependent  Mg  block  of  the  NMDA  receptor  and 
persistent  receptor  activation  by  ambient  glutamate  levels.  Energy  failure  also  impairs 
calcium  buffering  and  results  in  an  influx  of  calcium,  which  leads  to  nitric  oxide  (NO)  and 
superoxide  (02)  generation.  The  reaction  of  NO'  and  Oz  can  generate  peroxynitrite 
(ONOO-),  which  is  a  key  mediator  of  oxidative  stress  (Beckman  and  Crow,  1993). 
Although  there  are  a  number  of  intracellular  sources  of  free  radicals,  the  mitochondria  are 
thought  to  be  the  most  important.  Mitochondria  can  buffer  increased  intracellular  calcium 
by  fast  sequestration  through  the  electrochemical  gradient  across  the  inner  mitochondrial 
membrane.  Exposure  of  mitochondria  to  an  overload  of  calcium  influx  leads  to 
mitochondrial  generation  of  hydroxyl  and  other  free  radical  species  (Dykens,  1994). 
Several  in  vitro  studies  have  linked  a  glutamate-induced  increase  in  mitochondrial  calcium 
to  mitochondrial  free  radical  generation  and  have  argued  that  mitochondria  are  the  main 
sink  for  calcium  accumulation  and  major  source  of  excitotoxic  reactive  oxygen  species 
(Nicholls  and  Budd,  1998).  When  energy  failure  or  mitochondrial  dysfunction  occurs,  the 
calcium-buffering  ability  will  be  diminished  and  more  free  radicals  will  be  generated. 
Therefore,  production  of  reactive  oxygen  species  (ROS)  induced  by  excitotoxicity  is 
augmented  by  mitochondrial  dysfunction.  Recently,  it  has  been  demonstrated  that 
inhibition  of  mitochondrial  complex  II,  but  not  complex  I,  induces  a  long-term  potentiation 
of  NMDA-mediated  synaptic  excitation  in  striatal  spiny  neurons  (Calabresi  et  at.,  2001). 
However,  this  inhibition  has  no  effect  on  excitatory  synaptic  transmission  in  striatal 
cholinergic  intemeurons  and  pyramidal  neurons.  3-NP-induced  long-term  potentiation  is 
also  critically  dependent  on  endogenous  dopamine  acting  through  D2  receptors.  In 
summary,  it  is  possible  that  mitochondrial  dysfunction  can  mediate  selective  neuronal 
vulnerability  to  oxidative  stress  via  excitotoxicity. 
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mechanism  for  eliminating  ROS-producing  cells.  Apoptosis  is  also  a  possible  mechanism 
of  cell  death  in  HD.  Mitochondria  harbour  two  nuclear-encoded  components,  cytochrome  c 
and  an  "apoptosis-inducing  factor"  (AIF),  which  are  released  upon  a  Cat+-induced  opening 
of  the  mitochondrial  transition  pore.  This  event  plays  a  major  role  in  the  apoptotic  cell 
death  cascade  (Susin  et  al.,  1999). 
Taken  together,  several  lines  of  evidence  suggest  that  mitochondria  play  a  central  role  in 
excitotoxicity,  energy  failure  and  oxidative  stress,  all  of  which  may  be  involved  in  HD 
pathogenesis. 
1.2.4.5  Mitochondrial  abnormalities  in  human  HD 
Severe  defects  in  the  activities  of  the  mitochondrial  respiratory  chain,  especially  complex 
II/III,  have  been  identified  in  caudate  and  putamen  of  HD  patients,  but  not  in  cortex, 
cerebellum  or  fibroblasts  (Brennan  et  al.,  1985;  Browne  et  al.,  1997;  Gu  et  al.,  1996; 
Tabrizi  et  al.,  1999).  In  addition,  aconitase  activity  is  decreased  by  92  %  in  HD  caudate,  73 
%  in  putamen,  and  48  %  in  cortex,  but  normal  in  HD  cerebellum  and  fibroblast  (Tabrizi  et 
al.,  1999).  Aconitase  is  particularly  vulnerable  to  free  radicals  such  as  NO'  and  ONOO-, 
and  the  decrease  of  aconitase  activity  is  more  prominent  than  that  of  complex  II/III  activity 
when  cells  are  exposed  to  NO'.  Therefore,  the  decreased  aconitase  activity  in  HD  striatum 
may  be  caused  by  NO',  ONOO-and  other  free  radicals  usually  generated  through 
excitotoxicity. 
Mitochondrial  DNA  (mtDNA),  which  encodes  13  subunits  of  mitochondrial  respiratory 
enzyme  complex,  is  particularly  susceptible  to  oxidative  damage,  due  to  its  proximity  to 
the  respiratory  chain,  limited  repair  mechanisms,  few  non-coding  sequences,  and  absence 
of  histones  (Richter  et  al.,  1988).  If  increased  oxidative  stress  occurs  in  HD,  it  is 
reasonable  to  expect  that  mtDNA  might  also  be  compromised.  Indeed,  a  significant 
increase  in  8-OHdG  in  mtDNA  of  the  parietal  cortex  was  found  in  late  stage  (Vonsattel 
grade  3-4)  HD  patients,  while  no  such  increase  was  found  in  frontal  cortex  or  cerebellum 
(Polidori  et  al.,  1999).  In  addition,  a  marked  increase  in  mitochondrial  DNA  deletion  level 
has  been  reported  in  the  temporal  and  frontal  cortex  of  HD  patients  (Horton  et  al.,  1995). 
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of  mtDNA  content.  If  mtDNA  is  depleted,  it  is  possible  that  expression  levels  of 
mitochondrial  mRNA  may  be  decreased.  Indeed,  decreased  expression  levels  of 
cytochrome  c  oxidase  I  mRNA  has  been  recently  shown  in  striatum,  external  globus 
pallidus  and  putamen  of  HD  brain  (Gourfinkel-An  et  al.,  2002). 
1.2.5  Models  of  cell  loss  in  HD 
Even  though  many  lines  of  evidence  argue  strongly  for  a  period  of  protracted  cellular 
dysfunction  prior  to  cell  death,  the  neuropathological  hallmark  of  HD  is  striatal  cell  loss.  It 
has  been  argued  that  understanding  the  mechanism  of  cell  death  may  help  identify 
therapeutic  strategies.  Therefore,  evidence  supporting  different  mechanisms  that  may 
account  for  the  cell  death  in  HD  is  discussed  in  the  following  sections. 
1.2.5.1  Apoptosis  in  HD 
Although  the  precise  biochemical  mechanisms  underlying  cell  loss  in  HD  are  not  yet 
completely  understood,  the  available  evidence  supports  an  apoptotic,  rather  than  necrotic, 
mode  of  cell  death.  Apoptosis  is  programmed  cell  death-a  conserved  cellular  mechanism 
initiated  by  diverse  stimuli  that  leads  to  activation  of  aspartate-specific  proteases 
(caspases)  and  culminates  in  DNA  fragmentation  and  cell  death.  A  subset  of  neurons  and 
glia  in  the  neostriatum  of  post-mortem  HD  brains,  assayed  with  terminal  transferase- 
mediated  deoxyuridine  triphosphate-biotin  nick-end  labelling  (TUNEL),  have  shown  DNA 
strand  breaks  typical  of  apoptosis  (Dragunow  et  al.,  1995;  Portera-Cailliau  et  al.,  1995; 
Thomas  et  al.,  1995).  Further  studies  have  shown  that  proteins  with  expanded 
polyglutamine  tracts  kill  cells  through  apoptotic  pathways  (Sanchez  et  al.,  1999;  Saudou  et 
al.,  1998;  Sawa  et  al.,  1999).  Huntingtin  protein  itself  has  been  shown  to  be  an  apoptotic 
substrate  and  is  cleaved  in  a  CAG  repeat-length  dependent  manner  by  apopain  (Goldberg 
et  al.,  1996).  The  presence  of  activated  caspase-8  in  the  insoluble  fraction  of  affected  brain 
regions  from  HD  patients  has  also  been  demonstrated  (Sanchez  et  al.,  1999).  Furthermore, 
intranuclear  mutant  huntingtin  increases  activity  of  caspase-1  and  caspase-3,  and  promotes 
cytochrome  c  release,  leading  to  apoptosis  in  cell  culture  (Li  et  al.,  2000b).  Further  studies 
have  shown  that  caspase-1  inhibition  delays  the  onset  of  disease  and  prolongs  survival  in 
54 R6/2  HD  mice  (Ona  et  al.,  1999).  These  lines  of  evidence  suggest  that  caspase-  induced 
apoptosis  may  be  involved  in  the  cell  death  associated  with  HD. 
1.2.5.2  Endosomal-lysosomal-vacuolar  pathway  (autophagy)-induced  cell  death 
in  HD 
It  has  been  shown  that  in  dying  neurons  in  the  HD  brain,  huntingtin  aberrantly  accumulates 
in  perinuclear  regions  and  in  numerous  punctuate  cytoplasmic  structures  that  resemble 
endosomal-lysosomal  organelles  (Sapp  et  al.,  1997).  The  endosomal-lysosomal-vacuolar 
pathway  has  been  implicated  in  the  handling  of  other  disease  proteins,  such  as  prions 
(Taraboulos  et  al.,  1992)  and  Aß  peptide  1-42  (Cataldo  et  al.,  1996),  and  cell  death  by 
autophagy,  a  process  whereby  cells  remove  cytosolic  proteins  and  organelles  and  degrade 
themselves  from  within.  Autophagy  may  precede  and  coexist  with  apoptosis,  and  may 
contribute  to  cell  death  in  neurons  through  the  regulation  of  lysosomal  proteases  cathepsin 
B  and  D  (Ohsawa  et  al.,  1998). 
In  clonal  mouse  striatal  cell  lines  transiently  transfected  with  mutant  and  normal  human 
huntingtin,  exogenous  wild-type  and  mutant  huntingtin  accumulated  diffusely  in  the 
cytoplasm,  forming  vacuoles  or  nuclear  and  cytoplasmic  inclusions  (Kim  et  al.,  1999a). 
The  vacuoles  had  the  ultrastructural  features  of  an  autophagosome  and  proved  to  associate 
with  exogenous  huntingtin  and  the  lysosomal  enzyme  cathepsin  D  (Kegel  et  al.,  2000).  In 
this  study,  transfected  cells  that  developed  huntingtin-positive  vacuoles  became  shrunken 
and  developed  nuclear  invaginations,  which  are  features  observed  in  human  HD  brains 
(Tellez-Nagel  et  al.,  1974)  and  in  HD  transgenic  mice  (Davies  et  al.,  1997).  A  recent  study, 
using  a  postnatal  striatal  cell  culture  system  composed  predominantly  of  DARPP-32 
(dopamine-  and  cyclic  AMP-regulated  phosphoprotein  of  a  molecular  weight  of  32  kDa)- 
expressing  neurons,  showed  that  mutant  huntingtin-containing  neurons  were  far  more 
susceptible  to  dopamine-induced  stress,  leading  to  a  cascade  of  oxyradical  formation  and 
induction  of  neuronal  autophagy  (Petersen  et  al.,  2001).  Moreover,  autophagy  has  been 
shown  to  be  involved  in  the  degradation  of  aggregate-prone  proteins,  since  they 
accumulates  when  cells  are  treated  with  different  inhibitors  acting  at  distinct  stages  of  the 
autophagy-lysosomal  pathway  and  their  appearance  is  reduced  when  cells  are  treated  with 
rapamycin,  a  substance  that  can  stimulate  autophagy  (Ravikumar  et  al.,  2002).  These 
55 findings  suggest  that  an  autophagic  process,  induced  by  the  cytoplasmic  accumulation  of 
mutant  huntingtin,  may  contribute  to  HD  neuropathology. 
1.3  Other  triplet  repeat  diseases 
An  increasing  number  of  inherited  neurodegenerative  diseases  including  HD  are  caused  by 
the  expansion  of  unstable  trinucleotide  repeat  tracts.  Common  features  shared  by  these 
diseases  include:  1)  the  mutant  repeats  show  both  somatic  and  germline  instability, 
frequently  expanding  rather  than  contracting  in  successive  transmissions  through  the 
generations  of  a  family;  2)  an  earlier  age  of  onset  and  increasing  severity  of  phenotypes  in 
subsequent  generations  (a  phenomenon  known  as  anticipation)  that  correlates  with  larger 
repeat  lengths;  3)  the  parental  origin  of  the  disease  allele  can  often  influence  anticipation, 
with  paternal  transmission  carrying  a  greater  risk  of  expansion  for  many  of  the  disorders. 
Trinucleotide  repeat  diseases  can  be  categorized  into  two  subclasses  based  on  the  relative 
location  of  the  trinucleotide  repeat  in  the  gene.  The  first  subclass  has  its  repeat  in  non- 
coding  sequences.  The  second  subclass,  the  so-called  polyglutamine  diseases,  is 
characterized  by  exonic  (CAG)n  repeats  that  code  for  polyglutamine  tracts. 
1.3.1  Non-coding  trinucleotide  repeat  diseases 
The  non-coding  trinucleotide-repeat  diseases  are  characterized  by  large  variable  repeat 
expansions  that  result  in  multiple  tissue  dysfunction  and  degeneration.  At  least  7  diseases 
of  this  category  have  been  identified  (Table  1.1).  The  pathogenic  mechanism  varies  from 
disease  to  disease,  depending  on  the  consequences  of  the  lost  function  of  the  respective 
protein,  or  the  gain  of  function  of  a  toxic  transcript,  or  both.  Despite  the  various 
pathogeneses,  a  number  of  similarities  exist  within  this  group  of  diseases.  For  example,  the 
non-coding-repeat  diseases  are  typically  multi-system  disorders  involving  dysfunction  or 
degeneration  of  many  different  tissues.  In  addition,  the  size  and  variation  of  the  repeat 
expansions  are  much  greater  in  the  non-coding  trinucleotide-repeat  diseases  than  in  the 
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a  t 1.3.2  Polyglutamine  diseases 
All  eight  known  polyglutamine  disorders  (Table  1.2)  are  characterized  by  progressive 
neuronal  dysfunction  that  typically  begins  in  mid-life  and  results  in  severe 
neurodegeneration.  Although  the  mutant  proteins  do  not  share  any  homology  outside  the 
polyglutamine  tract,  the  polyglutamine  diseases  have  several  similar  features  and  probably 
share  common  pathogenic  mechanisms.  Despite  the  ubiquitous  expression  of  all  eight 
genes,  only  a  certain  subset  of  neurons  is  vulnerable  in  each  disease.  All  the  diseases  are 
probably  caused  by  a  gain  of  function  mechanism  conferred  by  the  expanded 
polyglutamine  tract.  However,  the  selective  neuronal  vulnerability  is  probably  influenced 
by  aspects  of  the  respective  gene  involved. 
There  are  several  families  and  individuals  with  HD-like  symptoms  who  do  not  have  the 
HD  mutation  (Andrew  et  al.,  1994).  One  such  family  affected  by  an  early  onset,  autosomal 
recessive  disorder  resembling  juvenile-onset  HD  was  reported  recently  (Kambouris  et  al., 
2000).  The  manifestations  include  choreoathetosis,  ataxia,  dystonia,  seizure,  spasticity, 
mutism,  and  general  intellectual  impairment.  Brain  magnetic  resonance  imaging  findings 
included  progressive  frontal  cortical  and  bilateral  striatal  atrophy.  The  gene  responsible  for 
this  disease  has  been  localized  to  4p15.3,  distinct  from  the  HD  gene  location  at  4p16.3 
(Kambouris  et  al.,  2000). 
Another  large  pedigree  with  an  autosomal  dominant  disorder  that  is  clinically  similar  to 
HD  has  been  reported  to  arise  from  a  different  CAG  expansion  mutation  (Margolis  et  al., 
2001).  The  disorder  termed  Huntington's  disease  like-2  (HDL2)  is  characterized  by  onset 
in  the  fourth  decade,  involuntary  movements  and  abnormalities  of  voluntary  movement, 
psychiatric  symptoms,  weight  loss,  dementia,  and  a  relentless  course  with  death  about  20 
years  after  disease  onset.  Brain  magnetic  resonance  imaging  scans  and  autopsy  studies 
revealed  marked  striatal  atrophy  and  moderate  cortical  atrophy,  with  striatal 
neurodegeneration  that  occurs  in  a  dorsal  to  ventral  gradient  and  occasional  intranuclear 
inclusions.  Affected  individuals  have  a  CAG  repeat  expansion  of  50  to  60  triplets. 
Unexpanded  allele  sizes  range  from  6  to  27  triplets.  The  expansion  is  unstable  in  vertical 
transmission,  but  the  range  of  repeat  length  among  family  members  is  narrow.  More 
recently,  the  CAG  repeat  was  found  to  be  located  in  the  non-coding  strand  between  exon  1 
58 and  2  of  the  gene  encoding  junctophilin-3  (JPH3)  (Holmes  et  al.,  2001).  Therefore,  the 
expanded  triplet  sequence  in  the  gene  JPH3  is  (CTG)n.  Junctophilin-3  is  a  component  of 
the  junctional  complex  that  anchors  the  plasma  membrane  to  endoplasmic  reticulum  and 
may  be  involved  in  the  functional  coupling  between  cell-surface  voltage  sensors  and 
intracellular  calcium  channels  (Holmes  et  al.,  2001).  It  is  not  clear  whether  the 
pathogenesis  of  HDL2  is  different  from  that  of  HD  and  other  neurodegenerative  disorders 
caused  by  CAG  repeat  expansion  (Holmes  et  al.,  2001). 
Disease  Gene  Locus  Protein  CAG  repeat  size 
Normal  Disease 
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Atrophin-1  6-35  49-88 
Spinocerebellar  ataxia  type  1  SCAT  6p23  Ataxin-1  6-44  39-82 
Spinocerebellar  ataxia  type  2  SCA2  12q24.1  Ataxin-2  15-31  36-63 
Spinocerebellar  ataxia  type  3  SCA3  14q32.1  Ataxin-3  12-40  55-84 
Spinocerebellar  ataxia  type  6  SCA6  19q13  au-voltage- 
dependent 
calcium  channel 
subunit 
4-18  21-33 
Spinocerebellar  ataxia  type  7  SCA7  12g12- 
13 
Ataxin-7  4-35  37-306 
Spinocerebellar  ataxia  type  17  TBP  6q27  TATA-binding 
protein 
29-42  47-55 
Table  1.2  Diseases  caused  by  expanded  polyglutamine  tracts. 
This  table  is  modified  from  Table  2  in  (Cummings  and  Zoghbi,  2000). 
1.4  Tools  to  study  HD  pathogenesis 
The  pathogenesis  that  causes  selective  neurodegeneration  in  HD  remains  unknown.  HD  is 
a  devastating  illness  and  at  present  there  are  no  effective  therapies  to  prevent  onset  and 
progression  of  the  disease.  The  ultimate  aim  of  scientific  research  in  the  field  is  to  find 
treatments  that  can  cure  the  disease  or  at  least  prevent  its  progression.  In  order  to  achieve 
the  aim,  determining  the  detailed  molecular  changes  associated  with  the  disease  is 
important.  However,  the  lack  of  brain  tissues  from  patients,  especially  presymptomatic 
patients,  makes  investigation  of  early  pathogenesis  difficult.  For  this  reason,  researchers 
have  developed  appropriate  model  systems  to  investigate  the  molecular  basis  of  HD. 
59 1.4.1  In  vitro  models  of  HD 
Various  cell  culture  systems  have  been  established  as  in  vitro  models  of  HD  to  study 
aspects  of  the  pathology  such  as  the  potential  role  of  the  N-terminal  fragments  of  mutant 
huntingtin,  mechanisms  involving  protein  misfolding  and  aggregation,  and  interactions 
between  huntingtin  and  other  proteins. 
The  advantages  of  cell  culture  systems  are  as  follows:  1)  they  are  easily  manipulated  to 
overexpress  or  inhibit  different  genes  within  short  periods  of  time;  2)  they  are  generally  a 
single  cell  type,  therefore  presenting  less  confounding  factors  that  might  influence  the 
experimental  results.  However,  cell  models  also  have  disadvantages:  1)  cells  expressing 
mutant  gene  may  not  reproduce  the  phenotypes  of  HD  except  the  cytotoxicity  and  cell 
death;  2)  consequences  of  overexpressed  mutant  huntingtin  in  cells  do  not  necessarily 
reflect  the  consequences  in  the  organism;  3)  overexpression  of  mutant  full-length 
huntingtin  in  cell  culture  is  not  associated  with  aggregate  formation,  suggesting  differences 
between  in  vivo  and  in  vitro  models;  4)  most  cellular  models  overexpress  N-terminal 
fragments  of  mutant  huntingtin,  suggesting  the  pathogenic  role  of  full-length  mutant 
huntingtin  may  not  be  investigated  in  these  model. 
1.4.2  Invertebrate  models  of  HD 
Invertebrate  model  systems  such  as  Drosophila  melanogaster  and  Caenorhabditis  elegans 
also  offer  experimental  advantages  that  can  potentially  address  some  of  the  questions 
regarding  the  pathogenic  processes  underlying  HD.  Recently,  Drosophila  was  shown  to  be 
a  useful  system  for  studying  polyglutamine-induced  diseases.  An  N-terminal  fragment  of 
huntingtin  containing  2,75  or  120  polyglutamine  repeats  was  expressed  in  fly  eyes 
(Jackson  et  al.,  1998).  Late  onset  neurodegeneration  and  nuclear  inclusions  that  were 
dependent  on  the  length  of  the  glutamine  repeat  in  the  expressed  transgene  were  observed. 
Another  study  using  a  Drosophila  model,  expressing  short  (20  repeat)  and  long  (127 
repeat)  polyglutamine  tracts  (fused  to  an  HA  epitope)  in  fly  eyes,  also  demonstrated 
polyglutamine-induced  eye  degeneration  (Kazemi-Esfarjani  and  Benzer,  2000).  Crossing 
these  transgenic  strains  to  a  series  of  de  novo  P-element  insertion  strains  resulted  in  the 
recovery  of  30  eye  degeneration  suppressor  and  29  eye  degeneration  enhancer  mutations. 
60 Two  of  the  suppressor  mutations  were  identified  as  dHDJ1  and  dTPR2,  both  encoding 
proteins  with  "J"  domains,  homologous  to  the  mammalian  DNA  J  chaperone  protein. 
N-terminal  huntingtin  fragments  containing  polyglutamine  tracts  of  various  sizes  were  also 
expressed  in  the  sensory  neurons  of  C.  elegans  (Faber  et  al.,  1999).  In  this  study, 
phenotypes  were  observed  predominantly  in  worms  expressing  the  longest  (150  repeat) 
polyglutamine  tract.  GFP::  polyglutamine  repeat  fusion  proteins  were  also  expressed  in  C. 
elegans  body  wall  muscle  (Satyal  et  al.,  2000).  Fusion  proteins  containing  a  long  (82 
repeats)  but  not  a  short  (19  repeats)  polyglutamine  tract  formed  cytoplasmic  aggregates, 
causing  a  delay  in  larval  to  adult  development  and  inducing  expression  of  a  small  heat 
shock  protein.  The  toxic  effect  of  the  polyglutamine  expression  and  the  formation  of 
aggregates  could  be  reversed  by  co-expression  of  the  yeast  chaperone  Hsp104. 
The  experimental  benefit  of  invertebrate  model  systems  over  cell  culture  systems  is  that 
they  have  complex  organ  structure  and  can  express  phenotypes  other  than  only  cellular 
toxicity.  The  experimental  advantages  of  invertebrate  model  systems  over  mouse  model 
include  forward  genetic  screens  to  identify  suppressor  and  enhancer  genes,  which  have 
been  performed  in  Drosophila  model  studies  (Fernandez-Funez  et  al.,  2000;  Kazemi- 
Esfarjani  and  Benzer,  2000).  However,  there  are  disadvantages  associated  with 
invertebrate  model  systems.  First,  the  Drosophila  model  has  a  very  short  life  expectancy 
which  may  not  express  the  age-associated  nature  of  the  HD.  Second,  most  of  the 
invertebrate  models  that  have  been  generated  are  expressing  truncated  huntingtin,  which  do 
not  permit  the  investigation  of  molecular  pathological  changes  involving  mutant  full-length 
protein.  Finally,  most  Drosophila  models  express  mutant  huntingtin  in  their  eyes,  which 
have  different  physiological  nature  from  that  of  striatal  neurons.  Thus,  the  mutant 
huntingtin-induced  pathological  changes  in  Drosophila  models  may  not  reflect  that  of 
human  brains. 
1.4.3  HD  mouse  models 
Mouse  models  have  several  advantages  over  the  previously  mentioned  systems.  These 
include  the  biological  and  genetic  similarities  with  humans  and  the  abundance  of  tissue  for 
analysis.  It  is  therefore  not  surprising  that  several  transgenic  and  knock-in  HD  mouse 
61 models  have  been  generated  to  enable  the  exploration  of  early  pathological,  molecular,  and 
cellular  abnormalities  in  HD.  In  addition,  these  models  may  be  used  to  test  different 
approaches  to  delay  the  onset  or  slow  the  progression  of  HD. 
Given  that  the  similarity  between  human  HD  and  mouse  Hdh  genes  and  their  products 
(section  1.2.1),  it  is  probable  that  the  function  of  mouse  huntingtin  is  similar  to  that  of 
human  huntingtin.  Indeed,  the  lethality  associated  with  a  mouse  `knock-out'  model 
carrying  targeted  deletion  of  both  Hdh  gene  copies  can  be  rescued  by  human  huntingtin 
(Hodgson  et  al.,  1996). 
Two  types  of  HD  mice  have  been  generated.  The  first  category  is  transgenic  mice  (Table 
1.3a),  in  which  the  mutant  gene,  or  part  of  it,  is  inserted  randomly  into  the  mouse  genome, 
leading  to  the  expression  of  a  mutant  protein  in  addition  to  endogenous  huntingtin.  The 
second  category  is  `knock-ins'  (Table  1.3b),  in  which  the  mutation  is inserted  into  the 
mouse  Hdh  gene.  This  is  achieved  by  targeted  modification  of  the  gene  in  mouse 
embryonic  stem  (ES)  cells  by  homologous  recombination.  Knock-in  mice  express  the 
mutation  under  the  influence  of  the  endogenous  Hdh  promoter  and  in  the  appropriate 
genomic  context. 
1.4.3.1  Transgenic  mouse  models  of  HD 
The  phenotypes  and  neuropathological  changes  of  the  transgenic  HD  models  appear  to  be 
highly  variable,  which  is  probably  due  to  the  different  genetic  backgrounds  the  HD  mouse 
models  are  maintained  on,  different  expression  levels  of  mutant  huntingtin,  different  sizes 
of  N-terminal  fragments  of  mutant  huntingtin,  different  lengths  of  polyglutamine  tracts  and 
the  different  techniques  used  to  assay  the  mice. 
For  example,  the  expression  levels  of  mutant  huntingtin  among  the  transgenic  HD  models 
vary  greatly  from  line  to  line,  in  part  due  to  the  different  promoters  used  in  different 
models.  The  strong  CMV  promoter  in  the  HD89  mice  drives  high-level  expression  of 
mutant  protein.  In  contrast,  the  transgene  in  the  YAC72  mice  appears  to  produce  full- 
length  mutant  protein  at  about  30-50  %  the  level  of  endogenous  mouse  huntingtin.  In  the 
remaining  models  that  express  truncated  fragments  of  huntingtin,  the  level  of  mutant 
62 (a)  Transgenic  mouse  models  of  HD 
Mouse  Genetic  Htt  Pro  Number  Expression  Earliest  NIIs  Neuropathology  life  Ref 
line  background  expressed  of  CAG  of  m/e  (%)  motor  (mo)  span 
repeats  deficits  mo 
R6/1  CBA  Exon  1  HD  115  31  -4.5  5  NR  -10  A 
xC57BLJ6  months` 
R6t2  CBA  x  Exon  1  HD  145  75  5-6  1  all  loss  from  3-4  A 
C57BU6 
a  ceks#  14  weeks 
R6/5  CBA  Exon  1  HD  128-156  77  NR  13-  NR  15-  A 
xC57BU6  14  18 
N171-  C3H  Exon  1-4  Mouse  82  10-20  3-4  6.5  No  overt  cell  5-11  B 
82Q  xC57BL/6  Prion  months`  loss 
protein 
HD94-  CBA  Exon  1  CamK//a  94  >  100  -2.5  2  GFAP  -positive  >24  C 
tet  xC57BU6  -tTA  monthso  from  4.5  mo 
HD100  SJLx  1000  amino  Rat  100  -20  3-4  7  20%  of  cell  loss  >18  D 
C57B46  acids  of  neuron  months*  in  striatum  from 
huntingtin  specific  8  months 
enolase 
YAC-  Fvb/n  Full  HD  72  30-50  7  12  40  %  cell  loss  in  >12  E 
72  months'  striatum  from 
12  months 
HD89  Fvb/n  Full  CMV  89  400-500  -2  >3  20%  of  cell  loss  8-20  F 
months®  in  striatum  from 
6  months 
TUNEL  and 
GFAP-positive 
(b)  "knock-in"  mouse  models  of  HD 
Mouse  line  Genetic  Htt  Pro  Number  Expression  Earliest  Nlls  Neuropathology  life  Ref 
background  expressed  of  CAG  of  We  (%)  motor  (mo)  span 
repeats  deficits  mo 
Hdh°'11  CD1  Full  Hdh  111  100  24  -10  No  oven  cell  loss  >24  G, 
months  It 
Hdh/Q80  Fvb/n,  Full  Hdh  80  <100  4  -11  No  overt  cell  loss  >24  I,  ] 
(Glasgow  DBA/2,  months# 
HD  mice)  C57BU6 
CAG94  C57B1A  Full  Hdh  94  100  2  >18  No  overt  cell  loss  >12  K,  L 
months'  (up  to  8  mo) 
Hdht  X150  C57BU6  Full  Hdh  150  <100?  >  10  -10  No  overt  cell  loss,  >12  M 
months'  liosis 
Hdh77Q  C5713U6  Full  Hdh  77  <100?  NR  NO  No  overt  cell  loss,  >13  N 
gliosis 
Table  1.3  Transgenic  (a)  and  "knock-in"  (b)  mouse  models  of  HD. 
Abbreviations:  Pro,  promoter;  m/e,  mutant  huntingtin/endogenous  huntingtin;  htt, 
huntingtin;  Ref,  reference;  CMV,  cytomegalovirus;  NIIs,  neuronal  intranuclear  inclusions; 
GFAP,  glial  fibrillary  acid  protein;  mo,  month;  TUNEL,  terminal  transferase-mediated 
(TdT)  deoxyuridine  triphosphate  (d-UTP)-biotin  nick  end  labelling;  NR,  not  reported;  NO, 
not  observed;  ý  indicates  that  motor  deficit  was  detected  using  rotarod.  &  indicates  that 
motor  deficit  was  detected  by  assessing  dark  phase  activity.  @  indicates  that  motor  deficit 
was  detected  by  observation.  #  indicates  that  motor  deficit  was  detected  by  gait  analysis. 
A:  Mangiarini  et  al.,  1996.  B:  Schilling  et  al.,  1999.  C:  Yamamoto  et  al.,  2000.  D:  Laforet 
et  al.,  2001  E:  Hodgson  et  al.,  1999.  F:  Reddy  et  al.,  1998.  G:  Wheeler  et  al.,  2000.  H: 
Wheeler  et  al.,  2002.  I:  Shelbourne  et  al.,  1999.  J:  Li  et  al.,  2000.  K:  Levine  et  al.,  1999.  L: 
Menalled  et  al.,  2000.  M:  Lin  et  al.,  2001.  N:  Ishiguro  et  al.,  2001. 
63 protein  is  much  more  difficult  to  assess  because  of  the  technical  challenges  involved. 
These  include  the  fact  that  the  small  mutant  peptide  needs  to  be  compared  with  the  very 
large  endogenous  huntingtin  protein  on  the  same  blot  and  there  may  be  differences  in 
antibody  affinity  for  human  and  mouse  epitopes. 
Great  variability  of  phenotypes,  expression  levels  of  mutant  huntingtin  and  pathology  exist 
in  the  transgenic  HD  mouse  models  and  makes  comparison  between  the  different  mouse 
lines  difficult.  However,  the  studies  do  suggest  that  levels  of  the  mutant  huntingtin 
expression  and/or  the  length  of  glutamine  repeats  have  profound  effects  on  the  severity  of 
the  disease  and  mice  with  longer  repeat  expansions  have  more  widespread  neuronal 
pathology  than  those  with  shorter  repeat  expansions. 
1.4.3.2  'Knock-in'  mouse  models  of  HD 
The  expression  level  of  mutant  huntingtin  in  knock-in  models  appears  to  be  similar,  and 
this  is  not  surprising  since  their  respective  endogenous  promoters  are  identical.  Consistent 
features  of  the  knock-in  mice  include  nuclear  staining  and  microaggregates  of  huntingtin  in 
the  brains  of  mice  at  2-6  months  of  age,  Nils  only  observed  when  mice  are  older  (10-18 
months  depending  on  the  model)  and  no  significant  levels  of  cell  death  in  the  brains. 
When  `knock  in'  and  transgenic  mouse  models  of  HD  are  compared,  it  appears  that  full- 
length  mutant  huntingtin  is  less  pathogenic  than  polyglutamine-containing  N-terminal 
huntingtin  fragments.  For  example,  the  phenotype  of  the  Hdh«c"G»1S0repeat  mice  (Lin  et  al., 
2001)  is  not  as  severe  as  that  seen  in  the  R6/2  transgenic  mice  (Mangiarini  et  al.,  1996). 
These  results  suggest  that  a  polyglutamine  tract  of  a  given  length  is  more  toxic  when  it 
appears  in  the  context  of  a  smaller  protein,  underlying  the  importance  of  polyglutamine 
tract  length  as  a  determinant  of  disease  severity.  Mice  with  longer  repeats  have  more 
severe  phenotypes  and  widespread  neuropathology  than  those  with  shorter  repeat 
expansions. 
In  summary,  `knock  in'  mouse  models  showed  mild  and  late  onset  of  behavioural 
phenotypes  and  late  occurrence  of  intracellular  inclusions  without  overt  neuronal  death, 
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for  investigating  early  pathological  events  in  HD. 
1.43.3  Psychomotor  abnormalities  in  mouse  models  of  HD 
Because  psychomotor  abnormalities  are  cardinal  features  of  human  HD,  studies  of 
psychomotor  abnormalities  of  HD  mice  may  help  provide  a  basis  for  correlating  molecular 
changes  to  clinical  symptoms  and  to  test  potential  treatments. 
All  transgenic  HD  models  have  shown  early  and  progressive  psychomotor  abnormalities 
(Carter  et  al.,  1999;  Dunnett  et  al.,  1998;  Hodgson  et  al.,  1999;  Laforet  et  al.,  2001;  Lione 
et  al.,  1999;  Luesse  et  al.,  2001;  Schilling  et  al.,  1999).  Various  tools  were  used  to  assess 
the  psychomotor  function  of  mice  in  these  studies,  including  a  swimming  tank,  rotarod 
apparatus,  raised  beam  walking,  paw-print  pattern  analysis,  spontaneous  activity  measures, 
prepulse  inhibition  and  the  Morris  watermaze.  Psychomotor  abnormalities  detected  in  HD 
mice  include  hyperactivity  and  decreased  spontaneous  explorative  behaviour,  impaired 
motor  aspects  of  swimming,  poor  four-limb  co-ordination  and  balancing,  abnormal 
sensorimotor  gating  control  and  visuospatial  learning.  As  previously  mentioned  (section 
1.4.3.1),  the  different  tools  used  to  assess  the  mice,  the  different  genetic  backgrounds  the 
HD  mouse  models  are  maintained  on,  the  different  expression  levels  of  mutant  huntingtin, 
the  different  sizes  of  N-terminal  fragments  of  mutant  huntingtin,  and  the  different  lengths 
of  polyglutamine  tracts  make  it  difficult  to  directly  compare  psychomotor  abnormalities  in 
these  mouse  models. 
Motor  deficits  have  been  found  in  HdhQ111  mice  at  24  months  of  age  using  gait  analysis. 
Motor  abnormalities  have  been  found  in  CAG94  mice  at  2  months  of  age  by  observation  of 
their  daily  activity.  Deficits  in  gait  analysis  in  Hdh(CA°)1S0mice  at  10  months  of  age  have 
been  reported.  Behaviour  abnormalities  (aggressive  behaviour)  were  found  in  the  Glasgow 
HD  mice  at  3  months  of  age.  However,  similar  experiments  have  not  been  carried  out  in 
other  `knock  in'  mouse  models.  The  discrepancy  found  in  the  onset  of  the  motor  deficits  of 
knock-in  models  is  probably  due  to  the  different  CAG  repeat  length,  different  genetic 
backgrounds  of  mice  and  different  methods  used  to  detect  the  motor  abnormalities.  Since 
`knock  in'  HD  mice  are  probably  modelling  early  stages  of  HD,  extensive  studies  on 
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correlate  the  early  phenotypic  abnormalities  to  early  pathological  and  molecular  changes, 
but  also  to  provide  more  reliable  markers  for  testing  the  efficacy  of  potential  treatments 
that  might  prevent  early  pathological  events  in  the  future. 
1.4.3.4  Excitotoxicity  in  HD  mouse  models 
Post-synaptic  and  pre-synaptic  abnormalities  of  the  corticostriatal  pathway  have  been 
shown  to  be  involved  in  glutamate-induced  excitotoxicity  in  human  HD  (section  1.2.4.1). 
Further  studies  in  HD  mouse  models  have  provided  further  evidence  of  glutamate-induced 
excitotoxicity  in  HD. 
Striatal  and  cortical  neurons  in  transgenic  and  "knock-in"  HD  mouse  models  (R6/2  and 
CAG94  respectively)  displayed  more  rapid  and  increased  neuronal  swelling  in  response  to 
NMDA  agonist  exposure  than  those  in  controls  (Levine  et  al.,  1999).  An  enhancement  of 
NMDA  receptor  current  as  well  as  an  enhancement  of  intracellular  Ca"  influx  induced  by 
selective  activation  of  NMDA  receptors  have  been  reported  in  both  symptomatic  and  pre- 
symptomatic  R6/2  mice  (Cepeda  et  al.,  2001).  These  findings  indicate  that  alterations  in 
NMDA  receptor  function  in  HD  may  predispose  the  striatal  neurons  to  excitotoxic  damage, 
leading  to  subsequent  neuronal  degeneration.  Indeed,  increased  sensitivity  to  NMDA 
receptor-mediated  excitotoxicity  has  been  shown  in  YAC72  HD  mice  (Zeron  et  al.,  2002). 
Importantly,  NMDA  receptor-mediated  excitotoxicity  of  cerebellar  granule  neurons  was 
not  enhanced,  consistent  with  cell-type  and  NMDA  receptor  subtype  specificity. 
However,  contrasting  results  were  observed  in  R6/1  and  R6/2  HD  mice  that  appear  to  be 
strongly  protected  from  acute  striatal  excitotoxic  lesions  (Hansson  et  al.,  2001;  Hansson  et 
al.,  1999).  A  recent  study  has  shown  that  expression  of  an  N-terminal  fragment  of 
huntingtin  has  less  NMDR-induced  excitotoxicity  than  full-length  huntingtin  in  a  cell  line 
(Zeron  et  al.,  2001).  Indeed,  a  recent  study  showed  that  HD100  transgenic  mice  that 
express  33  %  of  the  full  length  of  huntingtin  (R6/2  mice  express  around  3%  of  the  length 
of  huntingtin)  retain  sensitivity  to  NMDR-induced  excitotoxicity,  suggesting  that  the 
sensitivity  to  NMDR-induced  excitotoxicity  is  probably  huntingtin  length  dependent 
(Petersen  et  al.,  2002).  Furthermore,  the  development  of  nuclear  inclusions  and  more 
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NMDR-induced  excitotoxicity  in  R6/2  mice.  Collectively,  the  differential  sensitivity  to 
NMDR-induced  excitotoxicity  of  R6/2  and  YAC72  mice  is  probably  due  to:  1)  R6/2  mice 
express  only  a  small  fragment  of  mutant  huntingtin  protein,  whereas  YAC72  mice  express 
the  full  length  mutant  protein  and  thus  R6/2  mice  may  bypass  the  initial  steps  of 
pathogenesis  mediated  by  mutant  full-length  huntingtin;  2)  the  size  of  polyglutamine 
stretch  is  twice  as  large  in  R6/2  mice  compared  to  YAC72  mice  3)  R6/2  mice  show 
widespread  and  abundant  intranuclear  inclusions,  whereas  those  found  in  brains  of  YAC72 
mice  are  more  sparse  and  restricted  in  distribution. 
Increasing  evidence  supporting  the  idea  that  presynaptic  changes  in  the  striatum  may  also 
contribute  to  excitotoxicity  comes  from  studies  using  HD  mouse  models.  Recently,  the 
inhibitory  effects  of  mutant  huntingtin  on  vesicular  glutamate  uptake  have  been  shown  in 
the  knock-in  HD  mouse  line,  Hdh4/Q80  (Li  et  al.,  2000a).  Further  studies  have  also  shown 
that  impaired  glutamate  uptake  activities  in  the  striatum  of  R6/2  mice  (Lievens  et  al., 
2001).  In  addition,  changes  in  cortical  pyramidal  neurons,  which  may  result  in  presynaptic 
changes,  take  place  early  in  the  disease  in  a  transgenic  HD  mouse  model  (Laforet  et  al., 
2001).  Decreased  striatal  ascorbate  release  has  been  shown  in  transgenic  R6/2  HD  mice 
(Rebec  et  al.,  2002).  Striatal  ascorbate  release  depends  on  the  activation  of  glutamate- 
releasing  afferents  from  the  cortex,  most  likely  involving  heteroexchange  with  glutamate 
during  glutamate  uptake  (O'Neill,  1995).  The  decreased  striatal  ascorbate  is  probably  due 
to  the  decreased  heteroexchange  with  glutamate,  resulting  from  a  failure  of  glutamate  re- 
uptake  (Rebec  et  al.,  2002). 
1.43.5  Increased  oxidative  stress  in  HD  mouse  models 
A  role  for  increased  oxidative  damage  in  HD  pathogenesis  has  been  addressed  in  HD 
mouse  model  studies.  R6/1  mice  showed  a  progressive  increase  in  striatal  lipid 
peroxidation  that  parallels  the  worsening  of  neurological  phenotypes  (Perez-Severiano  et 
al.,  2000).  Increased  levels  of  inducible  nitric  oxide  synthase  and  3-nitrotyrosine  (3-NT) 
immunostaining  in  the  striatum  were  also  found  in  the  R6/2  mice  but  not  in  the  control 
mouse  brains  (Tabrizi  et  al.,  2000).  Furthermore,  increased  concentrations  of  8- 
hydroxydeoxyguanosine  (8-OHdG)  was  found  in  the  urine,  plasma  and  striatal 
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staining  during  late  stages  of  the  illness  (-  12  weeks)  (Bogdanov  et  al.,  2001).  It  is 
interesting  to  note  that  increased  8-OHdG  staining  was  present  throughout  the  brain  in  both 
cortical  and  subcortical  areas,  and  not  confined  to  the  striatum  of  R6/2  mice.  In  contrast, 
increased  levels  of  carbonyl  proteins  or  lipid  peroxidation  products,  and  loss  of  aconitase 
were  not  found  in  the  forebrain  of  end  stage  N171-82Q  mice  (mice  died  at  5-6  months  of 
age),  suggesting  that  increased  oxidative  stress  did  not  contribute  to  the  phenotypes 
demonstrated  by  these  transgenic  mice  (Schilling  et  al.,  1999).  A  possible  explanation  for 
the  absence  of  increased  oxidative  stress  in  N171-82Q  mice  is  that  the  mice  died  in  early 
life  and  so  the  mice  did  not  develop  time-dependent  levels  of  increased  oxidative  stress.  In 
addition,  the  tissue  examined  is  forebrain,  but  not  striatum  that  usually  degenerates  first  in 
human  HD. 
1.43.6  Mitochondrial  abnormalities  in  HD  mouse  models 
Several  lines  of  evidence  from  studies  in  HD  mouse  models  have  suggested  that 
mitochondrial  abnormalities  are  involved  in  HD  pathogenesis.  A  significant  reduction  of 
aconitase  activity  in  the  striatum  and  a  decrease  in  complex  IV  activity  in  the  striatum  and 
cortex  have  been  shown  in  R6/2  mice  at  -12  weeks  of  age  (Tabrizi  et  al.,  2000).  Cyanide 
(complex  IV  enzyme  inhibitor)-induced,  but  not  complex  II  or  III  inhibitor-induced 
mitochondrial  depolarisation  is  greater  in  the  lymphocytes  of  HD89  mice  compared  to 
controls,  suggesting  a  selective  mitochondrial  dysfunction  in  the  lymphoblasts  of  HD89 
mice  (Sawa  et  al.,  1999). 
1.5  Mitochondrial  Biology 
Many  lines  of  evidence  suggest  that  mitochondrial  abnormalities  play  an  important  role  in 
HD  pathogenesis.  As  part  of  the  present  study  involves  the  investigation  of  mitochondrial 
integrity  in  HD  mice,  mitochondrial  biology  is  briefly  reviewed. 
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Each  mitochondrion  is  bound  by  two  highly  specialised  membranes  that  create  two 
separate  compartments:  the  internal  matrix  space  and  a  much  narrower  intermembrane 
space.  The  major  working  part  of  the  mitochondrion  is  the  matrix  and  the  inner  membrane 
that  surrounds  it. 
The  inner  membrane  is  folded  into  numerous  cristae,  which  greatly  increase  its  total 
surface  area.  It  contains  proteins  with  three  types  of  function:  1)  those  that  carry  out  the 
oxidation  reactions  of  the  respiratory  chain,  2)  an  enzyme  complex  called  ATP  synthase 
that  makes  ATP,  and  3)  specific  transport  proteins  that  regulate  the  passage  of  metabolites 
into  and  out  of  the  matrix. 
The  matrix  contains  a  highly  concentrated  mixture  of  hundreds  of  enzymes,  including 
those  required  for  the  oxidation  of  pyruvate  and  fatty  acids  and  for  the  citric  acid  cycle. 
The  matrix  also  contains  several  identical  copies  (5-10)  of  the  mitochondrial  DNA 
genome,  special  mitochondrial  ribosomes,  tRNAs,  and  various  enzymes  required  for  the 
expression  of  the  mitochondrial  genes.  The  intermembrane  space  contains  several  enzymes 
that  use  the  AT?  passing  out  of  the  matrix  to  phosphorylate  other  nucleotides. 
1.5.2  Energy  generation  by  mitochondria 
The  citric  acid  cycle,  also  known  as  the  tricarboxylic  acid  cycle  or  the  Krebs  cycle, 
oxidizes  the  acetyl  group  of  pyruvate  or  fatty  acids  to  generate  CO2  and  high-energy 
electrons,  which  pass  via  NADH  and  FADH2  to  the  respiratory  chain.  The  high-energy 
electrons  move  along  the  respiratory  chain,  eventually  combining  with  02  to  produce  H2O 
and  energy. 
Mitochondria  trap  this  energy  in  the  form  of  ATP  by  the  process  of  the  oxidative 
phosphorylation  (OXPHOS).  The  proteins  involved  in  OXPHOS  are  located  within  the 
inner  membrane  and  include  the  electron  transport  chain  (ETC)  component,  ATP  synthase 
and  the  adenine  nucleotide  translocator  (ANT).  The  high-energy  electrons  borne  on  NADH 
are  transferred  to  complex  I  (NADH  dehydrogenase)  and  then  to  coenzyme  010  (CoQ).  The 
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dehydrogenase,  SDH)  and  to  CoQ.  From  CoQ,  the  electrons  are  passed  to  complex  III 
(cytochrome  b-c,  ),  then  to  cytochrome  c  (cyt  c),  then  to  complex  IV  (cytochrome  c 
oxidase).  The  energy  released  is  used  to  pump  protons  (H*)  out  of  the  inner  membrane  to 
create  an  electrochemical  gradient  (Delta  Psi)  that  is  positive  and  acid  on  the  outside,  and 
negative  and  alkaline  on  the  mitochondrial  matrix  side.  This  creates  a  capacitor  that  can  be 
depolarised  by  the  transport  of  protons  back  into  matrix  through  a  proton  channel  in  the  FO 
membrane  component  of  ATP  synthase  (ATPase).  The  proton  flux  drives  the  ADP  and  P, 
(inorganic  phosphate)  to  make  ATP,  which  is  then  exported  to  the  cytosol  in  exchange  for 
the  spent  ADP  by  the  ANT.  In  this  way,  oxygen  consumption  by  the  ETC  is  coupled  to 
ADP  phosphorylation  by  the  ATPase  through  the  electrochemical  gradient  (Wallace, 
1999). 
1.5.3  The  mitochondrial  genome 
In  addition  to  the  genetic  information  housed  in  the  cell  nucleus,  most  animal  cells  also 
contain  a  mitochondrial  genome.  In  vertebrates,  mitochondrial  DNA  (mtDNA)  is  present 
in  multiple  copies  (usually  103-104  copies/cell).  Vertebrate  mtDNA  is  a  circular  double 
stranded  DNA  -16-18  Kb  in  length,  coding  for  seven  of  the  43  subunits  of  complex  I 
(ND1,2,3,4,4L,  5,  and  6),  one  of  the  11  subunits  of  complex  III  (cytocchrome  b,  cyt  b), 
three  of  the  13  subunits  of  complex  IV  (COI,  COII,  and  COIII)  and  two  of  16  subunits  of 
ATPase  (ATPase  6  and  8).  It  also  codes  for  the  small  and  large  rRNAs  and  22  tRNAs 
(Shadel  and  Clayton,  1997). 
1.5.4  Mitochondrial  transcription 
The  two  mtDNA  strands  can  be  separated  on  denaturing  cesium  chloride  gradients,  owing 
to  a  strand  bias  in  G+T  content.  They  are  thus  designated  the  heavy  strand  (H-strand)  and 
the  light  strand  (L-strand).  Transcription  of  each  strand  occurs  from  one  or  two  promoters 
(depending  on  the  species).  These  promoters  are  designated  as  either  a  light-strand 
promoter  (ISP)  or  a  heavy-strand  promoter  (HSP),  depending  on  which  mtDNA  strand 
serves  as  the  template  for  transcription.  Transcriptional  initiation  appears  to  require  only  a 
few  nuclear-coded  protein  factors.  Transcription  of  the  H-strand  begins  at  the  light-strand 
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most  likely  a  second  transcription  factor.  Large  polycistronic  transcripts  are  produced  from 
each  strand  that  are  then  processed  to  generate  mature  tRNAs,  rRNAs  and  mRNAs 
(Clayton,  1991). 
Transcripts  made  on  the  H  strand  are  extensively  cleaved  by  RNA  processing  events  to 
yield  two  rRNAs,  14  tRNAs,  and  10  poly  A-containing  RNAs  (Doersen  et  al.,  1985).  In 
contrast,  the  L  strand  transcript  is  processed  to  produce  only  8  tRNAs  and  1  small  poly  A- 
containing  RNA.  The  remaining  90  %  of  this  transcript  apparently  contains  no  useful 
information  (being  complementary  to  coding  sequences  synthesised  on  the  other  strand) 
and  is degraded.  The  poly  A-containing  RNAs  are  the  mitochondrial  mRNAs.  Although 
they  lack  a  cap  structure  at  their  5'  end,  they  carry a  poly-A-tail  at  their  3'  end  that  is  added 
post-transcriptionally  by  a  mitochondrial  poly  A  polymerase  (Clayton,  1991). 
The  mRNA  species  corresponding  to  all  the  protein-coding  regions  have  been  identified; 
and  in  each  case,  an  initiation  codon  lies  within  six  bases  of  start  of  the  transcript.  The 
codon  used  for  initiation  apparently  can  be  AUG,  AUA,  or  AUU,  which  is  different  to 
those  used  for  initiation  of  nuclear  transcription.  Non-translated  5'and  3'  regions  of 
transcripts  are  virtually  absent.  Almost  all  of  the  genes  are  expressed  in  the  clockwise 
direction  (transcripts  made  on  H  strand)  (Fig.  1.1).  In  only  one  case  are  two  clockwise 
coding  regions  found  in  the  form  of  contiguous  genes  (ATPase  6  and  C03)  (Fig.  1.1).  In 
every  other  case,  at  least  one  tRNA  gene  separates  adjacent  coding  regions.  The 
punctuation  of  rRNA-  and  protein-coding  regions  by  tRNA  genes  does  not  leave  room  for 
promoters  such  as  those  found  in  eukaryotic  nuclei.  A  single  promoter  for  clockwise 
transcription  is  located  in  the  D-loop  of  the  H-strand  (Fig.  1.1).  Transcription  starts  just 
before  the  tRNA  gene  in  front  of  the  12S  rRNA  gene,  and  continues  almost  all  the  way 
around  the  circle,  to  terminate  in  the  D-loop.  The  significance  of  the  alternation  of  tRNA 
genes  with  rRNA-  and  protein-coding  genes  is  that  the  tRNAs  indicate  sites  of  cleavage. 
By  cleaving  the  primary  transcript,  which  is  mediated  by  a  mitochondrial  RNase  P,  on 
either  side  of  each  tRNA  gene,  all  of  the  genes  except  ATPase  6  and  C03  give  rise  to 
monocistronic  products  (Doersen  et  al.,  1985).  The  rRNA  molecules  appear  to  be 
synthesized  in  greater  amounts  than  the  mRNAs.  This  could  be  caused  by  premature 
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Figure  1.1  Schematic  representation  of  a  vertebrate  mitochondrial  genome.  Vertebrate 
mitochondrial  DNA  contains  22  tRNA  genes,  2  rRNA  genes,  and  13  protein-coding 
regions.  12  of  the  13  protein-coding  and  2  rRNA-coding  regions  and  14  of  the  tRNA 
genes  are  transcribed  in  the  clockwise  direction.  1  protein-coding  gene  and  8  tRNA  genes 
are  read  counter  clockwise.  indicates  tRNA  genes.  Thin  arrows  indicate  orientation 
of  the  gene  coding  sequence  5'-3'.  CO:  cytochrome  c  oxidase.  ND:  NADH  dehydrogenase. 
The  D-loop  form  of  mtDNA  is  shown  with  the  D-loop  regulatory  region  expanded  at 
the  top  of  figure.  The  mtDNA  H-strand  and  L-strand  are  depicted  as  heavy  and  thin  lines, 
respectively.  The  nascent  H-strand  (D-loop  strand,  thick  arrow)  is  shown  bound  (dashed 
lines)  to  the  parental  L-strand  and  displacing  the  parental  H-strand  (bubble)  to  form  the 
D-loop.  The  origin  of  H-strand  (Oll)  synthesis  is  labeled.  The  heavy-strand  promoter 
(HSP)  and  light  strand  promoter  (LSP)  are  depicted  as  bent  arrows  in  the  D-loop 
regulatory  region.  This  figure  is  modified  from  Figure  1  in  Shadel  et  al.,  1997  Annu. 
Rev.  Biochem.  66:  409-435. 
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C02  col have  been  transcribed.  This  idea  has  been  supported  by  the  observation  that  the  polymerase 
transcribing  the  rRNA  genes  more  frequently  stops  at  the  3'  end  of  16S  rRNA  due  to  the 
binding  of  a  mitochondrial  transcription  termination  factor  (mTERF)  to  mtDNA  (Kruse  et 
al.,  1989).  Mitochondrial  DNA  therefore  presents  the  closest  analogy  to  a  bacterial  operon 
in  eukaryotes.  It  is  transcribed  from  a  single  region,  but  individual  tRNAs,  rRNAs,  and 
mRNAs  are  released  from  the  transcript.  Processing  of  the  transcript  therefore  becomes  the 
central  event  in  gene  expression.  The  correct  production  of  5'  and  3'  ends  of  mitochondrial 
mRNA  is  important  for  mRNA  stability.  Incorrectly  processed  mRNA  is  often  either 
unstable  or  untranslatable. 
1.5.5  Replication  of  mitochondrial  DNA 
In  all  vertebrates  examined  to  date,  the  mtDNA  molecule  contains  a  non-coding  region  that 
harbours  the  promoters  for  transcription  initiation  and  a  closely  associated  origin  of  H- 
strand  DNA  replication.  In  this  region,  a  unique  displacement-loop  (D-loop)  form  of  the 
mtDNA  molecule  arises  from  the  template-directed  termination  of  H-strand  DNA  synthesis 
soon  after  initiation.  The  arrested  nascent  H-strand  remains  stably  hybridised  to  the 
circular  parental  molecule,  forming  a  triple-strand  structure  characterised  by  the  displaced 
parental  H-strand.  Because  the  promoters  and  leading-strand  origin  are  located  near  the  5'- 
boundary  of  the  D-loop  structure,  this  entire  locus  is  commonly  referred  to  as  the  D-loop 
regulatory  region  or  mtDNA  control  region  (Fig.  1.1). 
Mammalian  mtDNA  replication  begins  at  011,  which  is  located  directly  downstream  of  the 
LSP  in  the  D-loop  region  of  the  molecule.  This  fact  coupled  with  biochemical  analysis  of 
early  replication  intermediates,  has  led  to  a  model  in  which  RNA  transcripts  derived  from 
the  LSP  are  processed  to  yield  primers  for  H-strand  DNA  replication  (Clayton,  1991). 
Mammalian  mitochondrial  promoters  have  a  bipartite  structure  consisting  of  one  region 
encompassing  the  site  for  transcription  initiation,  and  a  second  region  upstream  that  is  the 
binding  site  for  a  transcription  factor,  mtTFA  (Chang  and  Clayton,  1984).  The  mtTFA 
molecule  has  the  ability  to  bend  and  unwind  the  DNA  upon  binding  (Fisher  et  al.,  1992). 
Therefore,  the  ability  of  mtDNA  to  activate  transcription  requires  binding  to,  and 
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initiation  site. 
In  all  vertebrates,  transcription  initiation  from  mitochondrial  promoters  in  vitro  requires  a 
mitochondrial  RNA  polymerase  (mtDNA  polymerase),  mtTFA  and  likely  a  second 
transcription  factor,  mtTFB  (Chen  et  al.,  1996)  (Fig.  1.2a).  Precise  mapping  of  RNA  and 
DNA  species  in  the  D-loop  region  provided  evidence  that  RNA  derived  from  the  LSP  can 
serve  as  a  primer  for  H-strand  DNA  replication  (Chang  et  al.,  1985).  As  transcription 
proceeds  across  the  origin,  a  RNA/DNA  hybrid  forms  which  involves  some  subsets  of  the 
conserved  sequence  blocks  (termed  CSBI,  CSBII,  CSBIII)  (Fig.  1.2b).  Evidence  has 
accumulated  suggesting  that  the  CSBs  are  involved  in  forming  a  properly  configured  RNA 
substrate  for  the  activities  that  process  the  mitochondrial  primer  RNA  (Xu  and  Clayton, 
1996).  Formation  of  a  stable  RNA-DNA  hybrid  structure  at  O￿  is  an  important  feature  for 
H-strand  replication  (Xu  and  Clayton,  1996). 
For  a  RNA  molecule  to  serve  as  a  primer  for  initiating  DNA  replication  it  must  provide  a 
donor  3'-hydroxyl  group  for  extension  by  DNA  polymerase.  To  provide  a  properly 
positioned  primer,  the  LSP  transcript  must  either  terminate  or  be  processed  at  sites  near  OIL 
A  site-specific  mitochondrial  RNA  processing  endoribonuclease  (RNase  MRP)  with  this 
activity  was  identified  in  mouse  and  human  cells.  RNase  MRP  does  not  cleave  single- 
strand,  origin-containing  RNAs  (Bennett  et  al.,  1992).  Evidence  has  suggested  that  the 
substrate  for  RNA  processing  is  likely  the  triple  RNA-DNA  hybrid  rather  than  single- 
strand  RNA  and  shown  that  cleavage  of  RNA-DNA  hybrid  were  completely  dependent  on 
the  presence  of  CSB  I  (Lee  and  Clayton,  1997)  (Figure  1.2c). 
In  vertebrates,  apparently  only  one  DNA  polymerase,  pol  y,  is devoted  to  mtDNA 
synthesis  (Figure  1.2d).  Pol  y  is  distinguished  from  other  cellular  DNA  polymerases  by 
certain  chemical  criteria,  including  high  activity  using  synthetic  RNA  templates  in  vitro, 
inhibition  by  both  N-methylmaleimide  and  dideoxynucleoside  triphosphates  (ddNTPs), 
resistance  to  aphidicolin  and  stimulation  by  salt.  Pol  y  from  all  sources  contain  3'-5' 
exonuclease  activity  (Gray  and  Wong,  1992).  Mutations  in  the  exonuclease  domain  result 
in  increased  mtDNA  mutation  rates  in  vivo,  consistent  with  a  role  for  this  region  in 
proofreading  misincorporated  nucleotides.  As  is  the  case  of  nuclear  DNA  polymerase,  pol. 
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Figure  1.2  A  general  model  for  initiation  of  vertebrate  H-strand  replication.  The  parental 
mtDNA  H-strand  and  L-strand  are  depicted  as  parallel  heavy  and  thin  lines,  respectively. 
Nascent  light  strand  promoter  (LSP)  RNA  transcripts  and  nascent  DNA  H-strands  are 
depicted  as  thin  and  heavy  arrows  respectively.  The  bubble  represents  the  displaced 
parental  H-strand.  The  initiation  mechanism  is  divided  into  four  steps  (a-d).  a)  The  process 
begins  with  the  initiation  of  transcription  at  a  light-strand  promoter.  This  involves  the  core 
RNA  polymerase  (grey  oval),  mtTFA  (white  oval),  and  most  likely  a  second  transcription 
factor,  mtTFB  (white  circle).  b)  As  transcription  proceeds  across  the  region,  a  RNA/DNA 
hybrid  (dashed  lines)  forms  involving  a  subset  of  the  CSBs  (CSB  I,  II,  and  III). 
c)  The  RNA/DNA  hybrid  ultimately  forms  a  stable  R-loop  configuration  that  creates  the 
substrates  for  RNA  processing  activities  (arrows)  that  lead  to  the  formation  of  RNA 
primers.  The  cleavage  pattern  generated  by  RNase  MRP  (grey  diamond)  on  synthetic 
R-loop  substrates  suggests  that  it  is  an  important  mtRNA  primer  processing  activity  in 
mitochondria.  d)  Initiation  of  H-strand  replication  (heavy  arrow  with  attached  circle) 
through  extension  of  an  RNA  primer  (thin  line  attached  to  circle)  by  DNA  polymerase  y 
(grey  rectangle),  initiates  near  CSB  I 
(Oii). 
This  figure  is  based  on  Figure  2  in 
Shadel  et  al.,  1997  Annu.  Rev.  Biochem.  66:  409-435. 
75 y  needs  to  associate  with  accessory  factors.  Mitochondria  from  several  organisms  contain  a 
single-stranded  DNA-binding  protein  (SSB)  that  is  similar  to  E.  coli  SSB,  both  in  amino 
acid  sequence  and  DNA-binding  properties.  Consistent  with  a  role  in  mtDNA  replication, 
SSB  stimulates  pol  y  activity  in  vitro  (Williams  and  Kaguni,  1995)  and  functions  in  helix 
destabilization  (Van  Tuyle  and  Pavco,  1985).  Also,  mtDNA  helicase  activity  has  been 
isolated  from  bovine  brain  tissue  and  is  predicted  to  act  on  the  mtDNA  template  ahead  of 
pol  y  (Hehman  and  Hauswirth,  1992). 
The  triplex  D-loop  is  a  conserved  feature  of  mtDNA  in  vertebrates,  which  suggests  that  it 
plays  a  crucial  role  in  mtDNA  metabolism.  Possible  roles  for  the  stable  D-loop  include 
maintaining  a  given  number  of  mtDNA  molecules  in  a  state  primed  for  subsequent  DNA 
replication  (Clayton,  1982),  and  providing  a  mtDNA  configuration  that  is  necessary  either 
for  transcription  regulation  (King  and  Low,  1987)  or  for  mtDNA  segregation.  In  some  cell 
types,  increased  D-loop  frequency  has  been  correlated  with  increased  oxidative  demand 
(Annex  and  Williams,  1990).  In  Xenopus  laevis,  elevated  D-loop  frequency  is  observed 
when  mtDNA  proliferates  during  oogenesis  (Callen  et  al.,  1983).  Such  findings  suggest 
that  D-loop  formation  and  frequency  is  regulated.  The  D-loop-containing  form  of  mtDNA 
arises  from  premature  termination  of  H-strand  synthesis  downstream  of  0,,.  The  terminated 
nascent  H-strand  remains  associated  with  the  parental  duplex.  3'-ends  of  D-loop  DNA 
strands  occurs  at  specific  locations  that  are  apparently  directed  by  short  (15  bp)  template 
sequences  (Doda  et  al.,  1981).  These  termination-associated  sequences  (TASs)  are  well 
conserved  in  vertebrates  and  are  found  at  similar  positions  upstream  of  the  D-loop  DNA  3'- 
ends  that  have  been  mapped  (Foran  et  al.,  1988).  These  findings  suggest  that  nascent  D- 
loop  strand  termination  is  a  template-directed  event  and  may  represent  one  potential 
control  point  for  regulating  D-loop  formation  in  vivo. 
1.5.5.1  Regulation  of  mtDNA  replication 
Linkage  of  transcription  to  H-strand  mtDNA  replication  in  vertebrates  suggests  that 
mtDNA  copy  number  may  be  controlled  ultimately  by  the  frequency  of  transcription 
initiation  at  the  LSP.  Because  of  its  documented  role  in  transcription  initiation,  much 
attention  has  been  directed  toward  understanding  mtTFA  structure,  function,  and 
regulation.  Human  mtTFA  contains  two  high-motility-group  (HMG)  boxes,  and  a  C- 
76 terminal  tail.  Studies  on  the  mechanism  of  transcriptional  activation  of  mtTFA  have 
revealed  that  human  mtTFA  (h-mtTFA)  forms  a  specific  DNA-binding  complex,  mediated 
by  both  HMG-box  domains  and  stabilised  by  the  C-terminal  tail,  which  promotes  a  specific 
bent  structure  in  the  DNA  that  allows  the  mitochondrial  RNA  polymerase  to  initiate 
transcription  (Dairaghi  et  al.,  1995). 
Regulation  of  mitochondrial  DNA  (mtDNA)  expression  is  crucial  for  mitochondrial 
biogenesis  during  development  and  differentiation.  Mitochondrial  transcription  factor 
(mtTFA)  has  been  demonstrated  to  regulate  mtDNA  copy  number  in  vivo  and  is  essential 
for  mitochondrial  biogenesis  and  embryonic  development  (Larsson  et  al.,  1998). 
Consistent  with  a  role  in  regulating  mtDNA  copy  number,  the  level  of  h-mtTFA  varies 
concomitantly  with  the  level  of  mtDNA  in  human  cells.  Firstly,  cultured  human  cells, 
depleted  of  mtDNA  by  treatment  with  ethidium  bromide,  contain  extremely  low  levels  of 
human-mtTFA  (h-  mtTFA)  (Davis  et  al.,  1996).  Secondly,  h-mtTFA  is  reduced  in  tissues 
from  patients  who  exhibit  a  mtDNA-depletion  phenotype  (Poulton  et  al.,  1994)  and  is 
elevated  in  tissues  from  patients  who  have  an  accumulation  of  mtDNA.  The  authors 
suggested  that  h-mtTFA  deficiency  in  these  patients  might  be  due  to  reduced  production  or 
stability  of  the  h-mtTFA  protein  in  tissues  with  diminished  mtDNA.  Some  studies  have 
shown  that  mRNA  of  h-mtTFA  can  be  elevated  in  cells  depleted  of  mtDNA  (Miranda  et 
al.,  1999).  However,  in  other  studies,  no  increased  or  decreased  levels  of  mtTFA  mRNA 
were  detected  after  mtDNA  depletion  by  ethidium  bromide  (Moraes  et  al.,  1999).  Although 
previous  studies  have  revealed  some  conflicting  results,  there  are  several  lines  of  evidence 
to  suggest  that  mtDNA  replication  is  regulated  by  coordinating  signals  from  the  nucleus 
and  mitochondria. 
Recently,  pol  y  has  been  examined  as  a  potential  mtDNA  regulatory  factor.  Mitochondrial 
DNA  depletion  in  AIDS  patients  appears  to  be  caused  by  the  inhibition  of  pol  y  activity  by 
antiviral  drugs  (Benbrik  et  al.,  1997).  However,  in  cells  lacking  mtDNA,  and  hence 
mtDNA  replication,  pol  y  was  expressed  in  a  stable  form  and  at  normal  levels,  suggesting 
that  pol  y  level  is  not  responsive  to  the  amount  of  mtDNA  in  a  cell  (Davis  et  al.,  1996). 
This  study  did  not  implicate  pol  y  as  a  major  regulator  of  mtDNA  copy  number.  These 
findings  indicate  that  other  nuclear-encoded  proteins  such  as  SSB,  mitochondrial  RNA 
77 processing  endoribonuclease  and  DNA  helicase  may  also  play  a  significant  role  in 
regulating  mtDNA  replication. 
1.5.6  Regulation  of  mitochondrial  biogenesis 
The  OXPHOS  capacity  can  vary  widely  in  different  tissues  of  the  body.  Thus,  during 
development  from  a  fertilised  oocyte  to  a  multicellular  organism,  mitochondrial  biogenesis 
is  regulated  and  OXPHOS  capacity  is  adapted  to  the  different  energy  demands  of  particular 
cell  types.  In  addition,  adult  animal  cells  can  also  adjust  OXPHOS  capacity  to  changing 
energy  demands  caused  by  various  physiological  or  pathological  conditions. 
Increased  transcription  of  mtDNA  seems  to  be  a  hallmark  of  mitochondrial  biogenesis  as 
an  adaptation  to  changes  of  energy  demands  caused  by  various  physiological  or 
pathological  conditions.  For  example,  the  number  of  mitochondria  increases  through  foetal 
life,  accompanied  by  increases  of  both  mtDNA  copy  number  and  mitochondrial  transcript 
levels  (Ostronoff  et  al.,  1996).  In  addition,  in  many  instances  of  mitochondrial  biogenesis 
stimulated  by  various  physiological  challenges,  increased  levels  of  mRNAs  for  both 
nuclear-  and  mitochondrial-encoded  OXPHOS  subunits  are  also  found,  emphasizing  the 
important  role  of  transcriptional  regulation.  Examples  where  this  occurs  include  endurance 
training  of  skeletal  muscle  (Hood  et  al.,  1989;  Williams,  1986),  hyperthyroidism  in  liver 
and  skeletal  muscle  (Wiesner  et  al.,  1992)  and  hyperglucocorticoidism  in  colon  epithelium 
(Rachamim  et  al.,  1995).  In  contrast,  during  cold  adaptation  in  brown  tissue  (Klingenspor 
et  al.,  1996)  and  during  heart  hypertrophy  induced  by  thyroid  hormones,  the  increase  of 
functional  mitochondrial  mass  is  brought  about  not  only  by  elevated  levels  of  such 
transcripts,  but  at  the  same  time  by  an  additional,  specific  stimulation  of  mitochondrial 
translational  capacity  (Leung  and  McKee,  1990;  Wiesner  et  al.,  1994).  Similarly,  the  rapid 
rise  of  OXPHOS  capacity  around  birth  in  developing  rat  liver  was  attributed  mainly  to 
stimulation  of  translation,  both  in  the  cytosol  and  mitochondrial  compartments  (Ostronoff 
et  al.,  1996).  It  remains  to  be  shown  whether  such  a  stimulation  of  mitochondrial 
translation  also  occurs  during  the  adaptive  processes  mentioned  above,  in  which 
mitochondria  increase  in  both  number  and  size  (training  of  skeletal  muscle),  or  size  only 
(hyperthyroid  state  of  liver  and  muscle).  With  the  exception  of  some  forms  of  skeletal 
muscle  training  and  heart  hypertrophy  induced  by  thyroid  hormones,  the  copy  number  of 
78 mtDNA  was  found  to  be  unchanged  under  most  conditions,  emphasising  that  up-regulation 
of  mtDNA  copy  number  is  probably  of  minor  importance  for  adaptive  stimulation  of 
mitochondrial  biogenesis  (Wiesner,  1992b). 
1.5.7  Reactive  oxygen  species  and  regulation  of  mitochondrial 
biogenesis 
Levels  of  mtTFA  mRNA  is  elevated  in  cells  experiencing  increased  oxidative  stress 
(Miranda  et  al.,  1999).  Levels  of  cytochrome  cl  and  cytochrome  b  mRNA  also  increase 
after  exposure  to  oxidative  stress  mediated  by  antimycin  A,  an  inhibitor  of  the 
mitochondrial  cytochrome  bcl  complex  (Suzuki  et  al.,  1998).  Furthermore,  in  the  hearts  of 
rats  or  patients  with  defects  in  energy  production,  mRNAs  of  both  nuclear  DNA-  and 
mtDNA-encoded  OXPHOS  genes  and  mtTFA  mRNA  have  been  shown  to  increase,  and  it 
has  been  suggested  that  this  is  mediated  through  ROS  (Heddi  et  al.,  1999;  Wiesner  et  al., 
1999).  All  of  above  studies  support  the  idea  that,  in  principle,  reactive  oxygen  species 
could  stimulate  expression  of  OXPHOS  genes  and  mtTFA  and  they  may  form  part  of  a 
mitochondrion-nucleus  regulatory  signalling  pathway. 
However,  there  is  still  some  uncertainty  about  whether  the  ROS  stimulates  or  represses  the 
biogenesis  of  mitochondria.  For  example,  one  study  demonstrated  that  an  oxidative  insult 
specifically  decreased  levels  of  a  mitochondrial  transcript  which  is  an  incompletely 
processed  product  of  the  mitochondrial  genome  encompassing  ATPase  subunit  6  and  8 
plus  the  adjacent  gene  for  cytochrome  c  oxidase  (Elliott  et  al.,  1999).  In  addition,  mtDNA 
depletion  and  a  compensatory  increase  of  mtDNA  transcription  rates  have  been  shown  in 
liver  after  alcohol  administration  that  caused  oxidative  stress  (Mansouri  et  al.,  1999). 
Similarly  mtDNA  depletion  has  been  shown  in  Freidriech's  ataxia,  a  condition  associated 
with  increased  oxidative  stress  (Bradley  et  al.,  2000).  Reduced  mtDNA  transcription  has 
been  reported  in  a  senescent  rat  heart  (Andreu  et  al.,  1998),  despite  the  fact  that  mtDNA 
content  appears  to  increase  with  aging  (Lee  et  al.,  1998).  Since  age  is  a  condition 
associated  with  increased  oxidative  stress,  these  studies  suggest  that  the  responses  of 
mtDNA  replication  and  mtDNA  transcription  to  increased  oxidative  stress  may  be 
different. 
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Mitochondria  biogenesis  requires  the  ordered  synthesis  of  the  requisite  proteins  and  lipids 
and  delivery  of  each  component  to  correct  organelle  subcompartments.  While  most  of  the 
proteins  in  mitochondria  are  encoded  by  nuclear  DNA,  some  are  encoded  by  mtDNA  and 
synthesized  on  ribosomes  within  the  mitochondria.  Contributions  from  the  two  genetic 
systems  to  the  construction  of  mitochondria  are  closely  coordinated  in  the  cell  (Poyton  and 
McEwen,  1996). 
The  nuclear  genome  exerts  a  great  deal  of  control  over  mitochondrial  gene  expression  and 
the  protein  import,  export,  and  assembly  pathways  required  for  biogenesis  of  functional 
mitochondria.  One  study  has  shown  that  transcription  of  human  mtTFA  is  activated  by 
NRF-1  (nuclear  respiratory  factor  1)  and  NRF-2  (nuclear  respiratory  factor  2),  two  general 
transcription  factors  that  regulate  expression  of  several  cellular  proteins  including  subunits 
of  mitochondrial  respiratory  proteins  encoded  by  nuclear  DNA  (Virbasius  and  Scarpulla, 
1994).  It  is  therefore  possible  that  the  expression  of  nuclear  and  mitochondrial  genes  in 
mammals  could  be  co-regulated  globally  through  NRF-1  and  NRF-2  proteins. 
Biogenesis  of  mitochondria,  either  during  development  or  in  response  to  an  alteration  in 
physiological  or  pathological  processes,  is  controlled  through  interactions  of  the  nuclear 
and  mitochondrial  genomes,  although  the  signal  transduction  pathways  that  connect  the 
two  genomes  are  not  well  understood.  Both  of  the  nuclear  and  mitochondrial  genomes 
contribute  essential  subunit  polypeptides  to  mitochondrial  proteins  and  they  collaborate  in 
the  synthesis  and  assembly  of  these  proteins. 
1.6  The  aims  of  study 
As  previously  reviewed,  whilst  many  aspects  of  HD  remain  unresolved,  several  lines  of 
evidence  suggest  that  mitochondria  play  a  central  role  in  excitotoxicity,  energy  failure  and 
oxidative  stress,  all  of  which  have  been  implicated  in  HD  pathogenesis.  Further  studies  of 
mitochondrial  function  in  HD  may  shed  light  on  the  mechanism  and  molecular  pathology 
of  HD.  To  this  end,  a  HD  "Knock-in"  mouse  model  (termed  the  Glasgow  HD  mice  and 
80 described  in  Shelboume  et  al.,  1999)  was  used  to  study  the  functional  consequences  of  the 
full-length  mutant  huntingtin  protein. 
The  Glasgow  HD  mice  were  generated  by  introducing  an  HD-like  mutation  (an  extended 
stretch  of  72-80  CAG  repeats)  into  the  endogenous  mouse  Hdh  gene.  Histological 
examination  of  Glasgow  HD  mouse  brains  revealed  that  mutant  brains,  on  average,  were 
10-15  %  smaller  than  normal  at  4-6  and  16-17  months  of  age,  although  no  significant 
neuronal  loss  was  detected  (Shelbourne  et  al.,  1999).  Mutant  mice  also  display  aggressive 
behaviour  at  3  months  of  age  and  electrophysiological  deficits  (a  significant  reduction  in 
long-term  potentiation)  at  8  months  of  age  (Usdin  et  al.,  1999),  suggesting  learning  and 
memory  impairments.  However,  studies  of  locomotor  performance  including  beam 
walking  and  rope  tests  did  not  show  significant  differences  between  HD  mice  and  wild- 
type  littermates  at  17  months  of  age  (Peggy  Shelboume,  unpublished  data). 
Glasgow  HD  mice  also  display  progressive  formation  of  nuclear  aggregates  in  the  striatum 
when  immunodetected  with  EM48  antibody  (Li  et  al.,  2000a).  At  4  months  of  age,  only 
weak  nuclear  staining  was  seen  in  the  striatum,  but  by  11  months  of  age,  this  nuclear 
staining  had  become  more  intense,  with  small  puncta.  By  21-27  months,  many  nuclear 
aggregates  had  appeared  and  nuclei  often  contained  a  single,  large  aggregate.  At  the  same 
time,  the  striatum  also  contained  neuropil  aggregates  aligned  in  linear  arrays  reminiscent  of 
processes.  However,  these  neuropil  aggregates  appeared  much  later  than  intranuclear 
aggregates  and  were  prominent  in  older  mice.  In  addition  to  intranuclear  aggregates, 
medium  spiny  neurons  also  formed  aggregates  in  their  processes  and  axonal  terminals  and 
they  might  interfere  with  the  synaptic  vesicle  function  of  glutamate  uptake  (Li  et  al., 
2000a).  This  finding  suggests  that  the  axonal  terminal  aggregates  may  contribute  to  the 
excitotoxicity  in  HD.  Investigation  of  the  repeat  size  of  individual  mutation  alleles  in 
tissues  of  Glasgow  HD  mice  has  shown  that  the  mutation  becomes  very  unstable  in  striatal 
tissue  and  repeat  instability  may  occur  by  mechanisms  that  are  not  replication-based 
(Kennedy  et  al.,  2000).  It  has  been  postulated  that  oxidative  damage  of  DNA  may  initiate 
DNA  repair  that  lead  to  mutation  expansion. 
Given  that  the  Glasgow  HD  mice  have  detectable  phenotypes  and  pathological  changes 
reminiscent  of  early  stages  of  human  HD,  more  thorough  experiments  investigating  motor 
81 function  and  molecular  pathology  in  these  mice  were  performed  and  the  aims  of  the  study 
were: 
1)  to  investigate  and  quantify  the  phenotypic  features  of  the  HD  mice  including  motor 
function,  weight  profile  and  limb  clasping; 
2)  to  investigate  mitochondrial  function  and  increased  oxidative  stress  as  early 
molecular  changes  in  HD  mouse  brain; 
3)  to  correlate  the  phenotypic  consequences  and  molecular  changes  in  the  HD  mice, 
with  a  view  to  providing  information  for  developing  therapeutic  strategies  in  the 
future. 
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2.1  Materials 
2.1.1  Chemicals  and  reagents 
Chemicals  of  molecular  biology  grade  were  obtained  from  Merck  Ltd.  (BDH  Laboratory 
Supplies),  except  for  the  following: 
Boric  acid,  sodium  dodecyl  sulphate  (SDS),  Trizma  base,  polyethylene  glycol  8000  (PEG), 
3-N-morpholino-propanesulfonic  acid  (MOPS),  Triton  X-100,  sodium  acetate, 
polyoxyethylene  sorbitan  monolaurate  (Tween  20),  dextran  sulphate,  diethyl  pyrocarbonate 
(DEPC),  paraformaldehyde,  hydrogen  peroxide,  sodium  hydroxide,  salmon  sperm  DNA, 
isopropylthio-ß-D-galactoside  (IPTG),  5-bromo-4-chloro-3-indolyl--ß-D-galactoside  (X- 
gal),  glycerol,  Ficoll,  dimethylsulfoxide  (DMSO)  and  poly-L-lysine  were  obtained  from 
Sigma  Chemical  Company  Ltd. 
Diaminoethanetetra-acetic  acid  disodium  salt  (EDTA),  sucrose,  chloroform,  methanol,  and 
disodium  hydrogen  orthophosphate  dihydrate  were  obtained  from  Fisher  Scientific 
International  Company. 
Bovine  serum  albumin  (fatty  acid  free,  BSA)  was  obtained  from  Boehringer  Mannheim  UK 
Ltd. 
G-50  Sephadex,  G-25  Sephadex  were  supplied  by  Amersham  Pharmacia  Biotech,  UK,  Ltd. 
Nonidet®P-40  was  obtained  from  Calbiochem. 
Hematoxylin  and  eosin  were  obtained  from  Surgipath. 
DPX  mounting  medium  was  purchased  from  Lamb. 
Histoclear  was  supplied  by  National  Diagnostics. 
83 2.1.2  Membranes  and  radiochemicals 
The  following  nylon  membranes  and  radiochemicals  were  obtained  from  Amersham 
Pharmacia  Biotech,  UK,  Ltd:  Hybond  N,  20  cm  wide  roll;  Hybond  N  plus,  20  cm  wide  roll; 
[y-32P}  AT?  (5000  Ci/mmol,  10  µCi/µl);  [a-32P]  dCTP  (3000  Ci/mmol,  10  µCi/µl). 
Biodyne  B  membranes,  30  cm  x3m,  for  northern  blot  analysis  were  obtained  from  Pall 
Gelman  Laboratory.  PVDF  membranes,  Immobilon  "'-P,  for  western  blotting  analysis  were 
obtained  from  Millipore.  3MM  chromatography  paper  was  supplied  by  Whatmann. 
2.1.3  Polymerase  chain  reaction  (PCR) 
All  PCR  amplifications  were  carried  out  in  a  thermal  cycler  (GeneAmp  PCR  System  9700, 
PE  Applied  Biosystem),  in  thin  walled  200  µl  tubes  (Anachem). 
2.1.4  DNA,  RNA,  and  Protein  markers 
All  DNA  samples  that  were  electrophoresed  on  gels  were  measured  against  the  1  kb  DNA 
size  ladder  or  the  1  kb  plus  DNA  size  ladder  (GibcoBRL). 
All  RNA  samples  electrophoresed  on  gels  were  measured  against  the  0.24-9.5  kb  RNA 
ladder  (GibcoBRL). 
All  protein  samples  that  were  electrophoresed  on  gels  were  measured  against  the  Sea  Blue 
Standard  (Novex,  Invitrogen). 
2.1.5  Gel  electrophoresis 
Agarose  was  obtained  from  Roche  Diagnostics.  Formamide  was  purchased  from  Scientific 
Imaging  System,  Eastman  Kodak  Company.  Formaldehyde  was  from  Sigma. 
Electrophoresis  tanks  for  agarose  and  northern  blot  gels  and  Power  Pac  300  were  from 
Biorad.  The  NuPage'  electrophoresis  system  used  for  western  blotting  was  purchased  from 
Novex,  Invitrogen. 
84 2.1.6  Photography,  autoradiography  and  image  analysis  for 
immunohistochemistry 
A  gel  documentation  system  (UVP  7500)  and  thermal  paper  K65HM-CE  (Mistubishi)  were 
used  to  take  gel  photographs.  Fuji  RX  X-ray  film  was  obtained  from  Genetic  Research 
Instrumentation  Ltd.  X-ray  film  was  developed  using  X-Ograph  Compact  X2  (X-Ograph, 
Ltd).  The  intensity  of  bands  on  the  gel  photographs  or  on  X-ray  film  was  measured  with 
Kodak  Digital  Science  ID  software  from  Kodak.  Images  of  immunohistochemistry  sections 
were  taken  using  a  Leica  DMRB  microscope  connected  to  a  digital  camera  (Cool  Snap-Pro, 
Media  Cybernetics)  and  a  computer  with  image  analysis  software  (Image  Pro  Plus  4.5, 
Media  Cybernetics). 
2.1.7  Oligonucleotides 
The  oligonucleotides  were  supplied  by  Sigma-Genosys.  The  sequences  of  oligonucleotides 
used  are  listed  below: 
85 Table  2.1  Oligonucleotide  information  Tin  =  (A+T)  x  2°C  +  (G+C)  x  4°C. 
Oligonucleotide  Sequence,  5'-.  3'  Tin 
0 
Annealing  to 
MHD  16  CCCATTCATTGCCTTGCTGCTAAG  62  Mouse  Hdh  gene  (Fig.  4.19) 
MUD  18  GACTCACGGTCGGTGCAGCGGTTCC  70  Mouse  Hdh  gene  (Fig.  4.19) 
Ll  CGCTCTACCT  CACCATCTCT  T  62  Mouse  mitochondrial  DNA 
(Fig.  4.1 
Hl  TGCFTACCTT  GTTACGACTT  A  57  Mouse  mitochondrial  DNA 
(Fig.  4.1 
L2  ACCAACAGCT  ACCATTACAT  T  58  Mouse  mitochondrial  DNA 
(Fig.  4.1) 
H2  TGATTGGGTT  TATGAGGTCT  G  62  Mouse  mitochondrial  DNA 
(Fig.  4.1) 
F3  CAAGTCCATGACCATTA  ACTGG  58  Mouse  mitochondrial  DNA 
(Fig.  4.1) 
MIMICL1  CGCTCTACCT  CACCATCTCT 
TAGAAGTTGT  CCATATTGGC  C 
79  Ecoli  CAT  gene  (Fig  4.7  and 
Fig.  4.8) 
MIMICH1  TGCTTACCFT  GTTACGACTT  A 
ATAACCAGA  CCGTTCAGCT  G 
78  Ecoli  CAT  gene  (Fig  4.7  and 
Fig.  4.8) 
MIMIC12  ACCAACAGCT  ACCATTACAT  T 
CGCAGTACTG  TTGTAATTC 
75  Ecoli  CAT  gene  (Fig  4.10  and 
Fig.  4.8) 
MIMICH2  TGATTGGGTT  TATGAGGTCT 
GATCACTGGA  TATACCACCG 
79  Ecoli  CAT  gene  (Fig  4.10  and 
Fig.  4.8) 
mGDH-A  CACTTGAAGGGTGGAGCCAAAC  69  Mouse  Gapdh 
mRNA  (Fig.  5.3a 
mGDH-BR  TGGGTGGTCCAGGGTTTCTTAC  68  Mouse  Gapdh 
mRNA  i  g.  5.3 
CLW2F  GAATTCAGGCTTAAGGAGGTCCGA 
C'TG 
61  Mouse  Dmpk  exon  2 
(Fig.  5.3b 
CLW4R  GAATTCGCAAAATGCAGCTGTGTG 
ATC 




TFA1  TCGCATCCCCTCGTCTATCAG  69  Mouse  Tfam  mRNA  (Fig.  5.4a) 
TFA2  TCGCATCCCCTCGTCTCTCG  67  Mouse  Tfam  mRNA  (Fig.  5.4a) 
COIF  CTGAGCGGGAATAGTGGGC  65  Mouse  Col  mRNA  (Fig.  6.1a) 
COIR  GCAAGCTCGTGTGTCTACC  63  Mouse  Col  mRNA  (Fig.  6.1a) 
COIIF  CTACAAGACGCCACATCCCC  67  Mouse  Coll  mRNA  (Fig.  6.1a) 
COIIR  CTAGGACAATGGGCATAAC  62  Mouse  Coll  mRNA  (Fig.  6.1a) 
CytbF  CATTCATTGACCTACCTGCC  65  Mouse  Cytb  mRNA  (Fig.  6.1a) 
CytbR  CTGGGTCTCCTAGTATGTG  58  Mouse  Cytb  mRNA  (Fig.  6.1a) 
HOF  CGTCCACAGC  CCGACAGCAT  73  Mouse  Hmox  1  mRNA 
i 
.  7.2a 








CROR2  AAGCI'TCAGCACTAGTCACAG  58  Mouse  Cryab  mRNA 
i 
. 7.4 
86 2.1.8  Enzymes 
Restriction  enzymes  were  obtained  from  GibcoBRL,  Boehringer  Mannheim,  or  New 
England  Biolabs.  Sources  of  other  enzymes  are  indicated  in  the  following  table: 
Table  2.2  Enzyme  information 
Enzyme  Supplier 
HPLC  pure  klenow  Amersham  Pharmacia  Biotech 
Amplitaq  Gold  Perkin  Elmer 
Taq  polymerase  Promega 
Proteinase  K  Boehringer  Mannheim 
RNasin  Promega 
Superscript'  II  reverse  transcriptase  GibcoBRL 
T4  DNA  polynucleotide  kinase  Promega 
RQ1  RNase  free  DNase  Promega 
87 2.1.9  Primary  antibodies 
The  sources  of  primary  antibodies  used  in  this  study  are  indicated  in  the  following  table: 
Table  2.3  Primary  antibody  information 
Antibody  Concentration  of  Dilution  typically  Supplier 
antibody  supplied  used  in  study 
Monoclonal  anti-  Not  known  1:  5000  Calbiochem 
orin  antibody 
Monoclonal  anti-ß  Not  known  1:  25000  Promega 
tubulin  III  antibody 
Polyclonal  anti-  Not  known  1:  15000  A  gift  from  David 
mtTFA  antibody  Clayton, 
Department  of 
Developmental 
Biology,  Beckman 
Center  for 
Molecular  and 
Genetic  Medicine, 
Stanford  University 
Monoclonal  anti-  Lyophilised  powder  4  gg/ml  Molecular  Probes 
cytochrome  c  (100µg) 
oxidase  subunit  I 
(COI),  1D6-E1-A8 
Monoclonal  anti-8-  Lyophilised  powder  1µg/ml  Nikken  Foods  Co, 
OH-deoxyguanosine  (100µg)  Japan 
8-OHdG 
Polyclonal  anti-4-  Not  known  1:  2000  Calbiochem 
hydroxynonenal  (4- 
HNE) 
Polyclonal  anti-  Not  known  1:  1500  Stressgen 
heure  oxygenase  1 
(HO-1),  SPA-895 
88 2.1.10  Secondary  antibodies 
The  sources  of  secondary  antibodies  used  in  this  study  are  indicated  in  the  following  table: 
Table  2.4  Secondary  antibodies 
Antibody  Concentration  of  Dilution  typically  Supplier 
antibody  supplied  used  in  study 
Donkey  anti-rabbit  IgG-  Not  known  1:  4000  Amersham 
horseradish  peroxidase 
I  G-HRP 
Goat  anti-mouse  IgG-HRP  Not  known  1:  60000  Jackson  Lab 
Horse  biotinylated  anti-  1.5  mg/ml  1:  500  Vector 
mouse  secondary  antibod 
Goat  biotinylated  anti-  1.5  mg/ml  1:  100  Vector 
rabbit  secondary  antibody 
89 2.1.11  Kits 
The  sources  of  kits  used  in  this  study  are  indicated  in  the  following  table: 
Table  2.5  Kit  information 
Kit  Supplier 
ABI  PRISMT'  Dye  Terminator  Cycle 
Sequencing  Ready  Reaction  kit 
Perkin  Elmer 
Random  Primers  DNA  Labeling  System  GibcoBRL 
QlAquick  Gel  Extraction  kit  Qiagen 
QIAgen  Plasmid  DNA  Miniprep  kit  Qiagen 
QIAgen  Plasmid  DNA  Midiprep  kit  Qiagen 
TOPOTM  TA  Cloning  Invitrogen 
SUPERSCRIPTV'  Preamplification 
System  for  the  First  Strand  cDNA 
Synthesis  Kit 
GibcoBRL 
TRI  REAGENT''  Sigma 
ExpressHyb  Hybridisation  Solution  Clontech 
SuperSignal  West  Pico  Chemiluminescent 
Substrate 
Pierce 
3'3'  diaminobezidine  tetrahydrochloride 
DAB  kit 
Vector 
VECTASTAIN®  Elite  ABC  kit  Vector 
Vectors  M.  O.  M.  Immunodetection  Kits  Vector 
2.1.12  Normal  serum 
Normal  goat  serum,  normal  horse  serum,  and  normal  donkey  serum  were  from  Vector. 
2.1.13  Medium  and  antibiotics 
Luria-  Bertani  (LB)  broth:  10  g  Tryptone,  5g  yeast  extract,  10  g  NaCl  and  dH2O  added  to  a 
final  volume  of  1  litre. 
90 LB  agar:  10  g  Tryptone,  5g  Yeast  extract,  10  g  NaC1,15  g  Agar,  and  dHZO  added  to  a  final 
volume  of  1  litre. 
Ampicillin:  Stock  solution:  50  mg/ml  in  dH2O.  Store  at  -20°C.  Working  solution:  50  µg/ml 
2.1.14  Bacterial  host  strains 
DH5a:  F-,  cp80dlacZAM15,  A(lac  ZYA-argF),  U169,  deoR,  recAl,  endAl,  hsdR17  (rK-, 
mK+),  supE44,  k,  thi-1,  gyrA96,  relAl  (Life  Technologies  Ltd). 
TOP1OF':  F'{lacI9Tn10  (TetR)}  mcrA  A  (mrr-hsdRMS-mcrBC)  (D801acZAM15  AlacX74 
recA1  deoR  araD139  A(ara-leu)7697  galU  glaK  rpsL  (Str)  endA1  nupG  (Invitrogen) 
2.1.15  Vectors 
pCR®2.1-TOPO®  in  TOPOT"'  TA  Cloning  kit  was  used  for  cloning  (Invitrogen). 
2.1.16  Storage  of  bacterial  culture  containing  recombinant  plasmids 
Long-term  storage  of  recombinant  plasmid  was  achieved  by  mixing  equal  volumes  of  an 
overnight  culture  of  the  host  containing  the  recombinant  clone  and  sterile  glycerol.  These 
stocks  were  stored  at  -70°C,  where  they  can  remain  viable  for  several  years. 
2.1.17  Solutions 
Api4Linin:  Stock  solution:  10  mg/ml.  Working  solution:  10  µg/ml 
Blocking  solution  for  western  blot:  0.2  %  casein  solution  in  1X  TBS  (Pierce),  0.1  %  normal 
goat  or  donkey  serum. 
10  mM  Citric  acid.  12H6.0:  2.1  g/l,  pH  to  6.0  with  10  M  NaOH. 
Cryoprotectant  for  free-floating  sections:  1.37  g  NaH2PO4,5.46  g  Na2HPO4,300  ml 
glycerol,  300  ml  ethylene  glycol  and  400  ml  water.  Store  at  -20°C. 
91 100  X  Denhardt  solution  (Denhardt,  1966):  2g  Ficoll,  2g  polyvinylpyrrolidone,  2g  BSA, 
and  dH2O  to  100  ml. 
Denaturing  solution:  1.5  M  NaCl,  0.5  M  NaOH 
Depurin  ig  solution:  0.25  M  HCI. 
5X  DNA  loading  dye:  0.5  %  (w/v)  SDS,  0.25  %  (w/v)  xylene  cyanol,  0.25  %  (w/v) 
bromophenol  blue,  1.5  %  (w/v)  Ficoll®400,3  X  TBE. 
Ethidium  bromide  (tBr):  Stock  solution:  10  mg/ml,  working  solution:  200  ng/ml. 
EBC  lysis  buffer:  5  ml  1M  Tris-HCI,  pH  8.0,2.4  ml  5M  NaCl,  1  ml  NP-40  made  up  to  100 
ml  with  water  and  stored  at  4°C. 
Formaldehyde  gel:  15  mis  10  X  MOPS,  pH  8.0,15  ml  formaldehyde,  120  ml  DEPC  water, 
and  1.95  g  agarose. 
Homogenizing  medium  A  for  purification  of  cell  nuclei:  0.25  M  sucrose,  5  MM  MgC121  10 
mM  Tris-HCI,  pH  7.4. 
Homogenizing  medium  B  for  purification  of  cell  nuclei:  2.2  M  sucrose,  '  MM  M9C12,10 
mM  Tris-HCI,  pH  7.4. 
Hybridization  buffer  for  Southern  blot:  5X  SSPE,  5X  Denhardts,  0.5  %  (w/v)  SDS,  7% 
(w/v)  Dextran  sulphate  and  100  µg/ml  salmon  sperm  DNA  in  distilled  water. 
Hybridization  buffer  for  using  a  synthetic  oligonucleotide  as  probe:  15  mis  20  X  SSPE,  1  ml 
50  X  Denhardts,  2  ml  10  %  (w/v)  SDS,  and  100  µl  of  50  mg/ml  yeast  t-RNA  in  32  ml 
distilled  water. 
I  TG  (Isopropylthip-a-D-galactoside):  Stock  solution:  300  mg/ml  in  dH2O.  Working 
solution:  30  µg/ml. 
92 ineptin:  Stock  solution:  1  mg/ml.  Working  solution:  10  µg/ml. 
10  X  MOPS  (pH  7  or  pH  8):  0.2  M  3-(N-morpholino)-propanesulfonic  acid  (MOPS),  50 
mM  sodium  acetate,  10  M  EDTA,  pH  to  7.0  or  8.0  with  10  M  NaOH,  wrap  with  foil  and 
stored  at  4°C. 
Neutralizing  solution:  1.5  M  NaCl,  0.5  M  Tris,  adjust  to  pH  7.0  with  HCI. 
Oligo  labelling  buffer:  Oligo  labelling  buffer  was  made  up  to  the  ratio  2A:  5B:  3C  and 
stored  at  -20°C.  Solution  A:  1.2  M  Tris  (pH8),  121  mM  MgC12,0.48mM  dAT?,  0.48  mM 
dGTP,  0.48  mM  dTTP,  18  µl  of  2-ß-mercaptoethanol  in  a  final  volume  of  1033  µl.  Solution 
B:  2M  Hepes,  pH  6.6  with  NaOH  (4°C).  Solution  C:  Pharmacia  Biotech  Ultrapure  dNTP's 
set  suspended  in  0.2  mM  EDTA  (pH7.0)  to  an  optical  density  of  90  OD  unit  ml'  (-20°C). 
Orange  G:  0.06  %  (w/v)  Orange  G,  50  %  (v/v)  glycerol. 
20  %  Paraformaldehyde  (PEA).  pH7.4:  Dissolve  20  g  PFA  in  100  ml  1X  PBS  adjust  pH  to 
7.4  with  NaOH,  filter  through  0.8  µm  filter  and  stored  at  -20°C. 
4 
-To 
Paraformaldehyde  (PFA).  12H7.4:  Thaw  20  %  PFA,  pH7.4  and  dilute  to  4%  PFA  with  1 
X  PBS. 
PEG  solution  for  precipitating  DNA:  26.2  %  polyethylene  glycol  (PEG)  8000,66  mM 
MgClz,  0.6  M  NaOAc,  pH  5.2,  and  autoclave. 
Pepstatin:  Stock  solution:  1  mg/ml.  Working  solution:  10  µg/m1. 
Phenol:  Phenol  saturated  in  10  mM  Tris  (pH  7.5),  1  mM  EDTA  (pH8.0) 
Phenol:  chloroform:  isoamyl  alcohol.  25:  24:  1:  Phenol:  chloroform:  isoamyl  alcohol,  25:  24: 
1  saturated  in  10  mM  Tris,  pH  7.5,1  mM  EDTA,  pH8.0. 
Phenylmeth,  ly  sulpphonvl  ^fl  uoride  (PMSF1:  Stock  solution  100  mM  in  propan-2-ol  (stored  at  - 
20°C).  Working  solution:  0.1-1  mM. 
93 10  X  Phosphate  buffered  saline  (PBS):  1.4  M  NaCl,  0.027  M  KCI,  0.1  M  Na2HPO4,  O.  021  M 
KH2PO4  adjust  to  pH  7.4  with  HCI. 
Pre-hybridisation  buffer  for  Southern  blot:  5X  SSPE,  5X  Denhardts,  0.5  %  (w/v)  SDS,  and 
100  tg/ml  salmon  sperm  DNA  in  distilled  water. 
Pre-hybridisation  buffer  for  using  a  synthetic  oligonucleotide  as  probe:  15  ml  20  X  SSPE,  5 
ml  5X  Denhardts,  2  ml  10  %  (w/v)  SDS,  and  100  µl  of  10  mg/ml  salmon  sperm  DNA  in  28 
ml  distilled  water. 
Proteinase  K:  working  stock  of  20  mg/ml  in  filter  sterilized  H2O. 
Proteinase  K  lysis  buffer:  100  mM  Tris  (pH8.5),  200  mM  NaCl,  0.2  %  (w/v)  SDS,  5  mM 
EDTA  pH8.0,100  µg/m. 
RNA  loading  buffer:  12  µl  of  ethidium  bromide  stock  solution  (10  mg/ml),  300  µl  of  10  X 
MOPS,  pH  8.0,80  µl  of  formaldehyde,  900  µl  of  deionised  formamide  [37-40  %  (w/v)]. 
Sephadex  G25:  Sephadex  G25,  equilibrated  with  TE,  pH7.6. 
Sephadex  G50:  equilibrated  with  TE,  pH7.6. 
20  X  SSC:  6M  NaCl,  0.6  M  Na3C6H5O7.2H20,  and  autoclave. 
20  X  SSPE:  0.2  M  NaH2PO4.2H20,3  M  NaCl,  0.02  M  EDTA  (pH8.0)  and  adjust  pH  to  7.4 
with  HCI. 
10  %  w/v,  SD  :  10  %  (w/v)  SDS  in  H20. 
Slot  blot  loading  buffer:  1  ml  deionised  formamide,  324  µl  of  37  %  (w/v)  formaldehyde  and 
200  µl  10  X  MOPS. 
E:  0.04  M  Trizma  base,  0.04  M  acetic  acid,  0.001  M  EDTA,  pH8.0. 
94 E:  0.09  M  Trizma  base,  0.09  M  boric  acid,  0.001  M  EDTA,  pH8.0. 
10  X  TBS:  1M  Trizma  base,  1.5  M  NaCl,  pH  to  7.5  with  HCl  and  autoclave. 
J  LX  TBST:  0.6  %  Tween-20  in  1X  TBS. 
TE:  10  mM  Tris  (pH  7.5),  1  mM  EDTA  (pH  8.0),  and  autoclave. 
1M  Tris  (pH7.5):  1M  Trizma  base,  add  HCI  to  pH  7.5  and  filter  sterilize. 
IM  Tris.  (pH8.3):  1M  Trizma  base,  add  HCl  to  pH  8.3  and  filter  sterilize. 
I 
-M 
Tris.  (pH8.0):  1M  Trizma  base,  add  HCl  to  pH  8.0  and  filter  sterilize. 
Tris  buffer  for  free-floating  section  staining:  6.05  g  Trizma  base,  6.76  g  NaCl  and  water  to  a 
final  volume  of  11. 
Xl  (5-Bromo-4-chloro-3-indolyl-ß-D-galactoside):  Stock  solution:  50  mg/ml  (in 
dimethylformamide)  and  wrap  in  foil.  Working  solution:  50  µg/ml. 
2.1.18  Mouse  lines 
The  mice  used  in  this  study  were  generated  by  inserting  a  HD-like  mutation  (an  extended 
stretch  of  72-80  CAG  repeats)  into  the  endogenous  mouse  Hdh  gene  to  mimic  the  molecular 
findings  on  human  HD  chromosome  by  Dr.  Peggy  Shelbourne  (Shelbourne  et  al.,  1999). 
The  resulting  mice  were  maintained  on  different  genetic  backgrounds  as  indicated  in  Table 
2.6. 
95 Table  2.6  Summary  of  mice  used  in  the  study 
Designation 
in  the  text  of 
this  study 
Mouse  line 
described  in 
Shelbourne  et 







Experiment  where  mice  used 
HD  or  Hdh6/Q72  Full  length  Fvb/n  The  integrity  of  mtDNA  in 
Glasgow  HD  HD  mice,  the  cause  of  striatal 
mice  mtDNA  depletion,  the  effects 
of  mtDNA  depletion  and  the 
direct  evidence  of  increased 
oxidative  stress  in  the  striatum 
of  HD  mice 
HD  or  Hdh6/Q72  Full  length  C57BL16  Locomotor  study 
Glasgow  HD 
mice 
2.2  Methods 
2.2.1  DNA  isolation 
2.2.1.1  Genomic  DNA  isolation 
The  tissue  samples  taken  from  mice  were  immediately  placed  on  dry  ice  or  kept  at  -80°C 
before  proceeding  to  DNA  extraction.  The  DNA  was  extracted  by  adding  700  µl  of  lysis 
buffer  containing  35  µl  of  2M  Tris  (pH  8.5),  28  µl  of  5M  NaC1,14  µ1  of  10  %  (w/v)  SDS, 
7  µl  of  0.5  M  EDTA  (pH  8.0),  0.7  µ1  of  proteinase  K  (100  mg/ml)  and  615  µl  of  distilled 
96 water.  The  mixture  was  incubated  overnight  with  shaking  at  55°C,  then  vortexed  hard,  and 
centrifuged  for  10  min  at  10,000  X  g.  The  supernatant  was  transferred  to  a  clean,  labelled 
eppendorf  tube  containing  700  µl  isopropanol  (propan-2-ol)  to  precipitate  the  DNA.  The 
DNA  pellet  was  resuspended  in  1X  TE  overnight  at  4°C. 
2.2.2  Phenol/chloroform  extraction  of  DNA  solutions 
A  DNA  solution  is  extracted  with  a  1:  1  phenol/chloroform  mixture  in  order  to  remove 
protein  contamination.  The  organic  solvents  precipitate  proteins,  and  these  are  left  as  a 
coagulated,  white  mass  at  the  interface  between  the  aqueous  and  organic  phases  after 
centrifugation. 
An  equal  volume  of  phenol/chloroform  (phenol:  chloroform:  octanol  =  25:  24:  1)  was  added 
to  the  DNA  solution  and  emulsified  by  mixing.  The  organic  and  aqueous  phases  were 
separated  by  centrifugation  (10,000  X  g,  10  min)  and  the  aqueous  phase  transferred  to  a 
clean  tube.  A  final  extraction  with  an  equal  volume  of  24:  1  chloroform/octanol  was 
performed  to  remove  any  remaining  phenol  that  might  inhibit  subsequent  enzyme  reactions. 
2.2.2.1  Extraction  of  plasmid  DNA 
1)  Small  scale  preparation 
Plasmid  DNA  preparation  was  prepared  by  the  alkali-lysis  method  (Sambrook  et  al.,  1989) 
using  the  Qiagen  QlAprep  miniprep  kit.  An  overnight  culture  of  the  host  bacteria  harboring 
the  recombinant  clone  was  grown  in  LB  broth  at  37°C  in  a  shaking  incubator.  Cells  from  1.5 
ml  of  this  culture  were  collected  by  centrifugation  at  6,000  Xg  for  5  min  and  resuspended 
in  250  µl  buffer  P1  and  subjected  to  the  protocol  specified  in  the  manufacturer's 
instructions.  The  DNA  was  finally  eluted  from  the  column  with  distilled  water. 
2)  Large  scale  preparation 
Plasmid  DNA  was  prepared  using  the  QlAgen  midiprep  kit  according  to  the  manufacturer's 
instructions.  Briefly,  5  ml  LB  broth  culture  containing  100  µg/ml  ampicillin  was  inoculated 
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used  to  inoculate  200  ml  LB  broth  (containing  100  µg/ml  ampicillin)  that  was  then 
incubated  at  37°C  overnight  with  shaking  (300  rpm).  Bacterial  cells  were  harvested  by 
centrifugation  (Beckman,  J2-MC)  at  6,000  Xg  for  15  min  at  4°C.  The  pellet  was  gently 
resuspended  in  buffer  P1  and  incubated  on  ice  for  5  minutes.  Buffer  P2  was  added  and  the 
mixture  was  gently  inverted  until  it  turned  clear.  This  mixture  was  incubated  on  ice  for  a 
further  5  min.  Buffer  P3  was  added  and  the  solution  mixed  gently  until  a  heavy  white 
protein  precipitate  was  formed.  The  solution  was  incubated  on  ice  for  15-20  min  and  then 
centrifuged  at  20,000  Xg  for  30  min  in  a  Beckman  rotor  at  4°C.  The  supernatant  was 
applied  to  a  QIAGEN-tip  100  column  equilibrated  with  4  ml  buffer  QBT  and  was  allowed 
to  flow  through  the  column  by  gravity.  Under  these  conditions,  the  plasmid  DNA  binds  to 
the  resin  whereas  protein  and  RNA  do  not.  30  ml  buffer  QC  was  added  to  the  column  and 
allowed  to  flow  through  by  gravity.  The  plasmid  DNA  was  eluted  with  buffer  QF  and  the 
elutant  mixed  with  0.7  volumes  of  isopropanol  to  precipitate  the  plasmid  DNA.  The  mixture 
was  centrifuged  at  10,000  Xg  for  30  min  followed  by  one  wash  in  70  %  (v/v)  ethanol.  The 
plasmid  DNA  pellet  was  resuspended  in  200  µl  TE  buffer. 
2.2.2.2  Preparation  of  nuclear  DNA  from  mouse  brain 
A  quarter  of  a  mouse  brain  was  chopped  finely  with  scissors  in  cold  homogenizing  medium 
A  (0.25  M  sucrose,  5  MM  MgC12,10  mM  Tris-HCI  pH  7.4).  The  homogenizing  medium  A 
was  poured  off  and  the  chopped  tissue  was  resuspended  in  9  volumes  of  fresh  homogenizing 
medium  A  (5  ml).  The  suspension  of  chopped  tissue  was  homogenized  using  a  Heidolph 
homogenizer  (Labplant)  with  a  loose-fitting  (0.1  mm  clearance)  Teflon  pestle  driven  at  1000 
r.  p.  m.  Approximately  40-50  up  and  down  strokes  were  performed  to  obtain  complete  cell 
breakage.  The  homogenate  was  filtered  through  four  layers  of  muslin  taking  care  not  to 
squeeze  the  muslin  to  obtain  the  last  few  drops  of  liquid.  The  homogenate  was  then 
centrifuged  at  600  Xg  for  10  min,  4°C.  The  supernatant  was  poured  off  and  the  pellet 
resuspended  in  half  the  original  volume  of  homogenizing  medium  A.  The  resuspended 
nuclei  were  centrifuged  at  600  Xg  for  10  min  at  4°C.  The  supernatant  was  discarded, 
leaving  a  pellet  of  crude  nuclei. 
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(2.2  M  sucrose,  1  mM  MgCI2,10  mM  Tris-HCI  pH  7.4)  and  homogenized  using  the 
Heidolph  homogenizer  with  a  loose-fitting  (0.1  mm  clearance)  Teflon  pestle  with  5-6  up 
and  down  strokes  driven  at  1000  rpm.  The  solution  was  transferred  to  a  centrifuge  tube  (13 
X  51  mm,  polyallomer  Quick-seal  centrifuge  tube,  Beckman)  using  a  glass  pipette.  The  tube 
was  sealed  and  centrifuged  at  60-80,000  Xg  for  80  min  at  4°C  in  a  fixed  angle  rotor  (35,000 
rpm  in  TLA100.4,  Beckman).  After  centrifugation,  the  nuclei  formed  a  cream  or  white 
coloured  fine  pellet  at  the  bottom  of  the  tube.  The  seal  of  tube  was  cut,  and  any  skin  that 
might  have  formed  at  the  top  of  the  dense  sucrose  was  removed  using  a  stainless  steel 
spatula.  The  tubes  were  emptied  by  rapid  inversion  and  any  remaining  sucrose  was  wiped 
out  with  a  tissue  wrapped  around  a  glass  rod  or  spatula.  The  nuclei  were  resuspended  in 
homogenizing  medium  A  and  stored  at  -20°C. 
To  check  there  was  no  contamination  of  cytoplasm,  the  nuclei  were  stained  with  1%  (w/v) 
methylene  blue.  The  nuclei  appeared  clean  without  any  membrane  adhering  to  the  outside  of 
the  nucleus. 
Promega  PCR  buffer  was  diluted  1  in  10  to  get  the  composition  of  10  mM  Tris-HCI,  50  mM 
KCI,  0.1  %  (v/v)  Triton,  and  2.5  mM  MgC12.  Proteinase  K  was  added  to  the  solution  to  a 
final  concentration  of  100  µg/ml.  The  resuspended  nuclei  in  homogenizing  medium  were 
centrifuged  at  600  Xg  for  10  min.  500  µl  PCR  buffer  containing  100  µg/ml  Proteinase  K 
was  added  to  the  pellet  and  incubated  at  55°C  for  3-4  hours.  After  incubation,  the  nuclear 
DNA  was  purified  by  phenol  and  chloroform  extraction. 
2.2.2.3  Concentration  of  DNA  samples 
Ethanol  precipitation  can  increase  the  concentration  of  DNA  and  also  remove  short  chain 
and  monomeric  nuleic  acid  components.  Either  of  the  following  protocols  was  used: 
1.  Addition  of  0.1  volume  of  3M  CH3COONa  (pH  4.8)  followed  by  2  volumes  of  absolute 
ethanol. 
2.  Addition  of  0.1  volume  of  3M  CH3COONa  (pH  4.8)  followed  by  equal  volume  of 
isopropanol  that  has  been  equilibrated  at  room  temperature. 
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at  least  30  min.  The  DNA  pellet  was  recovered  after  centrifugation  (10,000  X  g,  15  min), 
washed  in  70  %  (v/v)  ethanol  to  remove  excess  salt,  and  centrifuged  again  to  pellet  the 
DNA,  which  was  dried  and  resuspended  in  1X  TE  buffer.  If  required,  the  tube  containing 
the  DNA  pellet  was  left  at  37°C  in  a  water  bath  for  30-120  min  to  resuspend  the  DNA. 
2.2.3  Quantification  of  DNA  or  RNA 
Spectrophotometric  determination  is  used  to  quantify  the  amount  of  DNA.  Readings  are 
taken  at  wavelength  of  260  nm  and  280  nm.  The  reading  at  260  nm  allows  calculation  of  the 
concentration  of  nucleic  acid  in  the  sample.  An  OD  of  1  corresponds  to  approximately  50 
µg/ml  for  double-stranded  DNA,  40  gg/ml  for  single  stranded  DNA  and  RNA,  and  -20 
µg/ml  for  single  stranded  oligonucleotides.  The  ratio  between  the  readings  at  260  nm  and 
280  nm  (OD2w/OD2.  )  indicates  the  purity  of  the  nucleic  acid.  Pure  preparation  of  DNA  and 
RNA  have  OD20/OD2  values  of  1.8  and  2.0  respectively.  If  contamination  with  protein  or 
phenol  is  present,  the  OD,,,  /OD2.  will  be  significantly  less  than  the  values  indicated.  For 
double  stranded  DNA  or  RNA  the  concentration  was  calculated  using  the  following 
equations: 
Concentration  of  DNA=OD.  X  50  X  Dilution  factor  (µg/m1) 
Concentration  of  RNA=ODD  X  40  X  Dilution  factor  (µg/m1) 
2.2.4  Digestion  of  DNA  with  restriction  enzymes 
Restriction  digests  of  most  plasmids  and  genomic  DNA  were  carried  out  in  30  µl  reactions 
for  2  -15  hours  (depending  on  the  enzyme  used)  at  the  temperature  suitable  for  the  specific 
enzyme.  3-5  µg  DNA  was  digested  in  the  presence  of  3  µl  of  BSA  (100  pg/ml),  3  µl  of  10  X 
reaction  buffer,  1-2  µl  (20-30  units)  of  restriction  enzyme  and  distilled  water  to  a  total 
volume  of  30  µl. 
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2.2.5.1  PCR  primer  design 
Oligonucleotides  that  were  20  to  21  nucleotides  long  and  had  melting  temperatures 
(Tm={(A+T)  x  2°C  +  (G+C)  x  4°C})(Suggs  et  al.,  1981)  between  55°C  and  68°C  were 
designed.  Both  PCR  primers  in  a  set  were  designed  to  have  a  similar  Tm,  not  to  be 
complementary  at  their  3'  end,  not  self-complementary  and  not  to  contain  repeated 
sequences.  The  programs  GeneJockey  II  (Biosoft,  Cambridge,  UK)  were  used  to  aid  the 
design  of  the  primer  sets. 
2.2.5.2  Amplification  of  mitochondrial  DNA  (mtDNA) 
A  pair  of  primers  L1/H1(Table  2.1)  was  chosen  to  amplify  total  mtDNA  using  the 
following  PCR  conditions:  1)  94°C,  5  min;  2)  24  cycles  of  94°C,  40  s;  55°C,  20  s;  72°C,  40 
s;  3)  72°C,  8  min.  In  all  PCR  for  total  mtDNA  amplification,  5-15  ng  of  tissue  DNA  was 
amplified  in  the  presence  of  2.0  mM  MgC12  PCR  buffer,  1.2  µM  primers,  2.0  units  of  Taq 
polymerase  (Promega),  200  pM  dNTP,  in  a  total  reaction  volume  of  20  pl. 
Mitochondrial  DNA  molecules  containing  a  deletion  between  a  pair  of  direct  repeats  spaced 
3867  base  pairs  apart  were  specifically  amplified  with  primers  L2/H2  (Table  2.1)  using  a 
short  PCR  cycle  to  prevent  synthesis  of  a  full-length  product  from  undeleted  mtDNA:  1) 
94°C,  10  min;  2)  30  cycles  of  94°C,  35  s;  55°C,  20  s;  72°C,  35  s;  3)  72°C,  8  min.  In  all  PCR 
assays  for  deleted  mtDNA  amplification,  75  to  300  ng  of  tissue  DNA  was  amplified  in  the 
presence  of  1.5  MM  MgC12  PCR  buffer,  1.2  µM  primers,  2.0  units  of  Taq  polymerase 
(AmpliTaq  Gold,  Perkin  Elmer),  200  IN  dNTP,  5%  (v/v)  DMSO,  in  a  total  reaction 
volume  of  20  µl. 
2.2.5.3  Amplification  of  mouse  Hdh  gene 
The  CAG  repeat  sequence  in  the  mouse  Hdh  gene  was  amplified  using  published  primers, 
MHD16  and  MHD  18  and  PCR  conditions  (Shelbourne  et  al.,  1999).  Briefly,  a  touchdown 
PCR  protocol  was  used:  1)  94°C,  5  min;  2)  20  cycles  of  94  °C,  30  s;  71  °C  to  61  °C  for  30  s 
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30  s;  4)  72  °C,  7  min.  1,2,5  ng  of  DNA  extracted  from  purified  cell  nuclei  was  amplified  in 
the  presence  of  1.5  MM  MgCl2  buffer,  1.2  µM  primers,  2.0  units  of  Taq  polymerase 
(Sigma),  200  µM  dNTP,  10  %  (v/v)  DMSO  in  a  total  reaction  volume  of  10  µl. 
2.2.5.4  Amplification  of  first  strand  cDNA 
PCR  was  used  to  amplify  first  strand  cDNA  to  generate  hybridization  probes  for  northern 
blots  or  to  check  RNA  samples  for  DNA  contamination.  PCR  was  carried  out  using  -150 
ng  equivalent  of  RNA  as  a  template  and  each  of  the  following  primers  (see  Table  2.1)  to 
amplify  the  following  gene  sequences: 
A)  Mouse  glyceraldehyde-3-phosphate  dehydrogenase  (Gapdh)  mRNA:  The  PCR 
conditions  were  as  follows:  1)  94°C,  10  min;  2)  34  cycles  of  94°C,  50  s;  65  °C;  50  s,  72°C, 
50  s;  3)  72°C,  8  min.  The  pair  of  primers,  mGDH-A/mGDH-BR,  was  used  to  amplify  first 
strand  cDNA  from  the  mouse  Gapdh  mRNA  to  check  the  RNA  template  for  DNA 
contamination. 
B)  Mouse  myotonic  dystrophy  protein  kinase  (Dmpk)  mRNA:  The  PCR  conditions  were  as 
follows:  1)  94°C,  10  min;  2)  30  cycles  of  94°C,  60  s;  61°C,  60  s;  72°C,  60  s;  3)  72°C,  7 
min.  The  primer  CLW2F  is  in  the  exon  2  of  mouse  Dmpk  gene  and  the  primer  CLW4R  is in 
the  exon  4  of  mouse  Dmpk  gene.  This  pair  of  primers,  CLW2F/CLW4R,  was  used  to 
amplify  first  strand  cDNA  from  the  mouse  Dinpk  mRNA  to  check  the  RNA  sample  for 
DNA  contamination. 
C)  Mouse  mitochondrial  transcription  factor  A  (Tfam)  mRNA:  The  PCR  conditions  were  as 
follows:  1)  94°C,  10  min;  2)  34  cycles  of  94  °C,  50  s;  68°C,  50  s;  72°C,  50  s;  3)  72  °C,  10 
min.  This  pair  of  primers,  TFA1/TFA2,  was  used  to  amplify  first  strand  cDNA  from  mouse 
Tfam  mRNA. 
D)  Mouse  cytochrome  b  (Cytb)  mRNA:  The  PCR  conditions  were  as  follows:  1)  94°C,  10 
min;  2)  32  cycles  of  94°C,  40  s;  62°C,  60  s;  72°C,  60  s;  3)  72°C,  7  min.  This  pair  of 
primers,  cytbF/cytbR,  was  used  to  amplify  the  first  strand  cDNA  from  mouse  Cytb  mRNA. 
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follows:  1)  94°C,  10  min;  2)  32  cycles  of  94°C,  40  s;  65°C,  60  s;  72°C,  60  s;  3)  72°C,  7 
min.  This  pair  of  primers,  COIF/COIR,  was  used  to  amplify  first  strand  cDNA  from  mouse 
Col  mRNA. 
F)  Mouse  cytochrome  c  oxidase  subunit  II  (CoII)  mRNA:  The  conditions  of  PCR  were  as 
follows:  1)  94°C,  10  min;  2)  32  cycles  of  94°C,  40  s;  62°C,  60  s;  72°C,  60  s;  3)  72°C,  7 
min.  This  pair  of  primers,  COIIF/COIIR,  was  used  to  amplify  first  strand  cDNA  from 
mouse  Coil  mRNA. 
G)  Mouse  heure  oxygenase-1(Hmoxl)  mRNA:  The  PCR  conditions  were  as  follows:  1) 
94°C,  10  min;  2)  32  cycles  of  94°C,  30  s;  65°C,  50  s;  72°C,  50  s;  3)  72°C,  10  min.  This  pair 
of  primers,  HOF/HOR,  was  used  to  amplify  first  strand  cDNA  from  mouse  Hmoxl  mRNA. 
H)  Mouse  a-B  crystallin  (Cryab)  mRNA:  The  PCR  conditions  were  as  follows:  1)  94°C,  10 
min;  2)  32  cycles  of  94°C,  30  s;  55°C,  45  s;  72°C,  45  s;  3)  72°C,  10  min.  This  pair  of 
primers,  CRF/CROR2,  was  used  to  amplify  the  first  strand  cDNA  from  mouse  Cryab 
mRNA. 
In  all  PCR  reactions,  first  strand  cDNA  was  amplified  in  the  presence  of  1.5  mM  MgC12 
PCR  buffer,  1.2  µM  primers,  2.0  units  of  Taq  polymerase  (Perkin  Elmer),  200  µM  dNTP. 
All  PCR  products  were  visualised  after  electrophoresis  through  an  EtBr-stained  agarose  gel 
(1.5  %).  PCR  products  using  primers  TFA1F/TFA2R,  CytbF/CytbR,  COIF/COIR, 
COIIF/COIIR  and  HOF/HOR  were  visualized  on  the  gel,  cut,  gel  purified  and  cloned  using 
TOPO"m  TA  cloning  kit  from  Invitrogen,  indicated  in  section  2.2.9. 
2.2.6  Agarose  gel  electrophoresis  of  DNA 
DNA  fragments  were  electrophoresed  on  0.8-2.5  %  (depending  on  the  size  of  fragment) 
agarose  gels  using  Biorad  gel  electrophoresis  systems.  Most  gels  were  cast  and 
electrophoresed  in  1X  TBE  buffer.  All  gels  contained  ethidium  bromide  at  a  concentration 
of  0.1-0.2  µg/ml.  Electrophoresis  conditions  varied  depending  on  the  level  of  resolution 
required. 
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agarose  gels  at  1.5  volts/cm,  4°C,  overnight  or  longer  depending  on  the  resolution  level 
required. 
Plasmid  DNAs  and  their  restriction  fragments  were  typically  electrophoresed  on  1% 
agarose  gels.  Appropriate  band  resolution  was  normally  achieved  after  electrophoresis  at  6- 
8  volts/cm  for  2  hours. 
2.2.6.1  Sizing  DNA  fragments  on  agarose  gels 
Gel  electrophoresis  will  separate  different-size  DNA  molecules,  with  the  smallest  molecules 
travelling  the  greatest  distance  towards  the  positive  electrode.  The  formula  that  links 
migration  rate  to  molecular  weight  of  the  DNA  fragment  is 
D=a-b  (logM) 
Where  D  is  the  distance  moved,  M  is  the  molecular  weight  and  a  and  b  are  constants  that 
depend  on  the  electrophoresis  conditions. 
In  general,  a  DNA  marker,  comprising  fragments  of  known  size,  was  introduced  into  a  lane 
of  each  agarose  gel.  By  plotting  the  size  of  the  marker  fragments  against  the  distance  they 
migrated  on  semi-log  paper,  a  calibration  curve  for  that  gel  was  constructed.  This  was  used 
for  estimating  the  size  of  an  unknown  fragment  from  the  distance  it  had  migrated. 
2.2.7  Purification  of  DNA  fragments  from  agarose  gels 
In  order  to  extract  and  purify  DNA  fragments  from  agarose  gels,  one  of  two  methods  were 
used: 
1)  QIAquick  gel  extraction  kit  (Qiagen):  the  PCR  products  or  plasmid  DNA  fragments  after 
restriction  enzyme  digest  were  resolved  on  a1%  agarose  gel.  The  DNA  fragment  from  the 
agarose  gel  was  excised  with  a  clean  scalpel  blade.  3  volumes  of  buffer  QG  were  added  to  1 
104 volume  of  gel  (100  mg  =  100  µl),  followed  the  protocol  recommended  by  the  manufacturer. 
Finally  distilled  water  was  added  to  elute  the  DNA  from  the  column. 
2)  The  DNA  fragment  was  excised  from  the  agarose  gel  with  a  clean  scalpel  blade.  A  piece 
of  glass  wool  was  packed  tightly  in  between  two  sheets  of  3  MM  paper  and  placed  in  an 
eppendorf  tube  with  a  small  hole  at  the  bottom.  The  gel  slices  were  placed  in  the  tube  and 
the  tube  was  placed  into  another  eppendorf  tube  and  centrifuged  at  9,000  Xg  for  10  min. 
Purification  and  concentration  of  the  DNA  was  achieved  with  PEG  solution  (section 
2.1.17).  An  equal  volume  of  PEG  solution  was  added  to  the  DNA,  vortexed  thoroughly  and 
incubated  at  room  temperature  for  at  least  10  min  before  centrifugation  at  10,000  Xg  for  10 
minutes.  After  centrifugation,  the  pellet  was  rinsed  with  1  ml  of  100  (v/v)  %  alcohol.  The 
DNA  was  centrifuged,  air-dried  and  resuspended  in  distilled  water. 
2.2.8  Transformation 
2.2.8.1  Preparation  of  competent  cells 
A  50  ml  culture  inoculated  with  500  µl  overnight  culture  was  grown  with  aeration  in 
medium  A  [LB  with  10mM  MgSO4.7H20,0.2  %  (w/v)  glucose]  to  mid  logarithmic  phase. 
The  cells  were  kept  on  ice  for  10  min,  and  pelleted  at  1,500  Xg  for  10  min  at  4°C.  The  cells 
were  resuspended  gently  in  500  µl  of  pre-cooled  medium  A,  then  2.5  ml  storage  solution  B 
[36  %  (w/v)  glycerin,  12  %  (w/v)  PEG  (MW  7500),  12  mM  MgSO4.7H20  added  to  LB 
(pH7.0)]  was  added  and  mixed  well  without  vortexing.  The  competent  cells  were  divided 
into  aliquots  of  100  µl  each  and  stored  at  -80°C  until  use. 
2.2.8.2  Transformation  procedure 
100  µl  of  competent  cells  were  mixed  with  1  µl  of  diluted  plasmid  DNA  and  put  on  ice  for 
30  min.  The  cells  were  heat  shocked  at  42°C  for  1  min  and  put  back  on  ice  for  a  further  2 
min.  0.5  ml  pre-warmed  LB  broth  (no  antibiotic)  were  added  to  the  transformation  mix, 
mixed  well  and  incubated  in  a  37°C  water  bath  for  1  hour.  The  mix  was  then  plated  out  on 
selective  plates  and  incubated  overnight  at  37°C. 
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DNA  fragments  generated  by  PCR  or  RT-PCR  and  isolated  by  gel  purification  were  cloned 
using  the  TOPO  ` 'TA  cloning  kit  (Invitrogen).  The  plasmid  vector  (pCR®2.1-TOPO)  is 
supplied  linearized  with  a  single  3'  thymidine  (T)  overhang  for  TA  cloning  and 
topoisomerase  covalently  bound  to  the  vector  (Shuman,  1994).  Taq  polymerase  has  a  non- 
template-dependent  terminal  transferase  activity  that  adds  a  single  deoxyadenosine  (A)  to 
the  3'end  of  the  PCR  products.  This  allows  PCR  fragments  to  ligate  efficiently  with  the 
vector.  Generally,  the  molar  ratio  of  insert  to  vector  used  was  2:  1.  Cloning  reactions  were 
performed  by  adding  2  µl  (10  ng/µl)  PCR  product  into  a  total  volume  of  5  µl  in  the  presence 
of  1  µl  (10  ng/µl)  of  pCR®2.1-TOPO  vector.  After  mixing  gently  and  incubating  for  5  min 
at  room  temperature,  the  mixture  was  subjected  to  transfomation  using  TOP1OF  One 
Shot''  competent  cells  according  to  the  manufacturer's  instructions.  After  transformation, 
two  volumes  of  each  transformation  mixture  (one  tenth  and  nine  tenths)  were  spread  onto 
selective  plates  (LB  plate  with  50  µg/ml  of  X-Gal,  30  µg/ml  IPTG  and  50  gg/ml  of 
ampicillin)  and  incubated  overnight  at  37°C. 
Recombinant  and  nonrecombinant  colonies  were  differentiated  by  insertional  inactivation  of 
a  marker  gene.  This  method  of  selection  is  based  on  the  fact  that  the  bacteria  containing 
recombinant  plasmids  with  insert  DNA  inactivating  the  lacZa  gene  of  the  plasmid  vector 
cannot  synthesize  the  corresponding  ß-galactosidase  protein  that  convert  X-Gal  to  a  blue 
product.  Therefore,  cells  containing  recombinant  plasmids  vector  are  colorless  in  the 
presence  of  X-Gal,  while  cells  containing  non-recombinant  plasmids  are  blue.  A  white 
colony  was  selected,  inoculated  into  LB  broth  and  incubated  overnight  at  37°C  with  shaking 
(300  rpm)  for  subsequent  mini-preparation  of  plasmid  DNA. 
2.2.10  DNA  Sequencing 
After  the  required  template  has  been  cloned  and  purified,  DNA  sequencing  was  performed 
on  either  an  ABI  373A  or  an  ABI  377  sequencer  by  the  Molecular  Biology  Support  Unit  at 
the  University  of  Glasgow.  Reactions  were  performed  as  stated  in  the  ABI  PRISMTM  Dye 
Terminator  Cycle  Sequencing  Ready  Reaction  kit  protocol.  The  kit  is  based  on  the  dideoxy 
106 chain  termination  method  of  Sanger  and  colleagues  (Sanger  et  al.,  1977).  Ethanol 
precipitation  protocol  1  was  used  for  purifying  extension  products. 
The  dideoxy  sequencing  reactions  are  performed  with  fluorescent  dye-labeled  primers  or  3'- 
dye  labeled  dideoxynucleotide  terminators.  AmpliTaq®  or  77  DNA  polymerase  is  used  for 
primer  extension  during  cycle  sequencing.  Four  different  fluorescent  dyes  distinguish  the 
products  from  each  of  the  four  dideoxy  sequencing  reaction.  These  reactions  are  performed 
in  a  PCR  tube  and  loaded  into  one  lane  on  the  gel.  The  dye-labeled  DNA  fragments  are 
electrophoresed  through  an  acrylamide  gel  and  separated  according  to  the  size.  When  the 
fragments  reach  a  fixed  position  above  the  lower  buffer  chamber,  the  dye  fluorescence  is 
excited  by  light  from  a  laser,  which  scans  back  and  forth  across  this  area  of  the  gel.  A 
photomultiplier  tube  detects  four  different  wavelengths  of  fluorescent  light  and  converts  it 
into  electrical  signals.  These  signals  are  then  transmitted  to  a  computer  and  stored  for 
subsequent  analysis. 
DNA  sequences  were  edited  and  aligned  using  Sequence  Navigator  (Applied  Biosystems). 
If  necessary,  the  resulting  DNA  sequence  was  compared  to  the  GenBank  and  EMBL 
nucleotide  databases  at  the  National  Centre  for  Biotechnology  Information  (NCBI)  using 
the  BLAST  program  accessed  via  the  online  service. 
2.2.11  Preparation  of  labelled  probes  from  DNA  templates 
2.2.11.1  Random  primed  labeling  of  DNA  probes 
Radiolabeling  of  DNA  probes  for  Southern  or  northern  blots  was  achieved  by  a  random- 
primers  DNA  labeling  kit  (Gibco  BRL)  (Feinberg  and  Vogelstein,  1983).  20-30  ng  DNA 
template  was  heated  for  5  min  and  quenched  on  ice  for  2  min.  This  was  then  mixed  with  15 
µl  buffer,  1  µl  (3  units)  Klenow  fragment,  5  µl  (50  µCi)  [a  32P]  dCTP,  2  µl  of  1  kb  plus 
ladder  (0.1  ng/µl),  and  water  added  to  a  final  volume  of  50  µl.  The  mixture  was  incubated  at 
25°C  for  at  least  one  hour.  Non-incorporated  nucleotides  were  removed  by  passing  the 
reaction  mixture  through  a  Sephadex  G-50  column. 
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Oligonucleotides  or  primers  were  5'  end-labeled  using  T4  polynucleotide  kinase  (Promega) 
and  [y-32P]  ATP  (Amersham).  This  was  performed  by  adding  48  pmole  primer  or 
oligonucleotide  to  a  20  µ1  solution  in  the  presence  of  2  µl  10  X  polynucleotide  kinase  buffer 
(500  mM  Tris-HCI,  pH  7.5,0.1  M  DTT,  0.1  M  MgC1),  20  gCi  [y-32P]  ATP  (3000  Ci/mmol, 
10  µCi/µl),  and  10  units  of  T4  polynucleotide  kinase.  The  mixture  was  incubated  at  37°C 
for  90  min.  The  unincorporated  nucleotides  were  removed  by  passing  reaction  mixture 
through  a  Sephadex  G-25  column. 
2.2.12  Southern  blotting  and  hybridization 
2.2.12.1  Southern  blotting 
DNA  fragments  in  an  agarose  gel  were  transferred  onto  a  nylon  membrane  using  the  method 
described  by  Southern  (Southern,  1975).  Following  electrophoresis,  the  gel  was  immersed 
in  denaturing  solution  for  one  hour.  After  a  brief  rinse  in  H20,  the  gel  was  soaked  in 
neutralization  solution  for  a  further  hour.  The  gel  was  placed  on  two  sheets  of  3  MM 
Whatmann  paper  on  a  platform,  which  were  pre-wetted  in  2X  SSPE  and  made  to  function 
as  a  wick  by  dipping  into  a  reservoir  containing  20  X  SSPE.  The  edges  of  the  gel  were 
shrouded  by  plastic  film  in  order  to  prevent  the  20  X  SSPE  bypassing  the  gel  into  the 
blotting  materials.  A  Hybond  N,  or  Hybond  N  plus  membrane  (Amersham)  and  two  sheets 
of  3  MM  Whatmann  paper  were  cut  to  the  size  of  the  gel  and  soaked  in  2X  SSPE.  The 
blotting  membrane  was  carefully  placed  over  the  gel,  avoiding  trapping  any  air  bubbles 
between  them.  The  two  sheets  of  3  MM  Whatmann  paper  were  similarly  placed  over  the 
nylon  membrane.  A  pack  of  dry  paper  towel  was  laid  on  top  of  the  Whatmann  paper. 
Finally,  a  weight  (-1  Kg)  was  placed  on  the  towels.  Transfer  was  carried  out  overnight  at 
room  temperature.  The  membrane  was  then  rinsed  in  2X  SSPE  and  baked  at  80°C  for  2 
hours  to  fix  the  DNA  to  the  membrane. 
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To  prevent  repetitive  sequences  within  a  probe  hybridising  to  non-target  DNA,  the  probes 
was  competed  with  an  excess  of  low  molecular  weight  DNA  before  hybridisation.  The 
method  used  is  based  on  that  described  by  Sealey  and  colleagues  (Sealey  et  al.,  1985).  Coll 
mouse  DNA  (GibcoBRL)  was  used  as  low  molecular  weight  DNA  to  compete  a  probe.  The 
labelled  probe  was  added  to  125  µl  20  X  SSPE,  100  p1  Coil  DNA,  and  H2O  to  a  total 
volume  of  450  µl,  heated  at  100°C  for  15  min,  and  then  incubated  at  65°C  for  at  least  4 
hours  before  use. 
2.2.12.3  Hybridisation  of  Southern  blots 
For  pre-hybridisation,  the  membrane  was  sealed  in  a  Hybaid  hybridisation  bottle  with 
hybridisation  solution  at  65°C  for  at  least  5  hours  and  usually  overnight.  A  20  X  20  cm 
membrane  required  10  ml  hybridisation  solution.  If  the  labelled  probe  was  not  competed 
with  mouse  Cotl  DNA,  it  was  denatured  prior  to  hybridisation  by  boiling  for  5  min, 
followed  by  rapid  cooling  on  ice.  The  denatured  probe  or  the  competed  probe  was  then 
added  directly  to  the  bottle  containing  the  membrane.  The  hybridisation  was  performed  at 
65°C  in  a  Hybaid  rotating  oven  for  16-24  hours.  After  hybridisation,  the  membrane  was 
subjected  to  two  washes  of  2X  SSPE,  0.1  %  (w/v)  SDS  at  65°C  for  15-20  min.  High 
stringency  washes  were  performed,  where  necessary,  in  0.1  X  SSPE,  0.1  %  (w/v)  SDS  at 
65°C  in  a  Hybaid  oven  with  shaking.  After  washing,  the  membrane  was  left  to  air  dry, 
wrapped  in  cling  film  and  exposed  to  X-ray  film  at  -70°C  in  the  presence  of  intensifying 
screen. 
2.2.12.4  Hybridisation  using  synthetic  oligonucleotide 
Before  adding  radio-labelled  oligonucleotides,  the  membrane  was  pre-hybridised  in  pre- 
hybridisation  solution  containing  6X  SSPE,  5X  Denhardt's  solution,  0.4  %  (w/v)  SDS  and 
100  Vg/ml  denatured  salmon  sperm  DNA  at  x°C  (x  =  Tm  of  oligonucleotide-5°C)  for  at  least 
5  hours. 
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Tm,  where  Tin  is  the  melting  temperature  of  the  DNA  (Itakura  et  al.,  1984).  Hybridisations 
were  carried  out  at  5°C  below  the  Tm  in  the  presence  of  6X  SSPE,  5X  Denhardt,  0.4  % 
(w/v)  SDS  and  100  tg/ml  yeast  t-RNA.  After  hybridisation,  the  membrane  was  washed  in  6 
X  SSPE,  0.1  %  (w/v)  SDS  at  the  same  temperature  used  for  hybridization.  More  stringent 
washes  were  achieved  by  decreasing  the  salt  concentration  of  the  washing  solution. 
Membranes  were  then  wrapped  in  cling  film  and  exposed  to  X-ray  film  at  -70°C  in  the 
presence  of  intensifying  screens. 
2.2.13  Removal  of  probe  from  membranes 
Southern  blot  or  northern  blot  membranes  could  be  reused  if  the  unwanted  probe  was 
removed.  To  achieve  this,  the  membrane  was  immersed  in  a  solution  of  boiling  0.1  %  (w/v) 
SDS  and  allowed  to  cool  to  room  temperature  over  30  min  on  a  shaking  platform.  The 
membrane  was  finally  rinsed  in  2X  SSPE  or  2X  SSC  and  stored  damp  in  a  sealed  plastic 
bag. 
2.2.14  Western  blot  analysis 
2.2.14.1  Preparation  of  protein  lysates  from  mouse  brain 
Tissue  (4-5  mg)  was  homogenized  in  a  500  µl  EBC  lysis  buffer  containing  5  µl  PMSF  (100 
mM),  5  ul  Leupeptin  (1  mg/ml),  5  µl  pepstatin  (1  mg/ml)  and  0.5  µl  aprotinin  (10  mg/ml)  at 
4°C  using  a  sterile  0.5  mm  probe  driven  at  9,000  rpm  (Polytron  Kinematica  AG  PT-3000 
Homogeniser).  To  ensure  complete  lysis  of  the  cells,  the  sample  tube  was  then  put  on  a 
rotary  mixer  at  4°C  for  30  min.  After  complete  lysis,  the  homogenate  was  centrifuged  (at 
4°C)  with  19,000  Xg  for  15  min.  The  supernatant  was  removed  and  stored  at  -70°C. 
2.2.14.2  Preparation  of  the  standard  curve  for  the  Coomassie  blue  protein  assay 
Diluted  BSA  standards  were  prepared  from  2.0  mg/ml  BSA  stock  using  distilled  water  as 
the  diluent.  Two  replicates  of  each  standard  were  prepared.  1.0  ml  of  each  standard  was 
added  to  appropriately  labelled  tubes  and  1.0  ml  of  the  diluent  alone  was  used  for  the 
110 control  tube.  1  ml  of  Coomassie  blue  reagent  (Pierce)  was  added  to  each  tube  and  mixed 
well.  The  absorbance  of  each  tube  versus  the  control  was  measured.  A  standard  curve  was 
generated  by  plotting  the  average  control-corrected  595  nm  reading  for  each  BSA  standard 
versus  its  concentration  in  µg/ml.  The  standard  curve  was  used  to  determine  the  protein 
concentration. 
1  µl  of  protein  lysate  (unknown  concentration)  was  added  to  999  µl  distilled  water,  followed 
by  1.0  ml  of  Coomassie  blue  reagent.  The  absorbance  of  the  sample  at  595  nm  was 
measured  against  the  control.  The  concentration  was  determined  using  the  standard  curve 
and  multiplied  by  1000  (to  take  into  account  of  the  dilution  factor  of  the  sample). 
2.2.14.3  Western  blot  gel  electrophoresis  and  blotting  of  protein 
10-20  µg  of  protein  lysate  was  loaded  on  a  NuPage  10  %  Bis-Tris  gel  (Novex)  and  subject 
to  the  NuPageTm  electrophoresis  system  (Novex).  Blotting  of  the  proteins  onto  PVDF 
membrane  was  achieved  using  a  Novex  western  transfer  apparatus  according  to  the 
manufacturer's  instructions.  After  blotting,  the  membrane  was  washed  twice  with  1X  TBST 
for  5  min,  air  dried  and  sealed  in  a  plastic  bag. 
2.2.14.4  Immunodetection  of  blotted  protein 
The  dried  PVDF  membrane  was  wetted  with  methanol  followed  by  two  washes  in  1X 
TBST  for  10  minutes.  The  membrane  was  then  incubated  in  a  blocking  solution  [0.2  % 
(w/v)  casein  solution  (Pierce),  in  1X  TBS  +  0.1  %  (v/v)  normal  goat  serum  or  normal 
donkey  serum  depending  on  the  secondary  antibody]  at  4°C  overnight. 
The  membrane  was  incubated  in  primary  antibody  (see  Table  2.3)  diluted  with  1X  TBST  at 
room  temperature  with  shaking  for  3-4  hours.  After  washing  with  1X  TBST  (4  x  15  min)  at 
room  temperature,  the  membrane  was  incubated  in  secondary  antibodies  diluted  with  1X 
TBST  (see  Table  2.4)  at  room  temperature  for  2  hours.  After  washing  in  1x  TBST  (4  x  15 
minutes)  at  room  temperature,  the  membrane  (size:  8x8  cm)  was  immersed  to  3  ml  of 
chemiluminescent  substrate  (SuperSignal  West  Pico,  Pierce),  and  exposed  to  X-ray  film  for 
15-60  seconds  depending  on  the  antibody  used. 
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Stripping  of  antibody  from  the  western  blot  membrane  was  achieved  by  incubating  the 
membrane  in  the  solution  containing  6.25  ml  of  1M  Tris,  pH  6.7,20  mls  of  10  %  (w/v) 
SDS,  73.05  ml  water  and  700  µl  ß-mercaptoethanol  at  50°C  for  30-40  min.  After  stripping, 
the  membrane  was  washed  in  1X  TBST  for  two  10-min  periods,  air-dried  and  sealed  in  a 
clean  plastic  bag. 
2.2.15  Northern  blot  analysis 
2.2.15.1  Extraction  of  RNA  from  mouse  tissue 
As  RNA  is  vulnerable  to  degradation  from  nucleases,  the  following  precautions  were  taken: 
the  restriction  of  RNA  work  to  a  dedicated  bench,  the  use  of  dedicated  equipment  wherever 
possible  and  the  use  of  gloves  at  all  times.  All  solutions  required  for  RNA  related 
techniques  were  made  using  DEPC-treated  water.  DEPC  was  added  to  a  concentration  0.1 
%  (v/v),  mixed  and  allowed  to  stand  overnight  before  inactivation  by  autoclaving.  All 
plasticware  was  soaked  in  DEPC-treated  water  before  autoclaving.  Each  tissue  was  frozen 
immediately  on  dry  ice  after  dissection,  followed  by  storage  at  -70°C. 
When  preparing  RNA,  5-50  mg  tissue  was  defrosted  on  ice  in  a  bijou  before  adding  1  ml  of 
Sigma  TRI  REAGENT.  The  tissue  was  homogenized  using  a  sterile  0.5  mm  Polytron 
probe  driven  at  20,000  rpm  (Kinematica  AG  PT-3000  homogeniser).  RNA  was  then 
prepared  according  to  the  Sigma  TRI  REAGENT`'  protocol  and  resuspended  in  40  µl  of 
DEPC-treated  water.  If  necessary,  the  RNA  was  incubated  at  65°C  for  30  min  to  achieve 
resuspension.  To  avoid  genomic  DNA  contamination,  15  µl  of  RQ1  (RNase  free  DNase, 
Promega,  1  unit/µl)  and  10  µl  of  10  X  buffer  were  added  to  the  RNA  sample  and  made  up 
100  µl  with  DEPC-treated  water.  This  mixture  was  incubated  at  37  °C  for  30  min  before 
being  made  up  to  400  µl  with  DEPC-treated  water  and  extracted  using  an  equal  volume  of 
phenol:  chloroform:  isoamyl  alcohol.  After  vortexing,  the  mixture  was  centrifuged  at  10,000 
Xg  for  10  min  and  the  upper  layer  was  removed.  The  RNA  was  precipitated  by  adding  0.1 
volume  of  3M  CH3COONa  (pH  4.8)  followed  by  2  volumes  of  absolute  ethanol.  The  RNA 
was  pelleted  by  centrifugation  at  10,000  Xg  for  10  min,  rinsed  in  75  %  (v/v)  ethanol  and 
112 air  dried  for  not  more  than  30  min  before  being  resuspended  in  30-40  µl  1X  TE,  0.1  % 
(w/v)  SDS.  The  RNA  concentration  was  determined  by  spectrophotometry  by  diluting  1/80 
with  distilled  water  to  a  final  volume  of  400  µl  and  measuring  the  absorbance  of  the  RNA  at 
X  260  nm. 
2.2.15.2  RNA  visualization  by  agarose  gel  electrophoresis 
A1%  agarose  gel  containing  0.1  %  (w/v)  SDS  was  made  with  1X  TAE  buffer  (DEPC- 
treated).  10  µl  of  10  mg/ml  EtBr  was  added  to  200  ml  melted  agarose  gel.  5  µg  of  each 
RNA  sample  was  added  to  5X  loading  buffer,  loaded  on  the  gel  and  electrophoresed  at  10 
volts/cm  for  -1  hour. 
2.2.15.3  First  Strand  cDNA  synthesis 
First  strand  cDNA  was  synthesized  using  a  protocol  modified  from  the  SUPERSCRIPT'' 
Preamplification  System  for  First  Strand  cDNA  Synthesis  (GibcoBRL).  1  µl  Oligo  (dT)  12- 
18  base  primers  (GibcoBRL)  was  added  to  2.5  µg  total  RNA  and  made  up  to  a  final  volume 
of  9.5  µl  with  DEPC-treated  water.  A  control  reaction  containing  no  reverse  transcriptase 
(RT)  was  made  up  to  a  final  volume  of  11.5  µl.  The  tubes  were  heated  at  70°C  for  10  min, 
centrifuged  briefly,  and  placed  on  ice  before  adding  20  units  of  RNasin  (Promega),  10  mM 
of  DT17,1  mM  of  dNTPs  and  5X  Superscript  II  buffer.  The  final  volume  of  the  test  reaction 
was  18  µl  (20  µl  for  no-RT  control).  Each  sample  was  mixed  and  incubated  at  42  °C  for  2 
min  before  2  µl  (400  units)  of  SuperscriprlI  reverse  transcriptase  was  added  to  the  positive 
reaction  tubes  only.  The  tubes  were  incubated  at  42°C  for  a  further  50  min.  The  reaction  was 
stopped  by  heating  at  70°C  for  15  min.  20  µl  of  DEPC-treated  water  was  added  to  each 
sample  before  storing  the  cDNA  at  -70°C. 
2.2.15.4  Northern  blotting 
A  1.2  %  (w/v)  denaturing  formaldehyde-agarose  gel  was  generated  by  boiling  agarose  in 
120  ml  DEPC-treated  water  and  adding  15  ml  10  X  MOPS  (pH  8)  and  15  ml  37  %  (w/v) 
formaldehyde  before  pouring  into  the  gel  former.  8  µl  of  RNA  (10-15  µg)  was  added  to  6  µl 
denaturing  buffer  (300  µl  of  10  X  MOPS,  pH  8,80  µl  of  formaldehyde,  900  µl  formamide, 
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for  10  min,  cooled  on  ice,  loaded  into  the  wells  and  electrophoresed  in  1X  MOPS  buffer, 
pH  7  at  10  volts/cm  for  3-4  hours  in  a  fume  food. 
Before  proceeding  with  the  transfer  process,  the  integrity  of  the  separated  RNA  was 
checked  by  visualising  the  RNA  under  UV  light  and  looking  for  the  intact  28S  and  18S 
ribosomal  RNA  bands.  The  gel  was  photographed  with  a  fluorescent  ruler  aligned  along  the 
side  of  the  gel  and  then  soaked  in  6X  SSC  for  30  minutes  before  transferring  to  a  Biodyne 
B  membrane  (Pall  Gelman  Laboratory)  overnight  by  capillary  action  in  10  X  SSC.  After  the 
transfer  process,  the  membrane  was  baked  at  80°C  for  2  hours. 
2.2.15.5  Hybridisation  of  northern  blot  membranes 
The  northern  blot  membrane  was  prehybridised  in  5  ml  ExpressHyb  hybridisation  solution 
(Clontech)  at  68°C  for  1-2  hour,  after  which  the  denatured  radiolabelled  probe  was  added 
and  hybridised  for  a  further  1-3  hours.  The  membrane  was  washed  to  a  final  stringency  of 
0.1  X  SSC,  0.1  %  (w/v)  SDS  at  65-68°C  for  10  min-1  hour  (depending  on  the  probe  used). 
After  washing,  the  membrane  was  sealed  in  a  plastic  bag  and  exposed  to  X-ray  film  at  - 
70°C  in  the  presence  of  intensifying  screen. 
2.2.16  Slot  blot  analysis  of  total  RNA 
Slot  blotting  is  a  less  time  consuming  technique  than  northern  blotting  because  it  does  not 
involve  electrophoresis  and  transferring  RNA.  However,  genomic  DNA  contamination  must 
be  avoided  to  prevent  confounding  hybridisation  signals  from  DNA. 
The  slot  blot  equipment,  Minifold  II  (Schiender  and  Schell)  was  treated  with  3%  (v/v)  H202 
for  20  min  and  then  thoroughly  rinsed  with  DEPC-treated  water  to  removed  any  RNases.  5 
tg  of  each  RNA  sample  was  resuspended  in  11  µl  of  TE  /  0.1  %  (w/v)  SDS.  33  µl  of 
loading  buffer  (section  2.1.17)  was  added  to  each  sample,  followed  by  incubation  at  65°C 
for  10  min.  After  quenching  on  ice,  11  µl  of  20  X  SSC  was  added  to  each  sample.  The  slot 
blot  equipment  was  assembled  with  two  pieces  of  pre-wetted  3  MM  Whatmann  paper 
underlying  the  nylon  Biodyne  B  membrane  (Pall  Gelman  Laboratory)  (cut  to  size  and  pre- 
soaked  in  1X  TAE  for  30  min).  500  µl  of  1X  TAE  was  added  and  aspirated  through  the 
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each  sample  in  the  slot,  the  vacuum  was  applied  for  5  min.  When  the  samples  had  been 
aspirated  through,  500  µl  of  4X  SSC  was  added  and  aspirated  through  the  slot  twice.  The 
membrane  was  then  baked  for  2  hours  at  80°C,  hybridised  and  washed  using  the  procedures 
described  for  northern  blotting  (section  2.2.15.5). 
2.2.17  Immunohistochemistry 
2.2.17.1  Perfusion  and  fixation  of  mouse  tissue 
Each  mouse  was  anaesthetised  with  0.1  ml  Euthetal  (Rhone  Meriex,  Ltd)  via  intraperitoneal 
injection.  Following  the  absence  of  a  reflex  response  to  pain  stimulation,  the  mouse  was 
perfused  transcardially  with  50  ml  2%  (w/v)  xylocaine  in  1X  PBS  for  2  min  to  dilate  the 
blood  vessels.  This  was  followed  by  120  ml  4%  (w/v)  paraformaldehyde  (PFA)  in  1X 
PBS,  pH  7.4.  After  perfusion,  the  whole  head  of  mouse  was  immersed  in  4%  (w/v)  PFA  at 
4°C  overnight.  The  next  day  the  skull  was  removed  and  the  brain  left  in  4%  (w/v)  PFA  for 
a  further  2-3  hours. 
2.2.17.2  Preparation  of  free-floating  sections 
The  fixed  brain  was  left  in  30  %  (w/v)  sucrose  in  1X  PBS  until  it  sank  to  the  bottom  of  the 
container.  The  sucrose-protected  brain  was  immersed  in  isopentane  cooled  with  dry  ice  at  - 
42°C  for  2-5  min.  The  brain  was  then  mounted  on  a  chuck  with  Cryomatrix  (Shandon). 
Immediately,  after  the  Cryomatrix  solidified  completely,  the  brain  was  cut.  30  µm  serial 
coronal  sections  were  cut  with  a  Cryotome,  immersed  in  the  wells  of  Nunc  multidish  (Nunc 
International)  containing  cryoprotectant  (section  2.1.17)  and  stored  at  -20°C. 
2.2.17.3  Preparation  of  paraffin-embedded  tissue  sections 
The  fixed  brain  was  kept  in  1X  PBS  for  1-3  days  prior  to  paraffin-embedding  procedures. 
Fixed  brains  were  cut  into  three  coronal  blocks  using  a  rodent  brain  matrix.  Individual 
blocks  were  placed  into  labelled  embedding  cassettes  (Surgipath).  The  cassettes  were 
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automatic  processor: 
1.70  %  (v/v)  ethanol,  35°C  1  hour 
2.80  %  (v/v)  ethanol,  35°C  1  hour 
3.96  %  (v/v)  ethanol,  35°C  1  hour 
4.100  %  ethanol,  35°C  1  hour 
5.100  %  ethanol,  35°C  1  hour 
6.100  %  ethanol,  35°C  1  hour 
7.100  %  ethanol,  35°C  1  hour 
8.100  %  ethanol/Histoclear  (1:  1),  35°C  1  hour 
9.  Histoclear  1  hour 
10.  Histoclear  1  hour 
11.  Paraffin  wax  60°C  1  hour  X3 
Stainless  steel  moulds  were  prepared  by  cleaning  with  Histoclear  (National  Diagnostics). 
They  were  then  placed  on  a  hotplate  and  the  inside  surface  coated  with  a  thin  film  of 
glycerine.  The  moulds  were  then  filled  with  liquid  wax  and  returned  to  the  hotplate.  The 
embedding  cassettes  containing  brain  blocks  were  put  into  the  wax  moulds  and  removed 
from  the  hotplates.  Sufficient  melted  wax  was  added  to  ensure  that  cassette  and  mould 
remained  securely  connected. 
6  µm  serial  coronal  sections  of  paraffin-embedded  tissue  blocks  were  cut  with  a  microtome 
(Leica  RM  2135).  The  resulting  ribbons  of  sections  were  floated  on  a  water  bath  (42°C)  for 
several  minutes  to  allow  them  to  relax  and  stretch  into  their  normal  conformation  after 
cutting.  A  microscope  slide  (poly-L-lysine  coated)  was  then  placed  in  the  water  beneath  the 
end  of  the  ribbon.  Two  single  brain  sections  were  cut  from  the  ribbon  using  a  scalpel  blade 
and  mounted  on  the  slide. 
2.2.17.4  Immunostaining  of  free-floating  tissue  sections 
The  free-floating  sections  kept  in  cryoprotectant  were  transferred  to  new  wells  containing  1 
X  PBS  and  incubated  for  5  min.  The  sections  were  permeabilized  with  0.2  %  (v/v)  Triton  in 
1X  PBS  on  a  shaking  platform  for  30  min.  After  two  5-min  washes  in  1X  PBS,  the 
sections  were  treated  with  3%  (v/v)  hydrogen  peroxide  in  1X  PBS  for  20  min.  After  two  5- 
min  washes  in  1X  PBS,  the  sections  were  incubated  in  a  blocking  solution  [10  %  (v/v) 
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polyclonal  primary  antibodies;  10  %  (v/v)  normal  horse  serum  (Vector)  and  0.5  %  (w/v) 
bovine  serum  albumin  in  1X  PBS  for  monoclonal  primary  antibodies]  for  an  hour.  Tissues 
sections  were  incubated  in  primary  antibody  (see  Table  2.3)  overnight  at  4°C.  The  next  day, 
sections  were  subjected  to  two  10-min  washes  in  1X  PBS,  followed  by  1  hour  incubation  in 
biotinylated  secondary  antibody  [anti-mouse  secondary  antibody  for  monoclonal  primary 
antibodies  (1:  100;  Vector)  and  anti-rabbit  secondary  antibody  for  polyclonal  primary 
antibodies  (1:  100;  Vector)].  Sections  were  then  subjected  to  two  5-min  washes  in  1X  PBS 
and  incubated  for  1  hour  in  an  avidin  biotinylated  enzyme  complex  (VECTASTAIN®  ABC 
kit,  Vector).  Finally,  the  sections  were  subjected  to  two  5-min  washes  in  1X  PBS  and  the 
signal  developed  by  using  3'3  -diaminobenzidine  tetrahydrochloride  (DAB;  Vector)  as  the 
chromogen.  After  the  sections  appeared  brown,  the  DAB  were  washed  away  with  two  5-min 
washes  in  distilled  water.  After  incubation  in  Tris  buffer  (section  2.1.17)  for  10  min,  the 
sections  were  mounted  on  microscope  slides  and  air-dried  overnight.  The  next  day,  the 
sections  were  rinsed  in  running  water  for  1  hour,  and  then  dehydrated  through  serial 
concentrations  of  ethanol  and  Histoclear  [2  min  in  70  %  (v/v)  ethanol,  2  min  in  90  %  (v/v) 
ethanol,  two  2-min  periods  in  absolute  ethanol  and  two  2-min  periods  in  Histoclear].  A 
cover  slide  was  then  applied  using  DPX  mounting  medium.  Controls  for  the  specificity  of 
the  immunostaining,  by  omitting  the  primary  antibody,  were  included  in  each  experiment. 
2.2.17.5  Immunnostaining  of  paraffin-embedded  tissue  sections 
Paraffin-embedded  tissue  sections  were  dewaxed  at  60°C  for  20  min  and  then  immersed  in 
Histoclear  for  two  10-min  periods.  Sections  were  then  dehydrated  in  100  %  ethanol  for  two 
5-  min  periods. 
For  antigen  retrieval,  tissue  sections  were  pre-treated  by  microwaving  at  full  power  in  a  10 
mM  citric  acid  buffer  (pH  6.0)  for  two  5-min  periods.  After  a  cooling  period  of  40  min,  the 
sections  were  treated  with  3%  (v/v)  hydrogen  peroxide  in  methanol  for  30  min  to  block  the 
endogenous  peroxidase  activity.  After  rinsing  in  running  water  for  20  min,  sections  were 
washed  with  1X  PBS  for  two  5-min  periods.  Sections  were  then  incubated  in  a  blocking 
solution  [10  %  (v/v)  normal  goat  serum  (Vector)  and  0.5  %  (w/v)  bovine  serum  albumin  in 
1X  PBS  for  polycolnal  primary  antibodies;  or  a  mouse  IgG  blocking  reagent  kit  from 
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were  incubated  in  primary  antibody  (see  Table  2.3)  overnight  at  4°C.  The  next  day,  sections 
were  subjected  to  two  5-min  washes  in  1X  PBS,  followed  by  a  20  min  incubation  in 
biotinylated  anti-mouse  secondary  antibody  for  monoclonal  primary  antibodies  (1:  100  or 
1:  500;  Vector)  and  1  hour  in  biotinylated  anti-rabbit  secondary  antibody  for  polyclonal 
primary  antibodies  (1:  100;  Vector).  Sections  were  then  subjected  to  two  5-min  washes  in  1 
X  PBS  and  incubated  for  1  hour  in  an  avidin  biotinylated  enzyme  complex  (Vectastain® 
Elite  ABC  kit,  or  Standard  ABC  kit,  Vector).  Finally,  the  sections  were  subjected  to  two  5- 
min  washes  in  1X  PBS  and  the  signal  developed  by  using  3'3'  -diaminobenzidine 
tetrahydrochloride  (DAB;  Vector)  as  the  chromogen  with  (when  stained  with  anti-HO-1, 
anti-4-HNE,  and  anti-8-OHdG  antibodies)  or  without  Nickel  enhancement  (when  stained 
with  anti-COI  antibody).  After  the  sections  appeared  brown,  the  DAB  was  washed  away 
with  running  water  for  10  minutes.  After  dehydrating  the  sections  in  serial  concentrations  of 
ethanol  and  Histoclear  [2  min  in  70  %  (v/v)  ethanol,  2  min  in  90  %  (v/v)  ethanol,  two  2-min 
periods  in  absolute  ethanol  and  two  2-min  periods  in  Histoclear],  a  cover  slide  was  applied 
using  DPX  mounting  medium.  Controls  for  the  specificity  of  the  immunostaining,  by 
omitting  the  primary  antibody,  were  included  in  each  experiment. 
2.2.18  Assessing  locomotor  performance  of  mice  using  a  rotarod 
apparatus 
Motor  coordination  and  balance  of  mice  were  measured  using  a  rotarod  apparatus  (Dunham 
and  Miya,  1957;  Rozas  and  Labandeira  Garcia,  1997).  The  rotarod  was  built  in  house  by  the 
workshop  in  the  University  of  Glasgow.  The  rotarod  consists  of  a  revolving  rod  that  can 
rotate  at  different  speeds,  a  power  source  for  controlling  the  rod  speed  and  4  separators 
placed  along  the  rod  at  suitable  intervals  to  divide  the  rod  into  equal-sized  compartments  for 
simultaneous  testing  of  4  mice.  Four  timer  sets  corresponding  to  4  compartments  were  built 
into  the  device,  and  are  used  to  measure  the  latency  of  the  mouse  to  fall  off  the  rod.  The 
diameter  of  the  revolving  rod  is  3.5  cm  and  it  is  covered  with  a  layer  of  rubber.  The  rod  is 
about  60  cm  height  from  the  floor  of  the  device.  The  floor  of  the  device  is  made  of  a  rubber- 
like  material.  The  protocol  used  in  the  study  is  outlined  in  Table  2.7.  The  latency  to  fall  off 
the  rotarod  was  recorded  and  used  in  subsequent  analyses.  The  maximal  time  for  each  trial 
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the  week  prior  to  the  2nd  and  3rd  time  point  test,  each  mouse  was  retrained  by  subjecting  it  to 
three  trials  per  day  at  20  rpm  (maximum  1  min)  for  2  consecutive  days. 
Table  2.7  Protocol  for  locomotor  experiment 
Rotarod  speed  (rpm)  Maximum  Trials/day  Number  of 
time/trial  (min)  consecutive  days 
Acclimatisation:  day  1 
0  1  1  1 
5  1  1  1 
10  1  1  1 
15  1  1  1 
20  1  1  1 
Training:  day  2-4 
20  rpm  1  3  3 
Testing:  day  8-10 
5  1  1  3 
10  1  1  3 
15  1  1  3 
20  1  1  3 
25  1  1  3 
30  1  1  3 
35  1  1  3 
40  1  1  3 
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3.1  Introduction 
As  mentioned  previously  in  the  chapter  1,  the  aims  of  the  study  were  to  investigate  the 
pathological  changes  at  molecular  and  cellular  levels  of  HD  mice  and  the  phenotypic 
consequences  of  the  HD  mutation.  In  previous  studies,  it  has  been  shown  that  the  HD  mice 
display  abnormal  social  behaviour  at  3  months  of  age  (Shelbourne  et  al.,  1999)  and 
electrophysiological  deficits  (a  significant  reduction  in  long-term  potentiation)  at  8  months 
of  age  (Usdin  et  al.,  1999),  suggesting  learning  and  memory  impairments.  However,  studies 
of  locomotor  performance  including  beam  walking  and  rope  tests  did  not  show  significant 
differences  between  HD  mice  and  wild-type  littermates  at  17  months  of  age  (Peggy 
Shelbourne,  unpublished  data).  The  clasping  of  limbs,  which  is  commonly  present  as  a 
phenotypic  abnormality  in  some  HD  mouse  models  (Mangiarini  et  al.,  1996;  Hodgson  et 
al.,  1999;  Reddy  et  al.,  1999;  Yamamoto  et  al.,  2000),  was  not  noticed  in  the  HD  mice. 
Also,  HD  mice  could  not  be  distinguished  from  normal  mice  by  observing  the  daily  activity 
at  any  point  during  their  lifespan.  Since  motor  dysfunction  plays  a  prominent  role  in  early 
stages  of  HD  (Harper  et  al.,  1996),  it  was  decided  that  the  locomotor  function  of  HD  mice 
should  be  investigated  further.  A  rotarod  apparatus  (Dunham  and  Miya,  1957;  Rozas  and 
Labandeira  Garcia,  1997)  that  gives  the  tested  mice  a  more  challenging  task,  thus  providing 
a  more  sensitive  measure  of  locomotor  performance,  was  used  to  assess  four  limb  motor 
coordination,  balance  and  muscle  strength  of  HD  mice.  By  assessing  the  rotarod 
performance  of  HD  mice  at  different  time  points,  the  aims  of  the  study  were:  1)  to 
determine  whether  the  locomotor  dysfunction  is  present  in  HD  mice  as  a  functional 
consequence  of  the  HD  gene  mutation;  2)  to  determine  when  the  onset  of  locomotor 
dysfunction  occurs  in  HD  mice  and  whether  motor  function  progressively  deteriorates;  3) 
to  relate  molecular  and  cellular  findings  to  locomotor  dysfunction;  4)  to  investigate  the  use 
of  rotarod  performance  as  a  "biomarker"  to  assess  the  efficacy  of  potential  therapies  in  the 
future. 
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rotarod  apparatus 
Eight  male  HD  mice  and  8  male  wild-type  littermates,  and  8  female  HD  and  8  female  wild- 
type  littermates  were  tested  in  the  study  (see  details  of  the  mouse  cohorts  in  section  2.1.18). 
Mice  were  housed  together  according  to  litter  order  and  sex  rather  than  genotype,  and 
rotarod  experiments  were  performed  in  numerical  order  of  mouse  identification  tags.  As 
HD  mice  could  not  be  distinguished  from  normal  littermates  by  appearance  in  their  home 
cage,  the  rotarod  experiments  were  performed  in  a  manner  that  was  effectively  blind  to 
genotype. 
Although  8  male  HD  mice  were  used  at  the  beginning  of  study,  1  male  HD  mouse  died 
after  the  first  time  point  of  the  experiment  (4  months  of  age)  and  another  male  HD  mouse 
died  after  second  time  point  of  the  experiment  (12  months  of  age).  Therefore,  only  7  and  6 
male  HD  mice  were  used  at  the  second  (12  months  of  age)  and  third  time  points 
respectively  (18  months  of  age). 
Locomotor  assessments  commenced  at  4  months  of  age.  All  mice  were  subjected  to 
handling  twice  a  week  from  5  weeks  of  age  until  the  rotarod  assessments  began,  because  it 
was  felt  that  this  would  decrease  the  handling  stress  imposed  on  mice  when  they  were 
performing  the  rotarod  task.  During  the  week  prior  to  testing,  each  mouse  received  a 
training  course  (section  2.2.18),  which  again  was  designed  to  reduce  the  handling  stress  and 
allow  each  mouse  to  learn  the  task  and  reach  a  steady  baseline  level  of  performance.  Each 
mouse  was  then  tested  at  8  increasing  speeds  from  5-40  rpm,  1  trial  per  speed  per  day  for  3 
consecutive  days.  Each  mouse  was  tested  at  three  time  points:  4,12  and  18  months  of  age. 
The  latency  to  fall  off  the  rod  for  each  trial  of  each  mouse  was  recorded  after  each  trial  was 
completed.  The  performance  of  each  mouse  was  also  videotaped  for  data  backup  purposes. 
Since  each  mouse  has  3  data  points  per  speed  per  time  point  for  8  speeds  and  3  different 
ages,  a  complex  data  set  was  produced  and  so  a  number  of  alternative  methods  of  data 
analysis  were  explored. 
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the  rod  at  each  speed 
Initially,  the  rotarod  performance  of  male  HD  and  male  wild-type  cohorts  at  each  of  8 
different  speeds  (5-40  rpm)  at  4,12  and  18  months  of  age  was  analysed.  The  mean  time 
staying  on  the  rod  (from  3  trials)  at  each  speed  for  each  mouse  at  each  time  point  was 
determined.  The  data  points  from  HD  and  wild-type  littermates  were  combined  respectively 
and  compared  in  a  pair-wise  fashion  using  Student's  t  test  (Fig.  3.1).  No  significant 
differences  between  male  HD  and  male  wild-type  mouse  groups  were  observed  at  any 
speed  at  4  months  of  age  (Fig.  3.1a).  Male  HD  mice  showed  worse  rotarod  performances  at 
speeds  of  10-40  rpm  at  12  months  of  age  when  compared  with  male  wild-type  littermates 
(Fig.  3.1b).  Male  HD  mice  showed  worse  rotarod  performances  at  speeds  of  15-20  and  40 
rpm  at  18  months  of  age  when  compared  to  male  wild-type  littermates  (Fig.  3.1c).  The 
results  revealed  that  male  HD  mice  showed  worse  performances  at  7  speeds  and  3  speeds  at 
12  and  18  months  of  age  respectively,  when  compared  to  male  wild-type  littermates. 
The  same  method  was  used  to  compare  the  rotarod  performance  of  female  HD  and  female 
wild-type  cohorts.  No  significant  differences  between  female  HD  and  female  wild-type 
mouse  groups  were  observed  at  any  speed  at  4  months  of  age.  Female  HD  mice  showed 
worse  rotarod  performances  at  speeds  15-40  rpm,  and  15-30  and  40  rpm  at  12  and  18 
months  of  age  respectively  when  compared  to  female  wild-type  littermates.  However,  as 
the  data  set  obtained  from  each  cohort  was  complex,  it  was  difficult  to  draw  an  overall 
conclusion  about  performance  deficits  and  their  relationship  with  age. 
3.2.2  Analysis  of  the  rotarod  data  using  a  measure  of  overall 
performance 
Since  the  pair-wise  comparison  generated  many  data  points  for  each  mouse,  alternative 
representations  of  the  data  were  considered. 
The  sum  of  the  time  periods  staying  on  the  rod  at  8  speeds  was  used  to  represent  the  overall 
rotarod  performance  (ORP)  of  each  mouse.  Since  each  mouse  performed  3  trials  (1  trial  per 
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Figure  3.1  Pair-wise  comparisons  of  rotarod  performances  of  8  male  HD  mice  (black 
circle)  and  8  wild-type  littermates  (grey  square)  at  various  speeds  (5-40  rpm)  at  4  (a), 
12  (b)  and  18  months  of  age  (c).  The  male  HD  mice  showed  worse  performances 
(p  <  0.05  and  indicated  by  symbol*)  at  speeds  of  10-40  rpm  at  12  months  of  age  and 
15,20  and  40  rpm at  18  months  of  age  when  compared  to  the  male  wild-type  littermates 
using  the  Student's  t  test  (two-tailed)  for  statistical  analysis.  All  values  are  expressed 
as  mean  ±  S.  E. 
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Speed  of  rod  rotation  (rpm) day  for  3  consecutive  days)  at  each  speed,  either  of  two  different  measurements  (the  sum  of 
the  mean  or  the  maximum  time  staying  on  the  rod  from  3  trials  at  each  speed)  can  be  used 
to  represent  ORP.  The  data  were  analysed  using  both  methods  to  investigate  the  outcome  of 
using  the  different  measurements. 
3.2.2.1  Analysis  of  the  rotarod  data  using  the  sum  of  the  mean  time  staying  on  the 
rod  from  3  trials  at  each  speed 
The  sum  of  the  mean  time  staying  on  the  rod  from  3  trials  at  each  speed  (termed  `mean 
ORP')  of  each  mouse  at  4,12  and  18  months  of  age  was  determined.  A  comparison  of 
mean  ORP  of  HD  mice  and  wild-type  littermates  at  each  time  point  was  performed  using 
the  Student's  t  test  (two  tailed).  In  addition,  the  differences  in  mean  ORP  between  4  and  12 
months  of  age  and  between  12  and  18  months  of  age  for  each  mouse  cohort  were 
determined.  The  deterioration  of  overall  rotarod  performance  of  HD  mice  with  age  was  also 
compared  to  wild-type  littermates. 
The  results  revealed  that  female  HD  mice  showed  worse  mean  ORP  at  12  (p  =  0.002)  and 
18  months  (p  =  0.001)  of  age  when  compared  with  female  wild-type  littermates  (Fig.  3.2a). 
The  mean  ORP  of  female  HD  mice  appeared  to  deteriorate  significantly  from  4  to  12 
months  of  age  (p  =  0.04),  but  not  after  12  months  of  age  (Fig.  3.2b). 
Male  HD  mice  showed  a  significantly  worse  mean  ORP  at  12  (p  =  0.007)  and  18  months  of 
age  (p  =  0.01)  when  compared  to  male  wild-type  littermates  (Fig.  3.2c).  Male  HD  mice 
displayed  a  trend  toward  a  decreased  mean  ORP  with  age  from  4  to  12  months  (p  =  0.09), 
when  compared  to  wild-type  littermates  (Fig.  3.2d).  However,  the  mean  ORP  of  male  HD 
mice  did  not  appear  to  decline  significantly  after  12  months  of  age. 
3.2.2.2  Analysis  of  the  resulting  data  using  the  sum  of  the  maximum  time  staying 
on  the  rod  from  3  trials  at  each  speed 
The  sum  of  the  maximum  time  that  a  mouse  stayed  on  the  rod  from  3  trials  at  each  speed 
(termed  `maximum  ORP')  of  each  mouse  at  4,12  and  18  months  of  age  was  determined. 
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Figure  3.2  Comparisons  of  the  mean  overall  rotarod  performances  (mean  ORP) 
of  8  female  HD  and  8  female  wild-type  littermates  (a  and  b)  and  8  male  HD  and 
8  male  wild-type  littermates  (c  and  d)  at  3  time  points  using  the  sum  of  mean  time 
on  the  rod  from  3  trials  at  each  speed  as  the  mean  ORP.  Female  HD  mice  showed 
worse  performances  at  12  and  18  months  of  age  compared  to  the  female  wild-type 
littermates.  The  performances  of  female  HD  mice  declined  from  4  to  12  months 
of  age.  Male  HD  mice  showed  worse  performances  at  12  and  18  months  of  age, 
when  compared  to  male  wild-type  littermates.  Male  HD  mice  also  showed  a  trend 
toward  decline  in  ORP  from  4  to  12  months  of  age,  but  not  from  12  to  18  months 
of  age.  Data  are  expressed  as  mean  t  S.  E.  @  indicates  the  mean  value  was  obtained 
from  7  animals.  X  indicates  the  mean  value  was  obtained  from  6  animals.  The  p 
values  indicated  were  obtained  from  comparing  the  results  obtained  with  HD  mice 
(grey  column)  and  wild-type  littermates  (open  column)  using  the  Student's  t  test 
(two-tailed)  for  statistical  analysis.  The  decrease  in  ORP  of  each  mouse  group 
from  4  to  12,4  to  18  and  12  to  18  months  of  age  is  indicated  by  4-12  ORP,  4-18 
ORP  and  12-18  ORP  respectively. 
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4-12  ORP  4-18  ORP  12-18  ORP Comparisons  of  the  maximum  ORP  of  HD  mice  and  wild-type  littermates  at  3  time  points 
were  performed  using  the  same  statistical  methods  as  described  in  section  3.2.2. 
The  results  revealed  that  female  HD  mice  showed  worse  maximum  ORP  at  12  (p  =  0.001) 
and  18  months  of  age  (p  =  0.01)  when  compared  to  female  wild-type  littermates  (Fig.  3.3a). 
Female  HD  mice  also  showed  a  deterioration  in  maximum  ORP  with  age  from  4  to12 
months,  when  compared  to  the  female  wild-type  littermates  but  no  decline  in  maximum 
ORP  after  12  months  of  age  (Fig.  3.3b).  Male  HD  mice  showed  a  significantly  worse 
maximum  ORP  at  12  (p  =  0.002)  and  18  months  of  age  (p  =  0.03)  when  compared  to  male 
wild-type  littermates  (Fig.  3.3c).  Male  HD  mice  showed  a  significantly  worse  maximum 
ORP  with  age  from  4  to  12  months  when  compared  male  wild-type  littermates,  but  no 
significant  decline  in  maximum  ORP  after  12  months  of  age  (Fig.  3.3d). 
3.2.2.3  Summary 
The  results  obtained  by  using  two  different  methods  to  compare  the  overall  rotarod 
performance  of  HD  mice  and  wild  type  littermates  were  similar.  When  using  mean  ORP  or 
maximum  ORP  as  the  variable,  both  female  and  male  HD  mice  showed  worse 
performances  at  12  and  18  months  of  age,  when  compared  to  their  corresponding  wild-type 
littermates.  Both  female  and  male  HD  mice  showed  a  significant  deterioration  in  mean  and 
maximum  ORP  with  age  from  4  to  12  months,  when  compared  with  their  corresponding 
wild-type  littermates  (male  HD  mice  showed  a  trend  toward  decline  in  mean  ORP  from  4  to 
12  months  of  age).  However,  the  mean  and  maximum  ORP  of  both  female  and  male  HD 
mice  did  not  significantly  decline  after  12  months  of  age. 
3.2.3  Analysis  of  the  resulting  data  using  ANOVA 
Three-way  ANOVA  was  the  final  method  used  to  analyse  the  data  because  it  uses  all  raw 
data  points,  takes  into  account  different  factors  that  might  influence  the  rotarod 
performance,  and  reveals  the  relationship  between  different  factors.  The  Minitab  software 
package  was  used  for  data  analysis. 
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Figure  3.3  Comparisons  of  the  maximum  overall  rotarod  performances  (maximum 
ORP)  of  8  female  HD  and  8  female  wild-type  littermates  (a  and  b)  and  8  male  HD 
and  8  male  wild-type  littermates  (c  and  d)  at  3  time  points  using  the  sum  of  maximum 
time  on  the  rod  from  3  trials  at  each  speed  as  the  maximum  ORP.  Female  HD  mice 
showed  worse  performances  at  12  and  18  months  of  age,  when  compared  to  female 
wild-type  littermates.  Female  HD  mice  showed  a  decline  in  ORP  from  4  to  12  months 
of  age,  but  not  from  12  to  18  months  of  age.  Male  HD  mice  showed  worse  performances 
at  12  and  18  months  of  age,  when  compared  to  male  wild-type  littermates.  Male  HD 
mice  showed  a  significant  decline  in  ORP  from  4  to  12  months  of  age,  but  not  from  12 
to  18  months  of  age.  Data  are  expressed  as  mean  t  S.  E.  C  indicates  the  mean  value  was 
obtained  from  7  animals.  X  indicates  the  mean  value  was  obtained  from  6  animals.  The 
p  values  indicated  were  obtained  from  comparing  the  results  obtained  with  HD  mice 
(grey  column)  and  wild-type  littermates  (open  column)  using  the  Student's  t  test  (two- 
tailed)  for  statistical  analysis.  The  decrease  in  ORP  of  each  mouse  group  from  4  to  12, 
4  to  18  and  12  to  18  months  of  age  is  indicated  by  4-12  ORP,  4-18  ORP  and  12-18  ORP 
respectively. 
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4-12  ORP  4-18  ORP  12-18  ORP To  compare  the  rotarod  performances  of  HD  mice  and  their  corresponding  wild-type 
littermates  at  3  time  points  using  three-way  ANOVA,  genotype  (2  genotypes:  HD  and  wild- 
type),  speed  (8  speeds)  and  day  (3  consecutive  days)  were  used  as  3  factors.  The  results 
from  data  obtained  with  male  mice  at  4,12  and  18  months  of  age  are  shown  in  Table  3.1. 
At  4  months  of  age  (Table  3.1a),  the  rotarod  performance  of  male  mice  was  significantly 
different  between  the  2  genotypes  (F  1  =11.21,  p=0.001)  and  across  the  8  speeds  (F  7,3 
=151.58,  p=0.000),  but  not  over  the  3  days  (F  =  2.87,  p=0.058).  The  results  obtained 
from  analysing  the  interaction  of  genotype  and  speed,  and  genotype  and  day  showed  that 
the  difference  in  performance  between  the  HD  mice  and  wild-type  littermates  was 
maintained  at  all  8  speeds  (F  7=0.41,  p=0.899)  on  each  of  the  three  days  of  testing  (F 
_,  =1.57,  p=0.21).  The  results  obtained  from  analysing  the  interaction  of  speed  and  day 
showed  that  the  deterioration  in  performance  with  increased  speeds  was  similar  for  all  mice 
on  all  3  days  of  testing  (F  14,  m  =  0.63,  p=0.841).  The  results  obtained  from  analysing  the 
interaction  of  genotype,  speed  and  day  showed  that  the  differences  between  the  2  genotypes 
in  performance  were  not  affected  by  the  speed  and  day  in  an  interacting  manner  (F  14,383  = 
0.92,  p=  0536).  In  summary,  these  results  showed  that  the  rotarod  performance  of  male 
HD  mice  at  4  months  of  age  was  significantly  worse  than  that  of  wild-type  littermates  and 
the  worse  performance  was  not  affected  by  different  speeds,  and/  or  the  day  of  testing.  The 
results  also  suggested  that  the  effect  of  learning  the  rotarod  task  does  not  contribute  to  the 
worse  performance  of  HD  mice,  since  the  performance  of  all  mice  did  not  differ  over  the  3 
days  of  testing. 
The  results  from  analysing  the  data  obtained  with  male  mice  at  12  months  of  age  (Table 
3.1b)  were  similar  to  that  at  4  months  of  age  except  for  the  results  from  analysing  the 
interaction  of  genotype  and  speeds.  The  performances  of  different  genotypes  showed 
different  responses  to  different  speeds  i.  e.  the  differences  in  performance  between  the  HD 
mice  and  wild-type  littermates  were  exaggerated  at  some  speeds,  but  not  maintained  at 
other  speeds  (F  7,359  =  5.22,  p  =  0.000).  A  greater  significant  difference  between  the  HD 
mice  and  wild-type  littermates  at  12  months  of  age  (F  1,359  =  71.75,  p=0.000)  than  4 
months  of  age  was  noted.  In  summary,  these  results  suggested  that  the  rotarod  performance 
of  male  HD  mice  at  12  months  of  age  was  significantly  worse  than  that  of  wild-type 
littermates  and  that  the  worse  performance  of  male  HD  mice  at  12  months  of  age  was 
128 a)  Male  at  4  months  of  age 
Source  DF  Ad'  SS  Ad'  MS  F  P 
Genotype  1  1449.3  1449.3  11.21  <  0.001*** 
Speed  7  137192.  19598.9  151.58  <  0.001* 
Day  2  742.2  371.1  2.87  0.058 
Genot  e"S  eed  7  367.1  52.4  0.41  0.899 
Genot  e+day  2  405.6  202.6  1.57  0.210 
Speed  "  da  14  1139.0  81.4  0.63  0.841 
Genotype  *seed"da  14  1668.3  119.2  0.92  0.536 
Error 
-- 




b)  Male  at  12  months  of  aae 
Source  DF  Ad'  SS  Ad'  MS  F  P 
_Genotype 
1  7945.2  7945.2  71.75  <  0.001 
Seed  7  129035  18433.6  166.47  <0.001*** 
Day  2  517.3  258.6  2.34  0.098 
Genotype  "  speed  7  4046.1  578.0  5.22  <  0.001 
Genotypetday  2  251.8  125.9  1.14  0.322 
Speed*  da  14  1250.9  89.4  0.81  0.662 
Genotype  "s  eed  +day  14  507.4  36.2  0.33  0.990 
Error  312  34549.1  110.7 
Total  359 
c)  Male  at  18  months  of  age 
Source  DF  Ad'  SS  Ad'  MS  F  P 
Genotype  1  8511.0  8511.0  68.78  <  0.001*** 
Speed  7  85988.9  12284.1  99.27  <  0.001*** 
Day  2  822.7  411.3  3.32  0.037* 
Genoty  e"s  speed  7  2071.7  296.0  2.39  0.022* 
Genot  e"da  2  21.8  10.9  0.09  0.916 
S  eed+da  14  2394.9  171.1  1.38  0.160 
Genotype  "s  eed  +day  14  1376.4  98.3  0.79  0.675 
Error  288  35637.2  123.7 
Total  335 
Table  3.  lComparison  of  the  rotarod  performance  of  8  male  HD  and  8  male  wild-type 
littermates  at  4  (a),  12  (b)  and  18  (c)  months  of  age  using  three-way  ANOVA. 
The  rotarod  performance  of  mice  is  significantly  different  between  the  2  genotypes  and 
across  the  8  speeds,  but  not  over  the  3  days  of  testing  at  4  and  12  months  of  age.  The 
rotarod  performance  of  mice  is  significantly  different  between  the  2  genotypes,  across  the  8 
speeds  and  over  the  3  days  of  testing  at  18  months  of  age.  The  differences  in  performance 
between  the  2  genotypes  at  12  and  18  months  of  age  were  exaggerated  at  some  speeds  but 
not  maintained  at  other  speeds  (source:  genotype*speed).  DF:  degree  of  freedom,  Adj  SS: 
adjusted  sum  of  square,  Adj  MS:  adjusted  mean  of  square,  F:  F  ratio,  P:  p  value. 
f  indicates  interaction  between  factors. 
129 exaggerated  at  some  speeds  but  not  maintained  at  other  speeds.  This  emphasizes  that 
choosing  the  right  speeds  for  the  rotarod  test  is  important,  if  only  a  few  speeds  (less  than  8 
speeds)  are  to  be  tested  to  reveal  the  differences  in  performance  between  different 
genotypes  of  mice  in  the  future. 
The  results  from  analysing  the  data  obtained  with  male  mice  at  18  months  of  age  (Table 
3.1c)  were  similar  to  that  at  12  months  of  age  except  from  that  the  performance  of  male 
mice  was  significantly  different  over  the  3  days  of  testing  (F35  =  3.32,  p=0.037).  Since 
the  F  ratio  was  not  high,  it  suggested  that  male  mice  at  18  months  of  age  had  some  but  not 
huge  learning  of  rotarod  test.  Also,  it  was  not  known  whether  the  difference  is due  to  the 
improvement  or  deterioration  over  the  three  days  of  testing,  and  whether  genotype  and/or 
fatigue  (because  of  old  age)  contributed  to  the  difference.  Therefore,  the  learning  effect 
might  not  or  have  little  impact  on  the  difference  in  perfomances  between  HD  mice  and 
wild-type  littermates. 
The  results  from  data  obtained  with  female  mice  at  4,12  and  18  months  of  age  are  shown 
in  Table  3.2a,  2b,  and  2c  respectively. 
At  4  months  of  age  (Table  3.2a),  the  performance  of  female  mice  was  significantly  different 
between  the  2  genotypes  (F  1,383  =  14.5,  p=0.000),  across  the  8  speeds  (F  7,383  =  135.07,  p= 
0.000),  and  over  the  3  days  (F  Z383  =  4.52,  p=0.0  12).  The  difference  in  performance 
between  the  HD  mice  and  wild-type  littermates  was  maintained  at  all  8  speeds  (F  7,383  = 
0.84,  p=0.556)  and  on  all  3  days  (F  2.3&3  =  0.96,  p=0.386)  of  testing.  The  deterioration  in 
performances  of  mice  with  increased  speeds  was  different  over  the  3  days  of  testing  (F  14,383 
=  2.42,  p=0.003).  The  differences  between  the  2  genotypes  in  performance  were  not 
affected  by  the  speed  and  day  in  an  interacting  manner  (F  14,383  =  0.32,  p=0.992).  In 
summary,  these  results  suggested  that  the  rotarod  performance  of  female  HD  mice  at  4 
months  of  age  was  significantly  worse  than  that  of  wild-type  littermates  and  the  worse 
performance  was  not  affected  by  different  speeds,  and/or  days  of  testing.  It  was  also  noted 
that  female  mice  at  4  months  of  age  showed  difference  in  performance  over  the  3  days  of 
testing  and  the  difference  was  affected  by  the  speeds  tested.  However  it  was  not  known 
whether  the  difference  is  due  to  the  improvement  or  deterioration  over  the  three  days  of 
testing,  and  whether  the  genotype  of  mice  contributed  to  the  difference.  Since  the  F  ratio 
130 a)  Female  at  4  months  of  age 
Source  DF  Ad'  SS  Ad'  MS  F  P 
Genotype  1  2081.3  2081.3  14.5  <  0.001 
Speed  7  135718  19388.4  135.07  <  0.001 
Day  2  1297.4  648.7  4.52  0.012* 
Genot  e"s  eed  7  841.9  120.3  0.84  0.556 
Genotype  "  da  2  274.4  137.2  0.96  0.386 
S  eed  "  da  14  4869.3  347.8  2.42  0.003** 
. 
Genotype  *s  *day  14  633.6  45.3  0.32  0.992 
Error  336  48229.0  143.5 
Total  383 
b)  Female  at  12  months  of  age 
Source  DF  Ad'  SS  Ad'  MS  F  P 
_Genotype 
1  11169.4  11169.4  81.97  <  0.001*** 
Seed  7  148012  21144.6  155.17  <0.001*** 
Day  2  301.0  150.5  1.10  0.333 
Genoty  e+s  eed  7  2602.9  371.8  2.73  0.009** 
Genotype  +  day  2  697.5  348.8  2.56  0.079 
S  eed"da  14  1368.9  97.8  0.72  0.757 
Genotype  *seed"da  14  1309.5  93.5  0.69  0.788 
Error  336  45786.1  136.3 
Total  383 
c)  Female  at  18  months  of  age 
Source  DF  Ad'  SS  Ad'  MS  F  P 
_Genotype 
1  5490.4  5490.4  59.39  <  0.001*** 
Speed  7  160023  22860.5  247.30  <  0.001*** 
Day  2  283.4  141.7  1.53  0.217 
Genotype  is  eed  7  3485.7  498.0  5.39  <  0.001*** 
Genotype*  da  2  345.6  172.8  1.87  0.156 
S  eed"da  14  1973.6  141.0  1.53  0.1 
Genotype  *s+day  14  1394.7  99.6  1.08  0.377 
Error  336  31059.5  92.4 
Total  383 
Table  3.2  Comparison  of  the  rotarod  performance  of  8  female  HD  and  8  female  wild-type 
littermates  at  4  (a),  12  (b)  and  18  (c)  months  of  age  using  three-way  ANOVA. 
The  rotarod  performance  of  female  mice  is  significantly  different  between  the  2  genotypes, 
across  the  8  speeds,  and  over  the  3  days  at  4  months  of  age.  The  rotarod  performance  of 
female  mice  is  significantly  different  between  the  2  genotypes,  across  the  8  speeds,  but  not 
over  the  3  days  at  12  and  18  months  of  age.  The  deterioration  in  performances  with 
increased  speeds  for  all  mice  is  different  over  the  3  days  of  testing  at  4  months  of  age.  The 
differences  in  performance  between  the  2  genotypes  at  12  and  18  months  of  age  were 
exaggerated  at  some  speeds  but  not  maintained  at  other  speeds  (source:  genotype"speed). 
DF:  degree  of  freedom,  Ad  SS:  adjusted  sum  of  square,  Adj  MS:  adjusted  mean  of  square, 
F:  F  ratio,  P:  p  value.  f  indicates  interaction  between  factors. 
131 was  not  high  (F  zu3=  452,  p=0.012),  it  suggested  that  female  mice  at  4  months  of  age  had 
some  learning  of  the  rotarod  task.  Therefore,  the  learning  effect  might  not  or  have  little 
impact  on  the  difference  in  perfomances  between  female  HD  mice  and  female  wild-type 
littermates.  The  results  from  analysing  the  data  obtained  with  female  mice  at  12  (Table 
3.2b)  and  18  months  of  age  (Table  3.2c)  were  similar  to  that  of  male  mice  at  12  months  of 
age  (Table  3.1b). 
Three-way  ANOVA  was  also  used  to  analyse  the  deterioration  of  rotarod  performance  of 
each  mouse  group  with  age.  Age  (3  time  points;  4,12  and  18  months),  speed  (8  speeds), 
and  mouse  (individual  mice  in  the  cohort)  were  used  as  3  factors. 
The  results  from  analysing  the  data  obtained  with  male  HD  mice  are  shown  in  Table  3.3a. 
The  rotarod  performance  of  male  HD  mice  significantly  deteriorated  with  age  (F  2,43,  = 
12.6,  p=0.000),  and  increased  speed  (F7,431  =  205.73,  p=0.000).  Male  HD  mice  showed  a 
great  variability  in  performance  within  the  group  (F  5,431=  24.98,  p=0.000).  The  results 
obtained  from  analysing  the  interaction  of  mouse  and  age,  and  mouse  and  speed  showed 
that  the  performance  deficits  of  male  HD  mice  with  age  (F  10,431=  4.02,  p=0.000)  and 
increased  speeds  (F  35,43  =  3.85,  p=0.000)  were  exaggerated  in  some  mice  but  not 
maintained  in  other  mice.  The  results  obtained  from  analysing  the  interaction  of  age  and 
speed  showed  that  the  deterioration  of  performance  of  male  HD  mice  with  age  was 
exaggerated  at  some  speeds  but  not  maintained  at  other  speeds  (F  14,431=  3.07,  p=0.000). 
Different  ages,  speeds  and  mice  affected  the  performance  in  an  interacting  way  (F,  o,  a￿  _ 
1.59,  p  =  0.005).  In  summary,  the  rotarod  performance  of  male  HD  mice  significantly 
deteriorated  with  age.  However,  a  huge  variability  in  performance  was  present  among 
individual  mice  within  the  male  HD  group  and  it  was  noted  that  some  mice  showed  a  more 
prominent  deterioration  in  performance  with  age,  but  some  did  not  show  any  decline  at  all. 
This  variability  in  performance  suggested  that  a  longitudinal  study  testing  the  same  mice  at 
different  ages  is  probably  more  appropriate  rather  than  using  different  mice  of  different 
ages  to  investigate  the  deterioration  of  rotarod  performance  with  age.  Also,  the 
deterioration  of  performance  of  male  HD  mice  with  age  was  exaggerated  at  some  speeds 
but  not  maintained  at  other  speeds,  suggesting  that  the  rotarod  test  at  some  speeds  is  more 
sensitive  in  detecting  the  deterioration  of  performance  with  age. 
132 The  results  from  analysing  the  data  obtained  with  female  HD  mice  (Table  3.3c)  were 
similar  to  those  with  male  HD  mice  except  from  that  the  deteriorations  of  performance  of 
female  HD  mice  with  age  were  maintained  at  all  speeds  (F  14,575=  1.3  1,  p=0.2)  and  the 
performance  of  female  HD  mice  was  not  affected  by  the  interaction  of  different  ages, 
speeds  and  mice  (F  98,5,5  =  0.91,  p=0.699). 
The  results  of  the  performance  of  male  and  female  wild-type  littermates  are  shown  in  Table 
3.3b  and  3.3d  respectively.  Both  groups  of  wild-type  mice  like  both  groups  of  HD  mice 
showed  a  great  variability  in  performance  within  the  group  and  the  variability  were 
influenced  by  the  different  speeds  and  ages.  The  performance  of  male  wild-type  littermates 
(Table  3.3b)  did  not  decline  with  age  but  that  of  female  wild-type  littermates  (Table  3.3d) 
deteriorated  slightly  with  age  (F  2,575  =  3.28,  p=0.039).  However,  the  deterioration  of  HD 
female  rotarod  performance  (F 
,  575  =  5.62,  p=0.004)  was  greater  than  that  of  wild-type 
littermates  (F  Z,  75  =  3.28,  p=0.039). 
3.2.3.1  Summary 
Two  main  conclusions  were  drawn  from  the  results  obtained  by  using  ANOVA  to  analyse 
the  rotarod  performance  data.  Firstly,  both  male  and  female  HD  mice  showed  worse 
performances  at  4,12  and  18  months  of  age,  when  compared  with  their  wild-type 
littermates.  Secondly,  both  male  and  female  HD  mice  showed  a  significantly  greater 
deterioration  in  rotarod  performance  with  age  than  their  wild-type  littermates. 
All  methods  indicated  differences  between  HD  and  wild-type  cohorts  at  12  and  18  months 
of  age  but  the  results  obtained  by  using  ANOVA  and  by  using  overall  rotarod  performance 
to  analyse  the  data  were  different  at  4  months  of  age.  The  fact  that  ANOVA  tests  reveal  a 
difference  in  the  performance  of  both  male  and  female  HD  mice  at  4  months  of  age 
confirms  that  ANOVA  is  probably  a  more  powerful  data  analysis  approach  because  it  uses 
all  raw  data  points  and  takes  into  account  different  factors  that  might  influence  the  rotarod 
performance. 
133 a)  Male  HD 
Source  DF  Ad'  SS  Ad'  MS  F  P 
Age  2  2154.3  1077.1  12.6  <  0.001*** 
Mouse  5  10681.9  2136.4  24.98  <  0.001 
Speed  7  123156.9  17593.8  205.73  <  0.001*** 
Ae  +mouse  10  3435.9  343.6  4.02  <  0.001*** 
Age  "s  eed  14  3678.9  262.8  3.07  <  0.001 
Mouse  "s  eed  35  11537.2  329.6  3.85  <  0.001 
A  e"mouse+speed  70  9499.5  135.7  1.59  0.005** 
Error  288  24630.0  85.5 
Total  431 
b)  Male  wild-type 
Source  DF  Ad'  SS  Ad'  MS  F  P 
Age  2  161.7  80.9  1.05  0.353 
Mouse  7  5238.4  754.8  9.76  <  0.001*** 
Speed  7  214015.7  30575.1  395.2  <  0.001 
Age"mouse  14  5126.9  366.2  4.73  <0.001*** 
Age  is  eed  14  807.6  57.7  0.75  0.728 
Mouse+s  eed  49  6612.8  135  1.74  0.002** 
A  e"mouse*speed  98  8441.3  86.1  1.11  0.239 
Error  384  29707.3  77.4 
Total  575  270166.8 
c)  Female  HD 
Source  DF  Ad'  SS  Ad'  MS  F  P 
Age  2  1153.6  576.8  5.62  0.004*  * 
Mouse  7  10351.2  1478.7  14.42  <  0.001 
Seed  7  222382.1  31768.9  309.69  <0.001*** 
Age  "  mouse  14  3884.4  277.5  2.70  0.001** 
Age  4  seed  14  1876.2  134.0  1.31  0.2 
Mouse*  speed  49  9375.0  191.3  1.87  0.001 
Ae"  mouse  "s  eed  98  9194.4  93.8  0.91  0.699 
Error  384  39392.0  102.6 
Total  575 
134 d)  Female  wild-type 
Source  DF  Ad'  SS  Ad'  MS  F  P 
Age  2  698.1  398.1  3.28  0.039* 
Mouse  7  5943.6  5943.6  7.98  <  0.001*** 
Speed  7  224332.7  224332.7  31.033  <  0.001 
Ae  "mouse  14  4408.4  4408.4  2.96  <  0.001*** 
Ae"s  eed  14  2094.3  2094.3  1.41  0.147 
Mouse*  speed  49  7074.2  7074.2  1.36  0.062 
. 
Age  *mouse*  speed  98  9360.9  9360.9  0.90  0.736 
Error  384  40839.3  40839.3 
Total  575  294751.6 
Table  3.3  Comparing  the  rotarod  performances  over  3  time  points  (4,12  and  18  months  of 
age)  for  male  HD  (a)  and  wild-type  (b)  and  female  HD  (c)  and  wild-type  (d)  mice  using 
three-way  ANOVA. 
The  rotarod  performance  of  male  and  female  HD  mice  significantly  deteriorated  with  age 
(source:  age).  Both  male  and  female  HD  mice  show  significantly  different  performances 
among  individual  mice  within  the  group  (source:  mouse).  The  rotarod  performance  of  male 
and  female  HD  mice  significantly  deteriorated  with  increased  speeds  (source:  speed).  The 
deterioration  of  performance  with  age  is  exaggerated  in  some  mice,  but  not  maintained  in 
other  mice  within  both  male  and  female  HD  groups  of  mice  (source:  Age+mouse).  The 
deterioration  of  performances  with  increased  speeds  is  different  in  some  mice  in  both  male 
and  female  HD  groups  of  mice  (source:  mouse"speed).  The  deterioration  of  performance 
of  male  HD  mice  with  age  is  exaggerated  at  some  speeds,  but  not  maintained  at  other 
speeds  (source:  age*speed).  Different  ages,  speeds  and  individual  mice  affect  the 
performance  in  an  interacting  manner  in  male  HD  group  (source:  age"mouse  "speed).  DF: 
degree  of  freedom,  Adj  SS:  adjusted  sum  of  square,  Adj  MS:  adjusted  mean  of  square,  F:  F 
ratio,  P:  p  value.  f  indicates  interaction  between  factors. 
135 3.2.4  Investigating  possible  confounding  influences  affecting  the  rotarod 
performance  of  HD  mice 
Although  the  rotarod  paradigm  is  used  to  measure  locomotor  function  in  mice,  the 
performance  of  the  rotarod  task  is  also  influenced  by  body  weight,  age  and  cognitive 
function  including  memory,  learning,  attention  and  motivation.  It  is  essential  to  determine 
whether  confounding  influences  affect  the  rotarod  performance  of  HD  mice  before  drawing 
any  conclusions  from  the  data  about  motor  performance.  Therefore,  possible  confounding 
factors  affecting  the  rotarod  performance  of  HD  mice  were  investigated. 
3.2.4.1  Investigating  cognitive  effects  on  rotarod  performance 
During  the  week  prior  to  the  test  experiment,  each  mouse  received  a  training  course 
(section  2.2.18),  and  appeared  to  reach  a  steady  baseline  level  of  performance.  The  pre-test 
training  was  therefore  expected  to  reduce  the  confounding  effects  of  possible  cognitive 
defects  on  rotarod  performance  results.  To  determine  whether  there  was  any  evidence  of 
learning  of  the  rotarod  test  after  the  pre-test  training,  two  ANOVA  methods  were 
performed.  Firstly,  compared  the  overall  rotarod  performance  (ORP)  of  each  group  of  mice 
over  the  3  day  period  of  testing  at  each  age.  Secondly,  compared  individual  performances 
of  the  mice  over  the  3  day  period  of  testing  at  each  age. 
For  the  first  comparison,  the  sum  of  the  time  periods  of  staying  on  the  rod  at  8  different 
speeds  (ORP)  on  day  1,  day  2  and  day  3  at  each  age  tested  for  each  group  was  determined. 
Analysis  using  one-way  ANOVA  and  post  hoc  Tukey  test  indicated  that  there  was  no 
significant  difference  observed  in  day  1,  day  2  and  day  3  performances  for  any  group  of 
mice  at  any  age  tested,  although  most  of  the  mice  did  appear  to  spend  slightly  more  time  on 
the  rod  on  day  3,  compared  to  day  1  (Fig.  3.4).  The  results  using  the  ORP  as  the  measure 
suggested  that  none  of  the  cohorts  of  mice  used  in  the  study  showed  significant  Learning  of 
the  rotarod  test  during  the  three  days  of  assessment  at  any  time  point. 
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Figure  3.4  Comparisons  of  overall  rotarod  performance  obtained  from  day  I  (grey 
column),  day  2  (open  column)  and  day  3  (striped  column)  assessments  on  8  female 
wild-type  littermates  (a),  8  female  HD  mice  (h),  8  male  wild-type  littermates  (c)  and  8 
male  HD  mice  (d)  at  3  time  points.  Data  are  expressed  as  mean  ±  S.  E.  (a,  indicates  7 
animals  were  tested.  X  indicates  6  animals  were  tested.  One-way  ANOVA  and  post-hoc 
Tukey  test  were  used  to  compare  the  performances  of  each  group  of  mice  on  three 
consecutive  days  at  each  time  point.  No  significant  differences  are  shown  between  day  1, 
day  2,  and  day  3  performances  for  any  group  of  mice  at  any  time  point. 
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12  months  18  months 
4  months  l2  months  (a)  IH  months  (L) In  contrast,  the  three-way  ANOVA  tests  performed  in  section  3.2.3  suggested  that  the  day 
of  testing  may  have  a  small  influence  on  rotarod  performance  in  18  month-old  male  mice 
and  4  month-old  female  mice.  In  order  to  determine  whether  genotype  contributes  to  this 
effect,  two-way  ANOVA  was  used  to  analyse  the  difference  in  performance  of  each  group 
of  mice  over  the  3  consecutive  days  of  testing  using  day  and  speed  as  2  factors.  The  results 
showed  significantly  different  performances  across  the  3  consecutive  days  of  testing  in 
male  HD  mice  at  4  months  of  age  (F  2.191=  3.49,  p=0.033),  male  wild-type  littermates  at  12 
months  of  age  (F  2,191=  3.43,  p=0.035),  and  female  wild-type  littermates  at  4  months  of 
age  (F  2191  =  3.24,  p=0.042).  However,  since  the  F  ratios  were  not  very  high,  it  is  possible 
that  the  effect  of  learning  the  rotarod  task  has  a  subtle  and  inconsistent  influence  on  the 
results  obtained. 
3.2.4.2  Comparisons  of  the  body  weight  profiles  of  HD  mice  and  wild-type 
littermates 
Studies  in  the  literature  have  showed  that  weight  and/or  age  has  a  significant  effect  on 
rotarod  performance  in  rats.  In  one  study,  the  rotarod  performance  of  older,  heavier  rats 
was  significantly  worse  than  that  of  younger,  lighter  rats  (Rozas  and  Labandeira  Garcia, 
1997). 
To  determine  whether  the  weight  profile  of  HD  mice  is different  from  that  of  wild-type 
littermates,  a  comparison  of  the  weight  profiles  of  HD  mice  and  wild-type  littermates  was 
performed.  The  weights  of  each  mouse  used  in  the  study  at  1.5,2.5,3.5,4.5,5.5,7,8  and 
18  months  of  age  were  recorded.  Weights  at  different  ages  and  the  gain  of  weight  between 
two  consecutive  time  points  were  compared  between  HD  mice  and  wild-type  littermates. 
The  results  indicated  that  the  weights  of  male  and  female  HD  mouse  cohorts  at  all  time 
points  and  the  gain  of  weight  between  two  consecutive  time  points  were  not  different  from 
those  of  their  corresponding  wild-type  littermates  (Fig  3.5).  The  results  therefore  suggest 
that  the  differences  in  the  rotarod  performance  of  male  and  female  HD  mice  (compared  to 
wild-type)  cannot  be  attributed  to  weight  differences. 
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Figure  3.5  Comparisons  of  the  weight  profile  of  8  male  HD  mice  to  8  male  wild-type 
littermates  (a)  and  8  female  HD  mice  to  8  female  wild-type  littermates  (b),  at  8  different 
time  points.  Both  male  and  female  HD  mice  show  no  differences  in  weight  at  all  time 
points,  when  compared  to  their  wild  type-littermates.  Data  are  expressed  as  mean  ±  S.  E. 
HD  mice  (grey  column)  and  wild-type  littermates  (open  column)  were  compared  using 
the  Student's  t  test  (two-tailed).  X  indicates  only  6  mice  were  included. 
139 3.3  Investigating  general  neurological  deficits  in  HD  mice  using 
the  tail  suspension  test 
As  previously  mentioned  (section  3.1),  limb  clasping  (sudden  flexing  of  limbs  to  the  chest 
when  suspended  by  the  tail),  is  detected  in  some  transgenic  HD  mouse  models  (Mangiarini, 
et  al.,  1996;  Hodgson,  et  al.,  1999;  Reddy,  et  al.,  1999;  Yamamoto,  et  al.,  2000).  However 
it  has  not  been  found  in  other  mouse  models  (Levine,  et  al.,  1999;  Wheeler,  et  al.,  2000) 
including  the  HD  mice  used  in  this  study.  As  a  systematic  study  of  this  phenomenon  had 
not  been  previously  performed,  the  tail  suspension  test  was  used  to  determine  whether  and 
when  clasping  is  present  in  the  HD  mice.  The  cohorts  of  mice  used  in  the  tail  suspension 
test  were  the  same  as  the  cohorts  used  in  the  rotarod  locomotor  experiment  (section  3.2), 
but  a  single  test  was  performed  at  18  months  of  age.  During  the  test,  each  mouse  was 
picked  up  by  the  tail  and  suspended  in  this  position  at  a  height  of  -  50  cm  for  1  minute, 
then  slowly  lowered  and  released  upon  reaching  the  cage  floor.  During  this  period  of  time, 
the  frequency  of  limb  clasping  for  each  mouse  was  recorded  and  the  performance 
videotaped. 
Wild-type  mice  in  this  position  generally  struggled  with  limbs  outstretched  and  moving  in 
random  directions,  or  hung  without  struggling.  Previous  studies  had  provided  descriptions 
of  limb  clasping,  indicating  that  mice  showed  sudden  limb  flexion  against  the  chest 
(Mangiarini  et  al.,  1996).  Clasping  was  either  intermittent  or  the  limbs  were  held  stationary. 
In  the  present  study,  however,  the  results  confirmed  that  none  of  the  HD  (n  =  17)  or  wild- 
type  littermates  (n  =  17)  showed  a  single  episode  of  limb  clasping  (1,2,3  or  4  limbs) 
during  the  one-minute  test.  This  suggests  that  limb  clasping  is  not  a  common  feature  of  the 
HD  mice  used  in  this  study. 
140 4  Investigating  the  integrity  of  mtDNA  in  HD  mouse 
brain  as  an  indicator  of  early  molecular  pathology 
4.1  Background 
The  aetiology  of  selective  neuronal  death  in  HD  is  still  not  clear.  There  could  be  a  complex 
interplay  between  impaired  energy  metabolism,  excitotoxicity,  oxidative  stress  and 
apoptosis,  all  of  which  have  been  shown  to  play  an  important  role  in  the  pathogenesis  of 
HD  (section  1.2.4).  Slow  excitotoxicity  may  occur  as  a  consequence  of  a  defect  in  energy 
production  (Beal,  1995;  Beal,  1996)  and  excitotoxicity  can  lead  to  superoxide  generation 
(Beal,  1995;  Beal,  1996).  As  increased  oxidative  stress  may  further  compromise  energy 
metabolism  in  neurons,  a  vicious  cycle  may  be  initiated  that  finally  results  in  cell  death. 
Given  that  mitochondria  could  play  a  central  role  in  these  processes,  studies  of 
mitochondrial  function  in  HD  mice  may  shed  light  on  the  mechanism  and  molecular 
pathology  of  HD. 
Because  of  its  proximity  to  the  respiratory  chain  (the  most  important  source  of  free 
radicals),  limited  repair  mechanisms,  few  non-coding  sequences  and  absence  of  histones, 
mitochondrial  DNA  (mtDNA)  is  particularly  susceptible  to  oxidative  damage. 
Mitochondrial  DNA  damage,  after  exposure  to  high  levels  of  reactive  oxygen  species,  is 
mediated  predominantly  by  intramitochondrial  accumulation  of  8-hydroxydeoxyguanosine 
(8-OHdG)  (Richter  et  al.,  1988).  Incorporation  of  8-OHdG  into  mtDNA  causes  base 
mispairing,  point  mutations  and  deletions.  Many  studies  have  demonstrated  that  mtDNA 
deletions  increase  with  age  and  oxidative  stress  in  many  human  and  mouse  tissues  (Brossas 
et  al.,  1994;  Hayakawa  et  al.,  1991;  Liu  et  al.,  1998;  Tanhauser  and  Laipis,  1995). 
Decreased  levels  of  total  mtDNA  have  been  shown  in  affected  tissues  of  Friedreich's  ataxia 
(Bradley  et  al.,  2000)  and  Alzheimer's  patients  (de  la  Monte  et  al.,  1988;  Rodriguez- 
Santiago  et  al.,  2001),  conditions  associated  with  increased  oxidative  stress.  Furthermore, 
increased  levels  of  mtDNA  deletions  have  been  shown  in  the  cortex  of  individuals  affected 
by  HD  (Horton  et  al.,  1995).  Therefore,  the  levels  of  deleted  mtDNA  and  total  mtDNA 
content  were  investigated  in  HD  mouse  brain. 
141 Different  types  of  deleted  mtDNA  species  occur  in  aged  mice  (Tanhauser  and  Laipis,  1995). 
All  the  deletions  are  flanked  by  perfect  or  imperfect  direct  repeats.  While  many  deleted 
mtDNA  species  are  present  in  aged  mice,  they  are  uncommon,  and  any  one  deletion 
generally  constitutes  less  than  0.00006  %  of  total  mtDNA  in  mouse  brain  (Tanhauser  and 
Laipis,  1995).  Based  on  this  finding  it  is  anticipated  that  most  deletions,  other  than  the 
commonest  type,  will  be  difficult  to  detect  and  quantify  by  PCR.  Therefore,  the  commonest 
deletion  type  was  investigated  in  this  study  (Fig.  4.1). 
The  HD  mice  used  in  this  study  are  probably  modelling  early  stages  of  HD,  as  there  is  no 
evidence  of  acute  neurodegeneration  in  the  brains  of  the  mice  (Shelbourne  et  al.,  1999).  The 
behavioural  changes  of  these  mice  have  been  shown  to  occur  at  3  months  (Shelboume  et  al., 
1999)  and  as  shown  in  Chapter  3,  the  locomotor  abnormality  is  present  at  4  months  of  age. 
However,  the  molecular/cellular  pathology  in  HD  mice  has  not  been  investigated.  By 
investigating  the  integrity  of  mtDNA  in  the  brains  of  HD  mice  at  different  time  points,  the 
aims  of  this  study  were:  1)  to  determine  whether  mitochondrial  abnormalities  occur 
specifically  in  the  striatum,  but  not  in  other  brain  regions  of  HD  mice,  2)  to  determine 
whether  mitochondrial  abnormalities  in  HD  mice  are  progressive  phenomena  in  nature. 
4.2  Quantifying  mtDNA  levels  using  a  competitive  PCR 
approach 
A  competitive  PCR  assay  modified  from  a  previously  published  competitive  RT-PCR  assay 
(Siebert  and  Larrick,  1992;  Tanhauser  and  Laipis,  1995)  was  employed  to  quantify  the 
amounts  of  total  mtDNA  and  deleted  mtDNA  in  mouse  tissue  DNA.  The  use  of  a  DNA 
competitor  molecule  (mimic)  provides  not  only  an  internal  control  but  also  an  opportunity 
for  calculating  the  absolute  level  of  target  DNA,  since  the  initial  amount  of  competitor  DNA 
in  the  PCR  reaction  is  known  (Siebert  and  Larrick,  1992).  In  competitive  PCR,  the  mimic 
competes  with  the  target  template  for  primer  binding  and  amplification.  The  mimic  DNA 
shares  the  same  primer  sequences  as  the  target  DNA  sequence  but  has  a  different 
intervening  sequence  (Fig.  4.2). 
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Figure.  4.1  Diagram  of  mouse  mitochondrial  DNA  (16295  bp).  Primers  Ll  and  H1 
(see  sequence  in  section  2.1.7)  were  used  to  amplify  intact  mtDNA  molecules. 
Primers  L2  and  H2  (see  sequence  in  section  2.1.7)  were  used  to  amplify  deleted 
mtDNA.  A  common  large  DNA  deletion  (3867  bp)  occurs  between  a  pair  of  direct 
repeats  (indicated  by  arrows).  An  oligonucleotide  (F3)  (see  sequence  in  section  2.1.7) 
was  used  to  hybridize  the  product  of  deleted  mtDNA  amplification  in  a  Southern 
blot  analysis  to  confirm  the  identity  of  the  deleted  PCR  product.  Numbers  inside 
the  circle  indicate  the  relative  positions  of  mtDNA  features  in  bp. 
5'  3' 
Target  DNA 
3'  5' 
3' 
Mimic  DNA 
5' 
Figure  4.2  Schematic  illustration  of  mimic  and  target  DNA  templates  in  a 
competitive  PCR  assay.  The  mimic  template  shares  the  same  primer  sequences 
but  has  a  different  intervening  sequence  to  the  target  DNA.  The  mimic  DNA 
sequence  was  selected  so  that  the  product  size  of  PCR  and  the  CG  content  of  the 
mimic  DNA  template  are  close  to  those  of  the  target  DNA.  PCR  primers  are 
indicated  by  the  symbols  M  and  ®. 
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F3  (8644-8665  bp) Differences  in  sequence  length  and  content  between  the  target  and  the  mimic  DNA  may 
introduce  errors  (McDowell  et  al.,  1998).  Therefore,  the  mimic  DNA  sequence  must  be 
carefully  selected  so  that  PCR  product  size  and  GC  content  using  mimic  DNA  as  the 
template  are  close  to  that  of  products  when  the  target  DNA  is  used  as  template. 
The  mimic  is  generated  by  amplification  of  a  sequence  within  a  foreign  DNA  fragment 
using  two  composite  primers.  Once  the  mimic  sequence  has  been  chosen,  two  composite 
primers  for  mimic  construct  generation  are  synthesized.  Each  composite  primer  has  the 
target  gene  primer  sequence  attached  to  a  short  stretch  of  nucleotides  that  hybridize  to  the 
complementary  strand  of  the  mimic  sequence.  The  PCR  products  are  cloned  for  the 
subsequent  competitive  PCR  assay  (Fig.  4.3). 
In  order  to  quantify  the  target  DNA  species,  dilutions  of  the  cloned  mimic  DNA  are  co- 
amplified  with  a  constant  amount  of  target  DNA.  The  intensity  of  the  mimic  DNA  PCR 
product  on  agarose  gel  was  compared  to  that  of  the  target  DNA  PCR  product  in  the  same 
reaction  to  determine  the  number  of  amplifiable  target  DNA  molecules.  This  value  is 
determined  by  calculating  how  much  of  the  mimic  DNA  was  required  to  achieve  equal 
molar  amounts  of  the  respective  PCR  products. 
4.3  Investigating  mtDNA  levels  in  HD  mouse  tissue 
4.3.1  Amplification  of  mtDNA  from  mouse  tissue 
43.1.1  PCR  amplification  of  intact  mtDNA  molecules 
Intact  mtDNA  molecules  were  amplified  using  a  pair  of  primers  Ll  (mtDNA  645-665  bp) 
and  Hl  (mtDNA  999-979  bp)  within  the  gene  coding  the  12S  rRNA  near  the  D-loop  of 
mtDNA  (Fig.  4.1).  Because  the  D-loop  contains  the  replication  origin  of  the  heavy  strand 
that  is  important  for  mtDNA  replication,  the  flanking  region  near  the  replication  origin  of 
the  heavy  strand  is  unlikely  to  be  deleted.  The  primers  and  amplification  conditions  have 
been  previously  reported  (Tanhauser  and  Laipis,  1995).  In  this  study,  the  amplification 
conditions  were  slightly  modified  (PCR  cycles  changed  from  30  to  24  cycles  and  annealing 
temperature  changed  from  50  to  55°C)  in  order  to  optimize  yield  and  specificity  of  PCR 
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Clone  and  prepare  DNA  for  use  in  competitive  PCR  assays 
Figure  4.3  Generation  of  mimic  constructs  for  use  in  competitive  PCR  assays.  A 
composite  primer  is  synthesized  by  attaching  a  target  gene  primer  sequence  to  a 
short  stretch  of  nucleotides  that  hybridize  to  complementary  strand  of  a  foreign 
DNA  fragment  [e.  g.  from  bacterial  chloramphenicol  acetyltransferase  (CAT)  gene]. 
The  composite  primers  are  used  to  amplify  the  foreign  DNA  fragment  for  generation 
of  the  mimic  DNA  molecule. 
145 products  from  the  thermocycler  in  the  laboratory  (section  2.2.5.2).  The  size  of  PCR 
products  using  primers  Li  and  Hl  was  confirmed  as  355  bp  (Fig.  4.4a). 
43.1.2  Optimising  the  PCR  amplification  of  deleted  mtDNA  molecules 
Deleted  mtDNA  species  were  amplified  using  a  pair  of  primers  (L2  and  H2)  that  flank  the 
most  common  deletion  (3867  bp  between  a  pair  of  direct  repeats  shown  in  Figure  4.1). 
Primers  12  (mtDNA  8484-8504  bp)  and  H2  (mtDNA  13098-13078  bp)  could  only  amplify 
the  deleted  mtDNA  species,  because  the  fragment  of  undeleted  mtDNA  species  flanked  by 
12  and  H2  is  too  large  (4.6  kb)  to  be  amplified  by  PCR  with  a  short  extension  time  (20  s). 
The  predicted  size  of  the  target  PCR  product  was  748  bp.  At  first,  multiple  bands  instead  of 
a  single  band  were  obtained  using  previously  published  PCR  conditions  (Tanhauser  and 
Laipis,  1995).  Much  effort  was  put  into  optimising  the  PCR  conditions  for  amplification  of 
the  deleted  mtDNA  molecules  from  mouse  brain  and  liver  DNA.  The  optimisation  was 
achieved  by  testing  different  annealing  temperatures  (50-55°C),  adjusting  the  amount  of 
DNA  template  added  (from  75  ng  to  2  µg),  using  different  concentrations  of  MgCl2  in  the 
PCR  reaction  solution  (1  to  4  mM)  and  testing  Taq  polymerase  from  different  companies 
(Promega,  Sigma,  and  Perkin  Elmer).  Finally,  the  predicted  single  band  was  obtained  using 
the  PCR  conditions  (55°C  annealing  temperature,  75-200  ng  of  DNA,  1.5  mM  MgCl2  and 
Taq  polymerase  from  Perkin  Elmer)  detailed  in  section  2.2.5.2  (Fig.  4.4b  and  c).  The  PCR 
products  amplified  using  primers  1.2  and  H2  were  confirmed  by  Southern  blot  analysis 
(section  2.2.12.4),  using  a  radio-labelled  oligonucleotide  probe  termed  F3  (mtDNA  8644- 
8665  bp)  (Fig.  4.1)  located  between  the  L2  and  H2  primers.  This  probe  was  predicted  to 
hybridise  to  the  correct  PCR  products  (Fig.  4.5).  The  sequence  of  the  PCR  product  was  also 
confirmed  by  sequencing  (section  2.2.10)  as  showing  a  3867  bp  deletion  between  a  pair  of 
direct  repeats  located  in  the  mtDNA  molecule  (Fig.  4.6). 
4.3.2  Generation  of  mimic  constructs  for  quantifying  mtDNA  levels  in 
mouse  tissue 
In  this  study,  the  programs  Blast  search  (NCBI)  and  GeneJockey  II  (Biosoft,  Cambridge, 
UK)  were  used  to  choose  a  mimic  sequence  from  plasmid  pBcxm  [containing  the  gene 
encoding  E.  coli  chloramphenicol  acetyltransferase  (CAT)]. 
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Figure  4.4  Images  of  PCR  products  of  mtDNA  molecules  resolved  on  EtBr-agarose 
gels.  Products  of  intact  mtDNA  molecules  after  amplification  with  Ll  and  H1  primers 
from  5  ng  wild-type  mouse  brain  DNA  are  shown  in  lane  1  (a).  Products  of  deleted 
mtDNA  molecules  after  amplification  with  L2  and  H2  primers  from  75  ng  wild-type 
mouse  liver  DNA  are  shown  in  lane  2  (b)  and  from  300  ng  wild-type  mouse  brain 
DNA  are  shown  in  lane  1  (c).  Controls  for  DNA  contamination  of  the  PCR  reagents, 
using  water  as  a  template,  are  shown  in  lanes  2  (a),  1  (b)  and  2  (c).  M  indicates  the  1Kb 
plus  size  ladder. 
M 
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Figure  4.5  Confirmation  of  the  deleted  mtDNA  amplification  by  Southern  blot  analysis 
using  a  radiolabelled  oligonucleotide  (F3)  as  a  probe.  PCR  products  of  amplified  deleted 
mtDNA  molecules  from  200  ng  of  mouse  liver  DNA  were  resolved  on  an  EtBr-stained  gel  (a). 
Lanes  2  and  5  contain  PCR  products  from  the  DNA  of  wild-type  mice  and  lanes  3  and  4  from 
the  DNA  of  HD  mice.  A  control  for  DNA  contamination  of  PCR  reagents,  using  water  as 
a  template  is  shown  in  lane  1.  M  indicates  the  100  bp  size  ladder.  Southern  blot  analysis  of 
the  gel  indicated  in  (a)  probed  with  a  radio-labelled  oligonucleotide  (F3)  located  between 
primers  L2  and  H2  (Figure  4.1)  was  performed  (b)  to  confirm  the  correct  amplification 
of  the  deleted  mtDNA  molecules. 
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Figure  4.6  Sequencing  of  the  PCR  product  amplified  from  deleted  mtDNA.  A  PCR 
product  of  amplified  deleted  mtDNA  using  L2  and  H2  primers  was  sequenced  using 
primer  H2.  The  sequence  of  a  fragment  [Query  4-278  nucleotides  in  (a)]  of  deleted 
mtDNA  obtained  from  direct  DNA  sequencing  was  compared  to  the  Genbank  database 
[Sbjct  13071-8931bp  in  (a)]  using  the  Blast  programme  (NCBI).  The  results  show  that  a 
DNA  fragment  (3867  bp)  including  a  repeat  sequence  is  deleted  between  the  pair  of 
repeats  (underlined)  and  259  out  of  278  query  nucleotides  were  matched  to  the  Genbank 
sequence.  The  unmatched  nucleotides  are  probably  due  to  the  PCR  errors.  A  schematic 
map  of  intact  mtDNA  (16295  bp)  is  shown  in  (b).  A  schematic  map  of  deleted  mtDNA 
(12428  bp)  is  shown  in  (c).  A  DNA  fragment  (3867  bp)  including  a  repeat  sequence  is 
deleted  between  the  pair  of  direct  repeats. 
149 43.2.1  Generation  of  mimic  construct  for  quantifying  total  mtDNA  content  of 
mouse  tissue 
43.2.1.1  Selection  of  mimic  DNA  sequence  and  composite  primers 
As  mitochondrial  DNA  sequence  is  AT  rich,  the  DNA  sequence  of  mimic  p444  was  chosen 
from  the  bacterial  CAT  gene  (also  AT  rich)  according  to  the  principles  described  in  section 
4.2.  The  GC  ratio  of  the  mimic  DNA  sequence  was  42  %  and  the  GC  ratio  of  the  target 
mtDNA  sequence  flanked  by  primers  Ll  and  Hl  was  36  %.  Primers  were  selected  so  that 
the  predicted  size  of  the  mimic  PCR  product  was  444  bp,  which  is  close  but  distinguishable 
from  the  size  of  target  mtDNA  PCR  product,  355  bp.  The  composite  primers  MIMICL1 
and  MIMICH1  were  synthesized  by  attaching  primer  Ll  to  the  CAT  gene-specific 
oligonucleotide  CAT1  and  primer  Hl  to  the  CAT  gene-specific  oligonucleotide  CAT2  (Fig. 
4.7).  The  composite  primers  were  used  in  a  PCR  reaction  to  amplify  the  bacterial  CAT  gene 
to  generate  mimic  DNA  molecules  that  were  used  subsequently  for  the  p444  construction. 
4.3.2.1.2  Generation  of  mimic  construct 
Plasmid  pBcxm  (containing  the  bacterial  CAT  gene)  was  used  as  the  template  in  the  PCR 
amplification  of  mimic  molecules.  The  PCR  conditions  were  as  follows:  1)  94°  C,  5  min;  2) 
30  cycles  of  94°C,  40  s;  55°C,  20  s;  72°C,  40  s;  3)  72°C,  10  min.  In  the  PCR,  1  ng  of 
pBcxm  DNA  was  amplified  in  the  presence  of  1.5  mM  MgC12  PCR  buffer,  1.2  µM 
composite  primers  MIMICLI  and  MIMICHI,  2.0  units  Taq  polymerase  (Sigma),  200  µM 
dNTP,  in  a  total  reaction  volume  of  20  µl. 
The  PCR  products  were  resolved  on  a  1.5  %  EtBr-stained  agarose  gel  (Fig.  4.8).  These 
bands  were  gel  purified  using  the  QIAquick  Gel  extraction  kit  (section  2.2.7)  and  cloned 
using  the  TOPO  `  "'  TA  cloning  kit  (section  2.2.9).  Plasmid  DNA  was  isolated  by  the 
miniprep  isolation  procedure  (Qiagen).  The  plasmid  DNA  was  digested  with  EcoRI  to 
release  the  insert  to  ensure  that  the  correct  DNA  fragment  had  been  cloned  (Fig.  4.9). 
Confirmation  of  a  selected  colony  containing  recombinant  DNA  was  also  achieved  by 
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MIMICHI  primer  sequence  is: 
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Figure  4.7  Selection  of  mimic  DNA  sequence  and  composite  primers  for  quantifying 
total  mtDNA  content  in  mouse  brain  tissues.  The  composite  primers  (MIMICL1 
and  MIMICH1)  were  synthesized  by  attaching  primer  Ll  to  the  CAT  gene  specific 
oligonucleotide  CAT1  and  primer  H1  to  the  CAT  gene-specific  oligonucleotide  CAT2 
(a  and  b).  The  GC  ratio  of  the  mimic  DNA  sequence  is  42  %  and  the  size  is  444  bp  (a). 
The  GC  ratio  of  the  intact  mtDNA  sequence  amplified  by  Ll  and  H1  is  36  %  and  the 
size  is  355  bp  (c). 
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Figure  4.8  Generation  of  mimic  DNA  constructs  by  amplifying  the  bacterial  CAT 
gene  using  the  composite  primers.  The  PCR  products  amplified  from  the  bacterial 
CAT  gene  (in  a  plasmid  pBcxm)  using  the  composite  primers  were  visulized  on  an 
EtBr-stained  1.5  %  agarose  gel.  Lanes  1  and  2  contain  PCR  products  using  primers 
MIMICL1  and  MIMICHI.  Lanes  4  and  5  contain  PCR  products  using  primers 
MIMICL2  and  MIMICH2.  Lanes  3  and  6  are  the  controls  for  DNA  contamination 
of  PCR  reagents  using  water  as  a  template.  The  1  Kb  size  ladder  is  indicated  by  M. 
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Figure  4.9  Confirmation  of  the  recombinant  plasmid  p444.  A  restriction  map  of 
p444  shown  in  (a)  illustrates  the  position  of  appropriate  restriction  enzyme  recognition 
sites  for  EcoRI  and  PstI.  The  thin  line  represents  the  vector  Topo  2.1  (3808  bp).  The 
thick  line  represents  the  444  bp  insert  (arrow).  EcoRI  and  Pstl-digested  DNA  from 
p444  DNA  was  resolved  on  an  EtBr-stained  agarose  gel,  shown  in  (b).  The  462  bp 
DNA  fragment,  released  from  p444  digested  with  EcoRI  is  predicted  to  contain 
the  444  bp  cloned  insert.  The  3185  bp  DNA  fragment,  released  from  p444  DNA 
digested  with  Pstl,  is  predicted  to  contain  the  444  bp  cloned  insert.  The  1  Kb  size 




M  EcoR  I  Pst  I digesting  the  plasmid  DNA  with  a  specific  enzyme  (PstI  in  this  case)  that  has  two 
recognition  sites  in  the  vector  DNA  (Fig.  4.9).  After  enzyme  digestion,  the  DNA  was  cut 
into  two  fragments  of  DNA.  The  fragment  (predicted  size  3185  bp)  containing  the  correct 
cloned  insert  will  be  larger  than  the  equivalent  fragment  (predicted  size  2641  bp)  that 
comes  from  a  non-recombinant  plasmid  (Fig.  4.9b).  Plasmid  DNA  was  midiprepped  using  a 
commercial  kit  (section  2.2.2.1)  and  its  DNA  concentration  was  measured  by 
spectrophotometry.  Thereafter,  dilutions  of  known  concentration  of  mimic  DNA  were 
prepared  and  used  in  the  following  competitive  PCR  assays. 
4.3.2.2  Generation  of  mimic  construct  for  quantifying  levels  of  deleted  mtDNA 
molecules  in  mouse  tissue 
4.3.2.2.1  Selection  of  mimic  DNA  sequence  and  composite  primers 
The  DNA  sequence  of  mimic  p667  was  chosen  from  the  bacterial  CAT  gene  according  the 
principles  described  in  section  4.2.  The  GC  ratio  of  p667  was  44  %  and  the  GC  ratio  of  the 
target  mtDNA  sequence  flanked  by  primers  L2  and  H2  was  39  %.  Primers  were  selected  to 
generate  a  667  bp  mimic  DNA  fragment  that  is  close  but  distinguishable  from  the  size  of  the 
deleted  mtDNA  PCR  product,  748  bp.  The  composite  primers  (MIMICL2  and  MIMICH2) 
were  synthesized  by  attaching  primer  L2  to  the  CAT  gene  specific  primer  CAT3  and  primer 
H2  to  the  CAT  gene  specific  primer  CAT4  (Fig.  4.10).  The  composite  primers,  MIMICL2 
and  MIMICH2,  were  used  in  a  PCR  assay  to  amplify  mimic  DNA  molecules  and  the  PCR 
products  were  used  subsequently  for  p667  construction. 
43.2.2.2  Generation  of  mimic  construct 
The  PCR  conditions  for  using  primers  MIMICL2  and  MIMICH2  to  amplify  the  mimic 
DNA  sequence  were  the  same  as  for  using  primers  MIMICL1  and  MIMICH1  (section 
4.3.2.1.2).  The  PCR  products  were  resolved  on  a  1.5  %  EtBr-stained  agarose  gel  and 
products  of  the  expected  sizes  were  observed  (Fig.  4.8). 
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Figure  4.10  Selection  of  mimic  DNA  sequence  and  composite  primers  for  quantifying 
deleted  mtDNA  molecules.  The  composite  primers  (MIMICL2)  and  MIMICH2)  were 
synthesized  by  attaching  primer  L2  to  the  CAT  gene  specific  oligonucleotide  CATS 
and  primer  H2  to  the  CAT  gene  specific  oligonucleotide  CAT4  (a  and  b).  The  GC  ratio 
of  the  mimic  DNA  sequence  is  44  %  and  the  size  is 667bp  (a).  The  GC  ratio  of  the  intact 
mtDNA  sequence  amplified  by  L2  and  H2  is  39  %  and  the  size  is  748bp  (c). 
154 The  procedures  for  generating  mimic  construct  p667  were  the  same  as  for  p444  (section 
4.3.2.1.2)  including  the  gel  purification  of  PCR  products,  cloning,  preparation  of  plasmid 
DNA,  and  confirmation  of  the  correct  insert  in  the  plasmid  clone  (Fig.  4.11). 
4.3.3  Optimising  the  quantitative  competitive  PCR  assay  for  measuring 
mtDNA  levels  in  mouse  tissue 
4.3.3.1  Determining  the  PCR  conditions  for  measuring  levels  of  total  mtDNA 
molecules  in  mouse  tissue 
A  prerequisite  for  obtaining  quantitative  data  by  competitive  PCR  is  that  both  target  and 
mimic  DNA  are  co-amplified  in  the  exponential  phase  of  the  amplification  process  and  with 
similar  amplification  efficiencies.  To  ensure  this,  the  kinetics  of  the  competitive  PCR 
amplification  was  determined.  10  ng  of  mouse  liver  DNA  and  10  pg  of  p444  DNA  template 
were  amplified  separately  for  up  to  40  cycles  using  primers  Ll  and  H1  that  had  been  radio- 
labelled  with  [y-32P]  AT?  (section  2.2.11.2).  96  pmole  of  each  radio-labelled  primer  was 
mixed  with  504  pmole  of  non  radio-labelled  Ll  and  H1  and  distributed  evenly  amongst  25 
PCR  tubes  (12  tubes  for  p444  DNA  amplification,  12  tubes  for  mouse  liver  DNA 
amplification  and  1  tube  for  the  control).  The  PCR  conditions  for  amplification  of  mimic 
p444  were  the  same  as  for  intact  mtDNA  amplification  (section  2.2.5.2).  Two  of  the  PCR 
tubes  (one  from  p444  amplification  and  one  from  liver  DNA  amplification)  were  removed 
every  two  cycles  of  the  amplification  process  (between  18  to  40  cycles)  and  the  products 
resolved  on  an  EtBr-stained  2%  agarose  gel  (Fig.  4.12a).  The  radioactive  gels  were 
photographed,  the  appropriate  bands  excised  and  the  radioactivity  of  each  band  quantified  in 
a  liquid  scintillation  counter  (LS  5000  CE,  Beckhman).  The  log  of  radioactivity  for  each 
band  was  plotted  against  the  number  of  PCR  cycles  to  show  the  exponential  range  of 
amplification  efficiency  for  intact  mtDNA  and  mimic  p444  templates  (Fig.  4.12b).  The 
results  showed  that  intact  mtDNA  and  mimic  p444  templates  were  co-amplified  with  a 
similar  efficiency,  within  a  linear  range  of  between  18  and  24  cycles.  According  to  these 
results,  24  cycles  of  PCR  was  chosen  for  subsequent  competitive  PCR  assays  to  quantify 
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Figure  4.11  Confirmation  of  the  recombinant  plasmid  p667.  A  restriction  map  of 
p667  shown  in  (a)  illustrates  the  position  of  appropriate  restriction  enzyme  recognition 
sites  for  EcoRI  and  Pstl.  The  thin  line  represents  the  vector  Topo  2.1  (3808  bp).  The 
thick  line  represents  the  667  bp  insert  (arrow).  EcoRI  and  Pstl-digested  DNA  from 
p667  DNA  was  resolved  on  an  EtBr-stained  agarose  gel,  shown  in  (b).  The  685  bp 
DNA  fragment,  released  from  p667  digested  with  EcoRI  is  predicted  to  contain 
the  667  bp  cloned  insert.  The  3408  bp  DNA  fragment,  released  from  digesting 
p667  DNA  with  Pstl,  is  predicted  to  contain  the  667  bp  cloned  insert.  The  1  Kb  size 
ladder  is  indicated  by  M. 
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Figure  4.12  Kinetics  of  amplification  of  total  mtDNA  and  mimic  p444  molecules. 
Products  of  amplified  total  mtDNA  and  mimic  p444  molecules  after  18  to  40 
cycles  of  PCR  (numbers  above  the  panel)  were  resolved  on  an  EtBr-stained  agarose 
gel  shown  in  (a).  W  indicates  the  control  for  DNA  contamination  of  PCR  using 
water  as  a  template.  M  indicates  the  1  Kb  size  ladder.  The  plot  (b)  of  log  radioactivity 
of  each  band  from  the  gel  in  (a)  against  number  of  PCR  cycles  shows  that  the  linear 
range  of  PCR  amplification  for  both  total  mtDNA  and  mimic  p444  molecules  is 
18-24  cycles.  24  cycles  was  chosen  in  subsequent  competitive  PCR  assays  for 
quantification  of  total  mtDNA  levels. 
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molecules  in  mouse  tissue 
Determination  of  the  kinetics  of  competitive  PCR  for  deleted  mtDNA  and  p667  DNA 
templates  was  carried  out  using  the  same  methods  described  for  intact  mtDNA  and  mimic 
p444  (section  4.3.3.1).  75  ng  of  mouse  liver  DNA  and  150  fg  of  p667  DNA  templates  were 
amplified  separately  for  up  to  40  cycles  using  radio-labelled  L2  and  H2  primers  (section 
2.2.11.2).  The  PCR  conditions  for  mimic  p667  amplification  were  the  same  as  for  deleted 
mtDNA  amplification  (section  2.2.5.2).  The  results  showed  that  deleted  mtDNA  and  mimic 
p667  templates  were  co-amplified  with  a  similar  efficiency,  within  a  linear  range  between 
24  and  30  cycles  (Fig.  4.13). 
According  to  Figure  4.13,30  PCR  cycles  was  at  the  top  of  the  exponential  range  of 
amplification  efficiency  for  deleted  mtDNA  and  mimic  p667.  Ideally,  26  or  28  cycles 
should  be  chosen  for  the  amplification  cycle  of  competitive  PCR,  because  this  number  is in 
the  middle  of  the  exponential  range.  However,  when  26  cycles  was  used  to  amplify  deleted 
mtDNA  from  mouse  brain,  the  PCR  products  were  not  visible  on  an  EtBr-stained  agarose 
gel  (Fig.  4.13).  Therefore,  26  cycles  of  radioactive  and  30  cycles  of  non-radioactive 
competitive  PCR  were  performed  to  compare  the  results  of  amplifying  the  same  amount  of 
DNA  template.  200  ng  of  mouse  striatal  DNA  were  co-amplified  with  dilutions  of  p667 
using  26  PCR  cycles  and  L2  and  H2  primers  radio-labelled  with  [y  32p]  ATP.  96  pmole  of 
each  radio-labelled  primer  (20  %  of  total  primer  concentration  added  to  PCR)  was  mixed 
with  384  pmole  of  each  non  radio-labelled  primer  and  distributed  evenly  into  30  aliquots  for 
the  competitive  PCR  assay  of  deleted  mtDNA  (section  2.2.5.2).  The  resulting  PCR 
products  were  resolved  on  an  EtBr-stained  2%  agarose  gel.  The  resulting  gel  was  dried 
(under  vacuum)  until  it  was  paper-thin.  Then,  it  was  exposed  to  X-ray  film  at  -70°C 
overnight  in  the  presence  of  intensifying  screens.  The  resulting  autoradiograph  was  scanned 
and  analysed  (Fig.  4.14a).  30  cycles  of  non-radioactive  competitive  PCR  assays  were 
performed  and  the  PCR  products  were  resolved  on  an  EtBr-  stained  gel  (Fig.  4.14b).  The 
results  showed  that  the  amount  of  deleted  mtDNA  quantified  using  the  30  cycles  of 
competitive  PCR  reaction  was  similar  to  those  using  26  cycles  of  competitive  PCR.  Based 
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Figure  4.13  Kinetics  of  amplification  of  deleted  mtDNA  and  mimic  p667  molecules. 
Products  of  amplified  deleted  mtDNA  and  mimic  p667  molecules  after  18  to  40 
cycles  of  PCR  (numbers  above  the  panel)  were  resolved  on  an  EtBr-stained  agarose 
gel  shown  in  (a).  W  indicates  the  control  for  DNA  contamination  of  PCR  using  water 
as  a  template.  M  indicates  the  1  Kb  size  ladder.  The  plot  (b)  of  the  log  radioactivity 
of  each  band  from  the  gel  in  (a)  against  number  of  PCR  cycles  shows  that  the  linear 
range  of  PCR  amplification  for  both  deleted  mtDNA  and  mimic  p667  molecules  is 
24-30  cycles. 
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Figure.  4.14  Optimization  of  PCR  conditions  for  the  competitive  PCR  assays  for 
the  deleted  mtDNA  levels.  200  ng  of  striatal  DNA  from  each  mouse  (mouse  1-3)  was 
was  co-amplified  for  26  (a)  and  30  (b)  PCR  cycles  with  dilutions  of  p667  DNA 
(amount  in  fg  indicated  above  the  panel)  using  primers  L2  and  H2.  In  each  case,  the 
reaction  producing  equal  molar  amounts  of  mimic  and  target  DNA  products  is  indicated 
by  an  arrow.  When  it  falls  between  two  PCR,  an  intermediate  value  is  chosen 
(arrow  head).  The  autoradiograph  of  competitive  PCR  products  using  26  PCR  cycles 
(a)  suggests  that  PCR  product  concentrations  are  equivalent  in  the  reaction  containing 
5  fg  of  p667  in  each  case.  The  gel  image  of  competitive  PCR  products  using  30  PCR 
cycles  (b)  suggests  that  PCR  product  concentrations  are  equivalent  in  the  reactions 
containing  4  (mouse1),  4.5  (mouse  2  ),  and  5  (mouse  3)  fg  of  p667  respectively. 
The  amount  of  deleted  mtDNA  molecules  in  each  mouse  striatum  obtained  using 
26  cycles  of  radioactive  PCR  and  30  cycles  of  non-radioactive  PCR  shows  no 
significant  difference  and  so  30  cycles  of  non-radioactive  competitive  PCR  was 
used  in  subsequent  competitive  PCR  assays  so  that  products  can  be  visualized  on 
agarose  gels. 
160 mtDNA  to  enable  visualization  of  the  PCR  products  on  agarose  gels,  thus  avoiding  the  use 
of  radioactivity. 
4.3.3.3  Generating  a  standard  curve  for  determining  the  levels  of  mtDNA  by 
competitive  PCR 
When  the  products  of  target  and  mimic  amplification  in  the  dilutions  used  for  competitive 
PCR  assays  did  not  show  equal  molar  density,  a  standard  curve  was  constructed  by  plotting 
the  logarithm  of  the  ratio  of  target  mtDNA/mimic  DNA  PCR  product  intensity  against  the 
log  of  the  amount  of  mimic  template  added  to  the  PCR  reaction  (in  pg).  The  amount  of 
mtDNA  was  then  calculated  by  extrapolating  from  intersection  of  the  curves,  where  the 
molar  amounts  of  target  and  competitor  products  are  equal  (log  ratio  of  target/competitor  = 
0),  to  the  x-axis  (Fig.  4.15). 
4.33.4  Normalisation  of  input  DNA  used  in  competitive  PCR  assays 
Initially,  the  concentration  of  tissue  DNA  added  to  PCR  was  measured  by 
spectrophotometry.  In  order  that  results  from  samples  subjected  to  the  competitive  PCR 
assays  of  mtDNA  can  be  compared  directly,  it  is  imperative  that  the  same  amount  of  tissue 
DNA  is  added  to  each  PCR  reaction.  If  this  is  not  the  case,  the  results  of  the  assays  must  be 
normalized  to  take  into  account  the  relative  amounts  of  tissue  DNA  added  to  each  PCR 
tube.  Therefore  input  DNA  concentration  was  checked  by  Southern  blot  analysis  of  tissue 
DNA  from  each  sample  used  in  the  study.  Two  single  copy  nuclear  probes,  1.7  and  N1.6, 
were  used  separately.  Probe  1.7  is  a  1.7  kb  HindIIl/Scal  fragment  from  upstream  of  the 
mouse  Hdh  gene  (probe  a  in  Figure  1B  of  Shelbourne  et  al.,  1999).  Probe  N1.6  is  a  1.6  kb 
BssHII  fragment  from  a  plasmid  pmNN  (a  gift  from  Rosalind  John,  Wellcome/CRC 
institute,  Cambridge,  UK),  which  contains  a9  kb  insert  from  the  mouse  neuronatin  gene 
locus  (Fig.  4.16). 
All  DNA  samples  subjected  to  competitive  PCR  assays  in  the  study  were  digested  with 
HindIIl,  transferred  to  a  nylon  membrane  which  was  probed  with  N1.6  using  methods 
described  in  section  2.2.12.  The  Southern  blot  analysis  identified  two  fragments  (3.7  kb  and 
2.3  kb)  on  autoradiographs  (Fig.  4.17).  Only  the  3.7  kb  fragment  was  used  in  subsequent 
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Figure  4.15  Determining  mtDNA  levels  by  competitive  PCR  from  the  constuction 
of  a  standard  curve.  PCR  products  of  5  ng  tissue  DNA  co-amplified  with  dilutions 
of  mimic  p444  construct  were  resolved  on  an  EtBr-stained  agarose  gel  shown  in  (a). 
The  concentration  of  mimic  template  added  to  each  PCR  tube  is  indicated  by  the 
numbers  above  the  image  (in  pg).  C  indicates  the  control  using  water  as  a  template 
for  DNA  contamination  of  PCR  reagents.  A  standard  curve  (b)  was  generated  from 
the  data  shown  in  (a)  plotting  log  p444/total  mtDNA  band  intensity  of  PCR  products 
in  each  lane  against  log  amount  of  p444  construct  added  to  the  PCR  tube.  In  this 
case,  the  value  extrapolating  from  the  intersection  of  the  curves  where  the  molar 
amounts  of  target  and  competitor  products  are  equal  (log  ratio  of  target/competitor 
=  0),  to  the  x-axis  is  1.1  (indicated  by  arrows).  Therefore,  the  amount  of  p444 
template  added  in  the  competitive  PCR  assay,  where  the  PCR  product  amounts 
from  p444  and  from  total  mtDNA  are  equal,  is  12.6  pg.  Since  1  pg  of  p444  contains 
4.24  x  105  molecules,  the  amount  of  total  mtDNA  present  in  this  PCRtube  is 
5.34  x106  molecules. 
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Figure  4.16  Generation  of  probe  N1.6  for  normalising  input  DNA  in  competitive 
PCR  assays.  The  plasmid  pmNN  shown  in  (a)  contains  9128  bp  of  mouse  genomic 
DNA  from  the  neuronatin  locus  (represented  by  thin  line)  cloned  into  vector 
pBluescript  (represented  by0).  Probe  N1.6  is  a  1575  bp  fragment  (M)  released  by 
digesting  the  plasmid  DNA  with  BssHII.  The  predicted  DNA  fragments  generated 
from  digestion  of  plasmid  mNN  with  BssHII  were  visualized  on  an  EtBr-stained 
agarose  gel  in  (b).  Lanes  1-5  contain  digested  DNA  from  5  reactions.  The  1.6  Kb 
DNA  bands  were  excised,  gel  purified  and  4  µl  (-25  ng)  of  gel  purified  N1.6 
resolved  on  an  EtBr-stained  agarose  gel  in  (lane  1,  c).  4  µl  of  N1.6  was  used  in 
the  Southern  blot  analysis  for  normalisation  of  input  DNA.  The  1  Kb  plus  size  ladder 
is  indicated  by  M. 
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Figure  4.17  Normalization  of  input  DNA  added  to  competitive  PCR  assays.  Images  of 
autoradiographs  from  the  Southern  blot  analysis  (probed  with  N1.6)  of  striatal  DNA  (a), 
cortical  DNA  (b)  and  cerebellar  DNA  (c)  from  5  HD  (+/-)  and  5  wild-type  littermates 
(+/+).  Each  lane  contains  5  . tg  of  tissue  DNA  measured  by  spectrophotometry  except 
from  striata  of  mouse  382,385,412,414,416  (12.5  µg  was  loaded  into  each  lane). 
Numbers  above  the  image  indicate  animal  ID.  The  1  Kb  plus  size  ladder  is  indicated 
by  M. 
164 normalization  of  input  DNA.  The  resulting  blot  of  all  DNA  samples  from  striatum,  cortex 
and  cerebellum  of  mice  used  in  the  study  is  shown  in  Figure  4.17.  The  same  DNA  samples 
from  striatum  were  also  subjected  to  a  second  Southern  blot  analysis  using  the  probe  1.7  for 
DNA  input  normalization.  The  relative  amount  of  tissue  DNA  added  to  the  competitive 
PCR  was  determined  by  following  steps: 
1)  A  lane  was  chosen  at  random  to  represent  unity  (=1)  in  the  normalization  scale. 
2)  Normalization  factors  for  all  other  samples  on  the  same  membrane  were  determined 
by  comparing  the  intensity  of  the  fragment  with  that  of  the  fragment  chosen  in  step 
1. 
3)  Total  mtDNA  concentration  before  DNA  input  normalization  was  divided  by  the 
normalization  factor  obtained  in  step  2  to  generate  the  final  figure  representing  the 
total  mtDNA  concentration  in  each  competitive  PCR  assay  sample. 
4.3.3.5  No  amplification  of  mitochondrial  sequences  in  mouse  nuclear  DNA 
The  presence  of  nuclear  pseudogenes  corresponding  to  the  mtDNA  fragments  in  rho  zero 
(p°)  cells  have  been  reported  previously  (Michikawa  et  al.,  1999).  If  mtDNA  pseudogenes 
were  present  in  the  nucleus  and  varied  between  samples,  this  could  affect  the  quantification 
of  total  mtDNA  in  this  study.  Therefore  it  was  important  to  determine  whether  pseudogenes 
yield  PCR  products  with  the  mtDNA-specific  primers  used  in  this  study.  Purification  of  cell 
nuclei  from  mouse  brain  was  performed  using  methods  described  (section  2.2.2.2).  After  the 
absence  of  contaminating  cytoplasm  was  confirmed  by  staining  the  nuclei  with  1%  (w/v) 
methylene  blue  (Fig.  4.18),  DNA  extraction  from  purified  cell  nuclei  was  performed 
(section  2.2.2.2).  Dilutions  of  purified  nuclear  DNA  from  mouse  brain  were  amplified  with 
Hdh  specific  primers  MHD  16  and  MHD  18  (section  2.2.5.3)  to  demonstrate  the  presence  of 
nuclear  DNA.  The  resulting  amplification  products  were  visible  on  an  EtBr-stained  agarose 
gel  (Fig  4.19).  In  contrast,  when  the  same  amount  of  purified  nuclear  DNA  was  amplified 
with  the  mtDNA  specific  primers  Ll  and  Hi  (section  2.2.5.2),  no  products  were  visible  on 
the  EtBr-stained  agarose  gel  (Fig.  4.19).  The  amplification  of  similar  amounts  of  total  DNA 
with  Ll  and  H1  primers  (section  2.2.5.2)  were  also  included  as  positive  controls  (Fig.  4.19). 
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Figure.  4.18  Obtaining  nuclear  DNA  to  check  for  the  presence  of  mtDNA 
pseudogenes.  Purified  mouse  neuronal  nuclei  were  stained  with  1%  methylene 
blue.  No  cytoplasmic  membrane  adhering  to  the  outside  of  the  nucleus  (arrow) 
was  visible,  indicating  that  the  purified  nuclei  are  free  of  contaminating  cytoplasm 
and,  by  inference,  mitochondria.  Magnification:  x400. 
Hdh  gene  primers  mtDNA  primers 
purified  nuclear  DNA  brain  DNA  purified  nuclear  DNA 
290  hp  - 
355  hp 
Figure  4.19  Lack  of  visible  products  after  amplification  of  purified  nuclear 
DNA  with  mtDNA  specific  primers.  Different  amounts  of  purified  nuclear  DNA 
were  amplified  with  mouse  Hdh  gene-specific  primers  (MHD  16  and  MHD18)  and 
PCR  products  are  visible.  In  contrast,  when  purified  nuclear  DNA  is  amplified  with 
mtDNA  specific  primers  (L1  and  HI),  PCR  products  are  not  visible.  However,  when 
brain  DNA  is  amplified  with  primers  Ll  and  H1,  PCR  products  are  very  abundant. 
The  1  Kb  plus  size  ladder  is  indicated  by  M.  C  indicates  the  control  for  DNA 
contamination  of  PCR  reagents,  using  water  as  a  template.  The  numbers  above  the 
image  represent  the  amount  of  DNA  (in  ng)  added  to  each  PCR  tube. 
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-SC The  results  revealed  that  if  present,  nuclear  mtDNA  pseudogenes  in  mouse  brain  were 
unlikely  to  affect  the  quantification  of  mtDNA  using  the  competitive  PCR  assay  described 
in  this  study. 
4.3.4  Determining  mtDNA  levels  in  HD  mouse  brain  regions 
Mitochondrial  DNA  levels  in  6  HD  mice  and  6  wild-type  littermates  (section  2.1.18)  at  24- 
28  months  of  age  and  4  HD  and  4  wild-type  littermates  (section  2.1.18)  at  15  months  of  age 
were  investigated.  The  cortex,  striatum  and  cerebellum  from  each  mouse  brain  were 
harvested  and  DNA  purified  using  phenol/chloroform  extraction  (section  2.2.1). 
Quantification  of  mtDNA  species  in  all  samples  was  performed  in  duplicate  and  the  mean 
value  of  the  duplicate  was  used  in  subsequent  statistical  analyses  using  the  Student's  t  test 
(two-tailed,  paired).  In  24  month-old  mice  the  following  comparisons  were  performed:  1) 
The  levels  of  intact  mtDNA  in  striatum,  cortex  and  cerebellum  of  HD  mice  compared  to 
wild-type  littermates;  2)  The  levels  of  deleted  mtDNA  in  striatum  of  HD  mice  compared  to 
wild-type  littermates;  3)  As  total  mtDNA  may  influence  the  absolute  levels  of  deleted 
mtDNA,  the  ratios  of  deleted/intact  mtDNA  obtained  from  HD  mice  and  wild-type 
littermates  were  also  compared.  In  15  month-old  mice,  the  levels  of  intact  mtDNA  in  the 
striatum  of  HD  mice  were  compared  to  wild-type  littermates. 
43.4.1  Determining  total  mtDNA  levels  in  different  brain  regions  of  HD  mice 
Dilutions  of  the  mimic  p444  construct  (5,7.5,10,12.5,15  pg)  were  co-amplified  with  5  ng 
of  brain  DNA  from  each  mouse,  and  PCR  products  were  resolved  on  a2%  EtBr-stained 
agarose  gel  (for  an  example  see  Fig.  4.20).  In  this  example,  the  intensity  of  the  mimic  p444 
PCR  products  was  equal  to  the  intensity  of  total  mtDNA  PCR  products  in  the  second  lane. 
Since  the  concentration  of  mimic  p444  added  to  this  PCR  assay  was  7.5  pg  and  1  pg  of  p444 
contains  4.24  x  10s  molecules,  the  amount  of  total  mtDNA  in  this  PCR  was  3.18  x  106 
molecules.  If  a  series  of  dilutions  failed  to  produce  a  lane  where  both  bands  were  of  equal 
intensity,  the  amount  of  mtDNA  present  was  calculated  as  described  in  section  4.3.3.3. 
The  level  of  total  mtDNA  in  striatum  from  6  HD  mice  and  6  littermates  at  24  months  of  age 
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Figure  4.20  An  example  of  amplifying  total  mtDNA  levels  in  mouse  brain  tissue.  A 
constant  amount  of  cerebellar  DNA  (5  ng)  was  co-amplified  with  dilutions  of  p444 
DNA  [amount  (in  pg)  added  to  each  reaction  indicated  by  the  numbers  above  the  panel]. 
and  the  products  visualized  on  an  EtBr  stained  agarose  gel.  The  gel  shows  the  intensity 
of  the  two  bands,  representing  the  products  of  mimic  p444  and  total  mtDNA,  are  equal 
in  the  second  lane.  The  number  of  total  mtDNA  templates  is  approximately  equal  to  the 
number  of  p444  templates  added  to  this  PCR  tube  ie  7.5  pg  (arrow).  1  pg  of  mimic  p444 
contains  4.24  x  105  molecules.  Therefore,  the  amount  of  tortal  mtDNA  present  in 
this  PCR  is  3.18  x106  molecules.  C  indicates  the  control  for  DNA  contamination 
of  the  PCR  reagents,  using  water  as  a  template. 
168 before  and  after  normalization  of  input  tissue  DNA  (see  section  4.3.3.4)  is  shown  in  Table 
4.1  and  Figure  4.21.  The  results  of  statistical  analysis  using  data  before  normalization  of 
input  tissue  DNA  show  that  total  mtDNA  in  the  striatum  of  HD  mice  at  24  months  of  age  is 
significantly  decreased  when  compared  to  wild-type  littermates.  After  normalization  of 
input  DNA  using  probes  N1.6  and  1.7,  total  mtDNA  in  the  striatum  of  HD  mice  at  24 
months  of  age  still  showed  a  significant  reduction  when  compared  to  wild-type  littermates. 
The  -  30  %  reduction  of  total  mtDNA  was  confined  to  striatum,  since  it  was  not  detected  in 
the  cortex  or  cerebellum  of  HD  mice  (Table  4.2). 





Molecules  of 
total 
mtDNA/5n  S 
383  HD  1.27  x  106  0.62  2.05  x  106 
377  HD  2.54  x  106  2.36  1.08  x  106 
410  HD  2.54  x  106  1.8  1.41  x  106 
412  HD  0.85  x  106  0.59  1.44  x  106 
414  HD  2.12  x  106  1.13  1.88  x  106 
376  Wild-type  4.67  x  106  2.65  1.76  x  106 
382  Wild-type  2.97  x  106  1  2.97  x  106 
385  Wild-type  2.33  x  106  0.91  2.56  x  106 
409  Wild-type  5.51  x  106  2.57  2.14  x  106 
416  Wild-type  2.54  x  106  1.01  2.53  x  106 
Table  4.1  Levels  of  total  mtDNA  in  striatum  of  mice  at  24  months  of  age. 
1  indicates  that  5  ng  of  input  tissue  DNA  was  determined  by  spectrophotometry.  S  indicates 
5  ng  of  input  tissue  DNA  after  normalization  by  Southern  blot  analysis.  Normalization 
factors  for  input  tissue  DNA  as  determined  by  Southern  blot  analysis  (section  4.3.3.4)  are 
indicated  in  column  labelled  4. 
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Figure  4.21  Scatter  plot  of  total  mtDNA  levels  (normalised  for  input  tissue  DNA) 
in  the  striatum  of  24-month  old  HD  mice  (HD)  and  wild-type  littermates  (WT). 
170 a)  Striatum 
Wild-type  (n=5)  HD  (n=5)  p  value 
Total  mtDNA  2.39:  t.  0.2  1.57  ±  0.17  0.016 
molecules  x  106/5  ng 
input  tissue  DNA 
b)  Cortex 
Wild-type  (n=5)  HD  (n=5)  p  value 
Total  mtDNA  4.76  ±  0.45  3.67  ±  0.5  0.15 
molecules  x  106/5  ng 
input  tissue  DNA 
c)  Cerebellum 
Wild-type  (n=5)  HD  (n=5)  p  value 
Total  mtDNA  4.88.  ±  0.5  4.85  ±  0.09  0.95 
molecules  x  106/5  ng 
input  tissue  DNA 
Table  4.2  Levels  of  mtDNA  in  striatum  (a),  cortex  (b)  and  cerebellum  (c)  of  24  month-old 
mice  (corrected  for  amount  of  tissue  DNA  added  to  the  PCR  tube). 
Total  mtDNA  in  the  striatum  of  HD  mice  at  24  months  of  age  is  significantly  decreased 
compared  to  wild-type  littermates  (p  <  0.02).  The  reduction  of  total  mtDNA  is detected  in 
the  striatum  but  not  cortex  or  cerebellum  of  HD  mice.  Comparisons  were  made  using 
Student's  t-test  (two  tailed).  All  values  of  total  mtDNA  are  stated  as  mean  ±  SE. 
In  order  to  ascertain  whether  the  striatal  depletion  of  mtDNA  is  a  progressive  phenomenon, 
levels  of  total  mtDNA  in  the  striatum  of  HD  mice  at  15  months  of  age  were  investigated. 
Levels  of  total  mtDNA  in  the  striatum  of  4  HD  mice  and  4  wild-type  littermates  at  15 
months  of  age,  before  and  after  normalization  of  input  DNA  are  shown  in  Table  4.3  and 
Figure  4.22.  The  results  show  that  HD  mice  at  15  months  of  age  do  not  have  detectable 
differences  in  total  mtDNA  in  the  striatum  when  compared  to  wild-type  littermates  (Table 
4.4).  Total  mtDNA  levels  in  the  striatum  of  HD  mice  and  littermates  at  24  months  of  age  are 
significantly  reduced  when  compared  to  the  corresponding  groups  of  mice  at  15  months  of 
age  (Fig.  4.23).  However,  the  DNA  extraction  from  15  and  24  month-old  mice  were  not 
performed  at  the  same  time,  which  might  introduce  error  to  the  differences  in  the  total 
mtDNA  in  mouse  striatum  between  these  two  time  points.  Therefore,  further  experiment  is 
needed  to  confirm  the  result. 





Molecules  of 
total 
mtDNA/5n  S 
788  HD  6.57  1.16  5.66 
793  HD  4.24  0.93  4.56 
795  HD  2.97  0.7  4.24 
7104  HD  2.33  0.48  4.86 
791  Wild-type  6.36  1.15  5.53 
794  Wild-type  4.67  1  4.66 
796  Wild-type  5.51  1.1  5.00 
7101  Wild-type  4.03  1.07  3.77 
Table  4.3  Levels  of  total  mtDNA  in  striatum  of  mice  at  15  months  of  age. 
1  indicates  that  5  ng  of  input  tissue  DNA  was  determined  by  spectrophotometry.  S  indicates 
5  ng  of  input  tissue  DNA  after  normalization  by  Southern  blot  analysis.  Normalization 
factors  for  input  tissue  DNA  as  determined  by  Southern  blot  analysis  (section  4.3.3.4)  are 
indicated  in  column  labelled  4. 
Wild-type  (n=4)  HD  (n=4)  value 
Total  mtDNA  4.74:  t-  0.37  4.83  t  0.31  0.86 
molecules  (striatum)  x 
106/5  ng  input  tissue 
DNA 
Table  4.4  Comparison  of  total  mtDNA  levels  in  the  striatum  of  15  month-old  HD  mice  and 
wild-type  littermates  (corrected  for  amount  of  tissue  DNA  added  to  the  PCR  tube). 
No  significant  difference  was  found  in  total  mtDNA  levels  in  the  striatum  of  HD  mice  when 
compare  to  their  wild-type  littermates.  Comparisons  were  made  using  Student's  t-test  (two 
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Figure  4.22  Scatter  plot  of  total  mtDNA  levels  (normalised  for  input  tissue  DNA) 
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Figure  4.23  Comparisons  of  total  mtDNA  levels  in  the  striatum  of  mice  at  15  and 
24  months  of  age.  Total  mtDNA  levels  in  the  striatum  of  HD  mice  and  wild-type 
littermates  at  24  months  of  age  are  significantly  reduced  when  compared  to  the 
corresponding  groups  of  mice  at  15  months  of  age  (**p  <  0.001).  Total  mtDNA  is 
significantly  decreased  in  the  striatum  of  HD  mice  at  24  months  of  age  compared 
to  the  wild-type  littermates  (*p  <  0.05).  The  Student's  t  test  is  used  for  statistical 
analysis.  Data  are  expressed  as  mean  ±  S.  E. 
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N=4  N=6 43.4.2  Determining  levels  of  deleted  mtDNA  molecules  in  HD  mouse  brain 
regions 
Dilutions  of  the  mimic  p667  construct  (0,2.5,5,7.5,10  fg)  were  co-amplified  with  200  ng 
of  striatal  DNA  from  each  mouse,  and  PCR  products  were  resolved  on  an  EtBr-stained  2% 
agarose  gel  (for  an  example  see  Fig.  4.24).  In  this  example,  the  data  indicated  that  the 
intensity  of  mimic  p667  PCR  product  was  equal  to  the  intensity  of  deleted  mtDNA  PCR 
product  in  the  second  lane.  Since  the  concentration  of  mimic  p667  template  added  to  this 
PCR  was  2.5  fg  and  1  fg  of  p667  contains  403  molecules,  the  amount  of  deleted  mtDNA  in 
this  PCR  is  1,008  molecules.  The  input  tissue  DNA  concentrations  added  to  competitive 
PCR  assays  were  normalized  by  Southern  blot  analysis  (see  section  4.3.3.4).  The  resulting 
deleted  mtDNA  levels  in  the  striatum  of  the  6  HD  mice  and  6  wild-type  littermates  studied 
in  section  4.3.4.1  are  shown  in  Table  4.5.  The  results  show  that  the  amount  of  deleted  DNA 
in  the  striatum  of  HD  mice  at  24  months  of  age  is  not  significantly  different  from  that  of 
wild-type  littermates,  and  the  ratio  of  deleted  mtDNA/total  mtDNA  in  the  striatum  of  HD 
mice  is  not  significantly  different  from  that  of  wild-type  littermates  (Table  4.6). 
4.4  Summary 
This  study  suggested  that  total  mtDNA  was  significantly  decreased  in  the  striatum  of  24- 
month  old  HD  mice,  but  not  at  15  months  of  age,  when  compared  to  wild-type  mice.  This 
-30%  reduction  in  total  mtDNA  was  confined  to  striatum,  as  no  such  reductions  were 
detected  in  the  cerebellum  or  cortex  of  the  same  animals.  Loss  of  total  mtDNA  in  the  striata 
of  HD  mice  appeared  to  be  a  progressive  rather  than  a  developmental  phenomenon. 
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Figure  4.24  Determining  levels  of  the  common  deleted  mtDNA  species  in  mouse  brain 
regions.  A  constant  amount  (200  ng)  of  striatal  DNA  was  co-amplified  with  dilutions  of 
p667  mimic  DNA  and  the  products  resolved  on  an  EtBr-stained  agarose  gel.  Numbers 
above  the  image  represent  the  amount  of  mimic  p667  added  to  each  PCR  tube  (in  fg). 
The  image  of  the  resulting  gel  shows  equal  intensity  of  the  two  bands  representing 
deleted  mtDNA  and  p667  DNA  in  the  second  lane  (arrow).  2.5  fg  of  p667  DNA  was 
added  to  this  PCR  tube.  As  1  fg  of  p667  DNA  contains  403  molecules,  there  are  1008 
molecules  of  deleted  mtDNA  in  this  PCR  assay. 
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0  2.5  5  7.5  10 Animal  ID  Genotype  Molecules  of 
deleted 
mtDNA 
/200n  g) 
Normalisation 
factor4 
Molecules  of 
deleted 
mtDNA 
/200n  S 
Ratio  of 
deleted/total 
mtDNA 
383  HD  2216.5  0.62  3574  1.74  x  10-3 
377  HD  2418  2.36  1109  1.03  x  10"3 
410  HD  2821  1.8  1567  1.1  x  10-3 
412  HD  1621  0.59  2732  1.9  x  10"3 
414  HD  2418  1.13  2139  1.14  x  10-3 
376  Wild-t  e  2619.5  2.65  988  0.56  x  10"3 
382  Wild-  e  3425.5  1  3426  1.15  x  10-3 
385  Wild-type  2418  0.91  2657  1.04  x  10- 
1409  Wild-type  2821  2.57  1097  0.51  x  10-3 
416  Wild-  e  3425.5  1.01  3401  1.35  x  10 
Table  4.5  Levels  of  deleted  mtDNA  in  striatum  of  mice  at  24  months  of  age. 
0  indicates  that  200  ng  of  input  tissue  DNA  was  determined  by  spectrophotometry.  S 
indicates  200  ng  of  input  tissue  DNA  after  normalization  by  Southern  blot  analysis. 
Normalization  factors  for  input  tissue  DNA  as  determined  by  Southern  blot  analysis  (section 
4.3.3.4)  are  indicated  in  column  labelled  4. 
Wild-type  (n=5)  HD  (n=5)  p  value 
Deleted  mtDNA  2313  t  537  2224:  t-433  0.9 
molecules  (D)  /200  ng 
input  tissue  DNA 
Total  mtDNA  2.39:  t  0.2  1.57  t  0.17  0.016* 
molecules  x  106  (T)/  5 
ng  input  tissue  DNA 
Ratio  of  D/T  2.30  x  10':  f-.  4.12  x  10  3.46  x  10"5  t  4.53  x  10-6  0.096 
Table  4.6  Levels  of  deleted  mtDNA  and  ratios  of  deleted  mtDNA/total  mtDNA  in  the 
striatum  of  24  month-old  mice  (corrected  for  amount  of  tissue  DNA  added  to  the  PCR 
tube). 
Comparisons  were  made  using  Student's  t-test  (two  tailed).  All  data  are  expressed  as  mean 
t  SE.  *  indicatesp  <  0.05. 
176 5  Investigating  the  cause  of  reduced  levels  of  mtDNA  in 
24-month  old  HD  mouse  striatum 
5.1  Introduction 
The  results  shown  in  section  4.3.4.1  indicate  that  24-month  old  HD  mice  had  a  significant 
reduction  (-  30  %)  of  total  mtDNA  in  the  striatum.  It  is  notable  that  increased  oxidative 
stress  can  either  cause  loss  of  mitochondria  (Hirai  et  al.,  2001)  or  decreased  total  mtDNA 
content  (Mansouri  et  al.,  1999;  Mansouri  et  al.,  2001).  Therefore,  it  is  important  to  clarify 
whether  the  reduction  of  total  mtDNA  is  due  to  a  decreased  number  of  mitochondria,  or  a 
decreased  number  of  mtDNA  molecules  per  mitochondrion. 
Western  blot  analyses  (section  2.2.14)  of  the  mitochondrial  structural  protein  porin  were 
performed  to  determine  the  mitochondrial  mass  in  the  striatum  of  24  month-old  HD  mice 
and  wild-type  littermates.  If  the  mitochondrial  mass  in  the  striatum  of  HD  mice  is  not 
different  from  that  of  their  wild-type  littermates,  the  reduction  of  mtDNA  may  be  due  to  the 
decreased  number  of  mtDNA  molecules  per  mitochondrion. 
Mitochondrial  transcription  factor  A  (mtTFA)  has  been  demonstrated  to  regulate  mtDNA 
copy  number  in  vivo  and  is  essential  for  mitochondrial  biogenesis  (Larsson  et  al.,  1998). 
Consistent  with  a  role  in  regulating  mtDNA  copy  number,  the  level  of  human  mtTFA  varies 
concomitantly  with  the  level  of  mtDNA  in  human  cell  (Larsson  et  al.,  1994).  Mitochondrial 
transcription  factor  A  plays  an  important  role  in  the  maintenance  of  mtDNA  (Lee  and 
Clayton,  1997)  and  studies  have  shown  that  mRNA  of  human  mitochondrial  transcription 
factor  A  gene  (TFAM)  is decreased  in  patients  with  myopathy  associated  with  depletion  of 
mtDNA  (Poulton  et  al.,  1994).  Since  a-  30  %  reduction  of  mtDNA  was  found  in  the 
striatum  of  HD  mice,  the  hypothesis  that  decreased  mtTFA  expression  levels  might  be  the 
cause  of  the  mtDNA  depletion  is  conceivable.  Also,  the  30  %  reduction  of  mtDNA  might 
have  a  positive  feed  back  effect  on  the  expression  of  mtTFA  and  therefore,  mtTFA 
expression  level  increases  as  a  compensatory  response.  Therefore,  the  expression  levels  of 
mtTFA  in  HD  mouse  brain  regions  including  striatum,  cortex,  and  cerebellum  were 
177 investigated.  The  aims  of  this  study  were  to  determine  whether  the  change  of  mtTFA 
expression  level  is  related  to  the  depletion  of  mtDNA  in  the  striatum  of  HD  mice. 
5.2  Determining  levels  of  the  mitochondrial  structural  protein, 
porin  (representing  mitochondrial  mass),  in  24  month-old 
HD  mouse  striatum 
The  outer  membrane  of  the  mitochondrion  contains  many  copies  of  a  transport  protein 
called  porin  (VDAC,  voltage  dependent  anion  channel),  which  forms  large  aqueous 
channels  through  the  lipid  bilayer.  The  membrane  thus  resembles  a  sieve  that  is  permeable 
to  all  molecules  of  5000  daltons  or  less,  including  all  small  proteins.  Porin,  a  31  KiloDalton 
(kDa)  protein,  was  investigated  using  western  blot  analysis  to  determine  the  mitochondrial 
mass  present  in  the  striatum  of  HD  mice.  Levels  of  ß-tubulin  III  (50  kDa)  were  also 
investigated  to  provide  an  internal  control  for  normalizing  levels  of  protein  loading. 
Initially,  a  study  to  determine  the  intra-experimental  error  was  conducted.  Five  equal 
amounts  (12µg)  of  the  same  protein  lysate  from  one  animal  was  loaded  on  a  Bis-Tris  SDS 
gel,  and  the  ratios  of  porin  intensity/ß-tubulin  III  intensity  were  determined  by  western  blot 
analysis  for  each  lane  (Fig.  5.1).  The  coefficient  of  variation  (CV)  that  represents  the 
precision  of  the  experiment  was  6  %.  The  result  also  suggested  that  western  blot  analysis 
could  detect  at  least  -  13  %  difference  in  mean  value  between  2  groups,  if  the  variances  of  2 
groups  are  similar  to  that  of  this  experiment. 
The  next  experiment  was  to  compare  porin  levels  in  the  striatum  of  6  HD  and  6  wild-type 
littermates.  Animals  of  the  same  age  and  same  genetic  background  as  those  used  in  section 
4.3.4  were  used  for  the  analysis.  The  ratio  of  porin  intensity/ß-tubulin  III  intensity  for  each 
animal  was  determined  in  duplicate  by  western  blot  analyses  (Fig.  5.2).  The  results  showed 
that  the  ratio  of  porin/ß-tubulin  III  in  the  striatum  of  HD  mice  at  24  months  of  age  did  not 
differ  from  that  of  wild-type  littermates  (Table  5.1).  This  indicates  that  the  striatal 
mitochondrial  mass  in  HD  mice  does  not  differ  from  that  in  wild-type  littermates. 
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Figure  5.1  Determining  intra-experimental  error  associated  with  the  determination 
of  porin  levels  by  western  blot  analysis.  5  samples  of  the  same  brain  protein  lysate 
were  loaded  onto  a  Bis-Tris  SDS  gel  (12  µg  in  each  of  lanes  1-5).  The  proteins 
were  transferred  onto  a  membrane  and  immunodetected  with  anti-porin  and  anti- 
ß-tubulin  III  antibodies.  The  ratios  of  porin/ß-tubulin  III  (measured  by  intensity 
of  resulting  bands)  are  stated  below  the  panel.  The  coefficient  of  variation  (CV) 
that  represents  the  precision  of  the  experiment  is  6  %. 
+1- 
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ratio  -  0.48  0.5  0.46  0.48  0.53  0.59  0.41  0.43  0.38  0.38  0.42  0.44 
Figure  5.2  Determining  mitochondrial  mass  in  protein  lysates  of  mouse  striatal  tissue. 
12  µg  protein  lysate  from  the  striatum  of  6  HD  mice  (+/-)  and  6  wild-type  littermates 
(+/+)  was  loaded  onto  two  Bis-Tris  SDS  gels.  The  proteins  in  each  gel  were  transferred 
onto  a  membrane  and  immunodetected  with  anti-porin  and  anti-ß-tubulin  III  antibodies. 
The  ratios  of  image  intensity  of  porin/ß-tubulin  III  are  stated  below  the  panel. 
179 Wild-type  (n=6)  HD  (n=6)  value 
Porin/ß-tubulin  III  ratio,  0.56  t  0.039  0.52  t  0.039  0.51 
replicate  1 
Porin/ß-tubulin  III  ratio,  0.47  ±  0.029  0.44  ±  0.021  0.43 
,  replicate  2 
Table  5.1  Summary  of  western  blot  data  for  determining  the  mitochondrial  mass  in  striatum 
of  24  month-old  mice. 
The  porin/ß-tubulin  III  ratio  in  HD  mouse  striatum  does  not  differ  from  that  of  wild-type 
littermates.  Statistical  method  used:  Student's  t  test  (two  tailed).  All  values  of  porin/ß- 
tubulin  III  are  expressed  as  mean  ratio  ±  SE. 
5.3  Investigating  the  expression  levels  of  mitochondrial 
transcription  factor  A  (Tfam)  mRNA  in  HD  mouse  brain 
regions 
The  mitochondrial  transcription  factor  A  (Tfam)  mRNA  expression  levels  in  HD  mice  were 
investigated  using  northern  blot  and  RNA  slot  blot  analyses.  The  prerequisites  of  northern 
blot  analysis  are  the  good  quality  RNA,  good  probes,  an  internal  control  for  RNA  loading 
and  adequate  exposure  times  of  X-ray  film  to  radiolabelled  northern  blot  membranes. 
Therefore,  optimisations  for  those  requirements  were  performed. 
5.3.1  RNA  extraction  and  first  strand  cDNA  synthesis 
First  strand  cDNA  was  synthesized  from  RNA  obtained  from  a  whole  brain  of  a  wild  type 
mouse  using  methods  described  in  sections  2.2.15.1,2.2.15.2,  and  2.2.15.3.  Primers 
mGDH-A  and  mGDH-BR,  and  primers  CW2F  and  CLW4R  (see  section  2.1.7)  were  used 
to  amplify  first  strand  cDNA  from  the  mouse  glyceraldehyde-3-phosphate  dehydrogenase 
(Gapdh)  mRNA,  and  myotonic  dystrophy  protein  kinase  gene  (Dmpk)  mRNA  respectively, 
to  check  the  RNA  template  for  DNA  contamination  (section  2.2.5.4).  After  the  results 
suggested  that  DNA  contamination  was  not  present  (Fig  5.3),  the  first  strand  cDNA  was 
subjected  to  PCR  amplification  using  primers  TFA1  and  TFA2  for  generating  probes  which 
were  subsequently  used  in  northern  blot  and  RNA  slot  blot  analyses  of  Tfam  mRNA. 
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Figure  53  Confirmation  that  no  DNA  is  present  in  a  mouse  brain  RNA  sample 
for  first  strand  cDNA  synthesis.  Amplification  products  of  the  mouse  Gapdh  gene 
transcript  from  different  dilutions  (1:  1,1:  1,1:  10,1:  100)  of  the  first  strand  cDNA 
are  visualised  on  an  EtBr-stained  agarose  gel  (a).  Amplification  products 
of  the  mouse  Dmpk  gene  transcript  from  different  dilutions  (1:  1,1:  10,1:  100)  of 
the  first  strand  eDNA  are  visualised  on  a  EtBr-stained  agarose  gel  (b).  NoRT 
indicates  the  control  lanes  containing  the  reactions  where  the  RNA  template  had 
not  been  treated  with  reverse  transcriptase.  C  indicates  control  lanes  containing  the 
reactions  using  water  as  a  template.  The  1  kb  size  ladder  is  indicated  by  M. 
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M  1:  1  1:  10  1:  100  RT  C 5.3.2  Cloning  RT  PCR  products  as  a  probe  for  northern  blot  and  RNA 
slot  blot  analyses 
The  primers  TFA1  and  TFA2  (section  2.1.7)  were  carefully  chosen  from  mRNA  sequences 
published  in  GenBank  (NCBI)  to  amplify  mouse  mitochondrial  transcription  factor  A 
(Tfam)  cDNA  sequences  in  the  first  strand  cDNA  obtained  from  reverse  transcription  of 
mRNA  described  in  section  5.3.1.  The  size  of  the  PCR  product  amplified  from  first  strand 
cDNA  using  primers  TFA1  and  TFA2  was  predicted  to  be  632  bp  (Fig.  5.4a).  The  PCR 
products  were  gel  purified  and  cloned  using  the  methods  described  in  2.2.9.  The  resulting 
recombinant  plasmid  was  designated  pTFA.  Plasmid  DNA  from  the  clone  was  isolated 
(section  2.2.2.1)  and  digested  with  EcoRI  to  release  the  insert  to  ensure  that  the  correct 
DNA  fragment  had  been  cloned  (Fig.  5.4b).  The  identity  of  the  cloned  fragment  was 
confirmed  by  sequencing  (Fig.  5.5).  The  PCR  products  of  amplifying  pTFA  DNA  using 
primers  TFA1  and  TFA2  were  gel  purified  and  -25  ng  of  the  purified  DNA  fragments  (Fig. 
5.4c)  were  used  as  the  probe  for  visualizing  the  Tfam  mRNA  transcripts  on  northern  blots 
or  RNA  slot  blots. 
5.3.3  Using  ß-actin  as  an  internal  control  for  RNA  loading  in  northern 
blot  and  RNA  slot  blot  analyses 
ß-actin  was  used  as  an  internal  control  for  RNA  loading  in  northern  blot  and  RNA  slot  blot 
analyses.  Before  ß-actin  hybridisation,  the  Tfam  probe  was  stripped  off  the  membranes 
(section  2.2.13).  To  verify  that  no  radioactivity  was  left  on  the  membrane,  the  stripped 
membrane  was  exposed  to  X-ray  film  at  -70°C  overnight.  If  radioactivity  was  detected  after 
an  overnight  exposure,  the  membrane  was  subjected  to  further  stripping  until  no 
radioactivity  was  detected. 
The  probe  for  ß-actin  hybridisation  was  a  1.3  kb  fragment  of  mouse  ß-actin  cDNA  cloned 
into  a  plasmid  (pMoBA-10,  a  gift  from  Rosalind  John,  Wellcome/CRC  Institute, 
Cambridge,  UK). 
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Figure  5.4  Generation  of  the  probe  for  northern  blot  analysis  of  Tfam  mRNA. 
Amplification  products  of  amplifying  Tfam  gene  transcript  from  different 
dilutions  of  first  strand  cDNA  (1:  1,1:  10,1:  100,1:  200,1:  400)  are  resolved  on  an 
EtBr-stained  agarose  gel  (a).  NoRT  is  the  control  lane  containing  the  reaction 
where  the  RNA  template  had  not  been  treated  with  reverse  transcriptase. 
C  is  the  control  lane  containing  the  reactions  using  water  as  a  template.  PCR 
products  in  gel  (a)  were  purified  and  cloned  to  generate  a  recombinant  plasmid 
called  pTFA.  EcoRI-digested  DNA  from  pTFA  (lane  1)  was  visualized  on 
an  EtBr-stained  agarose  gel  (b).  4  µl  of  purified  insert  DNA  from  pTFA  was 
loaded  to  an  EtBr-stained  agarose  gel  (lane  1,  c).  2  µl  (-  30  ng)  of  the  purified 
insert  DNA  was  used  as  a  probe  in  northern  blot  analyses.  The  1  kb  plus  size 
ladder  is  indicated  by  M. 
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I!  MUS  musculus  transcription  factor  A,  mitochondrial.  (Tfam),  mRNA 
Length  =  1449 
Score  =  1197  bits  (604),  Expect  =  0.0 
Identities  -  623/632  (98%) 
Strand  =  Plus  /  Minus 
Query:  1  cggatc  tttcacacttcgacggatgagatcacttcgtccaacttca  ccatctgctctt  60 
Sbjct:  808  cggatcgtttcacacttcgacggatgagatcacttcgtccaacttcagccatctgctctt  749 
Query:  61  cccaagacttcatttcattgtcgtaacgaatcctatcatctttagcaagctgaatatatg  120 
IllllililillillllllillllllllllllllllllllllllillilllllllllllI 
Sbjct:  748  cccaagacttcatttcattgtcgtaacgaatcctatcatctttagcaagctgaatatatg  689 
Query:  121  cctgcttttcctcaggagacagatttttccaagcctcatttacaagcttcaattttccct  180 
IIIIIIIII1811111I  lii  11111111111111111111111111111111111111 
Sbjct:  688  cctgcttttcctcaggaqacagatttttccaagcctcatttacaagcttcaattttccct  629 
Query:  181  gagccgaatcatcctttgcctcctggaagctttcagatacataaatgttatatgctgaac  240 
IIIIIIIIIIIIIIilI  1111  lllllIII  11  llllilllllillI  I  III  II 
Sbjct:  628  gagccgaatcatcctttgcctcctggaagctttcagatacataaatgttatatgctgaac  569 
Query:  241  gaggtctttttggttttccaaycaaaattaattctcttctctctaccagngctttctttt  300 
IIIIIIIIIIII  I  llllllllIIIIIIII  III  lII  III  l  IIIIII  IIIIIIIIII 
Sbjct:  568  gaggtctttttggttttccaagcaaaattaattctcttctctttaccagtgctttctttt  509 
Query:  301  ttaaccgtctctgccgggcctccttctccatacccatcagctgacttggagttagctgct  360 
IIIlillllllliI  llll!  IIIIIIIIIIIIIIIIIiIIIlIIIIIIIi1!  1111111 
Sbjct:  508  ttaaccgtctctgccgggcctccttctccatacccatcagctgacttggagttagatgct  449 
Query:  361  ctttatactt  ctcacagcttctttgtatyctttccactcagctttaaaatcagcttcat  420 
1111  II!  IIII  II  lllII  IIIIiiI!  IliIII  IIIIIIIIH  IIIIIIIIIIIII 
Sbjct:  448  ctttatacttgctcacagcttctttgtatgctttccactcagctttaaaatcagcttcat  389 
Query:  421  aaaccnannnnnct  cttctggtagctccctccacag  get  caattttcctaaccaatt  480 
!  1111  IiI  III  !  1111111!  III!  IIIIý!  IlIP  II  !  Illlil!  iI  II 
Sbjct:  388  aaacctttttttctgcttctggtagctccctccacagggctgcaettttcctaaccaatt  329 
Query:  481  ctgaaagttttgcatctgggtgtttagctttaaatttgggtagctgttctgtggaaaatc  540 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct:  328  ctgaaagttttgcatctgggtgtttagctttaaatttgggtagctgttctgtggaaaatc  269 
Query:  541  gaa  gtatgaactcatag  tttcttt  ata  ctacccatgctggaaaaacacttcggaa  600 
Sbjct:  268  gaaggtatgaactcataggtttctttggatagctacccatgctggaaaaacacttcggaa  209 
Querys  601  tacagacaagactgatagacgagg  gat  cga  632 
1111111111111111111111117111  11 
Sbjct:  208  tacagacaaqactgatagacgaggqgatqcga  177 
Figure  5.5  Identity  of  the  pTFA  plasmid  insert  was  confirmed  by  DNA  sequencing. 
The  clone  pTFA  was  sequenced  and  the  resulting  data  (Query)  was  checked  using 
the  Blast  program  (NCBI)  and  a  matched  sequence  from  the  mouse  mtTFA  mRNA 
(Sbjct)  was  retrieved  from  the  Genbank  database.  The  result  shows  that  623  bp  out  of 
632  bp  (98  %)  are  matched.  Some  of  the  unmatched  sequence  may  be  due  to  artifacts 
or  errors  of  the  DNA  sequencing. 
184 The  resulting  images  of  the  autoradiographs  from  northern  slot  and  RNA  slot  blot  analyses 
were  captured  and  the  intensity  of  each  hybridising  band  was  measured  using  Kodak  Digital 
Science  ID  software.  The  intensity  value  of  each  band  representing  the  Tfam  transcript  level 
of  each  sample  was  obtained,  and  the  ratio  of  the  mRNA  transcript  level/ß-actin  mRNA 
transcript  level  was  determined  for  quantifying  levels  of  Tfam  gene  transcript. 
5.3.4  Optimising  the  exposure  time  of  X-ray  film  to  radiolabelled 
northern  and  RNA  slot  blot  membranes 
It  is  notable  that  the  linear  range  of  signal  response  of  X-ray  film  to  radioactivity  is 
narrower  than  that  obtained  by  using  a  phosphoimager.  However,  the  images  generated 
using  a  phosphoimager  in  the  laboratory  provided  less  clear  bands  than  autoradiography. 
Therefore,  autoradiographs  were  used  for  visualizing  the  transcripts  on  northern  and  slot 
blot  membranes.  In  order  to  ascertain  that  signal  response  of  X-ray  film  to  radiolabelled 
northern  blot  and  RNA  slot  blot  membranes  generated  in  the  study  was  within  the  linear 
range,  the  exposure  times  of  X-ray  film  to  radiolabelled  membranes  were  optimised. 
Generation  of  northern  blot  gels,  membranes  and  hybridisation  with  probes  were  performed 
using  the  methods  described  in  sections  2.2.15.5,  and  2.2.16.  The  northern  blot  membranes 
probed  for  visualization  of  the  ß-actin  mRNA  transcript  in  HD  and  wild-type  mouse  tissue 
(section  2.2.15)  were  washed  to  a  final  stringency  of  0.1  X  SSC,  0.1  %  (w/v)  SDS  at  68°C 
for  at  least  30-60  min  and  then  exposed  to  X-ray  film  at  -70°C  in  the  presence  of 
intensifying  screens  for  2,4,7,  and  16  hours.  The  resulting  images  of  the  autoradiographs 
were  captured  and  the  intensity  of  each  hybridizing  band  was  measured.  The  linear  range  of 
signal  response  of  X-ray  film  was  determined  by  plotting  the  intensity  of  each  band  against 
exposure  time.  The  linear  range  was  between  2-7  hours,  and  therefore  4-6  hours  of 
exposure  time  was  chosen  in  the  study  (Fig.  5.6). 
The  expression  level  of  Tfam  mRNA  in  normal  mouse  brain  regions  is  not  abundant  and  3- 
4  days  of  X-ray  film  exposure  time  were  required  to  visualize  the  transcript  on 
radiolabelled  membranes.  Therefore,  4  days  of  exposure  time  was  chosen  for  visualization 
of  the  Tfam  transcript  by  autoradiography. 
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Figure  5.6  Determining  the  linear  range  of  signal  response  of  X-ray  film  to  a 
radiolabelled  membrane  for  northern  blot  analysis  of  ß-actin  mRNA.  A 
northern  blot  membrane  of  RNA  from  8  HD  mice  (+/-)  and  7  wild-type 
littermates  (wt)  (lanes  1-15,  a)  was  hybridised  with  a  ß-actin  probe.  After 
washing,  it  was  exposed  to  X-ray  film  for  different  periods  of  time  (2-16 
hours).  The  resulting  autoradigraphs  are  shown  in  (a).  The  intensity  of  each 
band  in  the  autoradigraphs  is  plotted  against  exposure  time  (b).  Each  line 
represents  the  intensity  of  fragment  from  a  different  animal  (a,  1-15).  The 
linear  range  of  response  signal  of  X-ray  film  to  radioactivity  is  2-7  hours  for 
northern  blot  analysis  of  ß-actin  mRNA. 
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247  16 53.5  Comparison  of  intra-experimental  error  of  northern  blot  and  slot 
blot  analyses 
Northern  blot  and  RNA  slot  blot  analyses  can  be  used  for  investigating  expression  levels  of 
mRNA.  Each  approach  has  advantages  and  disadvantages.  Northern  blot  analysis 
fractionates  total  RNA  and  can  inform  on  RNA  degradation  and  non-specific  hybridisation. 
However,  RNA  slot  blot  analysis  requires  less  total  RNA  from  each  sample  and  the 
procedure  is  less  time  consuming.  Variations  of  RNA  slot  blot  methodology  exist.  For 
example,  test  and  ß-actin  mRNA  visualization  can  be  performed  on  the  same  slot  sample  or 
different  slot  samples.  The  former  involves  stripping  of  the  test  probe  before  hybridisation 
of  ß-actin  mRNA.  As  it  was  not  known  which  method  should  be  used  in  this  study,  a 
comparison  of  intra-experimental  error  associated  with  the  northern  blot  and  two  slot  blot 
methodologies  was  performed. 
Two  rows  of  10  slots  of  the  slot  blot  equipment  were  loaded  with  5  µl  of  total  RNA  (1 
µg/µl)  extracted  from  a  mouse  liver.  The  RNA  was  transferred  onto  a  membrane  using  the 
methods  described  in  section  2.2.16.  The  resulting  membrane  was  cut  into  2  strips,  each 
containing  a  row  of  10  slots  (A  and  B).  One  strip  (A)  was  hybridised  with  the  Tfam  probe, 
and  then  after  stripping  off  the  probe,  it  was  hybridised  with  the  ß-actin  probe  (re-probing 
the  slot  blot)  (Fig.  5.7a).  The  second  strip  (B)  was  hybridised  with  the  ß-actin  probe  only. 
The  Tfam  mRNA  levels  on  strip  A  were  compared  to  the  ß-actin  mRNA  levels  on  strip  B 
(no  re-probing  of  slot  blot)  (Fig.  5.7a).  Ratios  of  Tfam  mRNA  transcript  level  /ß-actin 
mRNA  transcript  level  were  determined  for  each  of  these  two  methods. 
Different  amounts  (5-10  µg)  of  total  RNA  (1  pg/pl)  from  the  same  sample  as  that  used  in 
the  slot  blot  analysis  were  loaded  onto  a  denaturing  formaldehyde-agarose  gel  for  northern 
blot  analysis  (section  2.2.15.4).  The  RNA  was  transferred  and  hybridised  with  Tfam  probe 
(Fig.  5.7b).  After  stripping  off  the  Tfam  probe,  the  membrane  was  re-hydridized  with  the  ß- 
actin  probe  (Fig.  5.7b).  Ratios  of  Tfam  mRNA  transcript  level  /ß-actin  mRNA  transcript 
level  were  determined  for  northern  blot  analysis.  A  comparison  of  the  results  (Table  5.2) 
showed  that  the  precision  (Coefficient  of  Variation)  of  each  method  was  around  5-6  %. 
Given  that  northern  blot  analysis  has  the  benefit  of  checking  for  degraded  RNA  and 
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Figure  5.7  Comparison  of  intra-experimental  error  associated  with  RNA  slot  blot  (a) 
and  northern  blot  (b)  analyses.  5  µg  of  total  RNA  extracted  from  a  mouse  liver  was 
loaded  into  each  of  20  slots.  The  resulting  membrane  was  cut  into  2  strips  (so  one 
strip  contains  10  slots).  One  membrane  was  probed  for  visualization  of  Tfam 
mRNA  (a,  panel  1).  The  other  membrane  was  probed  for  visualisation  of  ß-actin 
mRNA  (a,  panel  3).  The  Tfam  probe  on  panell  was  stripped  off  and  the  membrane 
re-probed  with  ß-actin  probe  (panel  2).  (b)  Different  amounts  of  total  RNA  (shown 
above  panel)  from  the  same  sample  as  the  slot  blot  were  loaded  onto  a  denaturing 
formaldehyde  agarose  gel.  The  RNA  was  transferred  and  hybridized  with  the  Tfam 
probe.  After  stripping  the  Tfam  probe,  the  membrane  was  reprobed  with  the  ß-actin 
probe.  Ratios  of  Tfam  mRNA  level/ß-actin  mRNA  level  for  each  analysis  were 
determined  and  presented  in  Table  5.2. 
188 non-specific  hybridisation,  northern  blot  analysis  was  used  to  investigate  levels  of  Tfam 
transcript.  If  enough  amount  of  sample  was  left  after  northern  blot  analysis,  RNA  slot  blot 
analysis  (followed  by  re-probing  for  ß-actin  transcript  level)  was  also  performed  to  check 
levels  of  Tfam  transcript. 
Based  on  the  data  obtained  with  the  northern  blot  analysis  of  different  amounts  (5-10  µg)  of 
the  same  RNA  sample,  as  described  above,  northern  blot  analysis  of  the  Tfam  mRNA  could 
detect  at  least  -  20  %  difference  in  mean  Tfam  mRNA  level  between  2  groups,  if  the 
variances  of  2  groups  are  similar  to  the  variance  of  this  experiment. 
Ratio  of  Tfam 
mRNA/ß-actin  mRNA 
Slot  blot:  re- 
probing 
Slot  blot:  no  re- 
probing 
Northern  blot 
Mean  0.247  0.518  0.378 
Standard  error  0.0044  0.0083  0.0085 
Standard  deviation  0.0141  0.0264  0.019 
Coefficient  variation  5.7  %  5.1  %  5.0  % 
Table  5.2  Summary  of  the  comparison  of  intra-experimental  error  associated  with  RNA  slot 
blot  and  northern  blot  analyses. 
The  coefficient  of  variance  represents  the  precision  of  each  experiment  and  does  not  vary 
significantly  between  different  experimental  approaches. 
5.3.6  Determining  the  expression  levels  of  Tfam  mRNA  in  HD  mouse 
brain  regions 
RNA  was  isolated  from  the  striatum,  cortex,  and  cerebellum  of  7  HD  mice  and  7  wild-type 
littermates  at  24  months  of  age  (for  details  of  mouse  cohort  used  see  section  2.1.18)  for  both 
northern  and  RNA  slot  blot  analyses.  RNA  was  extracted  using  the  methods  described  in 
section  2.2.15.1.15  µg  of  total  RNA  from  the  striatum,  cortex  and  cerebellum  of  each 
mouse  was  fractionated  on  denaturing  formaldehyde  EtBr-stained  agarose  gels  (section 
2.2.15.4).  Before  proceeding  with  transfer  process,  the  integrity  of  the  separated  RNA  was 
checked  by  visualising  the  RNA  under  UV  light.  The  intensity  of  the  28S  and  18S 
ribosomal  RNA  bands  indicated  intact  total  RNA  (Fig.  5.8).  Since  RNA  is  not  fractionated 
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Figure  5.8  Northern  blot  analyses  of  Tfam  mRNA  in  the  striatum  (a),  cortex  (b)  and 
cerebellum  (c)  of  24  month-old  mice.  15  µg  of  total  RNA  from  7  HD  mice  (+/-)  and 
wild-type  littermates  (+/+)  was  loaded  onto  a  formaldehyde  EtBr-stained  gel  (top 
panels  in  a,  b  and  c).  The  clear  and  abundant  18S  and  28S  rRNA  bands  indicate  good 
quality  RNA.  Total  RNA  in  the  gel  was  transferred  to  a  nylon  membrane  which  was 
probed  for  visualization  of  Tfam  and  (3-actin  mRNA  transcripts  (middle  and  bottom 
panels  in  a,  b  and  c).  The  level  of  (3-actin  mRNA  transcripts  was  used  as  an  internal 
control  for  RNA  loading. 
190 on  slot  blot  membranes,  it  was  also  important  to  ensure  the  RNA  samples  were  not  degraded 
before  RNA  slot  blot  analysis.  Each  northern  blot  membrane  and  each  slot  blot  membrane 
were  hybridised  with  the  Tfam  probe  and  after  stripping  the  Tfam  probe  (see  method  in 
section  2.2.13),  they  were  re-hybridised  with  a  ß-actin  probe  as  an  internal  control  for  RNA 
loading  (Fig.  5.8  and  Fig.  5.9). 
The  ratio  of  Tfam  mRNA  level/ß-actin  mRNA  level  was  determined  for  each  sample  and 
the  results  were  summarised  in  Table  5.3  and  Table  5.4  respectively.  The  results  reveal  that 
HD  mice  at  24  months  of  age  showed  no  significant  differences  in  mRNA  levels  of  Tfam  in 
any  brain  region  studied  when  compared  to  normal  littermates. 
5.4  Western  blot  analysis  of  mitochondrial  transcription  factor 
A  (mtTFA)  protein  in  the  striatum  of  HD  mice 
Results  in  the  previous  section  (section  5.3.6)  indicated  that  expression  levels  of  Tfam 
mRNA  in  HD  mouse  brain  regions  were  not  significantly  different  from  that  in  wild-type 
littermates.  However,  human  mitochondrial  transcription  factor  A  (mtTFA)  deficiency  in 
patients  associated  with  depletion  of  mtDNA  due  to  reduced  production  or  stability  of  the 
human  mtTFA  (h-mtTFA)  protein  has  been  reported  (Poulton  et  al.,  1994).  It  is  therefore 
possible  that  changes  of  mtTFA  may  occur  in  the  translation  rate  or  the  stability  level  of 
mtTFA  protein  in  HD  mice  despite  normal  transcription  levels.  Therefore,  steady-state 
levels  of  mtTFA  protein  in  the  striatum  of  HD  mice  were  investigated  using  western  blot 
analyses. 
5.4.1  Western  blot  analysis 
Western  blot  analyses  were  performed  on  protein  lysates  from  the  striatum  of  6  HD  mice 
and  6  wild-type  littermates  at  24  months  of  age  (for  details  of  mouse  cohort  and  western 
blot  methodology  see  section  2.1.18  and  2.2.14).  mtTFA  (25  kDa)  and  ß-tubulin  III  (50 
kDa)  proteins,  providing  an  internal  control  for  normalizing  levels  of  protein  loading,  were 
immunodetected  using  anti-mtTFA  and  anti-ß-tubulin  III  antibodies  respectively  (section 
2.2.14).  The  mtTFA  antibody  detected  multiple  bands  as  well  as  the  previously  reported 
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Figure  5.9  RNA  slot  blot  analyses  of  Tfam  mRNA  in  the  striatum  (a),  cortex  (b) 
and  cerebellum  (c)  of  24  month-old  mice.  5  µg  of  total  RNA  from  striatum,  cortex 
and  cerebellum  of  7  HD  mice  (+/-)  and  7  wild-type  littermates  (+/+)  was  loaded 
into  each  slot  and  transferred  to  a  nylon  membrane.  Each  membrane  was  probed  for 
visualization  of  Tfam  and  (3-actin  mRNA  transcripts.  The  level  of  (3-actin  mRNA 
transcripts  was  used  as  an  internal  control  for  RNA  loading. 
192 a)  Striatum 
HD  (n  =7)  WT  (n  =7)  value 
Tfam  0.92:  t  0.06  0.92:  t  0.05  0.955 
b  Cortex 
HD  n  =7)  1  WT  n  =7  value 
Tfam  10.89  ±  0.00.98±0.2  0.3 
c)  Cerebellum 
HD  (n  =7)  WT  (n  =7)  value 
Tfam  0.68  t  0.04  0.67  t  0.06  0.7 
Table  5.3  Northern  blot  analysis  of  mRNA  levels  of  Tfam  in  the  striatum  (a),  cortex  (b)  and 
cerebellum  (c)  of  7  HD  and  7  wild-type  (WT)  littermates  at  24  months  of  age. 
All  values  (ratios  of  Tfam  mRNA  expression  level/ß-actin  mRNA  expression  level)  are 
stated  as  mean  ratio  ±  S.  E.  The  Student's  t  test  (two  tailed)  was  used  for  statistical  analysis. 
a)  Striatum 
1,1  HD  (n  =7)  WT  (n  =7)  value 
Tfam  1.02  t  0.02  0.99_:  t  0.04  0.51 
b)  Cortex 
HD  (n  =7)  WT  (n  =7)  value 
Tfam  10.97:  t  0.1  0.97:  t  0.11  0.95 
c)  Cerebellum 
HD  (n  =7)  WT  (n  =7)  value 
Tfam  11.60  1.6710.31  0.6 
Table  5.4  Slot  blot  analysis  of  mRNA  levels  of  Tfam  in  the  striatum  (a),  cortex  (b)  and 
cerebellum  (c)  of  7  HD  and  7  wild-type  (WT)  littermates  at  24  months  of  age. 
All  values  (ratios  of  Tfam  mRNA  expression  level/ß-actin  expression  level)  are  stated  as 
mean  ratio  t  S.  E.  The  Student's  t  test  (two  tailed)  was  used  for  statistical  analysis. 
193 mtTFA  band  of  25  kDa  (Larsson  et  al.,  1996).  This  band  pattern  persisted  despite  trying 
different  dilutions  of  primary  (from  1:  10000  to  200000)  and  secondary  antibodies  (from 
1:  1000  to  1:  6000).  The  band  corresponding  to  the  previously  reported  25  kDa  band,  was 
therefore  chosen  for  the  quantification  of  mtTFA  protein.  The  ratio  of  mtTFA  band 
intensity/ß-tubulin  III  band  intensity  for  the  striatum  of  each  animal  was  determined  (Fig. 
5.10)  and  compared  using  the  Student's  t  test  (two-tailed).  The  results  showed  that  there  was 
no  significant  difference  in  the  observed  levels  of  mtTFA  protein  in  the  striatum  of  HD 
mice  and  wild-type  littermates  (Table  5.5). 
Wild-type  (n=6)  HD  (n=6)  value 
mtTFA/ß-tubulin  III 
ratio 
0.51±  0.07  0.53  ±  0.03  0.77 
Table  5.5  Summary  of  western  blot  data  for  determining  the  mtTFA  protein  levels  in  the 
striatum  of  24  month-old  mice. 
The  mtTFA/ß-tubulin  III  ratio  in  the  HD  mouse  striatum  does  not  differ  from  that  of  wild- 
type  littermates.  All  values  of  mtTFA/ß-tubulin  III  ratios  are  stated  as  mean  ratio  ±  SE. 
Statistical  method  used:  Student's  t  test  (two  tailed). 
5.5  Summary 
Mitochondrial  mass  in  the  striatum  of  24  month-old  HD  mice  was  not  decreased  compared 
to  wild-type  littermates,  which  suggested  that  mtDNA  depletion  in  the  striatum  of  24 
month-old  HD  mice  was  due  to  a  decrease  in  the  number  of  mtDNA  molecules  per 
mitochondrion. 
No  significant  differences  were  observed  in  the  levels  of  mtTFA  protein  and  Tfam  mRNA 
transcript  in  the  striatum  of  HD  mice  and  wild-type  littermates  at  24  months  of  age.  This 
result  suggested  that  the  reduction  of  mtDNA  molecules  in  the  striatum  of  HD  mice  might 
not  be  related  to  the  Tfam  mRNA  or  mtTFA  protein  levels. 
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Figure  5.10  Determining  mitochondrial  factor  A  (mtTFA)  levels  in  protein  lysates 
of  mouse  striatal  tissue.  20  µg  protein  lysate  from  the  striatum  of  6  HD  mice  (+/-) 
and  6  wild-type  littermates  (+/+)  at  24  months  of  age  were  separated  and  transferred 
onto  a  membrane.  Immunodetection  with  anti-mtTFA  and  anti-(3-tubulin  III 
antibodies  was  performed.  The  ratios  of  image  intensity  of  mtTFA/ß-tubulin  III 
are  stated  below  the  panels. 
195 6  Investigating  the  effect  of  depleted  mitochondrial  DNA 
levels  on  mitochondrial  gene  expression  in  HD  mouse 
striatum 
6.1  Introduction 
As  HD  mice  show  a-  30  %  reduction  of  total  mtDNA  in  the  striatum  (section  4.3.4.1),  the 
expression  levels  of  mitochondrial  DNA-encoded  respiratory  complex  enzymes  might  be 
affected  and  energy  production  might  be  compromised.  Therefore,  the  expression  levels  of 
cytochrome  b  (Cytb),  cytochrome  c  oxidase  I  (COI)  and  cytochrome  c  oxidase  II  (COII) 
were  investigated  in  different  brain  regions  (striatum,  cortex  and  cerebellum)  of  HD  mice. 
The  aims  of  this  study  were  to  determine  whether  the  expression  levels  of  mitochondrial 
gene  transcripts  and  the  mitochondrial  respiratory  complex  enzymes  are  specifically 
decreased  in  the  striatum  of  HD  mice. 
6.2  Investigating  the  expression  levels  of  cytochrome  b  (Cytb), 
cytochrome  c  oxidase  1  (Col),  and  cytochrome  c  oxidase  II 
(Coll)  mRNA  in  HD  mouse  brain  regions 
The  expression  levels  of  cytochrome  b  (Cytb),  cytochrome  c  oxidase  I  (Co!  ),  and 
cytochrome  c  oxidase  II  (Coll)  mRNA  in  HD  mice  were  investigated  using  northern  blot 
and  RNA  slot  blot  analyses.  Prerequisites  for  successful  northern  blot  analyses  are  good 
quality  RNA,  specific  probes,  an  internal  control  for  RNA  loading  and  adequate  exposure 
times  of  X-ray  film  to  radiolabelled  northern  blot  membranes.  Therefore,  optimisation  of 
these  requirements  were  performed  using  the  methods  described  in  section  5.3 
6.2.1  RNA  extraction  and  first  strand  cDNA  synthesis 
RNA  extraction  and  first  strand  cDNA  synthesis  were  performed  using  the  materials  and 
methods  described  in  section  5.3.1. 
196 6.2.2  Cloning  RT-PCR  products  as  probes  for  northern  blot  and  RNA 
slot  blot  analyses 
The  primers  COIF,  COIR,  COIIF,  COIIF,  CytbF  and  CytbR  (section  2.1.7)  were  carefully 
chosen  from  mRNA  sequences  published  in  GenBank  (NCBI)  to  amplify  fragment  from 
mouse  mitochondrial  cytochrome  b  (Cytb),  cytochrome  c  oxidase  I  (Col),  and  cytochrome  c 
oxidase  (CoI1)  cDNA  respectively.  The  size  of  the  PCR  products  amplified  from  first  strand 
cDNA  using  these  primers  were  as  predicted:  841  bp  using  primers  COIF  and  COIR,  610  bp 
using  primers  COIIF  and  COIIF,  711  bp  using  primers  CytbF  and  CytbR  (Fig.  6.1a).  The 
PCR  products  were  gel  purified  and  cloned  using  the  methods  described  in  section  2.2.9. 
The  resulting  recombinant  plasmids  were  designated  pCOI,  pCOII,  and  pCytb  respectively. 
Plasmid  DNA  from  these  clones  was  isolated  using  the  isolation  procedure  described  in 
section  2.2.2.1  and  digested  with  EcoRI  to  release  the  insert  to  ensure  that  the  correct  DNA 
fragment  had  been  cloned  (Fig.  6.1b).  The  identity  of  the  cloned  fragment  was  confirmed  by 
sequencing  each  of  the  3  clones.  The  PCR  products  of  amplifying  pCOI,  pCOII,  and  pcytb 
DNA  with  the  corresponding  primers  were  gel  purified  and  -  25  ng  of  the  purified  DNA 
fragments  (Fig.  6.1c)  were  used  as  the  probes  for  visualizing  CoI,  COIL,  and  Cytb  mRNA 
transcripts  on  northern  blots  or  RNA  slot  blots. 
6.2.3  Optimising  the  exposure  time  of  X-ray  film  to  radiolabelled 
northern  blot  membranes 
In  order  to  obtain  the  linear  range  of  signal  response  of  X-ray  film  to  radiolabelled 
membranes,  the  exposure  times  of  X-ray  film  for  northern  blot  analyses  of  Col,  Coll  and 
Cytb  mRNA  were  optimised  using  the  methods  described  in  section  5.3.4.  Exposure  times 
of  3-4,7  and  8  hours  were  chosen  for  quantifying  Col,  Coil  and  Cytb  transcript  levels 
respectively.  The  level  of  ß-actin  mRNA  was  used  as  an  internal  control  for  RNA  loading 
and  the  exposure  time  for  quantifying  ß-actin  mRNA  levels  was  4-5  hours  as  described  in 
section  5.3.4. 
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Figure  6.1  Generation  of  probes  for  northern  blot  analysis  of  Col,  Co!  I  and  Cytb 
mRNA.  a)  PCR  products  from  amplifying  first  strand  cDNA  are  resolved  on  an 
EtBr-stained  agarose  gel.  Lanes  1  and  2  contain  PCR  products  from  Cytb  mRNA 
using  primers  CytbF  and  CytbR.  Lanes  3  and  4  contain  PCR  products  from  Col 
mRNA  using  primers  COIF  and  COIR.  Lane  5  and  6  contain  PCR  products  from 
Coll  mRNA  using  primers  COIIF  and  COIIR.  Lane  7  is  the  control  lane  containing 
the  reaction  where  COIF  and  COIR  were  used  as  primers  and  the  RNA  template  had 
not  been  treated  with  reverse  transcriptase.  Lane  8  is  the  control  lane  containing  the 
reaction  using  water  as  a  template  and  using  COIF  and  COIR  as  primers.  PCR 
products  in  gel  (a)  were  purified  and  cloned  to  generate  recombinant  plasmids  called 
pCOI,  pCOII  and  pCytb.  b)  EcoRI-digested  DNA  from  pCOI,  pCOII  and  pCytb 
(lane  1,3,  and  4  respectively)  were  visualized  on  an  EtBr-stained  agarose  gel  . 
Lane 
2  contains  digested  DNA  from  a  candidate  bacterial  colony  containing  a  plasmid 
with  no  insert.  c)  1.5  µl  of  purified  insert  DNA  from  pCytb,  pCOI  and  pCOII  was 
loaded  onto  an  EtBr-stained  agarose  gel.  1  tl  (-30  ng)  of  each  of  the  purified  insert 
DNAs  was  used  as  a  probe  in  northern  blot  analyses.  The  1  kb  plus  size  ladder  is 
indicated  by  M. 
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m1234 6.2.4  Determining  the  expression  levels  of  cytochrome  b  (Cytb), 
cytochrome  c  oxidase  1  (Col),  and  cytochrome  c  oxidase  II  (Coll) 
mRNA  in  HD  mouse  brain  regions 
RNA  was  isolated  from  the  striatum,  cortex,  and  cerebellum  of  7  HD  mice  and  7  wild-type 
littermates  at  24  months  of  age  (for  details  of  mouse  cohort  used  see  section  2.1.18)  for 
northern  blot  analysis  of  Col,  Coll  and  Cytb  mRNA  and  RNA  slot  blot  analysis  of  Col 
mRNA.  The  northern  blot  membranes  of  striatal,  cortical  and  cerebellar  RNA  generated  in 
section  5.3.6  were  used  for  hybridisation  of  Coll  and  Cytb  mRNA  transcripts  (Fig.  6.2). 
Other  northern  blot  gels  and  membranes  of  striatal,  cortical  and  cerebellar  RNA  were 
generated  for  the  hybridisation  of  Coll  mRNA  transcripts  (Fig.  6.3).  The  slot  blot 
membranes  of  striatal,  cortical,  and  cerebellar  RNA  generated  in  section  5.3.6  were  used  for 
the  hybridisation  of  Col  mRNA  transcripts  (Fig.  6.4).  Each  membrane  was  hybridised  with 
ß-actin  probe  as  an  internal  control  for  RNA  loading.  Before  each  membrane  was  re-probed, 
previous  probes  were  stripped  off  the  membrane  using  the  method  described  in  section 
5.3.3. 
Ratios  of  Col,  Coll  and  Cytb  mRNA  level/ß-actin  mRNA  level  were  determined  for  each 
sample.  The  results  are  summarised  in  Table  6.1  and  Table  6.2  respectively.  They  reveal 
that  HD  mice  at  24  months  of  age  showed  no  significant  differences  in  mRNA  levels  of 
Col,  Coil  and  Cytb  in  any  brain  region  studied  when  compared  to  normal  littermates. 
However,  the  HD  mice  showed  a  trend  toward  decreased  levels  of  Col  mRNA  in  the 
striatum  in  both  slot  blot  (p  s  0.065)  and  northern  blot  analyses  (p  a  0.11)  when  compared 
to  wild-type  littermates,  although  the  difference  did  not  reach  statistical  significance. 
6.3  Immunohistochemical  detection  of  cytochrome  c  oxidase  I 
(COI)  in  HD  mouse  brain  tissue 
Results  from  the  study  described  in  the  previous  section  (6.2.4)  showed  that  mRNA  levels 
of  mitochondrial  respiratory  enzymes  do  not  appear  to  be  compromised  in  the  striatum  of 
HD  mice  despite  mtDNA  depletion.  However,  the  striatum  of  HD  mice  showed  a  trend 
toward  decreased  cytochrome  c  oxidase  I  (Col)  mRNA  levels  in  both  RNA  slot  blot  and 
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Figure  6.2  Northern  blot  analyses  of  CoI  and  Cytb  mRNA  in  the  striatum  (a),  cortex 
(b)  and  cerebellum  (c)  of  24  month-old  mice.  15  tg  of  total  RNA  from  7  HD  mice 
(+/-)  and  7  wild-type  littermates  (+/+)  was  loaded  onto  a  formaldehyde  EtBr-stained 
gel  (top  panels  in  a,  b,  and  c).  Total  RNA  in  gel  was  transferred  to  a  nylon  membrane 
which  was  probed  for  visualization  of  CoI,  Cytb  and  (3-actin  mRNA  transcripts 
(lower  panels  in  a,  b  and  c).  The  level  of  (3-actin  mRNA  transcripts 
was  used  as  an  internal  control  for  RNA  loading. 




Coll  o*  """'b*fb"  ""  e-0.7kb 
ß-actin-.  "  "0*00".  r,.  r-1.8kb 
b)  Cortex 
Coll-  0A"0 
4a*0*  *  10i 
-0.7kb 
ß-actin-  "  ýMr  +ý  "-1.8  kb 
c)  Cerebellum 
+/-  +/+  +/+  ++++«+-4-+-  +/+  +/+  +/+  +/- 
Zös- 
lös  - 
CoII  -  (0 
»00*i900  "r  0.7kb 
ß-actin-ý40m9"  1.8  kb 
Figure  6.3  Northern  blot  analyses  of  Coll  mRNA  in  the  striatum,  cortex  and  cerebellum 
of  24  month-old  mice.  15  µg  of  total  RNA  from  striatum  (a),  cortex  (b)  and  cerebellum 
(c)  of  7  HD  mice  (+/-)  and  7  wild-type  littermates  (+/+)  was  loaded  onto  a  formaldehyde 
EtBr-stained  gel  (top  panel  in  a,  b,  and  c).  Total  RNA  in  each  gel  was  transferred,  and 
probed  for  visualization  of  Coil  and  (3-actin  mRNA  transcripts.  ß-actin  mRNA 
transcripts  was  used  as  an  internal  control  for  RNA  loading.  Two  RNA  samples  from 
2  wild-type  striatal  tissues  (a)  were  degraded.  Therefore,  the  Coil  and  ß-actin  mRNA 
transcripts  of  these  two  samples  are  not  visible  on  the  appropriate  autoradiographs. 
201 a)  Striatum 
COI  ß-actin 
+/-  r- 
+/+  -  ýýº 
+/+  - 
+/- 
+/+  -- 
+/+  i- 
+/-  - 
+/-  -- 
+/-  -- 
+/-  -- 
+/+  -- 
+/+  -- 
+/+  -- 
+/-  --  - 
b)  Cortex 
Col  ß-actin 
+/- 
+/+  ý s  i 
+/+ 
+/-  - 
+/- 
+/+  - 
+/-  - 
c)  Cerebellum 
Col  ß-actin 
+/-  ý..  .ý 
+/+  - 
+/+  - 
+/-  -- 
+/+  i- 
+/+  r 
+/-  ýn  - 
+/-  -- 
+/-  -- 
+/-  -- 
+/+  -- 
+/+ 
+/+  -- 
+/-  - 
Figure  6.4  RNA  slot  blot  analyses  of  CoI  mRNA  in  the  striatum  (a),  cortex  (b) 
and  cerebellum  (c)  of  24  month-old  mice.  5  µg  of  total  RNA  from  striatum,  cortex 
and  cerebellum  of  7  HD  mice  (+/-)  and  7  wild-type  littermates  (+/+)  was  loaded 
into  each  slot  and  transferred  to  a  nylon  membrane.  Each  membrane  was  probed  for 
visualization  of  CoI  and  (3-actin  mRNA  transcripts.  The  level  of  (3-actin  mRNA 
transcripts  was  used  as  an  internal  control  for  RNA  loading. 
202 a)  Striatum 
HD  (n  =7)  WT  (n  =7)  value 
Cytb  1.72:  t  0.13  2.14  ±  0.24  0.17 
Col  0.68:  t  0.04  0.77.  t  0.04  0.11 
CoII  0.97  1.09  ±  0.11@  0.21 
Cortex 
HD  n  =7)  WT  (n  =7)  value 
Cytb  9.06t  0.58  9.58  t  1.37 
.. 
0.52 
CoI  3.74.  t  0.93  3.86  t  0.26  0.78 
CoII  0.91t  0.25  0.96  ±  0.14  0.63 
c)  Cerebellum 
HD  (n  =7)  WT  (n  =7)  value 
Cytb  1.61  ±  0.34  1.710.4  0.7 
CoI  7.42±0.33  7.47±0.93  0.9 
CoII  0.58.  t  0.13  0.63  ±  0.26  0.7 
Table  6.1  Northern  blot  analysis  of  mRNA  levels  of  Cytb,  Col  and  Coll  in  the  striatum, 
cortex  and  cerebellum  of  7  HD  and  7  wild-type  (WT)  littermates  at  24  months  of  age. 
Because  degraded  RNA  was  present  in  the  striatal  samples  from  2  wild-type  littermates, 
only  5  wild-type  littermates  are  included  in  the  northern  blot  analysis  of  Coil  mRNA  levels 
in  striatum  (indicated  by  @).  All  values  (ratio  of  target  gene  expression  level/ß-actin 
expression  level)  are  stated  as  mean  ratio  t  S.  E.  The  Student's  t  test  (two  tailed)  was  used 
for  statistical  analysis. 
A  Striatum 
HD  (n  =7) 
WT  -(n 
=7)  value 
Col  0.78:  t  0.03  1.00  ±  0.06  0.065 
b)  Cortex 
HD  (n  =7)  WT  (n  =7)  value 
CoI  2.80  ±  0.23  2.96±0.32  0.7 
c)  Cerebellum 
HD  (n  =7)  WP  (n  =7)  value 
Col  2.48.  t  0.24  2.94  ±  0.14  0.13 
Table  6.2  Slot  blot  analysis  of  mRNA  levels  of  CoI  in  the  striatum  (a),  cortex  (b)  and 
cerebellum  (c)  of  7  HD  and  7  wild-type  (WT)  littermates  at  24  months  of  age. 
HD  mice  show  a  trend  toward  reduction  of  CoI  mRNA  expression  levels  in  the  striatum 
when  compared  to  normal  littermates.  All  values  (ratio  of  target  gene  expression  level/ß- 
actin  expression  level)  are  stated  as  mean  ratio  t  S.  E.  The  Student's  t  test  (two  tailed)  was 
used  for  statistical  analysis. 
203 northern  blot  analyses,  although  this  failed  to  reach  statistical  significance.  It  is  conceivable 
that  changes  in  individual  cells  or  localized  to  a  small  area  of  striatum  may  be  masked  by 
analysis  of  the  bulk  tissue  homogenate  used  in  northern  blot  and  slot  blot  analyses. 
Therefore,  immunohistochemical  detection  of  COI  was  performed  to  investigate  its 
expression  at  single  cell  resolution. 
6.3.1  Comparison  of  free-floating  and  paraffin-embedded  sections  for 
immunohistochemical  detection  of  COI 
Several  methods  of  preparing  tissue  sections  have  been  employed  in  immunohistochemical 
studies,  including  free-floating  (section  2.2.17.2)  and  paraffin-embedded  (section  2.2.17.3) 
sections.  There  are  advantages  and  disadvantages  associated  with  both  methods.  Free- 
floating  sections  tend  to  show  more  non-specific  staining  than  paraffin-embedded  sections. 
However,  free-floating  sections  can  reveal  more  about  the  morphological  relationship 
between  different  cell  types  in  brain  tissue  than  paraffin-embedded  sections.  In  order  to 
obtain  good  quality  immunostaining,  a  pilot  study  comparing  the  two  methods  of  tissue 
preparation  for  anti-COI  antibody  staining  was  conducted.  Brains  from  two  HD  mice  and 
two  wild-type  mice  were  fixed  by  transcardial  perfusion  (section  2.2.17.1).  After  fixation, 
brains  from  one  HD  and  one  wild-type  mouse  were  subjected  to  paraffin-embedded  section 
preparation  (section  2.2.17.3)  and  the  remaining  HD  and  wild-type  mouse  brain  tissue  was 
subjected  to  free-floating  section  preparation  (section  2.2.17.2).  In  this  pilot  study,  positive 
control  sections  from  rats  that  had  received  a  cortical  injection  of  a-amino-3-hydroxy-5- 
methyl-4-isoxazolepropionate  (AMPA)  (a  gift  from  Jill  Fowler,  Wellcome  Surgical 
Institute,  Glasgow)  were  included  in  the  immunostaining  experiment  of  free-floating 
sections.  Positive  control  sections  from  rats  treated  with  cerebral  artery  occlusion  were 
included  in  the  immunostaining  experiment  of  paraffin-embedded  sections  (a  gift  from 
Debbie  Dewar,  Wellcome  Surgical  Institute,  Glasgow).  Negative  control  sections,  omitting 
the  primary  antibody,  were  also  included  in  the  study.  Both  paraffin-embedded  and  free- 
floating  sections  were  subjected  to  immunohistochemical  detection  with  different 
concentrations  of  primary  antibody:  4,2,1,0.4,0.2  and  0.1  µg/ml.  These  sections  were  then 
treated  with  secondary  antibodies,  anti-mouse  IgG  (1:  100)  and  ABC  kits  using  methods 
described  in  sections  2.2.17.4  and  2.2.17.5.  After  examination  using  light  microscopy,  the 
204 best  free-floating  sections  stained  with  anti-COI  antibody  (2  pg/ml)  were  compared  with  the 
best  paraffin-embedded  sections  stained  with  anti-COI  antibody  (4  jig/ml).  The  results 
indicated  that  paraffin-embedded  sections  provided  better  resolution  and  less  background 
than  free-floating  sections  (Fig.  6.5).  Therefore,  paraffin-embedded  sections  were  used  in 
subsequent  immunodetection  experiments. 
6.3.2  Optimization  of  immunohistochemical  assays 
6.3.2.1  Positive  control  sections  for  assays 
Immunostaining  conditions  for  the  anti-COI  antibody  were  optimised  in  a  pilot  study  where 
rat  brain  sections  with  an  ischemic  lesion  were  used  as  a  positive  control  (section  7.3.1). 
However,  HD  is  a  slowly  progressive  degenerative  disorder  whilst  acute  pathological 
changes  occur  immediately  after  an  ischemic  insult.  Therefore,  the  acute  pathological 
changes  observed  in  rat  brain  sections  with  an  ischemic  lesion  may  not  provide  an  ideal 
positive  control  for  investigating  HD  pathology.  Reports  in  the  literature  have  shown  that 
systemic  injection  of  3-nitropropionic  acid  (3-NP)  (an  irreversible  mitochondrial  enzyme 
complex  II  inhibitor)  in  rodents  and  non-human  primates  is  sufficient  to  replicate  most  of 
the  clinical  and  pathophysiological  hallmarks  of  HD  (Borlongan  et  al.,  1997;  Guyot  et  al., 
1997;  Vis  et  al.,  1999).  Both  3-NP  and  malonate  (a  reversible  mitochondrial  enzyme 
complex  II  inhibitor)  are  mitochondrial  enzyme  complex  II  inhibitors.  After  malonate  or  3- 
NP  treatment,  the  striatum  shows  similar  pathological  changes,  which  include  increased 
oxidative  stress.  However,  since  3-NP  generates  symmetrical  striatal  lesions  after  systemic 
injection,  the  contrast  between  the  damaged  and  the  contralateral  normal  striatum  is  lost.  A 
malonate  injection  into  the  striatum  of  mice  allows  the  comparison  of  malonate-treated  and 
contralateral  normal  striatum.  Therefore,  sections  of  brain  from  mice  that  had  received 
injections  of  malonate  into  the  striatum  (a  gift  from  Daniel  Cuthill,  Wellcome  Surgical 
Institute,  Glasgow)  were  used  as  positive  controls  for  subsequent  immunohistochemical 
assays. 
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Figure  6.5  An  example  of  the  comparison  between  free-floating  and  paraffin-embedded 
sections  stained  with  the  anti-COI  antibody.  The  paraffin-embedded  section  (a)  from  a 
normal  mouse  brain  showed  better  staining  resolution  and  less  background  than  the  free- 
floating  section  (b)  from  a  normal  mouse  brain.  Neurons  with  normal  cytoplasmic 
staining  are  indicated  by  arrows.  Scale  bar  =  50  pm 
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a)  Paraffin-embedded  mouse  brain  section 
b)  Free-floating  mouse  brain  section 6.3.2.2  Optimization  of  immunohistochemical  detection  of  COI 
The  positive  control  sections  (with  malonate  injection)  subjected  to  the  conditions  for  anti- 
COI  staining  determined  by  the  pilot  study  showed  increased  cytoplasmic  staining  around 
the  lesion  in  the  striatum  (Fig  6.6a),  when  compared  to  the  non-lesion  striatum  (Fig  6.6b). 
However,  the  negative  control  sections,  omitting  the  primary  monoclonal  anti-COI 
antibody,  subjected  to  the  conditions  for  anti-COI  staining  determined  by  the  pilot  study, 
showed  strong  staining  in  the  malonate-injected  brain  section  (Fig  6.6c).  The  strong  staining 
of  the  malonate  lesion  in  these  negative  control  sections  was  probably  due  to  the  non- 
specific  binding  of  the  secondary  antibody  to  endogenous  mouse  IgG.  To  solve  this 
problem,  the  dilution  of  secondary  antibody  used  was  changed  from  1:  100  to  1:  500.  In 
addition,  the  Mouse  on  Mouse  Immunodetection  kit  (M.  O.  M)  (Vector)  for  blocking  non- 
specific  binding  to  endogenous  mouse  IgG  was  applied  when  staining  sections  with  the  anti- 
COI  antibody  (Fig  6.6d).  The  staining  intensity  was  also  enhanced  by  using  the  Elite  ABC 
kit  instead  of  the  standard  ABC  kit.  The  resulting  optimized  methods  used  for 
immunohistochemical  detection  of  COI  are  described  in  section  2.2.17.5. 
6.3.3  COI  immunostaining  levels  in  HD  mouse  brain 
Immunohistochemical  detection  of  COI  was  performed  on  paraffin-embedded  brain 
sections  from  4  HD  mice  and  4  wild-type  littermates  at  -  25  months  of  age  (for  details  of 
mouse  cohorts  and  methodology  used  see  sections  2.1.18,2.2.17,2.1.9,2.1.10  and 
2.2.17.5).  A  Leica  DMRB  microscope  connected  to  a  digital  camera  (Cool  Snap-Pro, 
Media  Cybernetics)  and  a  computer  with  image  analysis  software  (Image  Pro  Plus  4.5, 
Media  Cybernetics)  were  employed  to  photograph  the  images  of  the  resulting  sections. 
Before  analysing  the  results,  all  slides  used  were  labelled  with  random  numbers  by  another 
person  so  that  the  quantitative  analysis  was  performed  in  a  manner  blind  to  genotype. 
For  semi-quantitative  analysis  of  COI  immunostaining,  one  caudal  striatum  (right  striatum 
in  a  section),  the  most  vulnerable  region  of  HD  brain,  from  each  mouse  was  analysed.  Each 
striatum  was  divided  into  4  approximately  equal  parts,  i.  e.  dorsomedial,  dorsolateral, 
ventromedial  and  ventrolateral  (Fig.  6.7).  Two  images  from  each  striatal  subarea  were 
captured  at  x400  magnification.  Care  was  taken  to  ensure  these  2  images  did  not  overlap. 
207 a)  Malonate  lesion  without  MOM  kit  b)  Non-lesion  side  without  MOM  kit 
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Figure  6.6  Optimization  of  immunostaining  with  the  anti-COI  antibody.  The  striatal 
malonate  lesion  stained  with  the  anti-COI  antibody  without  the  Mouse  on  Mouse  kit 
(MOM  kit)  (a).  When  compared  to  the  non-lesion  side  (b),  the  area  around  lesion  (a) 
showed  increased  cytoplasmic  staining  (indicated  by  arrows).  The  negative  control 
section  (c)  adjacent  to  the  section  shown  in  (a)  was  stained  using  the  same  procedure 
as  (a),  but  omitting  the  anti-COI  antibody.  This  section  (c)  showed  non-specific 
staining  of  cytoplasm  (indicated  by  arrow).  The  non-specific  staining  in  striatum 
was  significantly  decreased  by  using  the  MOM  kit  (d).  Scale  bar  =  50  pm. 
208 Figure  6.7  A  mouse  brain  map  for  quantifying  levels  of  COI  immunostaining. 
One  image  from  layer  V  of  the  cortex  in  each  mouse  brain  section  was  captured. 
The  striatum  in  one  hemisphere  of  each  mouse  was  divided  into  4  equal  parts, 
a,  b,  c  and  d  (dorsomedial,  ventromedial,  dorsolateral,  and  ventrolateral 
respectively).  Two  images  (e.  g.  al  and  a2)  from  each  subarea  of  the  striatum 
were  captured. 
209 The  area  of  cortex  showing  greatest  pathology  in  HD  is  layer  III  and  V  of  the  primary 
sensory  cortex.  Therefore,  one  image  of  the  primary  sensory  cortex  (containing  layer  V) 
was  captured  from  one  brain  section  per  mouse  at  the  level  of  caudal  striatum  (Fig.  6.7). 
COI  immunostaining  of  cells  was  classified  into  one  of  three  groups  [weak  staining  (score 
1),  moderate  staining  (score  2)  and  intense  staining  (score  3)],  according  to  the  intensity  of 
cytoplasmic  immunostaining  (Fig.  6.8).  An  area  of  0.06  mm2  from  the  centre  of  each  image 
was  selected  and  the  number  of  cells  with  weak,  moderate,  or  intense  staining  counted. 
From  these  results,  a  total  score  [(number  of  weakly  staining  cells  x  1)  +  (number  of 
moderately  staining  cells  x  2)  +  (number  of  intensely  staining  cells  x  3)]  was  calculated  for 
each  image. 
The  two  staining  scores  from  each  striatal  subarea  of  each  mouse  were  averaged  (Table 
6.3).  The  score  of  each  subarea  from  the  striatum  of  HD  mice  was  combined  and  compared 
to  that  of  wild-type  littermates  using  the  Student's  t  test  (two  tailed).  Ap  value  of  less  than 
0.05  was  considered  statistically  significant.  The  results  showed  that  COI  immunostaining 
was  significantly  decreased  in  the  dorsolateral  striatum,  but  not  in  any  other  part  of  striatum 
of  HD  mice,  when  compared  to  wild-type  littermates  (Fig.  6.9a).  However,  it  is  notable  that 
other  parts  of  the  striatum  of  HD  mice  also  showed  a  trend  toward  decreased  staining 
scores  when  compared  to  wild-type  littermates.  When  the  scores  from  the  four  parts  of 
striatum  were  combined,  the  result  also  showed  that  the  immunostaining  of  COI  is 
significantly  decreased  in  the  striatum  of  HD  mice  when  compared  to  wild-type  littermates 
(Fig.  6.9a).  Immunostaining  in  the  cell  soma,  but  not  the  axon,  was  quantified.  The  finding 
that  COI  immunostaining  was  decrease  in  the  cell  soma  in  HD  striatum  may  be  due  to  the 
re-distribution  of  mitochondria  to  the  cell  processes.  However,  when  examing  COI 
immunostaining  in  the  axons  of  HD  mice  and  wild-type  littermates,  decreased  axonal 
staining  intensity  was  observed  in  the  HD  striatum  when  compared  to  wild-type  littermates 
(Fig.  6.10).  This  observation  suggests  that  mitochondrial  re-distribution  is  unlikely  and  COI 
immunostaining  in  both  cell  soma  and  processes  is  decreased  in  HD  striatum.  The  staining 
score  of  cortex  from  each  mouse  was  also  calculated  (Table  6.4).  The  results  showed  that 
no  significant  difference  in  COI  staining  scores  of  cortex  was  observed  between  HD  and 
wild-type  littermates  (Fig.  6.9b). 
210 Although  the  use  of  Student's  t-test  analysis  is  valid  in  this  situation,  it  might  inflate 
differences  between  mutant  and  wild-type  sections.  The  raw  data  showed  high  variability 
between  samples  within  each  group.  Therefore,  the  results  of  the  statistical  analysis  should 
be  considered  preliminary  and  should  be  confirmed  in  further  experiments  using  larger 
cohorts  and  multiple  tissue  sections  for  each  animal. 
Animal  ID  Genotype  Dorsomedial  Ventromedial  Dorsolateral  Ventrolateral 
7836  +/-  15  25  32  22 
7783  +/-  19  21  21  27 
7839  +/-  22  38  25  51 
7778  +/-  11  11  19  14 
7705  +/+  41  41  53  49 
7689  +/+  33  53  44  66 
7781  +/+  12  44  51  82 
7777  +/+  42  25  26  28 
Table  6.3  Cell  staining  scores  in  4  subareas  of  striatum  from  4  HD  mice  (+/-)  and  4  wild- 
type  littermates  (+/+)  subjected  to  immunostaining  with  the  anti-COI  antibody. 
Each  value  is  the  mean  of  2  staining  scores  from  each  striatal  subarea  of  each  mouse. 
Animal  ID  Genotype  Layer  V 
7836  +/-  54 
7783  +/-  83 
7839  +/-  77 
7778  +/-  60 
7705  +/+  79 
7689  +/+  88 
7781  +/+  55 
7777  +/+  56 
Table  6.4  Cell  staining  scores  in  layer  V  of  cortex  from  4  HD  mice  (+/-)  and  4  wild-type 
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Figure  6.8  Scoring  cytoplasmic  staining  with  the  anti-COI  antibody.  The  cortical 
image  from  an  HD  mouse  brain  section  shows  weakly  staining  (score  1,  arrow), 
moderately  staining  (score  2,  double  arrow),  and  intensely  staining  (score  3, 
arrow  head)  cells.  Scale  bar=50  pm 
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Figure  6.9  Immunostaining  of  COI  in  the  striatum  (a)  and  layer  V  of  cortex  (b)  of  4 
HD  mice  and  4  wild-type  littermates  at  ~25  months  of  age.  The  column  termed  Total 
represents  the  combined  results  from  four  subareas  of  striatum:  dorsomedial  (DM), 
ventromedial  (VM),  dorsolateral  (DL)  and  ventrolateral  (VL).  Stained  cells  were 
counted  and  a  score  for  weak  (1),  moderate  (2)  and  intense  staining  (3)  assigned. 
The  cell  staining  intensity  score  is  the  sum  of  the  individual  scores  within  an  0.06 
mm2  area.  Data  are  expressed  as  mean  t  S.  E.  Thep  values  indicated  are  obtained 
from  comparing  the  results  obtained  with  HD  mice  (grey  column)  and  wild-type 
littermates  (open  column)  using  the  Student's  t  test  (two-tailed)  for  statistical 
analysis.  *indicates  p<0.05. 
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Figure  6.10  An  example  of  comparison  of  COI  immunostaining  between  HD  mice 
and  wild-type  littermates.  HD  mouse  striatum  (a)  shows  decreased  COI  immunostaining 
in  the  cell  soma  (arrows)  and  the  axon  (fine  granule  staining  between  neurons)  when 
compared  to  the  wild-type  littermate  (b).  Bar  =  50  µm. 
214 6.4  Summary 
The  results  indicate  that  HD  mice  at  -  25  months  of  age  show  no  significant  differences  in 
mRNA  levels  of  CoI,  CoII,  and  Cytb  in  any  brain  region  studied  when  compared  to  normal 
littermates.  However,  the  HD  mice  show  a  trend  toward  decreased  levels  of  CoI  mRNA  in 
the  striatum  in  both  slot  (p  -  0.065)  and  northern  blot  analyses  (p  -  0.11)  when  compared  to 
wild-type  littermates,  although  this  does  not  reach  statistical  significance.  This  suggests  that 
the  mitochondrial  gene  expression  levels  may  not  be  significantly  compromised  when 
mtDNA  is  -  30  %  depleted. 
COI  immunostaining  was  significantly  decreased  in  the  dorsolateral  striatum,  but  not  in  any 
other  part  of  the  striatum  of  24  month-old  HD  mice  when  compared  to  wild-type  littermates. 
However,  when  the  results  from  all  four  parts  of  striatum  were  combined,  it  also  showed 
that  the  immunostaining  of  COI  was  significantly  decreased  in  the  whole  striatum  of  24 
month-old  HD  mice  compared  to  wild-type  littermates.  The  decreased  staining  was  not 
found  in  the  cortex  of  HD  mice  when  compared  to  wild-type  mice.  The  results  suggest  that 
immunohistochemical  detection  might  be  a  better  method  in  detecting  pathological changes 
in  HD  mice  where  the  changes  can  be  detected  at  single  cell  level  or  localized  to  a  small 
region.  The  results  of  CO-I  immunostaining  are  consistent  with  a  gradient  of  vulnerability 
within  the  striatum  of  HD,  with  the  dorsal  striatum  more  vulnerable  and  showing  earlier 
pathological  changes  than  other  regions  (Vonsattel  and  DiFiglia,  1998). 
215 7  Investigating  the  direct  evidence  of  increased  oxidative 
stress  in  the  striatum  of  HD  mice 
7.1  Background 
The  study  in  chapter  4  showed  that  mtDNA  depletion  is  present  in  striata  of  24  month-old 
HD  mice.  The  striatal  depletion  of  mtDNA  in  striatum  is  probably  not  caused  by  decreased 
expression  levels  of  the  Tfam  mRNA,  a  key  regulator  of  mtDNA  replication  (section  5.3  and 
5.4).  Several  lines  of  evidence  from  the  literature  support  the  speculation  that  mtDNA 
depletion  can  occur  as  a  consequence  of  increased  oxidative  damage  of  mtDNA  possibly 
through  DNA  mispairing,  point  mutations,  deletions,  and  fragmentation  (Barazzoni  et  al., 
2000;  Bradley  et  al.,  2000;  de  la  Monte  et  al.,  1988;  Rodriguez-Santiago  et  al.,  2001). 
Searching  for  direct  evidence  of  increased  oxidative  stress  in  the  HD  mice  is  then 
imperative  for  trying  to  account  for  the  finding  of  mtDNA  depletion  in  the  striata  of  HD 
mice. 
Direct  markers  of  increased  oxidative  stress  can  be  categorized  into  the  following  three 
groups  (Toyokuni,  1999).  The  first  category  includes  those  molecules  that  are  generated  in  a 
reaction  with  reactive  oxygen  species  (ROS),  such  as  8-hydroxydeoxyguanosine  (8-OHdG), 
4-hydroxy-2-nonenal  (4-HNE),  malondialdehyde  and  nitrotyrosine.  These  molecules  are 
subjected  to  either  cross-linking  or  covalent  modification  in  reactions  with  ROS. 
Accordingly,  the  amount  of  these  molecules  will  be  increased  when  increased  levels  of  ROS 
are  generated.  The  second  category  consists  of  proteins  associated  with  ROS  metabolism, 
such  as  glutathione,  glutathione  peroxidase,  superoxide  dismutase,  heat  shock  proteins  and 
DNA  repair  enzymes.  In  most  cases,  the  steady  state  levels  and  activity  of  these  molecules 
are  reduced  immediately  after  exposure  to  ROS.  However,  levels  tend  to  recover  and  may 
even  show  an  overshooting  response  hours,  days  or  even  weeks  after  exposure.  The  third 
category  is  transcription  factors,  such  as  NF-kB,  c-myc  and  c-fos.  It  has  been  shown  that 
ROS  modulate  not  only  the  expression  of  transcription  factors  but  also  their  transcriptional 
activity  via  redox  regulation  (Sun  and  Oberley,  1996).  When  considering  these  different 
categories  of  molecules,  modulation  of  transcription  factors  requires  moderate  levels  of 
oxidative  stress  (Toyokuni,  1999)  and  difficulty  in  visualizing  low-level  effects  in  paraffin- 
216 embedded  tissues  is  anticipated.  Levels  of  proteins  in  the  second  category  are  difficult  to 
evaluate  because  of  the  differential  response  over  time,  as  previously  mentioned.  Therefore, 
the  first  category  molecules  are  pragmatically  the  most  straightforward  targets  for 
visualizing  ROS-induced  damage.  Furthermore,  the  first  category  molecules  are 
proportionally  responding  to  the  dosage  of  oxidative  stress  and  so  the  markers  accumulate 
and  will  be  detected  precisely  at  the  place  where  the  free  radical  damage  takes  place 
(Toyokuni,  1999). 
Among  the  first  category  of  markers  of  increased  oxidative  stress,  increased  levels  of  8- 
OHdG,  a  product  of  DNA  oxidation,  have  been  found  in  nuclear  DNA  and  mtDNA  in  the 
striatum  of  HD  patients  (Browne  et  al.,  1997;  Polidori  et  al.,  1999)  and  in  R6/2  mice 
(Bogdanov  et  al.,  2001)  and  also  in  aged  human  brain.  Increased  level  of  malondialdehyde, 
a  product  of  lipid  peroxidation,  has  been  shown  in  the  brains  of  HD  patients  (Browne  et  al., 
1997).  Increased  level  of  4-HNE  modified  protein,  a  toxic  product  of  lipid  peroxidation,  has 
also  been  shown  in  the  affected  regions  of  Parkinson's  disease  (Yoritaka  et  al.,  1996), 
Alzheimer's  disease  (Markesbery,  1997)  and  olivopontocerebellar  atrophy  (Yamashita  et 
al.,  2000);  disorders  that  are  associated  with  increased  oxidative  stress.  The  expression 
levels  of  8-OHdG  and  4-HNE  in  HD  mouse  brains  were  investigated  using 
immunohistochemical  detection.  Among  the  second  category  of  markers  of  increased 
oxidative  stress,  increased  levels  of  heure  oxygenase-1,  which  shows  a  compensatory 
response  to  oxidative  stress,  have  been  demonstrated  in  the  striatum  of  HD  patients  (Browne 
et  al.,  1999)  and  the  affected  brain  regions  of  Parkinson's  disease  (Castellani  et  al.,  1996; 
Schipper  et  al.,  1998)  and  other  neurodegenerative  disorders  (Castellani  et  al.,  1995).  The 
expression  level  of  heure  oxygenase-1  in  mouse  brains  was  investigated  using 
immunohistochemical  detection  and  northern  blot  analysis.  Alpha  B-crystallin,  a  heat  shock 
protein,  has  been  shown  to  be  increased  in  the  brain  regions  of  patients  with  some 
neurodegenerative  disorders  (Braak  et  al.,  2001;  Iwaki  et  al.,  1992;  Renkawek  et  al.,  1999). 
Therefore,  expression  levels  of  aB-crystallin  in  mouse  brains  were  also  investigated  using 
RNA  slot  blot  analysis. 
Previous  studies  of  cytochrome  c  oxidase  I  expression  in  HD  mouse  brain  tissues  showed 
that  changes  in  individual  cells  or  localized  to  a  small  area  of  striatum  were  probably 
masked  by  analysis  of  the  bulk  tissue  homogenate  used  in  northern  blot  and  slot  blot 
217 analyses.  Striatum  in  HD  mice  showed  a  decreased  expression  level  of  COI  when  compared 
to  littermates  using  immunohistochemical  detection  (section  6.3).  For  this  reason,  the 
expression  levels  of  heure  oxygenase-1,8-OHdG  and  4-HNE  in  HD  mouse  brain  tissues 
were  also  investigated  using  immunohistochemical  detection,  to  avoid  a  possible  masking 
effect  of  bulk  tissue  analysis. 
The  experiments  were  conducted  on  striatum,  cortex  and  cerebellum  from  HD  mouse 
brains.  These  brain  regions  were  chosen  because  mtDNA  levels  were  significantly  reduced 
in  the  striatum  of  24-month  old  HD  mice,  but  not  in  cortex  or  cerebellum,  when  compared 
to  wild-type  littermates  (section  4.4).  Therefore,  cortex  and  cerebellum  were  included  to  ask 
whether  any  changes  in  the  expression  levels  of  oxidative  stress  markers  were  specific  to 
HD  mouse  striatum. 
7.2  Quantifying  levels  of  heure  oxygenase-1  (Hmoxl)  and  aB- 
crystallin  transcripts  in  mouse  brain  tissue 
The  heure  oxygenase-1  (Hmoxl)  gene  expression  levels  in  HD  mice  were  investigated  using 
northern  blot  analysis  and  aB-crystallin  gene  expression  levels  were  investigated  using 
RNA  slot  blot  analysis.  The  reason  for  using  a  slot  blot  approach  to  quantify  aB-crystallin 
expression  levels  was  that  northern  blot  analysis  revealed  two  aB-crystallin  mRNA 
transcripts  of  similar  sizes.  These  were  not  easily  differentiated  and  therefore,  measuring 
the  intensity  of  each  band  was  difficult  (Fig.  7.1). 
The  primers  HOF  and  HOR  (section  2.1.7)  were  carefully  chosen  from  the  mouse  Hmoxl 
mRNA  sequence  published  in  GenBank  (NCBI)  to  amplify  specific  products  from  first 
strand  cDNA.  The  size  of  the  PCR  product  amplified  from  first  strand  cDNA  using  HOF 
and  HOR  primers  was  799  bp,  as  predicted  from  the  Genbank  sequence  (Fig.  7.2a).  The 
PCR  product  was  gel  purified  and  cloned  using  the  methods  described  in  section  2.2.9.  The 
resulting  clone  was  designated  pHO.  Plasmid  DNA  from  pHO  was  isolated  as  described  in 
section  2.2.2.1,  and  digested  with  EcoRI  to  release  the  insert  to  check  that  the  correct  DNA 
fragment  had  been  cloned  (Fig.  7.2b).  The  identity  of  the  cloned  fragment  was  confirmed  by 
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Figure  7.1  Northern  blot  analysis  of  aB  crystallin  mRNA  in  the  striatum  of  24 
month-old  mice.  Total  RNA  from  6  HD  mice  (+/-)  and  5  wild-type  littermates  (+/+) 
was  resolved  on  a  EtBr-stained  formaldehyde  gel  (a).  10-15  µg  total  RNA  was 
loaded  into  each  lane.  The  clear  and  abundant  18S  and  28S  rRNA  bands  indicate 
good  quality  RNA.  Total  RNA  in  gel  (a)  was  transferred  to  a  membrane  which  was 
hybridized  with  the  aB  crystallin  probe  (b).  Two  mRNA  transcripts  of  similar  sizes 
were  identified  (arrows)  and  not  easily  differentiated.  Therefore,  the  measurement 
of  the  intensity  of  each  band  was  difficult. 
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b)  EcoRI-digested  DNA  from  pHO 
Ml  2 
Vector 
799  hp 
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Figure  7.2  Generation  of  the  probe  for  northern  blot  analysis  of  Hmoxl  mRNA. 
PCR  products  amplified  from  dilutions  of  first  strand  cDNA  (1:  1,1:  10,1:  10,1:  100) 
using  primers  HOF  and  HOR  were  visualized  on  an  EtBr-stained  agarose  gel  (a). 
NoRT  indicates  the  control  lane  containing  the  reaction  where  the  RNA  template  had 
not  been  treated  with  reverse  transcriptase.  EcoRI-digested  DNA  from  pHO  was 
visualized  on  an  EtBr-stained  agarose  gel  (b).  Lanes  1  and  2  contain  digested 
plasmid  DNA  derived  from  different  colonies.  4  µl  of  purified  799  bp  insert  DNA 
from  pHO  was  loaded  onto  an  EtBr-stained  agarose  gel  (c).  2  µl  (-  30ng)  of  purified 
insert  DNA  was  used  as  a  probe  in  the  northern  blot  analysis.  The  1  kb  plus  size 
ladder  is  indicated  by  M. 
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Figure  7.3  Identity  of  the  cloned  insert  of  pHO  plasmid  was  confirmed  by  DNA 
sequencing.  The  clone  pHO  was  sequenced  and  the  resulting  data  (Query)  was  checked 
using  the  Blast  program  (NCBI)  and  a  matched  sequence  from  the  mouse  HO-1  gene 
(Sbjct)  was  retrieved  from  the  database  search  (Genbank).  The  result  shows  that  760  bp 
out  of  772  bp  (98%)  are  matched.  Some  of  the  unmatched  sequence  may  be  due  to  the 
genetic  background  differences  of  the  mice  used  in  query  and  sbjct,  or  due  to  sequencing 




1  f' primers  was  gel  purified  and  -25  ng  of  the  purified  DNA  fragment  (Fig.  7.2c)  was  used  as 
the  probe  for  visualization  of  Hmoxl  mRNA  on  northern  blot  membranes. 
The  probe  for  hybridisation  of  aB-crystallin  mRNA  was  obtained  from  amplifying  plasmid 
DNA  containing  part  of  the  aB-crystallin  cDNA,  paB-CRO  (previously  constructed  by 
Peggy  Shelbourne).  The  size  of  the  PCR  product  amplified  using  CROF  and  CROR2 
primers  (section  2.1.7)  was  610  bp  and  the  purified  PCR  product  was  used  as  the  probe  for 
RNA  slot  blot  analysis  (Fig.  7.4). 
7.2.1  Northern  blot  and  RNA  slot  blot  analyses  of  heure  oxygenase-1 
(Hmoxl)  and  aB-crystallin  expression  levels 
In  this  study,  RNA  from  the  striata  of  6  HD  mice  and  6  wild-type  littermates  at  24  months 
of  age  (section  2.1.18)  was  investigated  for  expression  levels  of  Hmox1  mRNA  from  the 
striata,  cerebellum  and  cortex  of  6  HD  mice  and  6  wild-type  littermates  at  24  months  of  age 
was  investigated  for  aB-crystallin  mRNA  expression  levels. 
The  level  of  ß-actin  mRNA  was  used  as  an  internal  control  for  RNA  loading  (section  5.3.3). 
The  intensity  value  of  each  band  representing  the  mRNA  transcript  level  (aB-crystallin, 
Hmox1,  or  ß-actin)  of  each  animal  was  obtained,  and  the  ratio  of  the  test  mRNA  transcript 
level/(3-actin  mRNA  transcript  level  was  determined.  Statistical  analysis  of  the  data  was 
performed  using  the  Student's  t  test  (two  tailed). 
7.2.1.1  Northern  blot  analysis  ofHmoxl  mRNA  expression  levels 
Northern  blot  analysis  was  performed  using  the  methods  described  in  sections  2.2.15.4, 
2.2.15.5  and  2.2.16.  The  northern  blot  membranes,  probed  for  visualization  of  Hmoxl 
mRNA  transcripts,  were  washed  to  a  final  stringency  of  0.1  X  SSC,  0.1  %  (w/v)  SDS  at 
65°C  for  10  min  and  exposed  to  X-ray  film  at  -70°C  in  the  presence  of  intensifying  screens 
for  about  4  days  to  ensure  that  only  the  Hmoxl  mRNA  transcripts,  and  no  non-specific 
hybridization,  were  detected  (Fig.  7.5).  The  northern  blot  analysis  of  Hmoxl  mRNA 
transcript  levels  was  performed  in  duplicate  using  2  different  northern  gels.  The  results 
222 a)  Amplification  of  paB-CRO  insert  DNA  using  primers  CROF  and  CROR2 
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b)  Purified  insert  DNA  from  paB-CRO 
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610  bp- 
Figure  7.4  Generation  of  the  hybridization  probe  for  slot  blot  analysis  of  aB-crystallin 
mRNA.  PCR  products  amplified  from  dilutions  of  paB-CRO  DNA  (1:  10,1:  10,1:  20, 
1:  20,1:  100,1:  100)  using  primers  CROF  and  CROR2  were  resolved  on  an 
EtBr-stained  agarose  gel  (a).  C  indicates  the  negative  control  using  water  as  a 
template  to  check  for  DNA  contamination  of  PCR  reagents.  5  µl  of  purified  PCR 
products  from  (a)  was  loaded  onto  an  EtBr-stained  agarose  gel  (b).  2.5  µl  (-30  ng)  of 
purified  PCR  products  from  (a)  was  used  as  a  probe  in  the  RNA  slot  blot  analysis. 
The  1  kb  plus  marker  is  indicated  by  M. 
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Figure  7.5  Northern  blot  analysis  of  Hmox1  mRNA  in  the  striatum  of  24  month-old  mice. 
Total  RNA  from  6  HD  mice  (+/-)  and  6  wild-type  littermates  (+/-)  was  resolved  on  an 
EtBr-stained  formaldehyde  gel  (a).  15  µg  total  RNA  was  loaded  into  each  lane.  The 
clear  and  abundant  18S  and  28S  rRNA  bands  indicate  good  quality  RNA.  Total  RNA 
in  the  gel  (a)  was  transferred  onto  a  membrane,  and  probed  for  visualization  of  Hmox1 
and  (3-actin  mRNA  transcripts  (b).  The  levels  of  (3-actin  mRNA  transcript  were  used 
as  an  internal  control  for  RNA  loading. 
224 revealed  that  24  month-old  HD  mice  showed  no  significant  differences  in  the  Hmoxl 
mRNA  level  in  the  striatum,  when  compared  with  wild-type  littermates  (Table  7.1). 
HD  WT  value 
Ratio  of  Hmoxl/ß-  0.62:  t  0.04  (n=6)  0.7.  t  0.04  (n=6)  0.14 
actin  mRNA  level, 
replicate  I 
Ratio  ofHmoxl/ß-  0.50  ±  0.06  (n=5)  0.54  t  0.03  (n=5)  0.52 
actin  mRNA  level, 
replicate  II 
Table  7.1  Northern  blot  analysis  of  Hmoxl  mRNA  levels  in  the  striatum  of  HD  and 
wild-type  littermates  (WT)  at  24  months  of  age. 
The  results  show  that  no  significant  differences  were  found  in  the  ratios  of  Hmox1/ß-actin 
mRNA  level  in  the  striatum  of  HD  mice  compared  to  wild-type  littermates.  All  values  are 
stated  as  mean  ratio  t  S.  E.  The  Student's  t-test  (two  tailed)  was  used  for  statistical  analysis. 
I  and  II  indicate  the  first  and  second  northern  blot  analyses  respectively.  The  RNA  samples 
used  in  these  two  experiments  were  obtained  from  different  animals. 
7.2.1.2  RNA  slot  blot  analysis  of  aB-crystallin  mRNA  expression  levels 
RNA  slot  blot  analysis  does  not  involve  electrophoresis  of  RNA.  Therefore,  genomic  DNA 
contamination  or  non-specific  hybridisation  must  be  avoided  to  prevent  confounding 
hybridization  signals  when  an  RNA  slot  blot  membrane  is  used  for  semi-quantitative 
analysis.  To  ensure  this,  northern  blot  analysis  of  aB-crystallin  mRNA  was  optimised  to 
avoid  non-specific  hybridisation  (Fig.  7.1).  After  this,  RNA  slot  blot  analyses  were 
performed  using  the  methods  described  in  section  2.2.16.  The  resulting  slot  blot  membranes, 
probed  for  visualization  of  aB-crystallin  mRNA  transcripts,  were  washed  to  a  final 
stringency  of  0.1  X  SSC,  0.1  %  (w/v)  SDS  at  65°C  for  30  min  and  exposed  to  X-ray  film  at 
-70°C  in  the  presence  of  intensifying  screens  for  about  2  days  (Fig.  7.6). 
The  results  (Table  7.2)  revealed  that  24  month-old  HD  mice  showed  no  significant 
differences  in  the  levels  of  aB-crystallin  mRNA  in  the  striatum,  cerebellum  and  cortex, 
when  compared  with  wild-type  littermates. 
225 a)  Striatum  b)  Cortex  c)  Cerebellum 
«B  ß-actin  ocB  ß-actin  «B  ß-actin 
+/+  ...  +/+  ý.  A  +/-  -  .... 
+/-  .  ...  +/-  ...  -  - 
AMW 
+/+  i  "" 
+/+  -  40.  +/+  - 
+/-  -  +/+  -  "w..  +/-  . 
+/+  ....  ....  +/-  -  +/+  -  +/-  ý  +/-  +r  000 
4100 
Now 
+/+  -  ... 
+/-  --  +/+  am  4Mº  +/-  -  ow  .  rR 
+/+  --  +/-  -  .. 
+/_  ......  +/+  *Mº  -  +/+  ..  r..  - 
+/+  --  -  +/-  ...  -  +/+  ..,..  - 
Figure  7.6  Slot  blot  analysis  of  ocB-crystallin  mRNA  in  stratum  (a),  cortex  (b)  and 
cerebellum  (c)  of  HD  mice  (+/-)  and  wild-type-littermates  (+/+)  at  24  months  of  age. 
5  µg  of  total  RNA  from  was  added  to  each  slot.  The  visualization  of  (3-actin  mRNA 
transcripts  was  used  as  an  internal  control  for  RNA  loading.  «B  indicates  «B 
crystallin  data. 
0-1 
,  :a 
226 HD  (n  =6)  WT  (n  =6)  value 
Ratio  of  aB-crystallin/ß-  0.78t  0.09  0.78.  t  0.1  1.0 
actin  mRNA  level  in  the 
striatum 
Ratio  of  aB-crystallin/ß-  1.29  t  0.12  1.31  ±  0.1  0.9 
actin  mRNA  level  in  the 
cortex 
Ratio  of  aB-crystallin/ß  1.15  t  0.12  1.17  t  0.14  0.9 
actin  mRNA  level  in  the 
cerebellum 
Table  7.2  Slot  blot  analysis  of  aB-crystallin  mRNA  levels  in  the  striatum,  cortex  and 
cerebellum  of  6  HD  and  6  wild-type  littermates  (WT)  at  24  months  of  age. 
The  results  show  that  no  significant  differences  were  found  in  the  ratios  of  aB-crystallin/ß- 
actin  mRNA  level  in  striatum,  cerebellum,  or  cortex  of  HD  mice  compared  to  wild-type 
littermates.  All  values  are  stated  as  mean  ratio  ±  S.  E.  The  Student's  t-test  (two  tailed)  was 
used  for  statistical  analysis. 
7.3  Immunohistochemical  detection  of  heure  oxygenase-1  (HO- 
I),  4-hydroxy-2-nonenal  (4-HNE),  and  8- 
hydroxydeoxyguanosine  (8-OHdG)  in  HD  mouse  brain 
tissue 
7.3.1  Comparison  of  free-floating  and  paraffin-embedded  sections  for 
immunohistochemical  detection  of  HO-I  and  4-HNE 
In  the  literature  both  free-floating  and  paraffin-embedded  sections  have  been  used  for 
staining  4-HNE  and  HO-1.  In  order  to  obtain  good  quality  immunostaining,  a  pilot  study 
comparing  these  two  section  preparations  for  anti-4-HNE  and  HO-1  antibody  staining  was 
conducted  using  the  methods  described  in  section  6.3.1.  The  pilot  study  did  not  include  8- 
OHdG  immunostaining  as  only  paraffin-embedded  sections  were  used  in  previous  research 
studies.  Both  paraffin-embedded  and  free-floating  sections  were  subjected  to 
immunohistochemical  detection  with  serial  dilutions  of  primary  antibody;  anti-4-HNE 
(1:  500,1:  1000,1:  2000,1:  3000  and  1:  4000),  and  anti-HO-1(1:  500,1:  1000,1:  2000,1:  3000 
227 and  1:  4000).  These  sections  were  then  treated  with  secondary  antibodies,  anti-rabbit  IgG 
(1:  100)  and  ABC  kits  using  methods  described  in  sections  2.2.17.4  and  2.2.17.5.  After 
examination  using  the  light  microscope,  the  best  free-floating  sections  [anti-4-HNE 
(1:  2000),  and  anti-HO-1(1:  2000)]  were  compared  with  the  best  paraffin-embedded  sections 
[anti-4-HNE  (1:  2000),  and  anti-HO-1(1:  2000)]  for  each  primary  antibody.  The  results 
revealed  that  paraffm-embedded  sections  for  each  primary  antibody  used  in  the  study 
provide  better  resolution  and  less  background  than  free-floating  sections  (Fig.  7.7). 
Therefore,  paraffin-embedded  sections  were  used  in  subsequent  immunodetection 
experiments. 
7.3.2  Optimization  of  immunohistochemical  assays 
7.3.2.1  Positive  control  sections  for  assays 
Sections  of  brain  from  mice  that  had  received  injections  of  malonate  into  the  striatum 
(section  6.3.2.1)  were  used  as  positive  controls  for  the  detection  of  4-HNE,  HO-1  and  8- 
OHdG. 
7.3.2.2  Optimization  of  immunohistochemical  detection  of  4-HNE  and  HO-1 
Although  conditions  for  anti-4-HNE  and  anti-HO-1  immunostaining  used  in  the  pilot  study 
differentiated  ischemic  lesions  from  normal  tissue,  they  were  unable  to  stain  the  malonate 
lesion  clearly.  The  refinement  of  immunostaining  conditions  for  both  test  and  malonate- 
treated  positive  control  sections  was  performed.  Faint  staining  with  anti-4-HNE  and  anti- 
HO-1  antibodies  within  the  malonate  lesion  section  was  enhanced  by  using  the  Elite  ABC 
kit  instead  of  a  standard  ABC  kit  (Vector)  and  by  increasing  the  concentration  of  the  anti- 
HO-1  antibody  used  (using  a  dilution  of  1:  1500  instead  of  1:  2000)  (Fig.  7.8).  The  resulting 
optimised  methods  used  for  immunohistochemical  detection  of  4-HNE  and  HO-1  are  more 
comprehensively  detailed  in  section  2.2.17.5. 
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Figure  7.7  An  example  of  a  comparison  between  a  free-floating  section  and  a  paraffin- 
embedded  section  stained  with  the  anti-4-HNE  antibody.  The  paraffin-embedded  brain 
section  (a)  from  a  mouse  with  an  ischemic  lesion  showed  better  staining  resolution  and 
less  background  than  free-floating  brain  section  (b)  from  a  mouse  that  received  a  cortical 
AMPA  injection.  Neurons  with  increased  staining  are  indicated  by  arrows.  a  indicates 
the  ischemic  lesion  and  ß  indicates  the  lesion  generated  by  an  AMPA  injection.  Scale 
bar  =  50  ym 
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Figure  7.8  Optimization  of  4-HNE  (a  and  b)  and  HO-1  immunostaining  (c  and  d)  in 
mouse  brain.  A  malonate  lesion,  stained  with  the  anti-4-HNE  antibody  (1:  2000  dilution) 
and  visualized  using  the  Elite  ABC  kit  and  Nickel  enhancement  (a)  showed  better 
staining  resolution  than  the  malonate  lesion  stained  with  the  anti-4-HNE  antibody 
(1:  2000  dilution)  and  visualized  using  an  ABC  kit  (b).  The  malonate  lesion,  stained 
with  the  anti-HO-I  antibody  (1:  1500  dilution)  and  visualized  using  the  Elite  ABC  kit 
and  Nickel  enhancement  (c)  showed  better  staining  resolution  than  the  malonate 
lesion,  stained  with  the  anti  HO-lantibody  (1:  1500  dilution)  and  visualized  using  the 
ABC  kit  (d).  Increased  neuronal  cytoplasmic  staining  is  indicated  by  arrows. 
Scale  bar  =  60  Pm 
230 73.23  Optimization  of  immunohistochemical  detection  of  8-OHdG 
Test,  positive  control  and  negative  control  sections  were  subjected  to  serial  dilutions  of  anti 
8-OHdG  antibody  (0.25,0.5,1,  and  2  pg/ml).  The  test  and  positive  control  sections  stained 
with  anti-8-OHdG  antibody  showed  best  staining  at  the  concentration  of  1  pg/ml  with  the 
Elite  ABC  kit  and  Nickel  enhancement  (Fig.  7.9a).  However,  as  previously  described  for 
COI  staining  (section  6.3.2.1),  the  negative  control  sections,  omitting  the  primary 
monoclonal  anti-8-OHdG  antibody,  showed  strong  staining  in  the  malonate-injected  brain 
section  (Fig.  7.9b).  To  solve  this  problem,  the  dilution  of  the  secondary  antibody  used  was 
changed  from  1:  100  to  1:  500,  and  the  primary  antibody  concentration  was  increased  to  2 
pg/ml.  In  addition,  the  Mouse  on  Mouse  Immunodetection  kit  (the  MOM  kit,  Vector)  for 
blocking  non-specific  binding  to  mouse  endogenous  IgG  was  applied  when  staining  sections 
with  anti-8-OHdG  antibody.  Using  the  resulting  optimized  methods  (section  2.2.17.5),  non- 
specific  staining  was  significantly  reduced  (Fig.  7.9c),  and  the  positive  control  sections 
showed  increased  nuclear  staining  around  the  lesion  of  the  striatum  when  compared  to  the 
non-lesion  side  (Fig.  7.9d  and  e). 
7.3.3  Comparisons  of  HO-I,  4-HNE  and  8-OHdG  immunostaining  levels 
in  HD  and  wild-type  mouse  brain 
The  mice  except  for  one  wild-type  mouse,  the  equipment  for  capturing  images,  and  the 
statistical  method  used  for  comparing  levels  of  HO-I,  4-HNE  and  8-OHdG  immunostaining 
were  the  same  as  those  used  in  the  investigation  of  COI  immunostaining  levels  in  HD 
mouse  brain  (section  6.3.3).  Quantitative  analyses  of  the  HO-I,  4-HNE  and  8-OHdG 
immunostaining  were  also  performed  in  a  manner  blind  to  genotype. 
73.3.1  Analysis  of  HO-I  immunostaining  levels  in  mouse  brain 
Images  of  mouse  brain  sections  stained  with  anti-HO-1  antibody  were  captured  at  a 
magnification  of  x200  for  semi-quantitative  analysis.  Two  brain  sections  from  each  mouse 
at  the  level  of  caudal  striatum  (the  most  vulnerable  part  of  HD  brain)  were  analysed.  The 
striatum  in  each  hemisphere  was  divided  into  4  approximately  equal  subareas  -  dorsomedial, 
dorsolateral,  ventromedial  and  ventrolateral  (Fig.  7.10).  The  cortex  in  each 
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Figure  7.9  Optimization  of  immunostaining  with  the  anti-8-OHdG  antibody.  The  striatal 
malonate  lesion  stained  with  the  anti-8-OHdG  (lµg/ml)  without  the  Mouse  on  Mouse  kit 
(MOM  kit)  (a).  The  negative  control  section  (b)  adjacent  to  (a)  was  stained  using  the  same 
procedure  as  (a),  but  omitting  anti-8-OHdG.  This  section  (b)  showed  non-specific  staining 
of  nuclei.  The  non-specific  nuclear  staining  in  striatum  was  significantly  decreased  by 
using  the  MOM  kit  (c).  The  striatum  around  the  malonate  lesion  stained  with  anti-8-OHdG 
(2  /Cg/ml)  and  the  MOM  kit  (d).  When  compared  to  the  non-lesion  side  (e),  the  lesion  side 
(d)  showed  increased  nuclear  staining  (indicated  by  arrows).  Scale  bar=60  }gym. 
232 Figure  7.10  A  mouse  brain  map  for  quantification  of  neurons  with  increased  HO-1 
and  4-HNE  staining.  The  cortex  in  each  hemisphere  was  divided  into  7  equal  parts 
indicated  by  numbers  1-7.  The  striatum  in  each  hemisphere  was  divided  into  4  equal 
parts,  a,  b,  c  and  d  (dorsomedial,  ventromedial,  dorsolateral,  and  ventrolateral 
respectively).  One  image  from  each  subarea  was  captured. 
233 hemisphere  was  divided  into  7  approximately  equal  subareas  (Fig.  7.10).  The  cells  were 
classified  into  one  of  two  groups  (weak  staining  or  intense  staining)  according  to  the 
intensity  of  cytoplasmic  immunostaining.  When  cytoplasmic  staining  masked  nuclear 
staining  and  blurred  the  nuclear  boundary,  the  cell  was  classified  in  the  intense  staining 
group  (Fig.  7.11).  The  brain  sections  from  normal  mice  showed  a  basal  staining  level  [(faint 
staining)  (Fig.  7.11)]  in  most  cells  and  the  brain  sections  from  malonate-treated  mice 
(positive  control)  showed  intense  staining  in  the  cells  around  the  lesion  (Fig.  7.11).  An  area 
of  0.2  mm'  was  chosen  from  the  centre  of  each  of  the  8  striatal  subareas  and  14  cortical 
subareas  per  mouse  brain  section.  The  cells  showing  intense  staining  within  this  area  were 
counted.  The  mean  cell  count  of  the  four  striatal  subareas  of  each  mouse  (e.  g.  4  dorsolateral 
regions  from  right  and  left  striatum  of  2  brain  sections)  was  determined  (Table  7.3).  The 
data  from  4  HD  and  4  wild-type  littermates  were  combined  and  a  comparison  between  each 
striatal  subarea  of  HD  mice  and  corresponding  subarea  of  wild-type  littermates  was 
performed.  None  of  these  comparisons  showed  significant  differences  between  HD  mice 
and  littermates  (Fig.  7.12a).  When  the  scores  from  all  four  subareas  (dorsomedial, 
dorsolateral,  ventromedial  and  ventrolateral)  of  the  striatum  of  each  mouse  in  the  cohort 
were  combined,  the  result  also  showed  that  the  HO-I  immunostaining  in  HD  striatum  was 
not  significantly  different  from  that  in  wild-type  littermates  (Fig.  7.12a).  The  mean  cell 
count  of  the  4  cortical  subareas  of  each  mouse  (e.  g.  subarea  1  from  right  and  left  cortex  of  2 
brain  sections)  was  determined  (Table  7.4).  Comparisons  between  each  cortical  subarea  of 
4  HD  mice  and  corresponding  subarea  of  4  wild-type  littermates  were  performed.  None  of 
these  comparisons  showed  significant  differences  between  HD  mice  and  littermates  (Fig. 
7.12b).  When  the  mean  scores  from  all  7  subareas  of  the  cortex  from  each  mouse  in  the 
cohort  were  combined,  the  result  also  showed  that  levels  of  HO-I  immunostaining  in  HD 
cortex  did  not  significantly  differ  from  wild-type  littermates  (Fig.  7.12b).  In  summary,  these 
results  suggest  that  HO-I  immunostaining  in  the  cortex  and  striatum  of  HD  mice  is  not 
increased  compared  to  wild-type  mice. 
73.3.2  Analysis  of  4-HNE  immunostaining  levels  in  mouse  brain 
The  level  of  4-HNE  immunostaining  in  tissue  sections  was  analysed  using  the  same 
procedures  as  for  HO-1  immunostaining  levels  (section  7.3.3.1).  The  mice  used  were  the 
same  as  those  in  the  HO-1  immunostaining  study  except  for  one  animal.  The  cells  showing 
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Figure  7.11  Classification  of  cell  immunostaining  with  the  anti-HO-1  antibody.  a)  The 
striatum  in  a  brain  section  from  a  normal  mouse  shows  a  basal  staining  level  in  most 
cells,  which  is  classified  as  faint  staining  (except  the  cell  indicated  by  an  arrow). 
b)  The  striatum  in  a  brain  section  from  a  mouse  treated  with  a  malonate  injection  shows 
an  increased  number  of  cells  with  intense  staining  indicated  by  arrows.  Scale  bar 
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Figure  7.12  Immunostaining  levels  of  HO-I  in  the  striatum  (a)  and  cortex  (b)  of  4 
HD  mice  and  4  wild-type  littermates  at  -25  months  of  age.  The  column  termed 
Total  in  (  a)  represents  the  combined  results  from  the  four  subareas  of  striatum: 
dorsomedial  (DM),  ventromedial  (VM),  dorsolateral  (DL)  and  ventrolateral  (VL). 
The  column  termed  Total  in  (b)  represents  the  combined  results  from  7  subareas 
of  cortex.  Thedata  are  expressed  as  mean  ±  S.  E.  Thep  values  indicated  were 
obtained  from  comparing  the  results  obtained  with  HD  mice  (grey  column)  and 
wild-type  littermates  (open  column)  using  the  Student's  t  test  (two-tailed)  for 
statistical  analysis. 
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Cortical  subarea Animal  ID  Genotype  Dorsomedial  Ventromedial  Dorsolateral  Ventrolateral 
7836  +/-  1  1  1.5  2 
7783  +/-  2.75  2.25  3.75  2.75 
7839  +/-  1.25  0.25  1.75  1.75 
7778  +/-  1  1  0.75  1.5 
7781  +/+  1.75  1  1  0.75 
7689  +/+  1.25  1.25  2.25  2 
7687  +/+  0.5  0.25  1  0.5 
7777  +/+  0.75  0.75  11  1.25 
Table  7.3  Number  of  intensely  staining  cells  in  4  subareas  of  striatum  from  4  HD  (+/-)  mice 
and  4  wild-type  littermates  (+/+)  subjected  to  immunostaining  with  the  anti-HO-1  antibody. 
Each  value  is  the  mean  of  the  cell  counts  for  each  striatal  subarea  (e.  g.  the  average  of  4 


















7836  +/-  3.5  8.75  6.25  11.5  1.5  0.5  0.75 
7783  +/-  11  6.25  8.25  6.25  3.25  0.75  3.75 
7839  +/-  6  3.5  3.75  8.25  6.75  6.75  5.5 
7778  +/-  10.75  2.5  4.5  3.75  2.5  0.5  3 
7781  +/+  12.25  3.25  12.75  12.5  11.25  14.25  14.5 
7689  +/+  1  3.75  3  14.25  7.25  0  2.5 
7687  +/+  3.75  2.25  4  3.5  2  0.75  5 
7777  +/+  2.5  1.75  1.75  1.75  0.5  0.25  0 
Table  7.4  Number  of  intensely  staining  cells  in  7  subareas  of  cortex  from  4  HD  mice  (+/-) 
and  4  wild-type  littermates  (+/+)  subjected  to  immunostaining  with  the  anti-HO-1  antibody. 
Each  value  is  the  mean  of  the  cell  counts  for  each  cortical  subarea  (e.  g.  the  average  of  4  cell 
counts  obtained  from  right  and  left  cortex  of  2  brain  sections)  of  each  mouse. 
237 intense  staining  within  each  subarea  of  striatum  were  counted  (Table  7.5).  The  results 
revealed  that  HD  mice  showed  no  significant  differences  in  the  4-HNE  staining  score  of  any 
striatal  subarea,  when  compared  to  wild-type  littermates  (Fig.  7.13a).  When  the  scores  from 
the  four  subareas  of  the  striatum  of  each  mouse  were  combined,  the  levels  of  4-HNE 
immunostaining  within  the  entire  striatum  of  HD  mice  were  not  significantly  different  from 
that  in  wild-type  littermates  (Fig.  7.13a).  The  cells  showing  intense  staining  within  each 
cortical  subarea  were  also  counted  (Table  7.6).  Comparisons  between  each  cortical  subarea 
of  HD  mice  and  the  corresponding  subarea  of  wild-type  littermates  were  performed.  None 
of  these  comparisons  showed  significant  differences  between  HD  mice  and  wild-type 
littermates  (Fig.  7.13b).  When  the  scores  from  the  7  subareas  of  the  cortex  of  each  mouse 
were  combined,  4-HNE  immunostaining  levels  in  the  cortex  of  HD  mice  were  not 
significantly  different  from  that  in  wild-type  littermates  (Fig.  7.13b).  In  summary,  the 
results  suggested  that  4-HNE  immunostaining  levels  in  the  cortex  and  striatum  of  HD  mice 
were  not  increased  compared  to  wild-type  littermates. 
7.3.33  Analysis  of  8-OHdG  immunostaining  levels  in  mouse  brain 
Four  caudal  striata  [2  consecutive  sections  x2  (right  and  left  striatum)]  from  each  mouse, 
the  most  vulnerable  part  in  HD  brain  (Vonsattel  et  al.,  1998),  were  analysed.  Each  striatum 
was  divided  into  4  approximately  equal  parts,  i.  e.  dorsomedial,  dorsolateral,  ventromedial 
and  ventrolateral  (Fig.  7.14).  Two  images  from  each  striatal  subarea  were  captured  at  x400 
magnification  for  semi-quantitative  analysis  of  8-OHdG  immunostaining.  Care  was  taken  to 
ensure  these  two  images  did  not  overlap.  Layer  III  and  V  of  the  primary  sensory  cortex  is 
the  most  vulnerable  area  of  cortex  to  HD  pathology.  Therefore,  2  images  of  the  primary 
sensory  cortex  (one  containing  layer  III  and  one  containing  layer  V)  were  captured  from  one 
brain  section  per  mouse  at  the  level  of  caudal  striatum  (Fig.  7.14).  8-OHdG  immunostaining 
of  the  cells  was  classified  into  one  of  two  groups  [weak  staining  (score  1)  and  intense 
staining  (score  2)]  according  to  the  intensity  of  nuclear  immunostaining.  Staining  of  the 
nucleus  that  masked  staining  of  the  nucleoli  and  blurred  the  boundary  of  nucleoli  was 
classified  as  intense  staining  (Fig.  7.15).  Brain  sections  from  normal  mice  showed  a  basal 
nuclear  staining  level  [(faint  staining)  (Fig.  7.9e)]  in  most  cell  nuclei  but  brain  sections  from 
malonate-treated  mice  showed  intense  staining  in  the  cell  nuclei  around  the  lesion  (Fig. 
238 Animal 
ID 
Genotype  Dorsomedial  Ventromedial  Dorsolateral  Ventrolateral 
7836  +/-  0  0.5  0.5  0.25 
7783  +/-  2.25  0  1.5  0.25 
7839  +/-  0.5  0.25  0  0.25 
7778  +/-  0  0  0  0 
7705  +/+  0.5  0.5  0.25  0.5 
7689  +/+  0.5  0  1  0.5 
7777  +/+  0.5  0  1.25  1.5 
7781  +/+  0  0  0  0 
Table  7.5  Number  of  intensely  staining  cells  in  4  subareas  of  striatum  from  4  HD  mice  (+/-) 
and  4  wild-type  littermates  (+/+)  subjected  to  immunostaining  with  the  anti-4-HNE 
antibody.  Each  value  is  the  mean  of  the  cell  counts  for  each  striatal  subarea  (e.  g.  the 
average  of  4  cell  counts-dorsolateral  striata  from  right  and  left  striatum  of  2  brain  sections) 
of  each  mouse. 
Animal 
ID 














7836  +/-  4.5  7.5  9.75  5.5  2.25  0  1 
7783  +/-  18.75  19.75  14.5  36.25  2.75  3.25  5.5 
7839  +/-  10.25  2  2.25  7.75  6.25  1.5  1.5 
7778  +/-  18.25  10.25  10.25  5.25  5.75  8.75  7 
7705  +/+  9.75  1.75  3  5.5  3.5  0.5  1.75 
7689  +/+  3  2.25  3  13  4  0.75  1.25 
7777  +/+  1  1.75  4.5  1  0.25  1  0.5 
7781  +/+  7.5  1  8.25  21.25  17.25  21.75  24 
Table  7.6  Number  of  intensely  staining  cells  in  7  subareas  of  cortex  from  4  HD  mice  (+/-) 
and  4  wild-type  littermates  (+/+)  subjected  to  immunostaining  with  the  anti-4-HNE 
antibody.  Each  value  is  the  mean  of  4  cell  counts  for  each  cortical  subarea  (e.  g.  the  average 
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Figure  7.13  Immunostaining  levels  of  4-HNE  in  the  striatum  (a)  and  cortex  (b)  of  4 
HD  mice  and  4  wild-type  littermates  at  -25  months  of  age.  The  column  termed 
Total  in  (a)  represents  the  combined  results  from  the  four  subareas  of  striatum: 
dorsomedial  (DM),  ventromedial  (VM),  dorsolateral  (DL)  and  ventrolateral  (VL). 
The  column  termed  Total  in  (b)  represents  the  combined  results  from  7  subareas 
of  cortex.  The  data  are  expressed  as  mean  ±  S.  E.  Thep  values  indicated  were 
obtained  from  comparing  the  results  obtained  with  HD  mice  (grey  column)  and 
wild-type  littermates  (open  column)  using  the  Student's  t  test  (two-tailed)  for 
statistical  analysis. 
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Cortical  subarea Figure  7.14  A  mouse  brain  map  for  quantification  of  neurons  with  increased 
8-OHdG  staining.  One  image  from  layer  III  and  layer  V  of  the  cortex  in  each 
mouse  brain  section  was  captured  .  The  striatum  in  each  hemisphere  of  each 
mouse  was  divided  into  4  equal  parts,  a,  b,  c,  d  (dorsomedial,  ventromedial, 
dorsolateral,  and  ventrolateral).  TWvo  images  (e.  g.  al  and  a2)  from  each  subarea 
of  the  striatum  were  captured. 















Figure  7.15  Scoring  nuclear  staining  using  the  anti-8-OHdG  antibody.  The  striatal 
image  (a)  from  an  HD  mouse  brain  section  shows  increased  cell  numbers  with  intense 
nuclear  staining  (score  2,  arrow  head).  The  striatal  image  (b)  from  a  wild-type  littermate 
brain  section  shows  faint  staining  in  most  nuclei  (score  1,  arrow).  Scale  bar  =  50  pm. 
242 7.9d).  An  area  of  0.06  mm2  from  the  centre  of  each  image  was  selected  and  the  number  of 
cells  with  weak  or  intense  staining  counted.  From  the  results,  a  total  score  [(number  of 
weakly  staining  cells)  x1+  (number  of  intensely  staining  cells)  x  2]  was  calculated  for  each 
image. 
Eight  staining  scores  for  each  of  the  four  striatal  subareas  (e.  g.  4  dorsolateral  regions  from 
right  and  left  striata  of  2  brain  sections  and  2  scores  from  each  dorsolateral  subarea)  of  each 
mouse  were  combined  (Table  7.7).  The  results  showed  that  8-OHdG  immunostaining  was 
significantly  increased  in  the  dorsomedial,  dorsolateral  and  ventromedial  striatum,  but  not  in 
the  ventrolateral  striatum  of  HD  mice  when  compared  to  wild-type  mice  (Fig.  7.16a).  When 
scores  from  all  four  parts  of  the  striatum  were  combined,  the  results  also  showed  that  8- 
OHdG  immunostaining  was  significantly  increased  in  the  HD  striatum  as  a  whole  when 
compared  to  wild-type  littermates  (Fig.  7.16a).  The  staining  score  of  each  cortical  subarea 
was  calculated  (Table  7.8).  The  score  of  each  subarea  from  the  cortex  of  HD  mice  was 
compared  to  that  of  wild-type  littermates.  None  of  these  comparisons  showed  significant 
differences  between  HD  mice  and  littermates  (Fig.  7.16b).  When  the  scores  from  the  2 
subareas  of  the  cortex  from  each  mouse  were  combined,  the  result  also  showed  that  the 
immunostaining  of  8-OHdG  in  cortex  of  HD  mice  was  not  significantly  different  from  that 
in  wild-type  littermates  (Fig  7.16b).  In  summary,  the  results  suggested  that  8-OHdG 
immunostaining  was  significantly  increased  in  the  striatum,  but  not  in  the  cortex  of  HD 
mice  when  compared  to  wild-type  littermates. 
As  it  is  possible  that  assigning  a  score  for  nuclear  staining  intensity  of  cells  might 
artificially  inflate  differences  between  mutant  and  wild-type  sections,  an  alternative  method 
was  used  to  quantify  the  8-OHdG  immunostaining  in  HD  mouse  brain  striatum.  The  ratio  of 
number  of  intensely  stained  nuclei/total  number  of  stained  nuclei  for  each  image  was 
determined  and  comparisons  were  performed  between  HD  and  wild-type  littermates  using 
two-way  ANOVA.  Genotype  and  individual  mouse  within  groups  were  used  as  the  2 
factors.  Every  mouse  has  8  repeated  data  points  for  each  striatal  subarea.  The  results  showed 
that  8-OHdG  immunostaining  was  significantly  increased  in  all  four  parts  of  HD  striatum 
when  compared  to  wild-type  littermates  (DM  subarea:  F  1,63  =18.66,  p<0.001;  VM 
subarea:  F  1ß3  =11.66,  p=0.001;  DL  subarea;  F  1,0  =14.26,  p<0.001;  VL  subarea:  F  1,63  = 
23.14,  p<0.001).  This  result  supports  the  previous  analysis  using  Student's  t  test  and 
243 Animal 
ID 
Genotype  Dorsomedial  Ventromedial  Dorsolateral  Ventrolateral 
7836  +/-  171  165.5  142.5  132.5 
7783  +/-  161  158  153.5  134.5 
7839  +/-  208  208.5  187.5  174.5 
7778  +/-  199  198.5  161  164.5 
7705  +/+  135  140  127  122.5 
7689  +/+  136  143  127.5  129 
7687  +/+  156  153.5  136.5  127 
7777  +/+  135  128  118.5  114 
Table  7.7  Score  of  cell  staining  in  4  subareas  of  striatum  from  4  HD  mice  (+/-)  and  4  wild 
type  littermates  (+/+)  subjected  to  immunostaining  with  the  anti-8-OHdG  antibody. 
Each  value  is  the  mean  of  8  staining  scores  for  each  striatal  subarea  (e.  g.  the  average  of  8 
scores-  dorsolateral  regions  from  right  and  left  striatum  of  2  brain  sections,  and  2  scores 
from  each  dorsolateral  region)  of  each  mouse. 
Animal 
ID 
Genotype  Layer  III  Layer  V 
7836  +/-  181  145 
7783  +/-  247  180 
7839  +/-  223  190 
7778  +/-  222  154 
7705  +/+  201  157 
7689  +/+  224  177 
7687  +/+  250  149 
7777  +/+  216  173 
Table  7.8  Score  of  cell  staining  in  2  subareas  (layer  III  and  layer  V)  of  cortex  from  4  HD 
mice  mice  (+/-)  and  4  wild  type  littermates  (+/+)  subjected  to  immunostaining  with  the 
anti-8-OHdG  antibody. 
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Figure  7.16  Immunostaining  of  8-OHdG  in  the  striatum  (a)  and  cortex  (b)  of  4  HD 
mice  and  4  wild-type  littermates  at  -  25  months  of  age.  The  column  termed  Total  in 
(a)  represents  the  combined  results  from  four  subareas  of  striatum:  dorsomedial  (DM), 
ventromedial  (VM),  dorsolateral  (DL)  and  ventrolateral  (VL).  The  column  termed 
Total  in  (b)  represents  the  combined  results  from  2  subareas  (layer  III  and  V)  of 
cortex.  Stained  cells  were  counted  and  a  score  for  weak  (1)  and  intense  staining  (2) 
was  assigned.  The  cell  staining  intensity  score  is  the  sum  of  the  individual  scores 
within  an  0.06  mm2  area.  Data  are  expressed  as  mean  t  S.  E.  The  p  values  indicated 
were  obtained  from  comparing  the  results  of  HD  mice  (grey  column)  with  wild-type 
littermates  (open  column)  using  the  Student's  t  test  (two-tailed)  for  statistical  analysis. 
*  indicates  p<0.05. 
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DM  VM  DL  VL showed  even  greater  significant  differences  in  striatal  8-OHdG  immunostaining  between 
HD  and  wild-type  mice. 
7.4  Summary 
24  month-old  HD  mice  showed  no  significant  difference  in  aB-crystallin  mRNA  level 
either  in  the  striatum,  cerebellum  or  cortex  when  compared  with  wild-type  littermates. 
24  month-old  HD  mice  showed  no  significant  differences  in  Hmoxl  mRNA  level  in  the 
striatum  and  HO-I  immunostaining  in  the  striatum  and  cortex  when  compared  to  wild-type 
littermates. 
24  month-old  HD  mice  showed  no  significant  differences  in  4-HNE  immunostaining  levels 
in  the  striatum  and  cortex  when  compared  to  wild-type  littermates. 
. 
The  results  from  using  Student's  t  test  to  analyse  the  data  showed  that  8-OHdG 
immunostaining  was  significantly  increased  in  the  dorsomedial,  dorsolateral  and 
ventromedial  striatum,  but  not  in  the  cortex  of  24  month-old  HD  mice  when  compared  to 
wild-type  littermates.  HD  mice  showed  a  trend  toward  increased  8-OHdG  immunostaining 
levels  in  the  ventrolateral  striatum  (p  =  0.06)  when  compared  to  wild-type  littermates, 
although  this  just  failed  to  reach  statistical  significance.  When  the  scores  from  the  four  parts 
of  striatum  were  combined,  the  result  also  showed  that  8-OHdG  immunostaining  was 
significantly  increased  in  the  striatum  of  HD  mice  when  compared  to  wild-type  littermates. 
However,  using  two-way  ANOVA  test,  the  result  showed  that  8-OHdG  immunostaining 
was  significantly  increased  in  all  four  parts  of  HD  striatum  when  compared  to  wild-type 
littermates. 
These  results  suggest  that  immunohistochemical  detection  might  be  a  better  method  for 
detecting  increased  oxidative  stress  in  HD  mice  where  the  increase  in  oxidative  stress 
markers  can  be  detected  at  the  single  cell  level  or  localized  to  a  small  region.  The  results  of 
8-OHdG  staining  are  consistent  with  a  gradient  of  vulnerability  within  the  striatum  of  HD, 
with  the  dorsomedial  striatum  more  vulnerable  and  showing  earlier  pathological  changes 
than  other  regions  (Vonsattel  and  DiFiglia,  1998). 
246 8  Discussion 
8.1  Locomotor  deficits  and  other  phenotypic  features  in  HD 
mice 
8.1.1  HD  mice  show  progressive  locomotor  deficits  in  rotarod 
performance  from  4  months  of  age 
Investigation  of  the  psychomotor  function  of  HD  mice  is  important,  since  the  aims  of  this 
study  are  to  provide  insights  into  the  link  between  molecular/cellular  pathology  and 
phenotype  and  to  investigate  the  use  of  progressive  phenotypic  abnormalities  as  a  surrogate 
marker  to  test  the  efficacy  of  potential  therapies  in  the  future.  Using  different  tools,  early 
and  progressive  psychomotor  abnormalities  have  been  shown  in  most  transgenic  HD  mouse 
models  (Carteret  al.,  1999;  Dunnett  et  al.,  1998;  Lione  et  al.,  1999;  Luesse  et  al.,  2001; 
Hodgson  et  al.,  1999;  Laforet  et  al.,  2001;  Guidetti  et  al.,  2001;  Schilling  et  al.,  1999). 
However,  the  present  study  uses  a  "knock-in"  HD  model  and  the  phenotype  of  the  mice  is 
much  more  slowly  progressive  than  that  observed  in  transgenic  HD  mice  and  more 
reminiscent  of  the  late  onset,  slowly,  progressive  disease  course  of  human  HD.  One  of 
current  limitations  of  using  "knock-in"  HD  mice  as  a  tool  to  investigate  HD  is  that  robust 
protocols  for  measuring  modest  behavioural  phenotypes  are  less  well  developed.  Therefore, 
the  development  of  more  sensitive  assays  and  more  robust  protocols  is  required  for 
assessing  these  mice.  Investigating  the  motor  function  of  HD  mice  may  maximize  the 
information  that  HD  "knock-in"  mice  can  provide. 
Despite  previous  efforts,  studies  of  locomotor  performance  using  beam  walking  and  rope 
tests  did  not  detect  significant  motor  deficits  in  Glasgow  knock-in  HD  mice  (Peggy 
Shelbourne,  unpublished  data).  Beam  walking  and  rope  tests  are  more  passive  tests,  which 
depend  very  much  on  the  motivation  and  attention  of  mice,  and  are  therefore  less  sensitive. 
This  prompts  the  need  for  developing  more  sensitive  and  appropriate  analytic  tools  to 
detect  motor  abnormalities  of  these  mice.  A  rotarod  apparatus  (Dunham  et  al.,  1957)  that 
gives  the  tested  mice  a  more  challenging  task,  thus  providing  a  more  sensitive  measure  of 
247 locomotor  performance  was  used  to  assess  four  limb  motor  coordination,  balance,  and 
muscle  strength  of  HD  mice. 
In  this  longitudinal  study,  a  rotarod  apparatus  was  used  to  investigate  the  locomotor 
function  of  HD  mice  at  4,12  and  18  months  of  age.  The  data  obtained  were  analysed  using 
different  methods.  All  methods  indicated  differences  in  locomotor  function  between  HD 
and  wild-type  cohorts  at  12  and  18  months  of  age,  but  the  results  varied  when  the  data 
obtained  at  4  months  of  age  were  analysed.  ANOVA  tests  detected  performance  deficits  in 
both  male  and  female  HD  mice  at  4  months  of  age  (p  =  0.001and  p<0.001  for  male  and 
female  respectively),  but  other  analyses  using  summary  measures  such  as  the  maximum 
overall  rotarod  performance,  did  not  (p  =  0.3  and  p=0.07  for  male  and  female 
respectively).  ANOVA  tests  detected  progressive  performance  deficits  in  both  male  and 
female  HD  mice  from  4  to  18  months  of  age  (p  <  0.001  andp  =  0.004  for  males  and 
females  respectively),  whilst  other  analyses  using  summary  measures  such  as  the  maximum 
overall  rotarod  performance,  only  detected  progressive  performance  deficits  in  both  male 
and  female  HD  mice  from  4  to  12  months  of  age  (p  =  0.008  and  p=0.008  for  males  and 
females  respectively),  but  not  from  12  to  18  months  of  age  (p  =  0.76  and  p=0.1  for  male 
and  female  respectively).  All  methods  show  that  male  and  female  cohorts  of  HD  mice  did 
not  differ  with  respect  to  the  onset  and  progression  of  performance  deficits.  It  could  be 
argued  that  ANOVA  is  probably  a  more  powerful  data  analysis  approach  because  it  uses  all 
raw  data  points  and  takes  into  account  different  factors  such  as  different  speeds,  days, 
individual  mice  and  their  interactions,  which  might  influence  the  rotarod  performance. 
Therefore,  it  is  very  likely  that  the  rotarod  performance  deficits  of  HD  mice  at  4  months  of 
age  and  the  progressive  performance  deficits  over  time  are  robust  findings. 
The  findings  have  implications  for  the  design  of  future  experiments,  particularly,  if  this 
assay  is  used  to  test  the  efficacy  of  treatments.  Firstly,  male  and  female  HD  mice  do  not 
show  significant  differences  in  the  onset  and  progression  of  performance  deficits, 
suggesting  that  one  gender  of  mice  is  enough  to  represent  the  HD  cohort.  However,  this 
study  indicates  that  the  ability  to  stay  on  rotarod  is  different  between  male  and  female  mice, 
suggesting  that  a  single  sex  cohort  should  be  used  rather  than  mixed  sex  cohort.  Secondly, 
mice  used  in  this  study  were  tested  at  8  different  speeds  per  trial,  which  is  a  tiring  task  for 
the  mice  and  time-consuming  for  the  experimenter.  Further  analyses  using  ANOVA  were 
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outcome.  The  results  of  the  analysis  indicated  that  mice  should  be  tested  at  least  at  three 
speeds,  and  that  maximum  information  was  obtained  at  15,20  and  25  rpm,  because  HD 
mice  did  not  significantly  differ  from  wild-type  littermates  in  rotarod  performance  at  low 
speeds  and  high  speeds.  Thirdly,  a  significant  variability  in  performance  was  present 
among  individual  mice  within  all  cohorts  tested  (male  and  female  HD  mice,  and  male  and 
female  wild-type  littermates).  It  was  noted  that  some  mice  showed  a  more  prominent 
deterioration  in  performance  with  age,  whilst  others  did  not  show  any  sign  of  decline.  This 
variability  in  performance  suggests  that  a  longitudinal  study  testing  the  same  mice  at 
different  ages  is  probably  more  powerful  than  using  different  mice  of  different  ages  to 
investigate  the  effects  of  age  on  rotarod  performance. 
Previously  published  studies  have  suggested  that  motor  deficits  in  knock-in  HD  mice  were 
difficult  to  detect  using  a  rotarod  apparatus  (Wheeler  et  al.,  2000;  Lin  et  al.,  2001). 
However,  deficits  in  Glasgow  HD  mice  were  detected  at  an  early  age  (-  4  month  of  age). 
This  discrepancy  might  be  explained  by  aspects  of  the  protocol  and  the  experimental  plan 
utilized  in  this  study.  Firstly,  after  8  rounds  of  backcrossing  onto  the  C57BL/6  background, 
the  cohort  of  mice  tested  had  a  reasonably  homogeneous  background  (statistically  99.7  % 
C57BL/6,0.3  %  129/Sv),  which  would  theoretically  reduce  the  effects  of  potential  genetic 
modifiers  on  rotarod  performance.  Secondly,  all  mice  were  subjected  to  handling  twice  a 
week  from  5  weeks  of  age  by  the  experimenter  until  the  rotarod  assessments  began.  It  was 
felt  that  this  would  decrease  the  handling  stress  imposed  on  mice  prior  to  performing  the 
rotarod  task.  Thirdly,  it  is  known  that  the  rotarod  task  can  be  influenced  by  several  factors 
such  as  weight,  sex,  learning  ability  of  test,  motivation  and  perseverance.  Learning  effects 
may  have  been  reduced  by  subjecting  each  mouse  to  a  training  course  that  included  trials  at 
0  to  20  rpm  for  1  day  and  3  trials  at  speed  20  rpm  per  day  for  three  consecutive  days.  The 
lack  of  influence  of  learning  effects  is  supported  by  the  observation  that  performances  did 
not  differ  over  3  days  for  any  group  of  mice  at  any  age  tested  when  the  data  was  analysed 
using  summary  measures  (overall  rotarod  performance).  However,  three-way  ANOVA  tests 
suggest  that  the  day  of  testing  may  have  a  small  influence  on  rotarod  performance  of  18 
month-old  male  mice  (F2,335=  3.32,  p=0.037)  and  4  month-old  female  mice  (FW83=  4.52, 
p=0.012).  Since  the  F  ratios  were  not  very  high  and  the  day  of  testing  has  influences  on 
both  wild-type  and  HD  mice,  it  is  probable  that  the  effect  of  learning  the  rotarod  task  had, 
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The  results  showed  that  differences  in  the  rotarod  performance  of  both  male  and  female  HD 
mice  (compared  to  wild-type)  could  not  be  attributed  to  weight  differences.  The  motivation 
and  perseverance  of  mice  is difficult  to  measure.  However,  it  was  observed  that  during  the 
training  course  one  wild-type  littermate  and  two  HD  mice  showed  no  effort  to  stay  on  the 
rod  and  fell  off  the  rod  immediately.  These  three  mice  were  excluded  from  further  testing. 
How  do  these  data  compare  with  studies  using  other  HD  mice?  Rotarod  tests  have  shown 
early  (from  5  weeks  to  3  months  of  age)  and  progressive  motor  deficits  in  other  transgenic 
HD  models.  R6/2  mice  showed  motor  deficits  in  rotarod  performance  at  5  weeks  of  age 
with  progressive  deterioration  (Carter  et  al.,  1999).  HD100  transgenic  mice  demonstrate 
progressive  motor  deficits  in  rotarod  performance  from  3  months  of  age  until  12-15  months 
of  age,  after  which  the  deterioration  of  motor  function  appears  to  plateau  (Laforet  et  al., 
2001).  Progressive  motor  deficits  in  rotarod  performance  have  been  shown  in  N171-Q82 
mice  progression  from  3  to  5  months  of  age  (Schilling  et  al.,  1999).  HD89  mice 
demonstrate  motor  deficits  in  rotarod  performance  at  -13  months  of  age  (Guidetti  et  al., 
2001).  It  is  not  known  whether  HD  89  mice  have  earlier  onset  and  progression  of  motor 
deficits  in  rotarod  performance,  since  HD  mice  were  tested  only  at  -13  months  of  age. 
Are  there  any  molecular/cellular  correlates  of  functional  deficits  that  can  be  drawn  from  the 
studies  of  the  Glasgow  HD  mice  and  the  transgenic  HD  mice?  Inclusions  have  been 
postulated  to  be  candidates  for  the  pathological  agent  in  HD.  Glasgow  HD  mice  show 
motor  deficits  prior  to  the  appearance  of  neuronal  inclusions  (11  months  of  age),  as  do  HD 
100  and  N171-Q82  mice,  suggesting  neuronal  inclusions  may  not  be  responsible  for 
initiating  the  motor  deficits.  However,  these  observations  do  not  exclude  the  possibility  that 
microaggregates  or  soluble  nuclear  mutant  huntingtin  may  be  involved  in  the  pathogenesis. 
Although  R6/2  mice  show  motor  deficits  in  rotarod  performance  just  after  the  presence  of 
neuronal  inclusions,  hyperactivity  in  spontaneous  locomotor  behaviour  at  3  weeks  of  age 
has  been  detected  by  a  modified  open  field  test,  suggesting  that  some  other  molecular 
pathological  changes  may  contribute  to  the  motor  dysfunction  (Lüesse  et  al.,  2001).  Motor 
deficits  are  present  in  Glasgow  HD  mice  at  the  earliest  age  (4  months)  tested  in  this  study. 
The  finding  that  motor  deficits  are  detected  early  (often  at  the  first  time  point  tested)  in 
most  of  other  studies  of  transgenic  HD  mice  raises  the  question  of  whether  developmental 
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cause?  Increasing  evidence  suggests  that  loss  of  normal  huntingtin  function  may  contribute 
to  the  phenotypes  of  HD  (Dragatsis  et  al.,  2000;  Zuccato  et  al.,  2001;  Leavitt  et  al.,  2001; 
Sun  et  al.,  2001;  Cattaneo  et  al  2001)  and  hypomorphic  alleles  might  cause  defects  in 
neurogenesis  (Auerbach  et  al.,  2001;  Nasir  et  al.,  1995;  White  et  al.,  1997).  Since  most 
models  express  a  very  long  expanded  polyglutamine  tract  (>  80  residues,  in  excess  of  the 
size  generally  associated  with  juvenile  HD  patients)  during  early  development,  the  toxic 
effect  of  the  long  polyglutamine  might  already  exist  during  the  early  embryonic 
development.  Despite  these  possible  developmental  effects,  the  motor  deficits  are 
progressive  in  most  models,  suggesting  that  an  additional  ongoing  pathological process 
might  be  involved.  Further  studies  to  determine  when  the  motor  deficits  start  to  occur  in 
these  mice  may  be  informative  to  help  clarify  the  developmental  effects  on  motor  deficits. 
How  do  the  results  of  the  present  study  compare  to  the  reported  motor  deficits  in  other 
"knock-in"  HD  mouse  models?  Motor  deficits  have  been  found  in  HdhQ111  mice  at  24 
months  of  age  by  using  gait  analysis  (Wheeler  et  al.,  2002),  but  were  not  detected  at  2-17 
months  of  age  by  using  an  accelerating  rotarod  apparatus  (Wheeler  et  al.,  2000).  As  details 
of  the  rotarod  protocol  were  not  described  in  the  paper,  it  is difficult  to  know  what  might 
account  for  the  discrepancy  between  this  and  the  present  study.  Hdh(c^°)ls°mice  at  mixed 
age  (15-40  weeks)  did  not  show  significant  deficits  in  rotarod  performance  (5  rpm only), 
whilst  mice  at  other  ages  were  not  tested  with  rotarod  apparatus  (Lin  et  al.,  2001).  The 
results  obtained  with  the  Glasgow  HD  mice  demonstrate  no  significant  differences  from 
wild-type  littermates  at  5  rpm  at  any  age  tested.  It  is  conceivable  that  the  use  of  the  5  rpm 
test  could  not  detect  subtle  deficits  and  that  applying  the  protocol  used  in  this  study  to  test 
the  rotarod  performance  of  Hdh(G1°)15Omice  might  allow  the  detection  of  earlier  motor 
deficits  in  these  mice.  In  summary,  the  present  study  may  provide  a  robust  rotarod  test 
protocol  that  can  be  used  as  a  reliable  tool  to  assess  the  efficacy  of  potential  treatments  on 
HD  mice  in  the  future. 
8.1.2  The  body  weight  profiles  of  HD  mice  and  wild-type  littermates 
Several  lines  of  evidence  suggest  that  weight  loss  is  a  clinical  feature  of  HD,  despite  an 
adequate  diet  and  feeding  (Morales  et  al.,  1989;  Pratley  et  al.,  2000).  A  characteristic 
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(Mangiarini  et  al.,  1996).  N171-82Q  mice  also  exhibit  a  progressive  loss  of  weight 
(Schilling  et  al.,  1999).  However,  there  is  no  evidence  that  either  male  or  female  HD  mice 
showed  progressive  weight  loss  in  the  present  study.  Also,  male  and  female  HD  mice  did 
not  show  significant  differences  in  the  weight  profile  when  compared  to  the  corresponding 
group  of  wild-type  littermates.  Weight  loss  has  not  been  observed  in  some  "knock-in"  HD 
mouse  lines  (Wheeler  et  al.,  2000;  Levine  et  al.,  1999),  but  after  25  weeks  of  age,  1  in  10 
Hdh(G1°)150mice  appeared  to  be  noticeably  smaller  than  its  wild-type  littermates  (Lin  et  al., 
2001).  These  findings  suggest  that  weight  loss  is  probable  not  a  common  feature  in  "knock- 
in"  HD  mice,  modelling  early  disease  stages  of  HD,  but  may  be  influenced  by  very  long  (- 
150  CAG)  repeat  lengths.  As  HD  mice  with  more  aggressive  phenotypes  tend  to  show 
weight  loss,  it  is  probable  that  weight  loss  is  a  feature  of  the  later  stages  of  the  disease 
process,  possibly  as  a  secondary  consequence  to  the  pathological  process. 
8.1.3  Absence  of  limb  clasping  phenotype  in  the  HD  mice 
Limb  clasping  is detected  in  some  transgenic  HD  mouse  models  (Mangiarini,  et  al.,  1996; 
Schilling  et  al.,  1999;  Hodgson,  et  al.,  1999;  Reddy,  et  al.,  1999;  Yamamoto,  et  al.,  2000), 
but  not  others  (Levine,  et  al.,  1999;  Wheeler,  et  al.,  2000).  The  result  of  a  tail  suspension 
test  in  the  present  study  indicates  that  limb  clasping  is  not  a  common  feature  of  the 
Glasgow  HD  mice.  The  clasping  phenomenon  has  also  been  observed  in  mouse  models  for 
other  neurological  disorders  (for  example,  "weaver"  and  "staggerer"  mice)  (Lalonde, 
1987a;  Lalonde,  1987b),  and  thus  appears  not  to  be  a  specific  phenotype  in  HD  mouse 
models.  As  "weaver"  and  "staggerer"  mice  show  pathological  changes  specifically  in  the 
cerebellum,  the  clasping  phenomenon  detected  in  transgenic  mouse  HD  models  might 
reflect  cerebral  lesions  other  than  the  striatal  lesion.  Indeed,  HD  mice  with  limb  clasping 
tend  to  show  a  diffuse  distribution  of  neuronal  inclusions  in  the  brain,  suggesting  that 
clasping  may  be  related  to  the  CAG  repeat  length,  mutant  huntingtin  expression  level  and 
the  genomic  context  of  mutation,  and  may  be  a  consequence  of  the  later  stages  of  disease 
process. 
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mouse  brain 
Several  lines  of  evidence  suggest  that  mitochondria  play  a  central  role  in  excitotoxicity, 
energy  failure  and  oxidative  stress,  all  of  which  may  be  involved  in  HD  pathogenesis. 
Investigating  the  mitochondrial  integrity  in  HD  mice  may  shed  light  on  the  mechanism  and 
molecular  pathology  of  HD  and  thus  provide  a  basis  for  developing  potential  treatments.  As 
mentioned  in  the  previous  section  (section  4.1),  mitochondrial  DNA  (mtDNA)  is 
particularly  susceptible  to  oxidative  damage.  mitochondrial  DNA  deletions  increase  with 
age  and  oxidative  stress  in  many  human  and  mouse  tissues  (Hayakawa  et  al.,  1991;  Liu  et 
al.,  1998;  Brossas  et  al.,  1994;  Tanhauser  et  al.,  1995).  Furthermore,  increased  mtDNA 
deletions  have  been  shown  in  the  cortex  of  individuals  affected  by  HD  (Horton  et  al.,  1995). 
Decreased  levels  of  total  mtDNA  have  been  shown  in  affected  tissues  of  Friedreich's  ataxia 
(Bradley  et  al.,  2000)  and  Alzheimer's  patients  (de  la  Monte  et  al.,  2000;  Rodriguez- 
Santiago  et  al.,  2001),  conditions  associated  with  increased  oxidative  stress.  Therefore,  the 
levels  of  deleted  mtDNA  and  total  mtDNA  content  were  investigated  in  Glasgow  HD  mice. 
8.2.1  Depletion  of  mtDNA  in  HD  mouse  striatum 
A  competitive  PCR  strategy  was  used  to  quantify  total  and  deleted  mitochondrial  DNA 
species.  The  reasons  for  using  competitive  PCR  assays  have  been  stated  in  section  4.2. 
Briefly,  They  provide  an  internal  control  (mimic  DNA)  and  an  opportunity  for  calculating 
the  absolute  level  of  target  DNA,  since  the  initial  amount  of  mimic  DNA  in  the  PCR 
reaction  is  known.  The  results  have  shown  that  total  mtDNA  is  significantly  decreased  in 
the  striatum  of  24-month  old  HD  mice,  when  compared  to  wild-type  mice.  This  -30% 
reduction  in  total  mtDNA  is  specific  to  striatum,  as  no  such  reductions  were  detected  in  the 
cerebellum  or  cortex  of  the  same  animals.  However,  the  level  of  deleted  mtDNA  species  is 
not  increased  in  HD  mice.  By  using  western  blotting  analysis  to  quantify  the  mitochondrial 
porin  protein  (representing  mitochondrial  mass),  the  study  shows  that  the  striatal 
mitochondrial  mass  in  HD  mice  does  not  significantly  differ  from  that  in  wild-type 
littermates.  Therefore,  the  reduction  of  total  mtDNA  in  striatum  is  most  likely  due  to  a 
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the  number  of  mitochondria  in  the  striatum. 
In  order  to  ascertain  whether  the  striatal  depletion  of  mtDNA  is  a  progressive  phenomenon, 
levels  of  total  mtDNA  in  the  striatum  of  HD  mice  at  15  months  of  age  were  investigated. 
The  results  show  that  HD  mice  at  15  months  of  age  do  not  have  detectable  differences  in 
total  mtDNA  in  the  striatum  when  compared  to  wild-type  littermates,  suggesting  mtDNA 
depletion  is  a  late-onset  and  progressive,  rather  than  a  developmental,  phenomenon. 
Recently  a  study  has  reported  that  proper  specimen  storage  is  a  critical  issue  in  quantitative 
mtDNA  analysis  and  that  poor  handling  and  storage  of  tissue,  such  as  thawing  tissues  at 
room  temperature  over  4  hours,  may  mimic  a  severe  mtDNA  reduction  (Berger  et  al.,  2001). 
Such  artefacts  have  been  avoided  in  the  present  study,  since  the  brain  was  immediately 
removed  from  the  animal  after  sacrifice,  dissected  and  quenched  on  dry  ice  or  stored  at  - 
80°C.  When  brain  tissues  were  removed  from  -80°C,  they  were  immediately  subjected  to 
DNA  extraction.  Moreover,  if  other  artifacts  influenced  our  technical  approach,  the 
reduction  of  mtDNA  might  also  be  observed  in  brain  regions  other  than  striatum.  Other 
efforts  deployed  to  increase  the  likelihood  of  the  correct  results  included  duplicate 
competitive  PCR  assays  for  each  sample  and  using  two  different  methods 
(spectrophotometry  and  Southern  blot  analysis)  to  determine  the  amount  of  DNA  template 
added  to  competitive  PCR  assays. 
Many  mitochondrial  abnormalities  including  decreased  activity  of  complex  enzymes  II/III 
(Brennan  et  al.,  1985;  Gu  et  al.,  1996;  Browne  et  al.,  1997;  Tabrizi  et  al.,  1999)  and  IV 
(Tabrizi  et  al.,  1999),  decreased  aconitase  activity  (Tabrizi  et  al.,  1999),  increased  levels  of 
mtDNA  deletion  (Horton  et  al.,  1995)  and  increased  8-hydroxydeoxyguanosine  (8-OHdG) 
mtDNA  (Polidori  et  al.,  1999)  have  been  found  in  brains  of  HD  patients.  A  significant 
reduction  in  aconitase  and  mitochondrial  complex  IV  activities  in  the  striatum  has  been 
shown  in  R6/2  mice  (Tabrizi  et  al.,  2000)  and  increased  cyanide  (complex  IV  enzyme 
inhibitor)-induced  mitochondrial  depolarization  has  been  demonstrated  in  the  lymphoblasts 
of  HD89  mice  (Sawa  et  al.,  1999).  However,  depletion  of  mtDNA  has  never  been  reported 
in  HD  patients  or  other  HD  mouse  models.  One  possible  explanation  is  that  depletion  of 
mtDNA  was  only  recently  recognized  as  a  heritable  infantile  mitochondrial  disease 
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Monte  et  al.,  2000;  Rodriguez-Santiago  et  al.,  2001)  was  not  fully  appreciated  until  recently 
it  was  also  found  in  other  diseases  such  as  chronic  liver  hepatitis  and  liver  cirrhosis 
(Barbaro  et  al.,  1999;  Pesce  et  al.,  2002),  and  in  patients  with  antiviral  drug-induced 
toxicity  (Lewis  et  al.,  2001).  The  present  results  draw  attention  to  the  fact  that  mtDNA 
depletion  may  play  a  role  in  HD  molecular  pathology. 
8.2.2  Decreased  mitochondrial  complex  enzyme  IV  subunit  I 
(cytochrome  c  oxidase  I)  in  HD  mice 
What  are  the  consequences  of  -30  %  reduction  of  total  mtDNA  in  the  striatum  of  HD  mice? 
Following  the  mtDNA  depletion,  the  expression  levels  of  mitochondrial  DNA-encoded 
respiratory  complex  enzymes  might  be  affected  and  energy  production  might  be 
compromised.  Northern  blot  and  RNA  slot  blot  analyses  of  cytochrome  b  (Cytb), 
cytochrome  c  oxidase  I  (Col)  and  cytochrome  c  oxidase  II  (Coll)  mRNA  demonstrate  that 
HD  mice  at  -25  months  of  age  show  no  significant  differences  in  mRNA  levels  of  Col, 
Coll,  and  Cytb  in  any  brain  region  (striatum,  cortex  and  cerebellum)  studied  when 
compared  to  normal  littermates.  However,  HD  mice  showed  a  trend  toward  decreased  levels 
of  Col  mRNA  in  the  striatum  in  both  slot  blot  (p=  0.065)  and  northern  blot  analyses  (p' 
0.11)  when  compared  to  wild-type  littermates,  although  the  difference  did  not  reach 
statistical  significance. 
COI  immunostaining  was  significantly  decreased  in  the  dorsolateral  striatum,  but  not  in  any 
other  part  of  the  striatum  of  24  month-old  HD  mice  when  compared  to  wild-type 
littermates.  The  significantly  decreased  CO-I  immunostaining  with  marginally  decreased 
CoI  mRNA  levels  in  striatum  may  suggest  that  when  levels  of  mtDNA  are  reduced, 
mtDNA  transcription  might  increase  as  a  compensatory  response,  but  the  stability  of  the 
resulting  mitochondrial  enzyme  is  decreased,  perhaps  due  to  increased  oxidative  damage 
(Morel  et  al.,  1995).  Depletion  of  mtDNA  with  compensated  mitochondrial  mRNA 
expression  has  been  reported  in  aged  rats  (Barazzoni  et  al.,  2000)  and  in  skeletal  muscle  of 
diabetes  mellitus  patients  (Antonetti  et  al.,  1995).  An  alternative  explanation  for  these 
findings  may  be  that  changes  in  individual  cells  or  a  small  area  of  the  striatum  might  be 
masked  by  analysis  of  the  bulk  tissue  homogenate  used  in  northern  blot  and  slot  blot 
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northern  blot  and  slot  blot  analyses  to  detect  pathological  changes  in  HD  mice  where 
changes  occur  at  the  single  cell  level  or  localized  to  a  small  region.  Interestingly,  the  results 
of  CO-I  immunostaining  are  also  consistent  with  a  gradient  of  neuropathological 
vulnerability  within  the  striatum  of  HD,  where  the  dorsal  striatum  is  more  vulnerable  and 
shows  earlier  pathological  changes  than  other  regions  (Vonsattel  et  al.,  1998). 
The  decreased  CO-I  immuostaining  in  the  striatum  of  the  Glasgow  HD  mice  is  reminiscent 
of  decreased  expression  levels  of  CoI  mRNA  in  the  striatum,  external  globus  pallidus  and 
putamen  of  HD  brains  (Gourfmkel-An  et  al.,  2002)  and  the  decreased  complex  enzyme  IV 
activity  in  the  striatum  of  HD  patients  (Tabrizi  et  al.,  1999).  How  do  the  results  of  the 
present  study  compare  to  the  reported  mitochondrial  enzyme  abnormalities  in  other  HD 
mouse  models?  Decreased  complex  enzyme  IV  activity  has  been  shown  in  the  striatum  and 
cortex  of  end-stage  R6/2  mice  at  -  12  weeks  of  age  (Tabrizi  et  al.,  2000).  In  contrast, 
activity  of  mitochondrial  complex  enzymes  I-IV  did  not  show  significant  changes  in  the 
brain  regions  of  HD89  mice  at  13-15  months  of  age  (Guidetti  et  al.,  2001),  suggesting  that 
HD89  mice  examined  were  at  the  age  when  onset  of  mitochondrial  abnormalities  had  not 
commenced.  This  supports  the  present  study,  which  suggests  that  mitochondrial 
abnormalities  are  a  relatively  late  pathological  event. 
8.2.3  Are  mitochondrial  abnormalities  primarily  responsible  for  motor 
deficits  in  HD  mice 
Total  mtDNA  is decreased  in  the  striatum  of  24-month  old  HD  mice,  but  not  at  15  months 
of  age,  when  compared  to  wild-type  mice.  This  suggests  that  the  reduction  of  total  mtDNA 
in  the  striatum  of  HD  mice  appears  to  be  a  progressive  rather  than  a  developmental 
phenomenon.  Locomotor  deficits  appeared  (4  months  of  age)  before  the  detection  of 
mtDNA  depletion  in  our  HD  mouse  model.  This  suggests  that  mitochondrial  abnormalities 
may  follow  the  pathological  events  responsible  for  the  motor  dysfunction.  Measurements 
of  mitochondrial  complex  enzymes  I-IV  did  not  reveal  changes  in  the  striatum  and  cerebral 
cortex  in  HD89  mice  at  13-15  months  of  age,  despite  evidence  of  motor  deficits,  suggesting 
that  mitochondrial  energy  impairment  might  follow  early  neuropathological  changes 
responsible  for  motor  deficits  (Guidetti  et  al.,  2001).  This  study  also  demonstrated  that  no 
256 significant  changes  of  mitochondrial  enzymes  were  found  in  brains  of  pre-symptomatic  HD 
patients.  Furthermore,  most  mitochondrial  abnormalities  detected  todate  have  occurred  in 
brain  tissue  from  end-stage  HD  patients  (Brennan  et  al.,  1985;  Browne  et  al.,  1997;  Gu  et 
al.,  1996;  Tabrizi  et  al.,  1999).  Taken  together,  these  findings  support  the  notion  that 
mitochondrial  abnormalities  may  occur  in  later  stages  of  the  disease  and  may  be  a 
consequence,  rather  than  a  cause,  of  early  pathological  changes  in  HD  mice. 
8.2.4  Increased  oxidative  stress  in  HD  mice 
Reduction  of  mtDNA  could  be  due  to  decreased  replication  of  mtDNA  or  increased 
oxidative  damage  of  mtDNA  and/or  insufficient  mtDNA  repair  activities.  Indeed,  reduced 
levels  of  mtDNA  have  been  shown  in  brains  of  several  diseases  associated  with  increased 
oxidative  stress  such  as  Friedreich's  ataxia  (Bradley  et  al.,  2000)  and  Alzheimer's  disease 
(de  la  Monte  et  al.,  2000;  Rodriguez-Santiago  et  al.,  2001).  Increased  levels  of  8- 
hydroxydeoxyguanosine  (8-OHdG)  have  also  been  shown  in  brains  of  Alzheimer's  disease 
(de  la  Monte  et  al.,  2000)  and  increased  levels  of  plasma  malondialdehyde  in  Friedreich's 
ataxia  (Emond  et  al.,  2000).  These  findings  suggest  mtDNA  depletion  is  strongly  associated 
with  increased  oxidative  stress.  Further  supportive  studies  have  demonstrated  that  massive 
reduction  of  mitochondrial  DNA  was  found  in  liver,  brain,  heart  and  skeletal  muscle  of 
mice  with  alcohol-induced  oxidative  stress  (Mansouri  et  al.,  1999;  Mansouri  et  al.,  2001). 
Reduction  of  mtDNA  can  occur  as  a  consequence  of  increased  oxidative  damage  of 
mtDNA  through  DNA  mispairing,  point  mutations,  deletions,  and  fragmentation 
(Barazzoni  et  al.  1999).  Mutation  of  the  mtDNA  replication  control  region  may  affect  the 
replication  of  mtDNA  by  interfering  with  transcription  factor  binding  to  mtDNA  promoter 
sites,  or  by  reducing  the  stable  structure  of  RNA-DNA  hybrid  structure  thereby  resulting  in 
reduced  mtDNA  content  (Michikawa  et  al.,  1999).  Insufficient  mtDNA  repair  activities 
(Shadel  et  al.,  1997)  may  aggravate  increased  oxidative  damage  and  lead  to  mtDNA 
depletion.  Cell-specific  differences  in  mtDNA  repair  capacity  have  been  shown  (Ledoux  et 
al.,  1998),  although  cell-specific  differences  in  mtDNA  repair  between  different  neuronal 
populations  have  not  been  previously  reported.  Given  that  striatum  has  diminished 
antioxidant  defences  than  other  brain  regions  (Cardozo-Pelaez  et  al.,  1999),  it  is 
conceivable  that  the  mtDNA  repair  ability  of  medium  spiny  neurons  may  be  selectively 
decreased,  which  makes  their  mtDNA  more  vulnerable  to  increased  oxidative  damage. 
257 Speculation  that  mtDNA  depletion  possibly  results  from  increased  oxidative  stress  prompts 
the  necessity  to  search  for  direct  evidence  of  increased  oxidative  stress  in  the  HD  mice.  By 
using  northern  blot  analysis  of  heme  oxygenase-1  (Hmoxl)  mRNA  and  RNA  slot  blot 
analysis  of  aB-crystallin  mRNA  in  mouse  brain  tissues,  the  present  study  reveals  that  24 
month-old  HD  mice  showed  no  significant  differences  in  the  levels  of  Hmox1  and  aB- 
crystallin  mRNA  in  the  striatum  when  compared  with  wild-type  littermates.  These  results 
and  negative  results  from  a  previous  study  that  determined  levels  of  malondialdehyde  in  the 
brain  regions  of  the  Glasgow  HD  mice  (Shelbourne,  unpublished  data),  did  not  provide 
evidence  of  increased  oxidative  stress  in  the  brains  of  HD  mice.  However,  both 
experiments  used  bulk  tissue  homogenates  for  analysis.  Changes  in  individual  cells  or  small 
areas  of  the  striatum  might  be  masked  by  analysis  of  the  bulk  tissue  homogenates  and  so 
immunochemical  detection  of  heure  oxygenase-1  (HO-I),  4-hydroxy-2-nonenal  (4-HNE) 
and  8-hydroxydeoxyguanosine  (8-OHdG)  in  HD  mouse  brain  tissue  was  performed.  The 
reasons  for  using  these  markers  as  an  indicator  of  increased  oxidative  stress  have  been 
described  in  section  7.1.  Importantly,  increases  in  the  levels  of  these  markers  have  been 
shown  in  the  brains  of  HD  patients  (Brown  et  al.  1999;  Polidori  et  al.,  1999;  Bogdanov  et 
al.,  2001). 
The  present  study  demonstrated  that  24  month-old  HD  mice  showed  no  significant 
differences  in  HO-1  and  4-HNE  immunostaining  levels  in  the  striatum  and  cortex  when 
compared  to  wild-type  littermates.  In  contrast,  8-OHdG  immunostaining  was  significantly 
increased  in  the  dorsomedial,  dorsolateral  and  ventromedial  striatum,  but  not  in  the  cortex 
of  24  month-old  HD  mice  when  compared  to  wild-type  littermates.  HD  mice  showed  a 
trend  toward  increased  8-OHdG  immunostaining  levels  in  the  ventrolateral  striatum  when 
compared  to  wild-type  littermates,  although  this  just  failed  to  reach  statistical  significance 
(using  Student's  t  test).  The  results  of  8-OHdG  staining  are  consistent  with  a  gradient  of 
vulnerability  within  the  striatum  of  HD,  with  the  dorsomedial  striatum  more  vulnerable  and 
showing  earlier  pathological  changes  than  other  regions  (Vonsattel  and  DiFiglia,  1998). 
These  results  also  suggest  that  immunohistochemical  detection  might  be  a  better  method 
for  detecting  increased  oxidative  stress  in  HD  mice  where  levels  of  oxidative  stress  markers 
can  be  resolved  at  the  single  cell  level  or  localized  to  a  small  region.  The  reason  that  4- 
HNE  and  HO-1  immunostaining  level  is  not  increased  in  HD  striatum  may  suggest  that  8- 
OHdG  is  a  more  sensitive  marker  of  increased  oxidative  stress  than  4-HNE  and  HO-1.  It 
258 may  also  reflect  a  selective  increase  of  oxidative  damage  of  DNA,  but  less  damage  of  lipids 
in  HD  striatum  at  the  stage  when  mice  were  examined.  The  presumption  of  selective 
increased  oxidative  damage  of  DNA  in  HD  striatum  is  supported  by  the  finding  that 
mtDNA  is  -  30  %  depleted  in  HD  striatum. 
Increased  8-OHdG  levels  are  also  observed  in  the  brains  of  end-stage  R6/2  mice  (Bogdanov 
et  al.,  2001)  and  in  the  striatum  of  HD  patients  (Browne  et  al.,  1997).  These  findings  and 
the  demonstration  that  mutant  huntingtin  causes  increased  levels  of  reactive  oxygen  species 
in  cell  culture  (Wyttenbach  et  al.,  2002)  support  the  notion  that  increased  oxidative  stress 
has  a  role  in  HD  pathogenesis.  It  is interesting  to  note  that  increased  8-OHdG  staining  was 
not  confined  to  the  striatum,  but  present  throughout  the  brain  in  both  cortical  and 
subcortical  areas  of  R6/2  mice.  In  contrast,  increased  8-OHdG  level  is  confined  to  the 
striatum  of  Glasgow  HD  mice,  suggesting  a  selective  vulnerability  to  oxidative  stress  in 
Glasgow  HD  mice.  Previous  studies  of  mutation  length  variability  in  somatic  tissue  of  the 
Glasgow  HD  mice  have  shown  evidence  that  the  largest  mutations  are  observed  in  the 
striatum  and  that  repeat  instability  may  occur  by  mechanisms  that  are  not  replication-based 
(Kennedy  and  Shelboume,  2000).  The  authors  suggest  normal  age-related  DNA  damage 
due  to  increased  oxyradical  concentrations  and  diminished  antioxidant  defences  in  the 
striatum  (Cardozo-Pelaez  et  al.,  1999)  could  be  exacerbated  by  the  functional  consequences 
of  the  HD  mutation,  thereby  initiating  a  vicious  cycle  of  mutation  expansion  and  associated 
cellular  pathology  in  vulnerable  cells.  The  present  study  provides  direct  evidence  of 
increased  oxidative  stress  specifically  in  the  striatum  of  HD  mice,  supporting  the  idea  that 
the  mutation  instability  may  be  caused  by  DNA  repair  in  response  to  increased  oxidative 
damage. 
Increased  oxidative  stress  in  the  striatum  of  HD  mice  could  be  the  cause  or  the  consequence 
of  mtDNA  depletion.  Mitchondrial  DNA  depletion  could  result  in  decreased  levels  of 
respiratory  enzyme  complexes  encoded  by  mtDNA,  which  then  compromise  energy 
production  and  lead  to  increased  oxidative  stress  (Esposito  et  al.,  1999).  This  study  does  not 
provide  any  direct  evidence  to  distinguish  the  causal  relationship  of  these  two  pathological 
changes.  However,  studies  have  shown  that  energy  production  by  neurons  is  impaired  only 
when  COI  activity  is  reduced  to  30  %  (Davey  et  al.,  1998).  In  addition,  myoblats  showed 
no  changes  in  energy  production  when  70  %  of  complex  IV  activity  was  inhibited  (Leary  et 
259 al.,  1998).  In  light  of  these  findings,  although  mtDNA  is  -  30  %  depleted  and  the  COI 
immunostaining  is  about  50  %  decreased  in  the  striatum  of  Glasgow  HD  mice,  the  striatal 
neurons  might  still  be  able  to  maintain  their  ATP  production.  This  suggests  that  it  is  less 
likely  that  the  increased  oxidative  stress  in  HD  mice  is  caused  by  energy  failure  through 
mtDNA  depletion  and  decreased  COI  levels.  Therefore,  the  mtDNA  depletion  and 
decreased  COI  levels  in  the  striatum  of  HD  mice  may  be  the  consequences  of  increased 
oxidative  stress. 
8.2.5  Maintenance  of  mitochondrial  DNA  (mtDNA)  in  HD  mice 
Reduced  levels  of  mtDNA  could  be  due  to  decreased  replication  of  mtDNA  or  increased 
oxidative  damage  of  mtDNA  and/or  insufficient  mtDNA  repair  activities  (Shadel  and 
Clayton,  1997).  Evidence  of  increased  oxidative  stress  in  the  striatum  of  HD  mice  has  been 
presented  in  the  current  study.  However,  does  decreased  replication  also  contribute  to  the 
depletion  of  mtDNA? 
Mitochondrial  transcription  factor  A  (mtTFA)  is  a  transcription  factor  that  is involved  in 
mtDNA  transcription  and  mtDNA  replication  (section  1.5.5).  mtTFA  is  essential  for 
mtDNA  replication  and  has  been  demonstrated  to  regulate  mtDNA  copy  number  in  vivo  . 
However,  the  present  study  has  shown  that  the  expression  levels  of  mitochondrial 
transcription  factor  A  (Tfam)  mRNA  and  mtTFA  protein  in  Glasgow  HD  mouse  striatum 
do  not  appear  to  differ  from  those  of  wild-type  littermates.  Therefore,  the  reduction  of 
mtDNA  in  the  striatum  of  HD  mice  is  probably  not  caused  by  decreased  mtTFA  levels. 
As  mentioned  in  chapter  1(section  1.5.5),  the  replication  of  mtDNA  requires  mtTFA  and 
other  factors  including  mitochondrial  RNA  polymerase,  mitochondrial  RNA  processing 
endoribonuclease  (RNase  MRP),  polymerase  y  (pol  y),  single-stranded  DNA-binding 
protein  (SSB),  and  nuclear  respiratory  factors  1  and  2.  In  addition,  deoxyguanosine  kinase 
and  thymidine  kinase-2  have  been  recently  reported  to  be  essential  for  the  mtDNA 
replication  (Mandel  et  al.,  2001;  Saada  et  al.,  2001).  The  reduction  of  mtDNA  in  the 
striatum  of  HD  mice  might  be  caused  by  a  decrease  in  one  or  more  of  these  factors,  which 
have  not  been  investigated  in  this  study  (because  of  limited  time).  Indeed,  the  mtDNA 
depletion  caused  by  antiviral  drugs  such  as  zidovudine  (AZT)  in  AIDS  patients  (Chariot  et 
260 al.,  1999;  Davison  et  al.,  1996)  appears  to  be  due  to  the  inhibition  of  pol  y  activity  by 
antiviral  drugs  (Benbrik  et  al.,  1997).  Furthermore,  there  have  been  reports  of  thymidine 
phosphorylase  gene  mutations  in  mitochondrial  neurogastrointestinal  encephalomyopathy 
(MNGIE),  an  autosomal  recessive  disorder  associated  with  mtDNA  depletion  and  multiple 
mtDNA  deletions  (Nishino  et  al.,  1999),  the  mitochondrial  deoxyguanosine  kinase  gene 
mutations  in  hepatocerebral  mitochondrial  diseases  with  mtDNA  depletion  (Mandel  et  al., 
2001)  and  thymidine  kinase  mutations  in  mitochondrial  DNA  depletion  myopathy  (Saada  et 
al.,  2001). 
When  considering  these  mtDNA  replication-related  factors,  it  is  interesting  to  note  that  pol 
y  contains  a  10-polyglutamine  tract.  Recently,  a  study  showed  that  expanded  polyglutamine 
strethes  particularly  interferes  with  CBP-activated  gene  transcription,  suggesting  that 
mutant  huntingtin  may  cause  dysregulation  of  transcription  (Nucifora  et  al.,  2001).  It  has 
been  postulated  that  CBP  contains  a  polyglutamine  tract  that  interacts  with  polyglutamine 
in  mutant  huntingtin  and  its  activity  is  thus  inhibited  (section  1.2.3.8).  It  is  possible  that 
mutant  huntingtin  might  interact  with  pol  y  through  their  respective  polyglutamine  tracts 
and  thus  interfere  with  the  activity  of  pol  y.  Alternatively,  the  transcription  levels  of  pol  y 
and  other  mtDNA  replication-related  proteins  might  be  decreased  due  to  the  transcriptional 
dysregulation  caused  by  the  interaction  of  mutant  huntingtin  with  CBP  and  other  nuclear 
transcription  factors.  Although  the  microarray  study  in  R6/2  mice  did  not  show  altered 
transcription  levels  of  some  of  mtDNA  replication-related  proteins  (Luthi-Carter  et  al., 
2000),  the  possibility  that  transcription  levels  of  the  mtDNA  replication-related  proteins  are 
decreased  still  cannot  be  excluded.  Investigating  thoroughly  the  expression  levels  and 
activity  of  the  mtDNA  replication-related  factors  in  HD  mice  are  necessary  to  determine 
whether  depletion  of  mtDNA  is  attributable  to  decreased  replication  of  mtDNA. 
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HD? 
This  study  has  shown  evidence  of  increased  oxidative  stress  in  the  striatum  of  HD  mice  at 
24  months  of  age.  Possible  mechanisms  by  which  mutant  huntingtin  causes  increased 
oxidative  stress  are  discussed  in  the  following  section. 
Striatal  neurons  in  transgenic  and  "knock-in"  HD  mouse  models  display  increased 
sensitivity  to  NMDA  receptor-mediated  excitotoxicity  (Levine  et  al.,  1999;  Zeron  et  al., 
2002).  The  possible  links  link  between  excitotoxicity  and  mutant  huntingtin  has  been 
discussed  in  the  literature  and  have  been  presented  in  sections  1.2.4.1  and  1.4.3.4.  In 
addition,  downregulated  genes  belonging  to  specific  neuronal  signalling  systems  including 
Ca2+  homeostasis  system,  have  been  shown  in  R6/2  mice  (Luthi-Carter  et  al.,  2000).  An 
impaired  Ca2+  homeostasis  system  will  result  in  intracellular  Ca2+  influx  that  will  also 
increase  sensitivity  to  excitotoxicity.  One  of  the  consequences  of  excitotoxicity  is  the 
generation  of  reactive  oxygen  species  (ROS)  and  increased  oxidative  damage  to  neurons.  It 
is  thus  postulated  that  glutamate-induced  excitotoxicity  and  impaired  Cat'  homeostasis  may 
contribute  to  the  increased  oxidative  stress  observed  in  the  striatum  of  Glasgow  HD  mice. 
Impairment  of  the  ubiquitin-proteasome  system  can  be  caused  by  polyglutamine 
aggregation  (Bence  et  al.,  2001)  and  chaperone  proteins  (heat  shock  proteins)  can  be 
sequestrated  into  intracellular  aggregates  in  cellular  and  mouse  models  of  polyglutamine 
diseases  (Cummings  et  al.,  1998;  Chai  1999  et  al.,  Stenoien  et  al.,  1999;  Warrick  et  al., 
1999;  Jana  et  al.,  2000).  There  is  evidence  that  the  proteasome  is  responsible  for  degrading 
oxidized  proteins  (Sitte  et  al.,  2000)  and  heat  shock  proteins  protect  cells  from  oxidative 
damage  (Ding  and  Keller,  2001).  It  has  also  been  reported  that  inhibition  of  proteasome 
function  results  in  increased  oxidative  damage,  because  inhibition  of  proteasome  function 
can  diminish  the  efficiency  of  degrading  oxidized  proteins  (Lee  et  al.,  2001).  In  addition, 
heat  shock  protein  27  can  prevent  cellular  polyglutamine  toxicity  and  suppress  the  increase 
of  reactive  oxygen  species  caused  by  mutant  huntingtin  in  cell  culture  (Wyttenbach  et  al., 
2002).  Therefore,  it  is  plausible  that  the  inhibition  of  proteasome  and  heat  shock  proteins 
by  intracellular  huntingtin  aggregates  results  in  increased  oxidative  damage  in  HD  mice. 
262 Increased  oxidative  stress  could,  in  turn,  further  inhibit  proteasome  function  (Ding  and 
Keller,  2001)  and  initiate  a  vicious  cycle  which  results  in  more  and  more  oxidative  damage. 
It  has  been  suggested  that  transcriptional  dysregulation  caused  by  expanded  polyglutamine 
is  involved  in  HD  pathogenesis  (sectionl.  2.3.8).  Cell  models  have  demonstrated  that 
CREB-dependent  transcriptional  activation  can  be  suppressed  through  the  binding  of 
TAFII130  (a  cofactor  for  CREB-dependent  transcriptional  activation)  and  CBP  (CREB- 
binding  protein)  to  expanded  polyglutamine  stretches  (Shimohata  et  al.,  2000;  Steffan  et  al., 
2000;  Nucifora  et  al.,  2001).  When  neurons  are  subjected  to  moderate  oxidative  stress, 
CREB-mediated  transcription  increases  in  response  to  a  pro-survival  signal  mediated  by  the 
activation  of  extracellular  signal-regulated  kinase  1  and  2  (ERK1/2)  (Bonni  et  al.,  1999; 
Crossthwaite  et  al.,  2002).  The  anti-apoptotic  Bcl-2  gene  is induced  by  hypoxia  and 
produces  a  protective  effect,  which  is  dependent  upon  the  cyclic  AMP  response  element 
(CRE)  in  the  Bcl-2  promoter  (Freeland  et  al.,  2001).  The  protective  effect  is  generated 
through  the  enhanced  phosphorylation  of  the  CREB  transcription  factor  and  enhanced 
transcriptional  activation  by  the  CBP  (Freeland  et  al.,  2001).  These  studies  suggest  that 
CREB-dependent  transcription  may  play  a  protective  role  in  the  event  of  oxidative  stress 
and  apoptosis.  Mutant  huntingtin  binds  strongly  to  specificity  protein  1  (Spl),  a 
transcription  factor,  inhibiting  the  Spl-dependent  transcription  activity  has  also  been  shown 
(Dunah  et  al.,  2002;  Li  et  al.,  2002).  Spi  activates  transcription  of  a  variety  of  genes 
including  the  human  SOD1  and  SOD2  genes  encoding  respectively  manganese  superoxide 
dismutase  1  and  2,  which  have  a  protective  role  against  increased  oxidative  stress 
(Porntadavity  et  al.,  2001;  Xu  et  al.,  2002).  Since  mutant  huntingtin  inhibits  Spi-dependent 
transcription,  the  expression  of  SOD1  and  SOD2  might  be  compromised,  leading  to 
increased  oxidative  stress.  Therefore,  it  is  conceivable  that  increased  oxidative  stress  might 
occur  due  to  decreased  Spl-  and  CREB-dependent  transcription  through  the  interaction  of 
Spl  or  CBP  with  expanded  polyglutamine  in  the  Glasgow  HD  mice. 
Defining  how  mitochondrial  abnormalities  and  increased  oxidative  stress  develop  in  HD 
mice  and  their  possible  relationship  to  mutant  huntingtin  expression  may  provide  insights 
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G4ý  cd 8.3  Prospects  for  potential  therapies 
As  previously  mentioned  (section  1.2.5),  there  is increasing  evidence  that  defective  energy 
metabolism,  oxidative  stress,  glutamate-mediated  excitotoxicity,  mitochondrial 
abnormalities  and  their  interplay  may  contribute  to  the  pathogenesis  of  Huntington's 
disease.  This  study  provides  evidence  of  mitochondrial  abnormalities  and  increased 
oxidative  stress  in  a  "knock-in"  HD  mouse  model,  thus  reinforcing  this  hypothesis. 
Strategies  that  reduce  glutamate-mediated  excitotoxicity,  preventing  generation  of  reactive 
oxygen  species  and/or  augmenting  mitochondrial  energy  production  might  have  significant 
therapeutic  benefits.  Indeed,  neuroprotective  effects  of  creatine  have  been  shown  in  R6/2 
mice  (Ferrante  et  al.,  2000).  Creatine  may  exert  its  effect  by  increasing  phosphocreatine 
levels  or  by  stabilizing  the  mitochondrial  permeability  transition.  Remacemide 
hydrochloride,  a  non-competitive  NMDA  receptor  antagonist,  and  Co-enzyme  Q10 
(CoQ10),  an  essential  cofactor  of  the  electron  transport  chain  and  a  potent  free  radical 
scavenger,  have  been  used  to  treat  HD  patients  in  a  5-year  clinical  trial  study  (HDCRG, 
2001).  CoQ10  showed  a  trend  toward  slowing  the  progression  of  disease,  but  statistical 
significance  was  not  achieved.  In  contrast,  remacemide  appeared  to  be  ineffective  as  did 
combination  therapy  in  the  clinical  trial.  However,  in  the  HD-N171-82Q  transgenic  mice, 
remacemide  and  CoQ10  administration  did  appear  to  transiently  improve  motor 
performance  on  the  rotarod,  but  did  not  prolong  the  survival  or  delay  the  appearance  of 
inclusions  (Schilling  et  al.,  2001).  These  results  suggest  that  further,  more  detailed  studies 
of  these  compounds  at  different  doses  in  other  HD  mouse  models,  and  possibly  in  HD 
patients,  are  warranted. 
8.4  Conclusions  and  future  studies 
Using  a  rotarod  test,  this  study  has  been  able  to  show,  for  the  first  time,  progressive  motor 
deficits  in  knock-in  HD  mice  from  4  months  of  age.  The  progressive  motor  deficits  can  be 
used  as  a  biomarker  to  test  the  efficacy  of  potential  therapy  strategies  in  the  future.  This 
study  has  also  defined  a  robust  rotarod  protocol  that  may  be  useful  in  studies  of  other  HD 
mouse  models. 
265 It  is  not  known  whether  motor  deficits  occur  in  the  Glasgow  HD  mice  before  4  months  of 
age.  Further  studies  should  include  earlier  time  points  to  determine  whether  developmental 
defects  also  contribute  to  the  motor  deficits.  Despite  the  presence  of  early-onset, 
progressive  motor  deficits,  weight  loss  and  limb  clasping  are  not  common  features  in 
Glasgow  HD  mice.  Total  mtDNA  content  is  reduced  in  the  striatum  of  Glasgow  HD  mice 
at  24  months  of  age,  but  not  at  15  months  of  age,  suggesting  mtDNA  depletion  is  a 
progressive  rather  than  a  developmental  phenomenon.  As  motor  deficits  appear  before 
mtDNA  depletion,  it  is  possible  that  mitochondrial  abnormalities  may  follow  the 
pathological  events  responsible  for  the  motor  dysfunction.  If  mtDNA  depletion  is  the 
primary  cause  of  mitochondrial  dysfunction  in  HD,  these  findings  raise  the  possibility  that 
potential  treatments  to  prevent  mtDNA  depletion  or  rescue  mitochondrial  function  may  not 
prevent  the  onset  of  motor  deficits.  Since  the  Glasgow  HD  mice  model  early  stages  of  HD, 
it  will  be  interesting  and  informative  to  determine  whether  mtDNA  depletion  is  present  in 
early  stages  of  human  HD  and  other  polyglutamine  diseases. 
Depletion  of  mtDNA  in  the  striatum  could  be  the  cause  or  the  consequence  of  increased 
oxidative  stress.  Increased  8-OHdG  immunostaining  in  the  dorsomedial,  dorsolateral  and 
ventromedial  striatum,  but  not  in  the  cortex  of  24  month-old  HD  mice  provides  direct 
evidence  that  increased  oxidative  stress  specifically  occurs  in  the  striatum.  COI 
immunostaining  is  also  specifically  decreased  in  the  dorsolateral  striatum,  but  not  in  any 
other  part  of  the  striatum  of  24  month-old  HD  mice.  The  decreased  levels  of  COI 
immunostaining  in  the  striatum  may  be  due  to  mtDNA  depletion,  or  increased  oxidative 
damage  of  the  enzyme,  or  both.  Although  mtDNA  is  -  30  %  depleted  and  COI 
immunostaining  is  about  50  %  decreased  in  the  striatum  of  Glasgow  HD  mice,  the  striatal 
neurons  might  still  be  able  to  maintain  their  Al?  production.  Therefore,  it  is  more  likely 
that  mtDNA  depletion  and  decreased  COI  levels  in  the  striatum  of  HD  mice  may  be  the 
consequences,  rather  than  the  cause,  of  increased  oxidative  stress.  Striatal  mtDNA 
depletion  could  also  be  caused  by  decreased  mtDNA  replication.  Although  altered  levels  of 
Tfam  mRNA  and  mtTFA  protein  in  the  striatum  of  HD  mice  could  not  be  detected  in  the 
present  study,  the  possibility  of  reduced  expression  or  activity  of  other  mtDNA  replication- 
related  factors  cannot  be  excluded.  Therefore,  further  studies  to  investigate  whether  these 
factors  are  involved  in  the  depletion  of  mtDNA  detected  in  HD  mouse  striatum,  are 
warranted. 
266 This  is  the  first  time  that  evidence  of  increased  oxidative  stress  in  a  "knock  in"  HD  mouse 
model  has  been  shown.  It  is  not  known  whether  the  increased  oxidative  stress  is  present 
when  the  HD  mice  are  yonger  than  24  months  of  age.  In  the  future,  it  will  be  important  to 
investigate  the  onset  of  increased  oxidative  stress  in  HD  mice  and  its  relationship  with 
other  molecular  changes  and  clinical  phenotypes,  because  the  relationship  will  determine 
what  benefits  may  be  obtained  from  treatments  that  prevent  increased  oxidative  damage. 
So  what  causes  the  increased  oxidative  stress  in  the  striatum  of  HD  mice?  Possible  links 
between  mutant  huntingtin  and  oxidative  damage  have  been  discussed  in  previous  section 
(section  8.2.6).  Future  studies  on  these  links  and  other  aspects  may  help  to  dissect  out  the 
HD  pathogenesis  and  identify  potential  novel  therapeutic  targets. 
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